[{"text": "Ford\u2019s Oakville, Ontario, Manufacturing Site Prepares to Build Next-Gen EVs; C$1.8 Billion Transformation Begins 2024", "labels": -0.947117839}, {"text": "Ford Motor Company Board Declares Dividend for Q2 2023", "labels": 2.3584886227}, {"text": "Ford Becomes America\u2019s Best-Selling Brand in the First Quarter on Rising Sales for Trucks, Vans, Broncos, Large SUVs, EVs, Mustang", "labels": -2.7353195503}, {"text": "Road to Better: Ford Releases 2023 Integrated Sustainability and Financial Report, Details Progress Toward Carbon Neutrality and Commitment to Responsible EV Supply Chain", "labels": 1.4937177803}, {"text": "Ford Motor Company Issues 2023 Proxy Statement, Announces May 11 as Date for Virtual Annual Meeting", "labels": 2.1293394582}, {"text": "PT Vale Indonesia and Huayou Sign Agreement with Ford Motor Co. Supporting Growth of the Global Sustainable EV Industry", "labels": 2.5396859365}, {"text": "Ford to Build Next Electric Truck \u2013 \u2018Project T3\u2019 \u2013 at BlueOval City; BlueOval Learning Will Prepare Nearly 6,000 for Jobs", "labels": 1.7361205515}, {"text": "\u2018Refounded\u2019 Ford to Show How Customer-Focused Segments Will Drive Value and Growth, Changes in Financial Reporting", "labels": -1.2163271863}, {"text": "Ford to Host March 23 \u2018Teach-In\u2019 About Financial Reporting, Strategic Implications of New Customer-Focused Segments", "labels": 2.7072718515}, {"text": "Ford\u2019s Sustainability Chief Bob Holycross to Speak at Deutsche Bank ESG Conference on March 9", "labels": 2.0030799159}, {"text": "Ford US February 2023 Sales Release", "labels": 5.3516764022}, {"text": "Ford China\u2019s Anning Chen Announces Intention to Retire; Sam Wu Will Follow Him as Company President and CEO", "labels": -3.7037051117}, {"text": "Ford, LG Energy Solution, and Ko\u00e7 Holding to Establish a Joint Venture to Produce Battery Cells as Ford Prepares to Bring More EVS to Customers In Europe", "labels": -4.1769031508}, {"text": "Ford Takes Next Steps to Transform European Business; Aligns Organization and Product Portfolio to Rapidly Changing Industry and Market Conditions", "labels": -0.4640284081}, {"text": "Ford Taps Michigan for New LFP Battery Plant; New Battery Chemistry Offers Customers Value, Durability, Fast Charging, Creates 2,500 More New American Jobs", "labels": 2.0046265461}, {"text": "People, Plan, Products Position Ford Well for \u2018Pivotal\u2019 2023 Despite Effect of Volume Shortfall on Q4, Full-Year 2022 Results", "labels": -7.1050624125}, {"text": "Ford to Significantly Increase Production of Mustang Mach-E in 2023, Reduces Prices Across the Board", "labels": 3.7009693306}, {"text": "Ford Releases First Sustainable Financing Report, Update on Allocation and Impact of Green Bond Investments", "labels": 1.1035746321}, {"text": "F-150 Lightning Wins MotorTrend Truck of the Year for 2023, Setting Precedent with Unanimous Vote by Judges", "labels": -2.2255180857}, {"text": "Ford, SK On Make Significant Construction Progress at BlueOval SK Battery Park, On-Plan to Train 5,000 Employees at On-Site Training Center", "labels": -2.442747482}, {"text": "Ford to Increase Investment at Halewood to Scale Up Electric Vehicle Portfolio", "labels": -1.6594580167}, {"text": "Ford produces 150,000th Mustang Mach-E", "labels": 2.1306853816}, {"text": "Ford Credit Earns Sixth J.D. Power Top Ranking Since 2015", "labels": 0.489517575}, {"text": "Ford's Jim Baumbick to Oversee Quality; Armstrong, Rowley, Falotico to Retire; Craig to lead Global Lincoln Business", "labels": 0.3016582487}, {"text": "Ford Strengthens Position As America\u2019s No. 2 EV Brand; All-New Super Duty Off to Hot Start \u2013Orders Exceed 50,000 in Five Days", "labels": 0.3016582487}, {"text": "Doug Field to Discuss Ford\u2019s Focus on Software-Defined Vehicles and Services at Bernstein Conference on Nov. 7", "labels": -3.9050481851}, {"text": "Ford Credit CFO Schaaf to retire; Eliane Okamura named CFO", "labels": 1.8656783072}, {"text": "Ford Fulfills Earnings Guidance, Has Strong Cash Flow in Q3; Will Accelerate Development of L2+/L3 ADAS Technology", "labels": 1.5384472002}, {"text": "Ford China Sells 133,000 Vehicles in Third Quarter; Strengthens Sales Rebound with Quarter-over-Quarter Growth", "labels": 0.7785390846}, {"text": "All-New Ford F-Series Super Duty Is Built Like Never Before With Next-Level Capability, Connectivity and Technology", "labels": -0.2462941363}, {"text": "Ford Announces New Manufacturing Investment and Jobs Commitment in Kentucky", "labels": -0.2462941363}, {"text": "Ford Announces Leadership Changes to Strengthen Product Creation and Transform Global Supply Chain Management", "labels": -6.5800175584}, {"text": "Ford Previews Effect of Parts Shortages on Q3 Performance, Reaffirms Full-Year Adjusted EBIT Guidance of $11.5-$12.5B", "labels": -10.7715776906}, {"text": "Benchmark for Street and Track, Ford Introduces Mustang Dark Horse and New Family of Track-Only Race Ponies", "labels": 0.8730690024}, {"text": "All-New Ford Mustang Redefines Driving Freedom with Immersive Digital Cockpit, Advanced Engines and Bold Style", "labels": 0.8730690024}, {"text": "Ford Pro Launches All-New Fleet Management Suite, Offers Bundled Solutions for Small Businesses", "labels": -2.3192325271}, {"text": "All-New, All-Electric E-Transit Custom from Ford Pro is Set to Spark the EV Revolution for Small Businesses", "labels": 1.6861266836}, {"text": "BlueCruise Adds Hands-Free Lane Changing, Tech to Make Road-Sharing Easy with Bigger Vehicles on Key 2023 Models", "labels": 1.6861266836}, {"text": "Bill Ford Statement On The Passing Of Queen Elizabeth II", "labels": 1.6861266836}, {"text": "Ford Motor Company and DTE Energy Announce the Largest Renewable Energy Purchase From a Utility in U.S. History", "labels": 2.274166}, {"text": "BlueCruise Ford Power-Up Software Update Transforms F-150, Mustang Mach-E Models for Hands-Free Driving", "labels": 5.1055131188}, {"text": "Ford Achieves Solid Second-Quarter 2022 Operating Results, While Organizing, Deploying Toward Ambitious Ford+ Future", "labels": 8.9285786778}, {"text": "Ford Releases New Battery Capacity Plan, Raw Materials Details to Scale EVs; On Track to Ramp to 600K Run Rate by \u201923 and 2M+ by \u201926, Leveraging Global Relationships", "labels": -0.4680312454}, {"text": "Ford to Provide Electric Vehicle Plan Update Thursday", "labels": 3.0769176573}, {"text": "700 Horsepower! New Ford F-150 Raptor R Is Most Powerful Raptor Ever for High-Performance Off-Roading", "labels": 3.4948404027}, {"text": "Ford Execs to Discuss Ford+ Plan, Q2 Results, 2022 Outlook During July 28 Fireside Chat with BNP Paribas Exane Analyst", "labels": 5.5555521918}, {"text": "Ford\u2019s Thai-Tang and Toney to Retire After Stellar Careers; Dave Bozeman Joins Ford to Lead FCSD, Enthusiast Vehicles", "labels": 5.5555521918}, {"text": "Ford Motor Company Announces Details for Q2 2022 Earnings Conference Call", "labels": 5.5555521918}, {"text": "Ford Speeds Toward All-Electric, Connected Future in Europe; Chooses Valencia Plant, Spain, for Next-Gen EV Architecture", "labels": 2.5951761404}, {"text": "Ford Credit Announces Expiration of Its Tender Offers for Certain Outstanding Debt Securities Maturing in 2022 and 2023; Increases Maximum Purchase Amount", "labels": 1.9197291933}, {"text": "Ford Credit Commences Cash Tender Offers for Certain Outstanding Debt Securities Maturing in 2022 and 2023", "labels": -0.8196693061}, {"text": "Ford To Invest $3.7B and Add 6,200 UAW Jobs To Help Deliver Ford+ Plan", "labels": -1.0370377771}, {"text": "Ford US May 2022 Sales Release", "labels": -1.0370377771}, {"text": "John Lawler to Discuss Continued Execution of Ford+ Plan at Deutsche Bank 2022 Global Automotive Conference", "labels": 3.0701800031}, {"text": "Jim Farley to Discuss Ford+ Plan for Growth, Value Creation, Shift to Digital EVs at Bernstein Conference on June 1", "labels": -1.7713363374}, {"text": "Ford Pro Reveals Exciting Next Phase of Electrification Journey with All-New, All-Electric E-Transit Custom", "labels": -3.7453260978}, {"text": "Ford US April 2022 Sales Release", "labels": 0.1376376284}, {"text": "How Ford F-150 Lightning Software Accurately Estimates Range to Give Customers Confidence While Towing", "labels": 3.7087954696}, {"text": "Ford\u2019s Q1 Demand Strong, Supplies Limit Product Shipments; Affirms Full-Year Adjusted EBIT Guidance of $11.5-$12.5 Billion", "labels": -1.1628033891}, {"text": "America\u2019s Best-Selling Vehicle Now Electric: Production Begins for F-150 Lightning Trucks", "labels": -1.6835008289}, {"text": "Leading From the Front: Ford Pro Open for Business to Drive Productivity for Europe\u2019s Commercial Fleets", "labels": -1.3596126538}, {"text": "Ford Motor Company Announces Details for Q1 2022 Earnings Conference Call", "labels": 1.9314542477}, {"text": "Ford China Sells 125,000 Vehicles in First Quarter, Accelerating Localization and Delivery of Ford+ Growth Plan", "labels": 1.0848657662}, {"text": "Lake Resources and Ford Sign Non-binding MoU to Negotiate for Lithium Offtake From the Kachi Project", "labels": 3.059890127}, {"text": "Lake Resources and Ford Motor Company sign non-binding MoU to negotiate for lithium offtake from the Kachi Project", "labels": 3.059890127}, {"text": "Ford Takes In Record 50,000 F-Series Retail Vehicle Orders in March; Ford Electrified Vehicle Sales Post Record; Ford Pro Continues Strong Momentum; Ford Bronco Family Achieves Record March Sales; Lincoln SUV Demand Strengthens", "labels": -5.3097389963}, {"text": "Ford to Hold 2022 Virtual Annual Shareholder Meeting on May 12", "labels": -2.1008256786}, {"text": "Ford Releases Inaugural Human Rights Report, Increases Climate Risk Disclosure in 2022 Integrated Report As It Transitions to Electric Future", "labels": -3.3033211135}, {"text": "Kiersten Robinson Selected for Ford Blue Operating Position; Jennifer Waldo, Christopher Smith Join as New Ford Leaders", "labels": 1.2872906132}, {"text": "Ford Takes Bold Steps Toward All-Electric Future in Europe; 7 New Connected EVs Support Plans to Sell 600K+ EVs Annually by 2026", "labels": -0.1868024522}, {"text": "Ford, SK and Ko\u00e7 Set to Create a Joint Venture to Accelerate Ford\u2019s Electrification Revolution in Europe", "labels": -0.1868024522}, {"text": "Ford Strengthens Further its Electric Vehicle Product Range and Commercial Vehicle Growth Capability in Craiova, Romania", "labels": -0.1868024522}, {"text": "Jim Farley to Discuss the Auto Industry\u2019s Shift to Electrification at CERAWeek Annual Conference", "labels": -1.9595784104}, {"text": "Hans Schep to Discuss How Ford Pro Drives European Leadership at Jefferies Spring Automotive Conference", "labels": -8.308603167}, {"text": "Ford Accelerating Transformation: Forming Distinct Auto Units to Scale EVs, Strengthen Operations, Unlock Value", "labels": 0.5681780222}, {"text": "Ford Takes In Over 72,000 New Retail Vehicle Orders In February; Record Start For Ford Brand SUV Retail Sales; Ford Electrified Sales Charge Ahead Conquesting From Competitors At 54 Percent; Lincoln SUVs Post Strong Sales Gains", "labels": 0.5681780222}, {"text": "Ford Plans Wednesday Announcement About Acceleration of Ambitious Ford+ Plan for Growth and Value Creation", "labels": 3.8121694634}, {"text": "Ford to Webcast Fireside Chats with Company Leaders on Feb. 23 & Feb. 24", "labels": 1.1660233633}, {"text": "Built for America, Ready for Work: Ford Pro\u2122 Begins Shipping Electric E-Transit to Customers, Works to Boost Production", "labels": 4.1961987544}, {"text": "Strategic Progress of Ford+ Growth Plan, Solid Financials in \u201921 Position Company for Connected EV Leadership in 2022, Beyond", "labels": -12.3051411379}, {"text": "Ford Begins 2022 With Record Electrified and SUV Sales Momentum; Electrified Vehicle Sales Expand At Almost 4 Times Rate Of Overall Industry Segment; F Series Hits 40 Millionth Sale; January New Retail Vehicle Orders Hit 90,000 A New Record", "labels": -4.6254425931}, {"text": "Ford and JMC Launch Passenger Vehicle Joint Venture in China", "labels": -7.4680241222}, {"text": "Farming of the Future: Ford Pro, Sonoma County Winegrowers Join Forces to Electrify Business of Farming", "labels": -7.4680241222}, {"text": "Productivity Accelerated: Ford Pro Announces New Partners, Services; Demand Strong with Orders for 10,000 E-Transits", "labels": -7.4680241222}, {"text": "Ford of Europe Q4 2021 Sales", "labels": -0.4520334521}, {"text": "Desert-Racing, Rock-Crawling 2022 Ford Bronco Raptor Debuts as Most Powerful Street-Legal Bronco Ever", "labels": 0.2502494585}, {"text": "Ford Provides Update on Certain Special Items for FY2021 Results", "labels": -10.7795086238}, {"text": "Ford Motor Company Announces Details For Q4 2021 Earnings Conference Call", "labels": -10.7795086238}, {"text": "Ford and ADT to Form Joint Venture to Fortify Vehicle Security With Breakthrough Technology", "labels": -10.7795086238}, {"text": "Ford-Stripe Agreement to Accelerate Easy Payment Experiences for Customers, Dealers", "labels": -10.7795086238}, {"text": "Ford China Full-Year 2021 Sales Increase with Significant Lincoln Gains, Building Foundation for Growth in Electric Vehicle Segment", "labels": 2.1834140768}, {"text": "Ford Motor Company Board Declares Dividend for First-Quarter 2022", "labels": 1.0266825912}, {"text": "Ford Best-Selling Automaker in Q4; Becomes No. 2 for Electric Vehicle Sales for 2021; F-Series Best-Selling Truck for 45thYear In Row and Best-Selling Vehicle for 40th straight year; SUV Share Expands", "labels": 1.6353239344}, {"text": "Full Speed Ahead: Ford Planning to Nearly Double All-Electric F-150 Lightning Production to 150,000 Units Annually; First Wave of Reservation Holders Invited to Order", "labels": 4.8182478437}, {"text": "Lend a Hand \u2013 and a Few Miles \u2013 to Your Friends Using Vehicle-to-Vehicle Charging on F-150 Lightning, F-150 Hybrid", "labels": 1.9364451483}, {"text": "Ford Pro Charging Launches to Help Businesses of All Sizes Overcome the Hurdle to Seamless Electrification", "labels": -4.046532499}, {"text": "John C. May, Chairman and CEO of Deere & Co., Named to Ford Board", "labels": 7.8787818629}, {"text": "Ford Invests US$900 Million to Modernize Thailand Manufacturing for Next-Gen Ranger and Everest; Adds 1250 New Jobs", "labels": -3.1170109498}, {"text": "Ford Launches VIIZR, a Technology Built on Salesforce to Help Small Businesses and Tradespeople Thrive", "labels": 0.807669125}, {"text": "Ford F-Series Best-Selling Truck for 45th Year In Row; Ford Brand SUVs Post Record November Retail Sales; Ford Electrified Vehicle Sales Hit New Record, Grow More Than 3 Times Faster Than Segment; November New Vehicle Orders Hit 74,000", "labels": -1.8808647513}, {"text": "Ford to Present Updates on Its Electric Vehicle Leadership at Dec. 3 Goldman Sachs, Credit Suisse Conferences", "labels": -0.2042994249}, {"text": "GlobalFoundries, Ford to Address Auto Chip Supply and Meet Growing Demand", "labels": -3.9711038214}, {"text": "Ford Pro CEO Ted Cannis to Discuss Electrification, Commercial Vehicles, Digital Connectivity at Barclays Global Automotive and Mobility Tech Conference", "labels": 1.6675148653}, {"text": "Ford and Purdue Patent Charging Station Cable for Research That Could Lead to Recharging EVs as Quickly as Gas Fill-Ups", "labels": -1.6879847942}, {"text": "Ford Pro Readies American Businesses; All-Electric E-Transit Customer Pilot Vehicles Debut Nationwide", "labels": 2.1836261976}, {"text": "Ford Motor Company Commences Cash Tender Offers for Outstanding Debt Securities", "labels": 1.9181138253}, {"text": "Ford Ford Credit Introduce Sustainable Financing Framework Prioritizing EV Clean Production Community Investments", "labels": 1.9181138253}, {"text": "New Products, Strong Inventory Make Ford America\u2019s Top-Selling Automaker For Second Straight Month; Ford Brand SUVs Post Best October Results in 21 Years; F-Series Expands Lead; October New Vehicle Orders Hit 77,000; Lincoln Brand SUV Sales Continue to Climb", "labels": 7.7239846526}, {"text": "Ford Achieves Strong Q3 Results, Raises Full-Year 2021 Guidance; Says Financial Flexibility Enables Ample Investment in Ford+ Plan", "labels": 6.3463724754}, {"text": "Ford of Europe Q3 2021 Sales", "labels": -2.6249910281}, {"text": "Mustang Mach-E Rolls Off Assembly Line in China for Delivery to Local Customers by Year End; Sold Through Network of Direct-to-Customer EV Stores", "labels": -0.9727552899}, {"text": "Ford to Invest \u00a3230 Million to Transform Halewood Operations in U.K. to Build its First Electric Vehicle Components in Europe", "labels": -0.9727552899}, {"text": "Ford China Year-to-Date Sales Grow 11%, Driven by Record Lincoln Sales", "labels": 0.5095631221}, {"text": "New Products, Improved Inventory Propels Ford To Top-Selling Automaker in September with Retail Sales Up 34.3 Percent Compared to August; 52,000 New Vehicle Orders Placed; Lincoln Brand Retail Sales Increase 52.6 Percent Over August as Nautilus Sales Soar", "labels": 0.1399597256}, {"text": "Ford Renews $15.5 Billion in Revolving Corporate Credit Lines, Aligning Them With Sustainability Priorities in Ford+ Strategic Plan", "labels": -2.1186477028}, {"text": "Ford to Lead America\u2019s Shift to Electric Vehicles with New Mega Campus in Tennessee and Twin Battery Plants in Kentucky; $11.4B Investment to Create 11,000 Jobs and Power New Lineup of Advanced EVs", "labels": 2.9350087516}, {"text": "Ford Motor Company Announces Details For Q3 2021 Earnings Conference Call", "labels": 3.1204567694}, {"text": "Ford, Redwood Materials Teaming Up on Closed-Loop Battery Recycling, U.S. Supply Chain", "labels": 5.76221771}, {"text": "New Ford Expedition Raises Bar Among Full-Size SUVs with Most Off-Road Capable, Most Powerful, Smartest Expedition Ever", "labels": 2.569920493}, {"text": "Ford Begins Pre-Production of All-Electric F-150 Lightning Truck, Boosts Investment, Adds Jobs in Michigan", "labels": 2.7306318152}, {"text": "Ford, Argo AI, and Walmart to Launch Autonomous Vehicle Delivery Service in Three U.S. Cities", "labels": 3.8059625193}, {"text": "Mike Amend Brings Multi-Industry Record of Growth, Value Creation To New Assignment as Ford\u2019s Chief Digital and Information Officer", "labels": 0.7776096171}, {"text": "Ford Pro Builds Accomplished Leadership Team Focused on Success of Commercial and Government Customers", "labels": -2.1293421108}, {"text": "Ford Restructures India Operations: Plans to Grow Ford Business Solutions; Serve Customers with Iconic Global Vehicles; Cease Local Vehicle Manufacturing", "labels": -2.1293421108}, {"text": "Lisa Drake to Discuss Ford\u2019s Plans to Lead in the Electric Revolution at Morgan Stanley Virtual Laguna Conference", "labels": -1.6457606541}, {"text": "Ford Names Doug Field Chief Advanced Technology and Embedded Systems Officer", "labels": 1.5349179863}, {"text": "Ford Retail Sales Grow 6.5 Percent From Last Month Due To Production and Inventory Improvements; 41,000 New Retail Orders, Up 4-Fold; F-Series Has Best Performance Since Semiconductor Chip Shortage Began, Up 11 Percent From July; F-150 Lightning Tops 130,000 Reservations", "labels": -1.5515846425}, {"text": "Ford Credit CFO Brian Schaaf to Speak August 12 at J.P. Morgan Automotive Conference", "labels": -2.4282601709}, {"text": "Ford Mustang Mach-E Sales Grew 15.8 Percent in July, Second Largest In Electric SUV Segment; New Vehicle Launches of F-150 Hybrid, Bronco, Mustang Mach-E Expand Ford\u2019s Competitive Conquest Rate; Ford Accessory Business Climbs 23 percent, On Track To Post New Record", "labels": -1.0211574697}, {"text": "Hau Thai-Tang to Discuss Ford+, Winning in Electrification At J.P. Morgan Virtual Automotive Conference Next Week", "labels": -4.879887171}, {"text": "Ford\u2019s Expectations for Better Full-Year 2021 Operating Results Driven by Strong Order Bank, Improving Semiconductor Supplies", "labels": 3.6831253573}, {"text": "Argo AI and Ford to Launch Self-Driving Vehicles on Lyft Network by End of 2021", "labels": -1.0064840086}, {"text": "Ford of Europe Q2 2021 Sales", "labels": -1.0064840086}, {"text": "Ford Provides Details on Three Safety Recalls in North America", "labels": -6.3252974228}, {"text": "Ford China First-Half Sales Grow 24%, Driven by Doubling of Lincoln Sales and Double-Digit Growth in SUV and Commercial Vehicle Sales", "labels": 3.5911692111}, {"text": "Mustang Mach-E Takes Top Spot in Car and Driver\u2019s Inaugural Electric Vehicle of the Year Award 2021", "labels": -2.489345026}, {"text": "Ford Names Steven Croley Chief Policy Officer, General Counsel, As Company Organizes to Support Ford+ Plan for Growth", "labels": -2.489345026}, {"text": "Ford Motor Company Announces Details For Q2 2021 Earnings Conference Call", "labels": -4.4975366955}, {"text": "Ford Electrified Vehicle Sales Up 117 Percent in June \u2013 Delivering New First Half Record - Mustang Mach-E Sales Up 27 Percent Over May; Ford SUVs Post Best First Half Retail Sales In 20 Years On Strength From New Products; Lincoln SUVs Set New Record, Retail Sales Up 23 Percent", "labels": -3.1724228574}, {"text": "Ford Motor Company Issues Safety Recall for Certain 2015-2020 Ford Transit Vehicles in Canadian Corrosion Provinces", "labels": -1.8716457814}, {"text": "Ford Says Q2 2021 Adjusted EBIT Will Exceed Its Expectations", "labels": -5.3719017268}, {"text": "Ford Acquires Electriphi to Provide Ford Pro Commercial Customers with Seamless Charging and Energy Management", "labels": -5.3719017268}, {"text": "Lincoln Accelerates Brand Transformation; Plans to Deliver a Full Portfolio of Connected and Electrified Vehicles by 2030", "labels": -2.234253524}, {"text": "Ford Motor Company Issues Safety Recall for Select 2021 Super Duty Vehicles", "labels": -1.5333309418}, {"text": "40 MPG City. Standard Hybrid. Seats Five. Starts Under $20K. All-New 2022 Ford Maverick: Did We Mention It\u2019s a Truck?", "labels": -1.8087809512}, {"text": "Ford CEO Jim Farley to Speak at Deutsche Bank Virtual Global Auto Industry Conference on June 17", "labels": -1.8087809512}, {"text": "Record Ford Electrified Vehicle Sales Run Continues \u2013 Up 184 Percent On Strength of F-150 PowerBoost Hybrid, Mustang Mach-E, Escape and Explorer Hybrid; Ford SUVs Post Best May Retail Sales Since 2003; Record SUV Sales for Lincoln on Gains From Entire Lineup", "labels": 5.1346269969}, {"text": "New \u2018Ford Pro\u2019 Vehicle Services and Distribution Business Redefining Transportation Value for Commercial Customers", "labels": 11.5591406061}, {"text": "Superior Value From EVs, Commercial Business, Connected Services Is Strategic Focus of Today\u2019s \u2018Delivering Ford+\u2019 Capital Markets Day", "labels": 11.5591406061}, {"text": "Ford Introduces All-Electric F-150 Lightning Pro, Built for Work with Next-Generation Technology, Seamless Overnight Charging", "labels": -4.4496409554}, {"text": "Ford Commits to Manufacturing Batteries, to Form New Joint Venture with SK Innovation to Scale NA Battery Deliveries", "labels": 6.0765038486}, {"text": "Ford Motor Company to Host Capital Markets Day on May 26", "labels": -1.0591375504}, {"text": "Ford to Reveal All-Electric F-150 Lightning May 19 with Livestreamed Event at Ford HQ", "labels": -1.7271130155}, {"text": "Ford Motor Company Issues Safety Recall", "labels": -1.7271130155}, {"text": "Ford Electrified Vehicle Sales Post Best Sales Month Ever \u2013 Up 262 Percent on Mustang Mach-E and F-150 PowerBoost Hybrid; F-Series Up 31.8 Percent; Ford Brand SUVs Achieve Record April Sales On Higher Bronco Sport Sales; Lincoln SUVs \u2013 Deliver Record April Sales", "labels": 0.6890557931}, {"text": "Ford Boosts Investment in Solid Power, Aiming to Accelerate Solid-State Vehicle Battery Development for Customers", "labels": -1.314634654}, {"text": "Ford Announces New Roles for Armstrong, Watters As Company Speeds Turnarounds of Key Regional Units", "labels": -11.9005335768}, {"text": "Enhanced Execution, Fresh Portfolio of Exciting Vehicles Drive Ford\u2019s Strong Q1 Profitability, As Trust in Company Rises", "labels": -11.9005335768}, {"text": "Ford Accelerates Battery R&D with Dedicated Team, New Global Battery Center of Excellence Named Ford Ion Park", "labels": 1.1262999748}, {"text": "Ford to Build New Light Commercial Vehicle in Romania in 2023; All-Electric Model Debuts Following Year", "labels": 1.1262999748}, {"text": "Ford of Europe Q1 2021 Sales", "labels": -1.7341177589}, {"text": "Ford: Virtual Annual Shareholder Meeting Details", "labels": -0.5723543653}, {"text": "Ford Director Jon Huntsman to Join Company as Vice Chair, Policy", "labels": 0.3267970801}, {"text": "Starting from RMB 265,000, Mustang Mach-E Manufactured in China Opens for Pre-order; Ford China Launches Direct Sales Model for Electric Vehicles", "labels": -1.225516969}, {"text": "Ford Motor Company Announces Details For Q1 2021 Earnings Conference Call", "labels": -1.2789755754}, {"text": "Ford China First-Quarter Sales Grow 73.3 Percent, Marking Fourth Consecutive Quarter of Year-Over-Year Growth", "labels": -2.8776966763}, {"text": "Ford Electrified Vehicle Sales Up 74 Percent on Strong Sales of Mustang Mach-E and F-150 PowerBoost Hybrid; F-Series Up 9.2 Percent; Ford Bronco Sport Powers Ford Brand SUVs To Best Retail Start in 20 Years; Lincoln SUVs \u2013 Best Retail Start Since 2001", "labels": 3.3070696565}, {"text": "Ford\u2019s New Science-Based, Interim Carbon-Neutral Targets Highlight First Integrated Sustainability, Financial Report", "labels": -2.3828994635}, {"text": "Ford Continues to Go All-In on Electrification with New Hybrid Engine and Increased Battery Pack Assembly in Spain; Continuing to Evolve Passenger Vehicle Range", "labels": 2.9268535314}, {"text": "Ford Announces FORDLiive \u2013 a New Commercial Vehicle Uptime Accelerator to Maximise Productivity for Businesses", "labels": -5.2416088786}, {"text": "Ford Motor Company Announces Pricing of $2.0 Billion Convertible Notes Offering", "labels": 1.2009703971}, {"text": "Next Generation Ford Transit Custom All-Electric Coming in 2023; New Vehicle Built in Turkey by Ford Otosan", "labels": -2.9157015371}, {"text": "Ford Motor Company Announces $2.0 Billion Convertible Notes Offering", "labels": -2.9157015371}, {"text": "Ford Motor Company Provides Details on Two Safety Recalls in North America", "labels": 3.1818079336}, {"text": "Ford Nominates Alexandra Ford English and Henry Ford III for Election to Board; Edsel B. Ford II to Retire After 33 Years as Director", "labels": 3.1818079336}, {"text": "Ford Senior Leaders to Describe Opportunities in Europe at Jefferies Conference on March 10", "labels": 4.6640351775}, {"text": "Ford Posts Record February Electrified Vehicle Sales on First Full Month of Mustang Mach-E and Strong F-150 PowerBoost Hybrid Sales; F-Series Expands Retail Sales and Share; Lincoln Navigator Delivers Best February Sales Since 2007", "labels": -5.6999197256}, {"text": "Ford Credit CFO Brian Schaaf to Speak March 2 at J.P. Morgan Global High Yield & Leveraged Finance Conference", "labels": 0.7653053737}, {"text": "Ford\u2019s Chief Sustainability, Environment & Safety Officer Bob Holycross to Speak at RBC Global ESG Conference on Feb. 25", "labels": 0.8605893679}, {"text": "Ford Motor Company Issues Safety Compliance and Safety Recalls in North America", "labels": 0.8605893679}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": 1.813486302}, {"text": "Ford CEO Jim Farley to Speak at Wolfe Research Virtual Global Auto, Auto Tech, and Mobility Conference on Feb. 24", "labels": -1.5748049466}, {"text": "Ford Europe Goes All-In on EVs on Road to Sustainable Profitability; Cologne Site Begins $1 Billion Transformation", "labels": -1.5748049466}, {"text": "Ford Raises Planned Investment in EV, AV Leadership to $29 Billion; Further Advances Turnaround of Global Automotive Business in Q4", "labels": 0.9556894173}, {"text": "Ford January Retail Sales Outpaced Overall Industry Retail by Four Percentage Points on Strong Truck and SUV Sales; F-Series Starts The Year As America\u2019s Best-Selling Truck; Ford Brand SUVs Post Record January Start; Lincoln SUVs Post Best Retail Sales In 20 Years", "labels": 3.9577945909}, {"text": "Ford Invests $1 Billion (R15.8) to Modernize, Expand South African Manufacturing for All-New Ranger; Adds 1,200 Jobs", "labels": 0.5357173097}, {"text": "Ford and Google to Accelerate Auto Innovation, Reinvent Connected Vehicle Experience", "labels": 1.9336933943}, {"text": "Ford to Manufacture Mustang Mach-E in China for Local Customers", "labels": -2.7985151732}, {"text": "Ford Motor Company Issues Safety Compliance Recall for 286 Ford Explorer Police Interceptor and Lincoln Aviator Vehicles in North America", "labels": 11.2749470625}, {"text": "Ford Europe 2020 Sales: Sixth Consecutive Year of Commercial Vehicle Leadership, Mustang Mach-E Ready to Accelerate Electrification", "labels": -0.1996044572}, {"text": "Ford China Fourth Quarter 2020 Sales Results", "labels": 4.9079709135}, {"text": "Ford Advances South America Restructuring; Will Cease Manufacturing in Brazil, Serve Customers With New Lineup", "labels": 9.3046919117}, {"text": "Ford Motor Company Announces Details for Q4 2020 Earnings Conference Call", "labels": 2.150538763}, {"text": "Truck Customers Make F-Series America\u2019s Best-Selling Pickup For 44 Straight Years; Ford Brand Achieves 11 Straight Years as America\u2019s Best-Selling Brand; Ford Explorer Claims Top Spot in 2020; Luxury Customers Propel Lincoln SUVs to Highest Sales in 17 Years", "labels": 2.9801351267}, {"text": "Ford\u2019s Ted Cannis to Discuss Commercial Vehicles, Electrification at Morgan Stanley Auto 2.0 Conference Jan. 11", "labels": 4.1855214117}, {"text": "Ford, Mahindra End Discussions for Auto Joint Venture", "labels": -3.7558469657}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": -0.9101341206}, {"text": "Ford US Sales, Inventory, and Production for November 2020", "labels": 0.5428948495}, {"text": "Ford Credit to Discuss Third Quarter Results at Bank of America Securities Conference", "labels": -0.7709322506}, {"text": "Suzy Deering Joining Ford in January as Global CMO; Linda Cash Retiring as Quality, New-Vehicle Launch Leader", "labels": -0.7709322506}, {"text": "Ford\u2019s Hau Thai-Tang to Present at Goldman Sachs Global Automotive Conference on Dec. 4", "labels": 6.6666700556}, {"text": "Ford\u2019s Lisa Drake to Present at Credit Suisse Industrials Conference on Dec. 2", "labels": 6.6666700556}, {"text": "Ford\u2019s Kumar Galhotra to Describe Customer, Company Benefits of Commercial Vehicle Ecosystem at Barclays Automotive Conference Nov. 19", "labels": 6.4772774981}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": 6.4772774981}, {"text": "Leading the Charge: All-Electric Ford E-Transit Powers the Future of Business with Next-Level Software, Services and Capability", "labels": 3.2786964116}, {"text": "Ford to Discuss The All-New E-Transit All-Electric Van And Opportunities For Connected Commercial Vehicles", "labels": 3.2786964116}, {"text": "Ford Taps Kansas City to Assemble All-Electric Ford E-Transit; Builds Out $3.2B North American EV Manufacturing Footprint", "labels": 1.2004860793}, {"text": "Ford Motor Company Issues Safety Recall for Select 2013-17 Ford Explorer Vehicles", "labels": 1.6270311145}, {"text": "Ford US Sales, Inventory, and Production for October 2020", "labels": -1.5706859951}, {"text": "Vijay Sankaran, Former TD Ameritrade CIO, Returns to Ford To Drive Innovative Technology, Software for Customers, Company", "labels": 0.6345187211}, {"text": "Ford\u2019s Strong Q3 Driven by Higher Demand, Operating Execution, With Game-Changing Vehicle Launches Starting in Fourth Quarter", "labels": 2.7848074229}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America and One Safety Compliance Recall in Canada", "labels": 0.7751943136}, {"text": "Ford China Third Quarter 2020 Sales Results", "labels": 3.2594577668}, {"text": "Ford Europe Third Quarter 2020 Sales Results", "labels": 3.2594577668}, {"text": "Jon Huntsman Returns to Ford Board", "labels": 3.2594577668}, {"text": "Ford Motor Company Announces Details for Q3 2020 Earnings Conference Call", "labels": -3.3025191786}, {"text": "Ford U.S. Third Quarter 2020 Sales Results", "labels": 5.6980127908}, {"text": "Ford Announces Operational and Leadership Changes", "labels": 2.6124832336}, {"text": "Ford Motor Company Issues One Safety Compliance Recall and Two Safety Recalls in North America", "labels": 2.0740627519}, {"text": "Ford Deepens Commitment to American Manufacturing, Celebrates Production Start of All-New F-150, Breaks Ground on New Electric F-150 Plant at Historic Rouge Center", "labels": 2.6279413727}, {"text": "Ford North America COO to Outline Opportunities in Launch, Quality and Cost at RBC Industrials Conference on Sept. 14", "labels": 2.0086243238}, {"text": "Ford Motor Company Issues Safety Recall for Select 2020 Ford Explorer and Lincoln Aviator Vehicles", "labels": -2.7859243884}, {"text": "Built for America: Ford\u2019s All-New F-150, Bronco Make New York City Debuts As Part of Bell-Ringing Event at New York Stock Exchange", "labels": -2.3222170951}, {"text": "Ford Motor Company Issues Three Safety Recalls in North America", "labels": -4.2674368543}, {"text": "Ford Senior Leaders to Describe Opportunities in Europe at J.P. Morgan Auto Conference on Aug. 12", "labels": -1.0203974676}, {"text": "Ford Announces Jim Hackett to Retire as President and CEO; Jim Farley to Succeed Hackett as Company Continues Transformation", "labels": 0.7183973437}, {"text": "Ford to Host Media Conference Today: Jim Farley to Succeed Hackett as Company Continues Transformation", "labels": 0.7183973437}, {"text": "New FordPass Rewards Visa Card Designed to Offer Ultimate Benefits for Drivers, Lower Cost of Vehicle Ownership", "labels": 3.0612157496}, {"text": "Ford Records Better-Than-Anticipated Q2 Operating Results As Company Manages for Both Coronavirus and Long Term", "labels": -1.9667091105}, {"text": "Ford Executive Galhotra to Speak During Jefferies Virtual Industrials Conference on Aug. 5", "labels": -4.5994178087}, {"text": "Ford Motor Company Issues Three Safety Recalls in North America", "labels": 1.900602438}, {"text": "Mellen Named Ford\u2019s General Counsel, Succeeding Gayton; Jennings Made Purchasing Vice President, Company Officer", "labels": -1.7964167363}, {"text": "Ford Europe Second Quarter 2020 Sales Results", "labels": 2.058832354}, {"text": "Ford and ALD Automotive Launch New Fleet Management Business in Europe to Support Commercial Vehicle and Fleet Growth", "labels": 2.058832354}, {"text": "Ford to Discuss Return of Legendary Bronco with BofA Securities", "labels": 3.3018842196}, {"text": "All-New Ford Bronco Sport Rugged Small SUV Equipped for Trails with Standard 4x4 and Built Wild Capability and Confidence", "labels": 3.3018842196}, {"text": "All-New 2021 Bronco Two-Door and First-Ever Four-Door Models: Built Wild SUVs with Thrilling 4x4 Capability, Ready for Fun", "labels": 3.3018842196}, {"text": "Ford Motor Company Announces Details For Q2 2020 Earnings Conference Call", "labels": 4.2904082643}, {"text": "Ford\u2019s Sales in Greater China Rebound in the Second Quarter; Grow 3 Percent Year-Over-Year", "labels": -4.9657415462}, {"text": "Bronco Returns: Ford\u2019s All-New Outdoor Brand Features \u2018Built Wild\u2019 4x4 Adventure Vehicles, Community, Off-Road Schools", "labels": -0.3267997638}, {"text": "Ford U.S. Second Quarter 2020 Sales Results", "labels": 1.4539475212}, {"text": "Ford and Disney Gear-Up to Reveal All-New Ford Bronco Family", "labels": 1.4539475212}, {"text": "'Ford Promise' Offers Peace of Mind to Potential Car Buyers and Lessees", "labels": 2.7960641139}, {"text": "Built for Getting Things Done, Ford Reveals the Toughest, Most Productive F-150 Ever and Most Powerful in Its Class", "labels": 0.8460180329}, {"text": "Ford Motor Company Issues a Safety Compliance Recall and a Safety Recall in North America", "labels": 0.8460180329}, {"text": "Carbon Neutrality By 2050: Ford Sustainability Leaders On Ambitious New Goal During Wolfe Research \u2018Fireside Chat\u2019", "labels": 0.8460180329}, {"text": "Ford Expands Climate Change Goals, Sets Target to Become Carbon Neutral By 2050: Annual Sustainability Report", "labels": -0.4975161129}, {"text": "Return To Work Non-Manufacturing Playbook- Working Together to Remain Safe and Healthy At Work", "labels": -1.9512069804}, {"text": "Return To Work Manufacturing Playbook- Working Together to Remain Safe and Healthy At Work", "labels": -1.9512069804}, {"text": "Ford to Provide \u2018Look\u2019 at All-New F-150 During Citi Conference Call", "labels": -8.5308013742}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": -19.575843495}, {"text": "Ford Credit University Webcast Available", "labels": -19.575843495}, {"text": "Ford, Volkswagen Sign Agreements for Joint Projects On Commercial Vehicles, EVs, Autonomous Driving", "labels": -19.575843495}, {"text": "Ford CEO Jim Hackett and COO Jim Farley to Address Deutsche Bank 2020 Global Auto Industry Conference", "labels": 15.5313388172}, {"text": "Ford VW Argo AV Announcement", "labels": 3.7156604794}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": 2.0442912414}, {"text": "Packing Heat: How Ford's Latest Tech Helps Police Vehicles Neutralize COVID-19", "labels": -2.7350538229}, {"text": "Ford to Provide COVID-19 Testing for Symptomatic Employees in SE Michigan, Kentucky, Missouri and Illinois", "labels": 3.3962155945}, {"text": "Ford Celebrates Workforce, Highlights Importance of American Manufacturing in New Campaign", "labels": -2.2495052607}, {"text": "Ford to Restart U.K. Operations; All European Production Facilities Running Under New Health and Safety Protocols", "labels": -2.2495052607}, {"text": "Ford Motor Company Issues Three Safety Recalls in North America", "labels": -9.1101594738}, {"text": "No More FOMO: New Ford Over-the-Air Updates Help Mustang Mach-E Get Even Better With Time \u2013 Without Leaving Home", "labels": -9.1101594738}, {"text": "Ford Provides Details of Thursday\u2019s 2020 Annual Meeting of Shareholders", "labels": -9.1101594738}, {"text": "Ford Executive Hau Thai-Tang To Speak At BofA Securities 2020 Global Automotive Summit", "labels": 3.1249872535}, {"text": "Ford to Begin Phased Production and Operations Restart in North America May 18 with Enhanced Safety Protocols", "labels": 6.4885409361}, {"text": "Ford and 3M Now Shipping Powered Air-Purifying Respirators to Health Care Workers; New Jersey Orders 500,000 Gowns", "labels": -3.6961049159}, {"text": "Restarting Ford: Safety Priority One as Ford Readies to Reboot Critical Manufacturing Worldwide", "labels": -4.8780638153}, {"text": "Restarting Ford: Company Hosts Media Briefing on How it Plans to Return to Work", "labels": -4.7151097092}, {"text": "Ford Protecting People, Preserving Cash, Preparing for Recovery As Pandemic Stops Most Operations, Drives Down Q1 Results", "labels": -4.3726145274}, {"text": "Ford Motor Company Issues Equipment Recall for Incorrect Replacement Headlamps for Select 2013-16 Lincoln MKZ Vehicles", "labels": -4.3726145274}, {"text": "Ford to Restart European Manufacturing Production with Enhanced Employee Protection Protocols in Place", "labels": -4.3726145274}, {"text": "Ford Motor Company Announces Details For 2020 Q1 Earnings Conference Call", "labels": -2.5157208813}, {"text": "Ford Motor Company Issues Safety Recall for Select 2020 Expedition Vehicles for Front Passenger Seat Belt Tension Sensor", "labels": -5.0314144811}, {"text": "Amid Coronavirus, Ford Continues European CV Sales Leadership Launches Key Models with Electrified Options", "labels": -3.8152677159}, {"text": "Ford\u2019s First Quarter Sales in Greater China exceeded 88,700 Vehicles; Significant Sales Rebound Experienced in March", "labels": 1.171868563}, {"text": "Ford Announces Changes to Automotive Operations to Further Accelerate Transformation Plan", "labels": 1.171868563}, {"text": "Ford to Produce Powered Air-Purifying Respirators, Masks for COVID-19 Protection in Two Michigan Facilities; Scaling Up Production of Gowns and Testing Collection Kits", "labels": -2.6465023856}, {"text": "Ford Motor Company, 3M Hosting News Conference Today", "labels": -2.6465023856}, {"text": "Ford Provides Preliminary First-Quarter 2020 Financial Results", "labels": -2.6465023856}, {"text": "Ford Motor Company Issues Safety Recall for Select 2020 Ford Ranger, F-150 and Expedition Vehicles", "labels": 3.5785465482}, {"text": "Ford Releases 2020 Proxy Statement, Announces Virtual Annual Meeting Date", "labels": 2.8697586336}, {"text": "Ford Temporary Suspension of European Production Remains at Least Until May 4; Continues Community Support Efforts", "labels": 2.8697586336}, {"text": "Ford U.S. First Quarter 2020 Sales Results", "labels": -3.5377523206}, {"text": "Ford Further Postpones NA Production Restart to Protect Workforce", "labels": -14.3181684655}, {"text": "Ford to Produce 50,000 Ventilators in Michigan in Next 100 Days; Partnering with GE Healthcare Will Help Coronavirus Patients", "labels": -5.7971186113}, {"text": "Ford Aims to Restart Production at Key North American Plants", "labels": -3.2755364955}, {"text": "Ford Motor Company Issues Two Safety Recalls for North America and One Safety Recall for Canada Only", "labels": -9.9047667256}, {"text": "Ford Reassessing Timing of N.A. Plants Resuming Production", "labels": 17.0686563533}, {"text": "Ford Works With 3M, GE, UAW to Speed Production of Respirators for Healthcare Workers, Ventilators for Coronavirus Patients", "labels": 17.0686563533}, {"text": "Ford Motor Company News Conference This Morning", "labels": 17.0686563533}, {"text": "Ford Temporarily Suspends Production in India, South Africa, Thailand and Vietnam in Response to Coronavirus", "labels": 13.7373657367}, {"text": "Ford Takes Action to Address Effects of Coronavirus Pandemic; Company Offers New-Car Customers Six-Month Payment Relief", "labels": 6.2045e-06}, {"text": "Ford Launches New \u2018Built to Lend a Hand,\u2019 Providing New Car Buyers Peace of Mind with Up to Six Months of Payment Relief", "labels": 6.2045e-06}, {"text": "Ford Motor Company Temporarily Suspends South American Production In Response To Coronavirus", "labels": 6.2045e-06}, {"text": "Ford Reduces North America Production to Help Keep Workforce Safe, Boosting Coronavirus Containment Efforts", "labels": -6.2639908819}, {"text": "Ford Temporarily Suspends European Production in Response to Coronavirus; Helps Containment Efforts", "labels": -12.8888794758}, {"text": "Committed To Lending A Hand, Ford Offers Assistance To Customers, Community During COVID-19 Outbreak", "labels": -0.5987970379}, {"text": "UAW, GM, Ford and FCA to Enhance COVID-19/ Coronavirus Protections for Manufacturing and Warehouse Workers", "labels": -0.5987970379}, {"text": "Ford Motor Company Issues Safety Recall for Select 2019 Ford Ranger Vehicles for an HVAC Blower Motor Issue", "labels": -13.2710327823}, {"text": "Ford to Offer All-Electric Transit; U.S.-Made, Zero-Emissions Van to Join All-Electric Mustang Mach-E and F-150 in Lineup", "labels": -2.9661078119}, {"text": "Ford Motor Company Issues a Safety Compliance Recall and Two Safety Recalls", "labels": -6.5187328367}, {"text": "Ford, Lincoln Work with Nationwide to Offer Insurance Program for Connected Vehicles Designed to Reward Safer Driving", "labels": -5.9445288195}, {"text": "Ford Executive Jim Farley to Speak at Wolfe Research Global Auto, Auto Tech, and Mobility Conference 2020", "labels": -2.6054526048}, {"text": "Ford Aims To De-Mystify Electrification With Unique \u2018Go Electric\u2019 Roadshow As All-Electric Mustang Mach-E Debuts", "labels": -1.358021648}, {"text": "Ford Goes Electric in Europe", "labels": -1.358021648}, {"text": "Ford Motor Company Issues Safety Recall for Select Vehicles for Rear Toe Link Fractures", "labels": 1.3333279077}, {"text": "Ford Announces Senior Leadership Changes as Company Continues Transformation", "labels": -1.8610211975}, {"text": "Ford Motor Company to Conduct News Conference This Morning", "labels": -1.8610211975}, {"text": "Ford\u2019s Q4, Full-Year Results in Europe, China Sharply Improve; Strategic Actions in 2019 Position Company for Long-Term Success", "labels": -9.2659464113}, {"text": "Lincoln, Rivian Partner to Deliver Lincoln\u2019s First All-Electric Vehicle", "labels": -0.1131271395}, {"text": "Ford Motor Company Issues Safety Recall in Canada for Select 2015-18 Ford F-150 Vehicles for Unintended Tailgate Opening", "labels": 1.0033561208}, {"text": "Ford\u2019s Green Initiatives, Low-Carbon Ambitions, Earn Company Climate \u2018A List\u2019 Designation From CDP", "labels": 0.1091869292}, {"text": "Ford Europe Fourth Quarter 2019 Sales Results", "labels": 0.2171461277}, {"text": "Ford Motor Company Announces Details For 2019 Q4 Earnings Conference Call", "labels": -0.3264563691}, {"text": "Ford China Fourth Quarter 2019 Sales Results", "labels": 0.4305560887}, {"text": "Ford Motor Company Declares Dividend for First Quarter 2020", "labels": 0.3239976337}, {"text": "Ford U.S. Fourth Quarter Sales Results", "labels": 1.6216084247}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": -0.6355909649}, {"text": "Ford Motor Company Issues Safety Recall for Select 2017-19 Ford Super Duty SuperCrew Vehicles", "labels": 0.7454667024}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": 0.554936468}, {"text": "Ford Executive Marion Harris To Address Connectivity At Deutsche Bank\u2019s 2019 AutoTech Conference", "labels": 1.28964e-05}, {"text": "Changing How We Work: Ford\u2019s Leader of Product Line Management To Participate In The Credit Suisse Industrials Conference", "labels": 1.3186989481}, {"text": "Ford Motor Company Issues Safety Recall for Select 2019 Ford Ranger Vehicles for Tail Lamp Function", "labels": 1.2208651283}, {"text": "Ford Mustang Expands Family: All-Electric Mustang Mach-E Delivers Power, Style, and Freedom For New Generation", "labels": -1.6854034118}, {"text": "New UAW-Ford Collective Bargaining Agreement to Increase Manufacturing Competitiveness, Protect U.S. Jobs", "labels": 1.1173120662}, {"text": "Ford Motor Company Issues Two Safety Recalls and a Safety Compliance Recall", "labels": 1.1173382485}, {"text": "Electric and Untamed: Ford\u2019s Electric-Vehicles Leader To Address Barclays 2019 Global Automotive Conference", "labels": 1.1173382485}, {"text": "Ford Announces New Executive Leaders For Sustainability/Safety, AV, Strategy, and Ford Credit", "labels": 0.8849642152}, {"text": "Ford Motor Company Announces Planned 2020 Quarterly Earnings Dates", "labels": 0.9977815811}, {"text": "Ford Motor Company Issues Three Safety Recalls in North America", "labels": -0.5854709274}, {"text": "Improvement in Key Automotive Markets, Ford Credit Contribute to Ford\u2019s Q3, YTD Operating Results", "labels": -4.7674158649}, {"text": "Ford Europe Third Quarter 2019 Sales Results", "labels": 2.7563198709}, {"text": "Ford China Third Quarter 2019 Sales Results", "labels": 1.0204045444}, {"text": "Ford Motor Company Declares Dividend for Fourth Quarter 2019", "labels": 2.2779116769}, {"text": "Ford U.S. Third Quarter Sales Results", "labels": -1.6073584184}, {"text": "Mahindra and Ford Announce a Joint Venture To Drive Profitable Growth in India and Emerging Markets", "labels": -6.7363577103}, {"text": "Ford Motor Company and Changan Automobile Strengthen Strategic Partnership; Changan Ford Unveils Acceleration Plan with China Speed, China Design and Intelligent Manufacturing in Chinese Market", "labels": -1.6519894748}, {"text": "Details of Ford Motor Company\u2019s Briefing on 2019 Third Quarter Results", "labels": 0.1086988438}, {"text": "Details of Ford Motor Company\u2019s Third Quarter 2019 U.S. Sales Conference Call", "labels": -0.2162109358}, {"text": "Ford Reveals Electrified Vehicle Line-Up that will Surpass Conventional Petrol and Diesel by 2022", "labels": 3.6093434165}, {"text": "Ford Goes Electric In Europe", "labels": 3.6093434165}, {"text": "The Tipping Point \u2013 Ford\u2019s New Breed Of Electrified Vehicles To Surpass Combined Diesel And Petrol Models By 2022", "labels": 3.6093434165}, {"text": "Avis Budget Group and Ford Team Up to Connect Cars, Reinventing the Rental Experience in Europe", "labels": 0.2173840987}, {"text": "Ford Announces Leadership Changes; Steven Armstrong to Succeed Nigel Harris as President, Changan Ford China JV", "labels": -3.1926994222}, {"text": "Ford Motor Company to Participate in the J.P. Morgan 2019 Auto Conference", "labels": 1.1542689463}, {"text": "Underlying Progress From Ford\u2019s Global Redesign Evident in Q2; New Explorer, Aviator Fortify Company\u2019s U.S. Strength in SUVs", "labels": -6.4853679031}, {"text": "Europe Second Quarter Sales Release", "labels": -0.3872213355}, {"text": "Details of Ford Motor Company Briefing on 2019 Second Quarter Results", "labels": 0.1903153747}, {"text": "Ford \u2013 Volkswagen expand their global collaboration to advance autonomous driving, electrification and better serve customers", "labels": 1.7274338353}, {"text": "Ford Motor Company Declares Dividend for Third Quarter 2019", "labels": 3.2411760246}, {"text": "Ford - Volkswagen AG Providing Update on Global Collaboration", "labels": 3.2411760246}, {"text": "Beth Mooney, Keycorp Chairman and CEO, Joins Ford Board of Directors", "labels": 1.67774e-05}, {"text": "China Second Quarter Sales Release", "labels": 0.1960735732}, {"text": "Ford Looks to the Future in Europe: Business Redesigned for Profitability, Efficiency, More New EVs and SUVs", "labels": 1.8572654621}, {"text": "Details of Ford Motor Company\u2019s Second Quarter 2019 U.S. Sales Conference Call", "labels": -1.0956141145}, {"text": "Ford, Lincoln Rank Among Top Five Brands in J.D. Power 2019 U.S. Initial Quality Study", "labels": -1.0956141145}, {"text": "Ford Confirms Start of Consultation on Potential Closure of Bridgend Engine Plant in Support of Business Redesign", "labels": 0.409846827}, {"text": "Innovating for Smart Vehicles in a Smart World", "labels": 0.5112464258}, {"text": "Ford Motor Company to Participate in UBS Global Industrials and Transportation Conference", "labels": 0.5133579642}, {"text": "Ford Motor Company To Participate In Goldman Sachs Industrials & Materials Conference 2019", "labels": -1.7647005853}, {"text": "Details of Ford Motor Company\u2019s 2019 annual Meeting of Shareholders", "labels": -1.7647005853}, {"text": "Ford Motor Company to Share Details on Mobility Business at Citi\u2019s 2019 Car of the Future Symposium", "labels": -1.3539618365}, {"text": "Ford Motor Company Reports First Quarter 2019 Results", "labels": 8.549479147}, {"text": "Rivian Announces $500 Million Investment from Ford; Partnership to Deliver All-New Ford Battery Electric Vehicle", "labels": -0.531941062}, {"text": "Ford Motor Company, Autonomic, and Amazon Web Services Collaborate to Advance Vehicle Connectivity and Mobility Experiences", "labels": 2.1943755982}, {"text": "Mahindra and Ford Sign Agreement to Co-Develop a Midsize Sports Utility Vehicle", "labels": -0.2105508627}, {"text": "Bank of America Merrill Lynch 2019 Auto Summit", "labels": 1.5707059662}, {"text": "Europe First Quarter Sales Release", "labels": -1.2820423601}, {"text": "China First Quarter Sales Release", "labels": -1.5005540128}, {"text": "Details of Ford Motor Company Briefing on 2019 First Quarter Results", "labels": 1.0581980562}, {"text": "Ford Makes Leadership Changes as it Speeds Transformation", "labels": 1.7039597791}, {"text": "Ford Motor Company to Participate at Bank of America Merrill Lynch 2019 Auto Summit", "labels": 0.6430772013}, {"text": "Ford China Names Song Yang as President of National Distribution Services Division", "labels": 0.3257172396}, {"text": "Ford Motor Company Declares Dividend for Second Quarter 2019", "labels": 0.3257172396}, {"text": "First Quarter Sales Release", "labels": 0.4324229925}, {"text": "Ford China 2.0\u201d Combines \u201cBest of Ford, Best of China\u201d: Marks Acceleration of Company\u2019s Transformation in World\u2019s Largest Auto Market; Supports Global Redesign", "labels": 1.8398508483}, {"text": "Ford Motor Company Participates in J.P. Morgan 2019 Europe Autos Tour", "labels": 2.0044589345}, {"text": "Details of Ford Motor Company\u2019s First Quarter 2019 U.S. Sales Conference Call", "labels": 1.4806532207}, {"text": "Ford Announces Key Changes to Global Leadership Team; Tim Stone to Succeed Bob Shanks as CFO", "labels": 0.4683668418}, {"text": "Ford Adds 2nd North American Site to Build Battery Electrics; Michigan Workers to Make Its First Autonomous Vehicles", "labels": 0.2301490971}, {"text": "Ford Releases 2019 Preliminary Proxy Statement and Announces Virtual Annual Meeting Date", "labels": 1.750288004}, {"text": "Ford Investigating Process for U.S. Emissions Certification Concerning Road Load", "labels": -2.640637672}, {"text": "Ford Exits Heavy Truck Business in South America; Key Milestone in Global Redesign of Company", "labels": 4.5861272362}, {"text": "Ford Invests $1 Billion in Chicago Plants; Creates 500 New Jobs to Launch Explorer, Police Interceptor, Lincoln Aviator", "labels": -2.7413354335}, {"text": "Ford Motor Company Reports Fourth Quarter and Full Year 2018 Results", "labels": 0.6976668739}, {"text": "Ford Details Commitment to Global Redesign \u2013 Reshaping Overseas Operations and Strengthening North America", "labels": -3.8277723209}, {"text": "Volkswagen AG and Ford Motor Company Launch Global Alliance", "labels": -3.8277723209}, {"text": "Ford Europe December Sales", "labels": -8.8057619592}, {"text": "Volkswagen AG and Ford Motor Company to Provide Update on Alliance Talks on Tuesday Conference Call", "labels": 0.4524721218}, {"text": "Ford China December Sales", "labels": 2.4471542091}, {"text": "Ford to Strengthen European Competitive Position and Profitability; Sets Vision for the Future", "labels": 1.2471582261}, {"text": "Details of Ford Motor Company Briefing on 2018 Fourth Quarter and Full Year Results", "labels": 2.5374933435}, {"text": "Ford Motor Company to Present at Wolfe Research Global Auto Industry Conference and Deutsche Bank Global Auto Industry Conference", "labels": 3.1063301077}, {"text": "Ford Recommends Shareholders Reject Below-Market Mini-Tender Offer by Baker Mills", "labels": 1.3613889661}, {"text": "Ford U.S. December Sales", "labels": 1.3613889661}, {"text": "Details of Ford Motor Company\u2019s December 2018 U.S. Sales Conference Call", "labels": -3.4782567398}, {"text": "Ford China November Sales", "labels": -0.235321637}, {"text": "Ford Europe November Sales", "labels": -1.6470747659}, {"text": "Trevor Worthington Appointed Vice President, Global Product Development Operations & Vehicle Programs", "labels": -3.3957848094}, {"text": "Ford Announces Retirements in Treasury, Product Development, and Manufacturing", "labels": -3.4013436082}, {"text": "Ford U.S. November Sales", "labels": -5.7734346624}, {"text": "Details of Ford Motor Company\u2019s November 2018 U.S. Sales Conference Call", "labels": 0.425076624}, {"text": "Ford Europe October Sales", "labels": -4.9723809342}, {"text": "Ford, Walmart and Postmates Team Up for Self-Driving Goods Delivery", "labels": -3.4371718216}, {"text": "Ford Motor Company Announces 2019 Earnings Dates", "labels": 0.1048242025}, {"text": "Ford China October Sales", "labels": 0.1048242025}, {"text": "Let\u2019s Go for a Spin: Ford Buys Scooter Company to Provide Customers a First-Last Mile Solution", "labels": -2.1322022903}, {"text": "Ford Motor Company to Share Update on Operational Efficiency Improvements at Barclays Global Automotive Conference", "labels": -1.4799416658}, {"text": "Ford U.S. October Sales", "labels": -1.7057778005}, {"text": "Ford and Baidu Announce Joint Autonomous Vehicle Testing", "labels": -3.5521813873}, {"text": "Details of Ford Motor Company\u2019s October 2018 U.S. Sales Conference Call", "labels": 3.4482681332}, {"text": "Ford Delivers Third Quarter $1.0B Net Income; $1.7B Adj. EBIT; On Track to Achieve Full - Year Adjusted EPS Guidance in the Range of $1.30 to $1.50", "labels": 5.4504924455}, {"text": "Ford Reorganizes Asia Pacific Markets to Strengthen Performance; Establishes Stand-Alone China Business", "labels": -1.4670089014}, {"text": "Avis Budget Group and Ford Team Up to Connect Cars, Enhance Car Rental Experience", "labels": -1.4670089014}, {"text": "Built Ford Proud: New Ad Campaign Kicks Off Onslaught of New Vehicles Headed to Ford Dealers", "labels": -1.4670089014}, {"text": "Ford Europe September Sales", "labels": -2.8235383223}, {"text": "Details of Ford Motor Company Briefing on 2018 Third Quarter Results", "labels": 1.4772501146}, {"text": "Ford China September Sales", "labels": -1.5890813941}, {"text": "Ford Motor Company Declares Dividend for Fourth Quarter 2018", "labels": -2.0833407113}, {"text": "Ford U.S. September Sales", "labels": -1.5334208568}, {"text": "Ford Smart Mobility and Zotye to Offer Chinese Ride-Hailing Operators Leasing and Fleet Solutions Under New JV", "labels": -0.5405473673}, {"text": "Ford Transit Custom Extends Leadership with Unique PHEV Model and Upgraded Features; Transit Connect Sport Debuts", "labels": 2.4540013997}, {"text": "Smartest and Most Productive Ford Transit Makes Global Debut at Hannover CV Show", "labels": 2.4540013997}, {"text": "Ford Announces New Ford Telematics and Ford Data Services Solutions for Fleet Customers", "labels": 2.4540013997}, {"text": "Ford Europe August Sales", "labels": 2.4540013997}, {"text": "Fixed Income Investor Presentation", "labels": 1.4613967145}, {"text": "Ford Tests C-V2X Technology for the First Time on Public Roads in China, Vehicles \u201cSpeak\u201d to the World Around Them", "labels": 1.4613967145}, {"text": "Ford China August Sales", "labels": -0.3198532439}, {"text": "Ford Motor Company to Participate in Morgan Stanley\u2019s Sixth Annual Laguna Conference; Company to Share Details on Mobility Business; How a 115 Year Old Auto Company is Thinking Like A Startup", "labels": -0.4241966456}, {"text": "Ford U.S. August Sales", "labels": -0.4215153722}, {"text": "A Matter of Trust: Ford\u2019s Approach to Developing Self-Driving Vehicles", "labels": 0.5235323901}, {"text": "Ford Europe July Sales", "labels": 0.525772951}, {"text": "Ford-Owned Autonomic Partners with Alibaba Cloud to Deliver Enhanced Mobility Experiences for Chinese Consumers; Partnership Marks Launch of Autonomic in China", "labels": -0.6349236502}, {"text": "Ford China July Sales", "labels": -4.7568752541}, {"text": "Ford Drives into the Heart of China with New Midsize SUV; All-New Territory Brings Affordability, Tech to New Buyers", "labels": -1.4127400088}, {"text": "Ford Motor Company to Participate in J.P. Morgan\u2019s Auto Conference 2018", "labels": 1.3944398162}, {"text": "Ford U.S. July Sales", "labels": -1.4112982173}, {"text": "Ford Delivers Second Quarter $1.1B Net Income, $1.7B Adj. EBIT; North America Building Momentum; Restructuring Opportunities Identified Globally", "labels": -4.3478018179}, {"text": "Ford Creates \u2018Ford Autonomous Vehicles LLC\u2019; Strengthens Global Organization to Accelerate Progress, Improve Fitness", "labels": 0.0950513929}, {"text": "Ford Ranger Keeps Rolling, Delivers Record First-Half Sales in Asia Pacific", "labels": -0.828758443}, {"text": "Details of Ford Motor Company Briefing on 2018 Second Quarter Results", "labels": -0.828758443}, {"text": "Ford Europe June Sales", "labels": -0.828758443}, {"text": "Ford Motor Company Declares Dividend for Third Quarter 2018", "labels": -1.0929330606}, {"text": "Ford China June Sales", "labels": 1.4285589014}, {"text": "Ford U.S. June Sales", "labels": -0.3616451357}, {"text": "Ford Announces Government Affairs Personnel Change", "labels": -1.9819857261}, {"text": "Ford China, Baidu Sign Strategic Collaboration LOI, Agree to Explore Opportunities in Multiple Areas to Enrich Customer Experience", "labels": -2.304957361}, {"text": "Details of Ford Motor Company\u2019s June 2018 U.S. Sales Conference Call", "labels": -2.304957361}, {"text": "Volkswagen AG, Ford to Explore Strategic Alliance to Extend Capabilities, Strengthen Competitiveness, Better Serve Customers", "labels": 0.421257652}, {"text": "Ford Acquires Iconic Michigan Central Station as Centerpiece of New Detroit Campus to Usher in Ford\u2019s Smart, Connected Future", "labels": 0.421257652}, {"text": "Ford to Participate in Morgan Stanley\u2019s 5G / AV Summit", "labels": 0.5887119245}, {"text": "Ford Motor Company Acquires Iconic Michigan Central Station", "labels": 0.5887119245}, {"text": "Ford\u2019s Automatic Transmission Facility in Bordeaux, France, Starts Information and Consultation Process; Priority Remains to Find a New Owner", "labels": 1.0743582965}, {"text": "Lincoln Names New President for Asia Pacific and China", "labels": 1.0743582965}, {"text": "Manage Your Fleet by Connecting to Better Data with Ford Commercial Solutions", "labels": 1.0743582965}, {"text": "F-Series Up 11 Percent for Best May Results Since 2000; New Expedition Retail Sales Jump 42 Percent, While Mustang Gains 11 Percent; New Navigator Sales Post Triple-Digit Gain", "labels": 0.5962585382}, {"text": "Details of Ford Motor Company\u2019s May 2018 U.S. Sales Conference Call", "labels": -1.0489655113}, {"text": "It\u2019s Not All About Millennials; Gen Z Drivers Help Make Subcompact Utility the Fastest-Growing Auto Segment", "labels": -1.2237831861}, {"text": "Ford to Participate in RBC Auto Tech Conference", "labels": 0.8680557144}, {"text": "Ford Restarting F-150, Super Duty Production Ahead of Schedule after Fire at Magnesium Parts Supplier", "labels": 2.1815108213}, {"text": "Ford Motor Company to Provide Update on Meridian Magnesium Products of America Fire, Parts Issue", "labels": 2.1815108213}, {"text": "Fiesta Claims Top Spot in Segment and SUVs Grow 32% on Record EcoSport, Kuga Sales", "labels": 2.6315675145}, {"text": "Ford Progresses Steadily Toward Its China 2025 Targets By Introducing The First Group Of New Products Into The Chinese Market In April", "labels": -0.3577760037}, {"text": "Ford Takes Steps To Ensure Supply Continuity And Availability Of Products For Customers Despite Fire At Parts Supplier", "labels": -1.45819e-05}, {"text": "Ford Motor Company to Provide Update on Response to Meridian Magnesium Products of America Fire, Parts Issue", "labels": -1.45819e-05}, {"text": "Ford to Participate in the Evercore ISI Global Auto/Auto-Tech Conference", "labels": -1.45819e-05}, {"text": "2018 Annual Meeting of Shareholders", "labels": 1.6725453997}, {"text": "Ford Represented by Autonomous Vehicle Development Partner Argo AI at Citi\u2019s 2018 Car of the Future Symposium", "labels": -0.5357147935}, {"text": "Ford Smart Mobility and Zotye to Form EV Solutions JV for China\u2019s Fast Growing Ride-Hailing Market", "labels": -0.5357147935}, {"text": "F-Series Posts Best April Results in 18 Years While New Expedition Climbs 26 Percent At Retail; New Navigator Retail Sales Jump 135 Percent", "labels": -0.3568375563}, {"text": "Ford Delivers First Quarter $1.7B Net Income, $2.2B Adj. EBIT; Fitness Actions Improve 2020 Outlook", "labels": 4.1119872795}, {"text": "Details of Ford Motor Company\u2019s April 2018 U.S. Sales Conference Call", "labels": 0.5400238396}, {"text": "Ford Launches Single Distribution Channel in China; Names New Leaders for China, Middle East & Africa, and Marketing", "labels": 0.5400238396}, {"text": "Ford Launches GoRide Service to Get Patients to Their Medical Appointments", "labels": -2.4574711787}, {"text": "Ford Rises to No. 2 Brand in Europe; Record Kuga and EcoSport Sales Power 15% SUV Growth in 1Q", "labels": -2.4574711787}, {"text": "Ford Repositions Business In China by Offering Customers a More Comprehensive Lineup - Lincoln Strong Sales Momentum", "labels": 0.2636039685}, {"text": "Details of Ford Motor Company Briefing on 2018 First Quarter Results", "labels": -0.6189067652}, {"text": "Ford Motor Company Declares Dividend for Second Quarter 2018", "labels": -0.0874955172}, {"text": "Ford SUVs Hit Record Sales Month \u2013 Retail Up; F-Series Posts Best Results Since 2000; All-New Expedition Retail Up 46 Percent, While Navigator Sees Triple-Digit Retail Gain", "labels": 2.8243671165}, {"text": "Ford Releases 2018 Proxy Statement, Announces Virtual Annual Meeting Date and Issues 2017 Annual Report", "labels": -0.644601817}, {"text": "Details of Ford Motor Company\u2019s March 2018 U.S. Sales Conference Call", "labels": 0.0920735193}, {"text": "Mahindra and Ford Sign MoUs to Co-Develop Midsize and Compact SUV, Electric Vehicle and Connected Car Solutions", "labels": -4.1666560423}, {"text": "Ford Readies North America\u2019s Freshest Lineup by 2020 with Onslaught of Connected New Trucks, SUVs and Hybrids", "labels": 0.896858669}, {"text": "Ford Co-Pilot360\u2122: Most Advanced Suite of Standard Driver-Assist Technologies Includes Automatic Emergency Braking", "labels": 0.896858669}, {"text": "Ford Suvs Power 8% Sales Growth In Europe; Ford Fiesta, Transit, Ranger Lead Segments", "labels": 1.6333856449}, {"text": "Ford Repositions Business In China February Sales Decline", "labels": 1.6651329301}, {"text": "Fixed Income Investor Presentation First Quarter 2018", "labels": -2.4038678691}, {"text": "Ford F-Series Marks Best February Results in 18 Years While All-New Ford Expedition Posts 41 Percent Retail Sales Increase; Lincoln Navigator Posts Gains In All Regions", "labels": -2.4038678691}, {"text": "We\u2019re Going to Miami: The First Proving Ground for Our Self-Driving Service", "labels": -3.0160288299}, {"text": "Ford Appoints Senior Leaders; Galhotra to Lead North America, Falotico to Head Lincoln, Marketing; McClelland to lead Ford Credit", "labels": 0.9345915093}, {"text": "Ford of Europe Passenger and Commercial Vehicle Sales Up, Remains Europe\u2019s No. 1 Commercial Vehicle Brand", "labels": 1.9516778394}, {"text": "Ford Increasing Production of All-New Lincoln Navigator, Ford Expedition to Meet Greater-Than-Anticipated Customer Demand", "labels": -0.7554653953}, {"text": "Ford Sells Nearly 76,000 Vehicles in China in January", "labels": 1.2149795157}, {"text": "Ford F-Series Posts Best January Sales Results Since 2004; New Lincoln Navigator Has Strongest Sales in a Decade; New Ford Expedition Sales Up in All Regions", "labels": -2.2409042915}, {"text": "Chariot Shuttle Service Comes to Europe, First Stop London with Four Routes Designed to Ease Travel for Commuters", "labels": -2.2409042915}, {"text": "Ford Credit Names Brian Schaaf as Chief Financial Officer", "labels": -2.4034703798}, {"text": "Details of Ford Motor Company\u2019s January 2018 U.S. Sales Conference Call", "labels": -2.4034703798}, {"text": "Ford Realigns Mobility Group; Acquiring Autonomic, TransLoc to Accelerate Growth", "labels": -2.4034703798}, {"text": "Ford Motor Company Reports Fourth Quarter and Full Year 2017 Results; Revenue Up, Net Income Higher, Adjusted Pre-Tax Profit Lower", "labels": -3.7164808943}, {"text": "Ford Details Plans to Improve Fitness, Refocus Model Lineup and Accelerate Introduction of Smart Vehicles and Services", "labels": -9.2775379027}, {"text": "All-New Lincoln Navigator Named North American Truck of the Year", "labels": -9.2775379027}, {"text": "Details of Ford Motor Company Briefing on 2017 Fourth Quarter and Full-Year Results", "labels": 2.27017e-05}, {"text": "Ford is Europe\u2019s CV Leader for Third Year Running", "labels": 1.5872631286}, {"text": "Ford Sold Nearly 1,200,000 Vehicles in China in 2017", "labels": -1.1512003293}, {"text": "First-Ever F-150 Diesel Offers Best-in-Class Torque, Towing, Targeted EPA-Est. 30 MPG; You\u2019re Welcome Truck Fans!", "labels": -0.9938902564}, {"text": "Ford Motor Company to Present at Deutsche Bank Global Auto Industry Conference", "labels": 2.3112359055}, {"text": "Ford SUVs Post Record Sales While F-Series Marks 41 Years as America\u2019s Best-Selling Pickup", "labels": 2.3112359055}, {"text": "Details of Ford Motor Company\u2019s December 2017 U.S. Sales Conference Call", "labels": -0.7126172772}, {"text": "Ford Fiesta UK and Germany\u2019s No.1 Small Car in November; Total Ford Vehicle Sales Up 4.0 Percent", "labels": -1.2038384853}, {"text": "Ford Sells Nearly 118,000 Vehicles in China in November Lincoln Sets Another Monthly Sales Record in China", "labels": 0.2381021991}, {"text": "Ford Motor Company Announces 2018 Earnings Dates", "labels": 0.3974626651}, {"text": "Ford Intensifies China Growth Plan: More Smart Vehicles, Expanded Local Production, Leaner Business Structure", "labels": -0.3230979765}, {"text": "Ford Sales up 6.7 Percent in November; F-Series Achieves Best Sales in 16 Years", "labels": 0.0791554239}, {"text": "Details of Ford Motor Company\u2019s November 2017 U.S. Sales Conference Call", "labels": -9.3855e-06}, {"text": "Ford Names John Veihmeyer to Board of Directors", "labels": 0.0832606695}, {"text": "Ford Europe SUV Sales Up 28.5 Percent in October; Total Vehicle Sales Grow 5.4 Percent", "labels": -0.8333381433}, {"text": "Ford to Participate in Barclays 2017 Global Automotive Conference", "labels": -0.8305592085}, {"text": "Ford and Zotye Sign Definitive JV Agreement in China to Meet Growing Demand for All-Electric Vehicles", "labels": -0.8305592085}, {"text": "Ford to Participate in Goldman Sachs Industrials Conference 2017", "labels": -2.4046544522}, {"text": "Ford Sells Nearly 106,000 Vehicles in China in October; Best October Sales for Lincoln and JMC", "labels": -2.4046544522}, {"text": "Ford Posts 6.2 Percent October Sales Gain, Marks Best F-Series Sales in 13 Years; Ford Brand SUV Sales Up 4.6 Percent, While Strong Customer Demand Lifts Lincoln SUV Sales 13.1 Percent", "labels": 0.1610102082}, {"text": "Ford Motor Company Third Quarter Results: Improved Growth, Profitability and Cash Flow, Supported by Fitness Actions", "labels": -1.1608572025}, {"text": "Details of Ford Motor Company\u2019s October 2017 U.S. Sales Conference Call", "labels": 0.9779932736}, {"text": "Ford of Europe Customer Order Bank at Record Level As New Fiesta Production Ramp-Up Continues", "labels": 0.4950645053}, {"text": "Ford Sells Nearly 113,000 Vehicles in China in September Lincoln Sales Up 79 Percent Year Over Year", "labels": -2.074708667}, {"text": "Ford Motor Company Declares Dividend for Fourth Quarter 2017", "labels": -2.074708667}, {"text": "Details of Ford Motor Company Briefing on 2017 Third Quarter Results", "labels": -2.074708667}, {"text": "Ford\u2019s Future: Evolving to Become Most Trusted Mobility Company, Designing Smart Vehicles for a Smart World", "labels": -0.1625899307}, {"text": "Ford Sales up 8.7 Percent in September; F-Series Trucks up 21.4 Percent", "labels": -0.1625899307}, {"text": "Ford Hires Lynn Antipas Tyson To Lead Investor Relations", "labels": 2.7552496668}, {"text": "How Ford and Lyft Are Teaming Up to Take Self-Driving Cars Mainstream", "labels": -0.1672028897}, {"text": "Ford Motor Company to Host CEO Strategic Update", "labels": -2.09445e-05}, {"text": "Mahindra and Ford to Explore Strategic Cooperation to Drive Profitable Growth in India and other Emerging Markets", "labels": 0.767931287}, {"text": "Ford Europe SUV Sales Grow By 21.3% in August; Total Sales Up 2.2% in First Eight Months of 2017", "labels": 0.7738579662}, {"text": "Ford China sales down one percent in August; big gains for Lincoln, JMC, Ford Mondeo and Ford EcoSport", "labels": -1.4084382568}, {"text": "Ford F-Series Pickup Truck Sales Rise 15.0 Percent in August", "labels": 1.5845272812}, {"text": "Ford Provides More Than $3.5M To Hurricane Relief; Offers 'Texas is Family' Package To Aid Victims", "labels": 1.5845272812}, {"text": "Ford Reports its Environmental Progress Across Business", "labels": 0.1853565713}, {"text": "Ford Motor Company to Host CEO Strategic Update", "labels": 0.6469719013}, {"text": "Ford Names New Chairman and CEO for Ford China; New Vice President of Powertrain Engineering", "labels": 0.9337103745}, {"text": "Ford Names Sarah-Jayne Williams As Its First Director of Smart Mobility In Europe", "labels": 0.9337103745}, {"text": "Ford Furthers Global Electrification Expansion; Signs MOU in China with Zotye Auto to Explore New All-Electric Vehicle JV", "labels": 0.9336928837}, {"text": "Ford of Europe Sales Up 2.6% in First Seven Months of 2017; CV Sales Up Nearly 10%", "labels": 0.1844960265}, {"text": "Ford Sells More Than 84,000 Vehicles in China in July; Lincoln Sales Up 68 Percent Year Over Year", "labels": 0.1831815141}, {"text": "Ford Overall Sales Down 7.5 Percent in July, Driven Largely by Lower Fleet Sales", "labels": -0.9999867587}, {"text": "Ford Delivers Second Quarter Net Income of $2.0B; $2.5B Adjusted Pre-Tax Profit; Total Company Revenue of $39.9B", "labels": 0.3577786236}, {"text": "Ford of Europe Sales Up 3.7 Percent in First Half; SUV and CV Sales Continue to Grow in June", "labels": 0.7666010747}, {"text": "Ford Motor Company Declares Dividend for Third Quarter 2017", "labels": 1.8835593206}, {"text": "Ford Achieves June Sales Record in China; Up 15 percent Year Over Year", "labels": -0.2664095707}, {"text": "Ford Motor Company\u2019s June 2017 U.S. Sales", "labels": -1.610008035}, {"text": "Ford Invests in Ky. Plant to Build New Expedition, Navigator; Smart, Spacious New Focus for N.A. to be Globally Sourced", "labels": -1.539827559}, {"text": "Ford Sales in Europe Rise 6% in May; SUVs Up 17% and Commercial Vehicles Up 16%", "labels": -0.8912895391}, {"text": "Lincoln Voted Most Satisfying Premium Brand Among Owners in AutoPacific Survey", "labels": -0.540544026}, {"text": "Best Start Ever For Ford Escape and Lincoln MKC SalesDrives More Production At Louisville SUV Plant", "labels": -0.540544026}, {"text": "Ford of China Sells Nearly 88,000 Vehicles in May; Best-Ever May Sales for JMC, Lincoln", "labels": -0.540544026}, {"text": "Ford Motor Company\u2019s May 2017 U.S. Retail Sales", "labels": 0.8810377881}, {"text": "Details of Ford Motor Company\u2019s May 2017 U.S. Sales Conference Call", "labels": 2.0758127772}, {"text": "Ford Announces Global Leadership Team Appointments", "labels": -0.2744706001}, {"text": "Ford Motor Company News Conference", "labels": -0.5429879301}, {"text": "Ford Appoints Jim Hackett as CEO to Strengthen Operations, Transform for Future; Farley, Hinrichs, Klevorn Take on New Roles", "labels": -0.5429879301}, {"text": "Ford of Europe SUV Sales Grow 17% in April; Brand Builds Market Share in 3 Key Markets", "labels": -0.1828195478}, {"text": "Details of Ford Motor Company\u2019s 2017 Annual Meeting of Shareholders", "labels": 1.078168797}, {"text": "Ford F-Series Surpasses the 70,000 Mark; Ford Brand SUVs Set Record; Company\u2019s Overall U.S. Sales Down 7.2 Percent", "labels": -2.0776992297}, {"text": "Ford Delivers First Quarter Revenue of $39.1B; $1.6B Net Income; $2.2B Adjusted Pre-Tax Profit", "labels": -1.6564915079}, {"text": "Details of Ford Motor Company\u2019s April 2017 U.S. Sales Conference Call", "labels": 1.1206972517}, {"text": "Details of Ford Motor Company Briefing on 2017 First Quarter Results", "labels": 0.5319239471}, {"text": "Ford Motor Company Declares Dividend for Second Quarter 2017", "labels": 0.1772913644}, {"text": "Ford Continues Drive to Be Global Electric Vehicle Leader, Reveals Industry\u2019s First Pursuit-Rated Hybrid Police Car", "labels": 0.1772913644}, {"text": "Ford Releases 2016 Annual Report, 2017 Proxy Statement; Announces Virtual Annual Meeting Details", "labels": -1.9230639541}, {"text": "Ford Investing $1.2 Billion in Three Michigan Facilities, Further Bolstering Leadership in Trucks, SUVs, Mobility", "labels": 1.4554849932}, {"text": "Corporate Responsibility Puts Ford Among World\u2019s Most Ethical Companies", "labels": -0.0796781384}, {"text": "Ford names Lynn Vojvodich to Board of Directors", "labels": -0.0797622333}, {"text": "Ford invests in Argo AI, a new artificial intelligence company, in drive for autonomous vehicle leadership", "labels": 0.9554222241}, {"text": "New Ford Commercial Center program keeps fleet and commercial customers on the road", "labels": -1.3843620533}, {"text": "London trials new plug-in hybrid vans that could help deliver cleaner air; supports push for EV leadership", "labels": -1.1372912436}, {"text": "Ford to close 2016 strong; declares regular and supplemental dividends; highlights progress in auto and mobility expansion", "labels": -0.2367676894}, {"text": "Ford reveals new F-150; Bronco is back; all-new Ranger coming to North America; company presents vision for City of Tomorrow", "labels": 0.4669156962}, {"text": "Unprecedented: Ford F-Series achieves 40 consecutive years as America's best-selling truck", "labels": -3.3944e-05}, {"text": "Alexa in the car: Ford, Amazon to provide access to shop, search and control smart home features on the road", "labels": -3.3944e-05}, {"text": "Ford and Toyota establish SmartDeviceLink Consortium to accelerate industry- driven standard for in-vehicle apps", "labels": -3.3944e-05}, {"text": "Ford adding electrified F-150, Mustang, Transit by 2020 in major EV push; Expanded U.S. plant to add 700 jobs to make EVs, autonomous cars", "labels": 7.3652384075}, {"text": "Ford debuts Next-Generation Fusion Hybrid autonomous development vehicle; Car to first appear at CES and North American International Auto Show in January", "labels": -1.1447122493}, {"text": "Ford announces senior leadership team changes", "labels": -9.064e-07}, {"text": "Ford tops industry for US patents granted in 2016", "labels": -1.4040816262}, {"text": "Ford Motor Company announces 2017 Earnings dates", "labels": 1.9904476127}, {"text": "BMW Group, Daimler AG, Ford Motor Company and Volkswagen Group with Audi and Porsche plan a joint venture for ultra-fast, high-power charging along major highways in Europe", "labels": 0.2508190188}, {"text": "Mark Fields: Ford focused on creating the City of Tomorrow", "labels": -0.5000104373}, {"text": "2017 Ford Super Duty named Motor Trend Truck of the Year", "labels": -1.9102749745}, {"text": "Global Leadership: How Ford Transit became the best-selling cargo van nameplate on Earth", "labels": 0.0}, {"text": "Ford Motor Company declares dividend for Fourth Quarter 2016", "labels": 0.0}, {"text": "Ford, University of Michigan accelerate autonomous vehicle research with Ford researchers in-house at new robotics lab on U-M campus", "labels": -0.2477348266}, {"text": "Ford outlines growth plan: Fortify profit pillars; Transform underperforming operations; Invest in emerging opportunities to be a leader in electrification, autonomy and mobility", "labels": -0.578023416}, {"text": "Ford partnering with global cities on new transportation; Chariot Shuttle to beacquired, Ford GoBike to launch in San Francisco", "labels": 0.7086446038}, {"text": "Ford names John S. Weinberg to Board of Directors", "labels": -0.9693092589}, {"text": "Ford Credit chairman and CEO Bernard Silverstone to retire after 37 years; Joy Falotico named as successor", "labels": 1.0317350172}, {"text": "Ford targets fully autonomous vehicle for ride sharing in 2021; Invests in new tech companies, doubles Silicon Valley team", "labels": 0.3228712812}, {"text": "Ford announces senior leadership team changes", "labels": 0.659334809}, {"text": "Ford Motor Company declares dividend for Third Quarter 2016", "labels": 1.47885e-05}, {"text": "Ford Sustainability Report unveils pilot program in South Africa to deliver healthcare, education, improve lives", "labels": 1.6006140314}, {"text": "Ford leaders honored among 100 Most Influential Women in Michigan", "labels": 2.2421296422}, {"text": "Ford invests in Pivotal to accelerate cloud-based software development; New labs drive Ford Smart Mobility innovation", "labels": 0.6696579734}, {"text": "Fearless, ferocious and fun; Ford introduces F-150 Raptor SuperCrew to China", "labels": -0.3681845824}, {"text": "Ford Smart Mobility LLC established to develop, invest in mobility services; Jim Hackett named subsidiary chairman", "labels": 0.0753778602}, {"text": "First Solar, Inc. to Announce First Quarter 2023 Financial Results on April 27, 2023", "labels": 3.3518989321}, {"text": "EDP Renewables Places Multi-Year Order for 1.8 GW of First Solar Modules", "labels": -0.5195424749}, {"text": "Indian Government Awards Production Linked Incentives to First Solar\u2019s India Manufacturing Facility", "labels": 0.5437856845}, {"text": "First Solar, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results and 2023 Guidance", "labels": 15.0449653948}, {"text": "Lightsource bp Places Multi-Year Order for 4 GW of First Solar Modules", "labels": 15.0449653948}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance on February 28, 2023", "labels": 6.0222817626}, {"text": "First Solar Completes Sale of 141 MW Luz del Norte Power Plant to Toesca", "labels": 3.9347334712}, {"text": "National Grid Renewables Orders 1.6 GW of First Solar Modules", "labels": -2.2053121799}, {"text": "Intersect Power Procures 4.9 GW for 2025-2029 Delivery, Increasing its Total 2022 Orders for First Solar Module Technology to 7.3 GW", "labels": 6.0624284115}, {"text": "First Solar Selects Alabama for Fourth American Manufacturing Facility", "labels": 4.5702469884}, {"text": "First Solar to Accelerate American Thin Film PV Innovation with $270 Million Investment in Dedicated R&D Innovation Center", "labels": 0.7085267614}, {"text": "First Solar, Inc. Announces Third Quarter 2022 Financial Results", "labels": 0.7085267614}, {"text": "Arevon Secures 2 GW Supply of Responsibly Produced American Solar Modules from First Solar", "labels": 0.7085267614}, {"text": "Swift Current Energy, First Solar in Agreement for 2 GW of American Solar Modules", "labels": 0.6479576858}, {"text": "First Solar, Inc. to Announce Third Quarter 2022 Financial Results on October 27, 2022", "labels": 1.7428676356}, {"text": "CORRECTION -- First Solar Completes Sale of Japan Operations & Maintenance Platform to PAG Real Assets", "labels": -6.8983801142}, {"text": "First Solar Completes Sale of Japan Project Development Platform to PAG Real Assets", "labels": -6.8983801142}, {"text": "Azure Power Signs Agreement for 600 MW of First Solar\u2019s High-Performance Modules", "labels": -1.3577357976}, {"text": "First Solar to Invest up to $1.2 Billion in Scaling Production of American-Made Responsible Solar by 4.4 GW", "labels": 1.9992183385}, {"text": "First Solar, Inc. Announces Second Quarter 2022 Financial Results", "labels": 9.6198458119}, {"text": "Intersect Power Orders 2.4 GW of First Solar\u2019s High-Performance Modules", "labels": 9.6198458119}, {"text": "First Solar Issues 2022 Sustainability Report Showcasing Continued Progress on Environmental, Social, and Governance Metrics", "labels": 3.8822345935}, {"text": "First Solar, Akuo in 500MW Global Supply Agreement for Advanced Thin Film Modules", "labels": 1.7398379565}, {"text": "Solarvest Orders 93 MW of First Solar Modules for Malaysian Projects", "labels": -1.0883054903}, {"text": "First Solar, Inc. to Announce Second Quarter 2022 Financial Results on July 28, 2022", "labels": -5.0406022441}, {"text": "First Solar Completes Sale of Japan Project Development Platform to PAG Real Assets", "labels": -1.0731545423}, {"text": "National Grid Renewables Orders 2 GW of Responsibly Produced First Solar Modules", "labels": 2.1692545307}, {"text": "Responsible Solar: First Solar\u2019s Ohio Manufacturing Complex Achieves Top Rating in RBA\u2019s Validated Assessment Program Audit", "labels": -4.3088239782}, {"text": "Scout Clean Energy Orders 378 MW of Responsibly Produced First Solar Modules", "labels": 0.9791912235}, {"text": "First Solar Signs Definitive Agreements to Sell Japan Project Development and O&M Platforms to PAG Real Assets", "labels": 2.5382260072}, {"text": "First Solar, Inc. Announces First Quarter 2022 Financial Results", "labels": 0.4381756815}, {"text": "First Solar, Inc. to Announce First Quarter 2022 Financial Results on April 28, 2022", "labels": -1.3729902764}, {"text": "Nevada Gold Mines Partners with First Solar Technology to Decarbonize Energy Supply", "labels": -0.908856963}, {"text": "Silicon Ranch and First Solar expand partnership with 4 GW supply agreement", "labels": -0.2383970498}, {"text": "Origis Energy Builds on Long-Term Alliance with Order for 750 MW of First Solar Modules", "labels": 3.0973413344}, {"text": "First Solar, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Guidance", "labels": -8.1427073209}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance on March 1, 2022", "labels": 2.1905954164}, {"text": "Swift Current Energy Selects First Solar\u2019s Thin Film PV Technology for 1.2GW Order", "labels": -2.9390538907}, {"text": "Lightsource bp and bp Sign Multi-Year Agreement for up to 5.4GW of First Solar Modules", "labels": -5.6841553127}, {"text": "First Solar, Inc. Announces Third Quarter 2021 Financial Results", "labels": 0.0515841801}, {"text": "First Solar, Inc. to Announce Third Quarter 2021 Financial Results on November 4, 2021", "labels": 1.9393687958}, {"text": "First Solar Breaks Ground on new $680m, 3.3 GW Ohio Manufacturing Facility", "labels": -2.3278166254}, {"text": "First Solar Commits to Science-Based Emissions Targets, Net Zero Emissions by 2050", "labels": 0.8799156186}, {"text": "First Solar, Inc. Announces Second Quarter 2021 Financial Results", "labels": 2.0920537338}, {"text": "First Solar Intends to Expand Global Manufacturing Footprint with New 3.3 GW Facility in India", "labels": 2.0920537338}, {"text": "First Solar Appoints Anita Marangoly George to Board of Directors", "labels": 1.6569941238}, {"text": "First Solar, Inc. to Announce Second Quarter 2021 Financial Results on July 29, 2021", "labels": -6.635526479}, {"text": "Responsible Solar: First Solar Invests $11 Million in Underserved American Communities", "labels": 3.587637413}, {"text": "First Solar to Invest $680m in Expanding American Solar Manufacturing Capacity by 3.3 GW", "labels": 3.6815908312}, {"text": "First Solar Joins Responsible Business Alliance", "labels": -2.7807407979}, {"text": "First Solar, Inc. Announces First Quarter 2021 Financial Results", "labels": -17.3004025545}, {"text": "First Solar, Inc. to Announce First Quarter 2021 Financial Results on April 29, 2021", "labels": 0.6863027901}, {"text": "First Solar Series 6 CuRe has Industry\u2019s Lowest Warranted Degradation Rate", "labels": -0.7509277963}, {"text": "First Solar Completes Sale of US Development Platform to Leeward", "labels": -6.8214605168}, {"text": "First Solar Completes Sale of North American O&M Business to NovaSource", "labels": -2.0081203678}, {"text": "First Solar Appoints Kathryn A. Hollister to Board of Directors", "labels": 4.032754464}, {"text": "Intersect Power Chooses Long-Term Reliability and Performance; Orders up to 2.4 GW of First Solar Series 6", "labels": 5.3952195359}, {"text": "First Solar, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results and 2021 Guidance", "labels": -7.0229605988}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full Year 2020 Financial Results and 2021 Financial Guidance on February 25, 2021", "labels": 0.0297754633}, {"text": "First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward", "labels": -3.5246869099}, {"text": "First Solar, Inc. Announces Third Quarter 2020 Financial Results", "labels": 10.9205820155}, {"text": "Vistra Corp. Buys American, Selects First Solar PV Modules for Texas Projects", "labels": -3.4119777892}, {"text": "Verified Sustainable: First Solar Series 6 is World\u2019s First EPEAT-Rated PV Module", "labels": -2.2848868628}, {"text": "First Solar, Inc. to Announce Third Quarter 2020 Financial Results on October 27, 2020", "labels": 5.6139566521}, {"text": "JP Energie Environnement Selects Lowest Carbon First Solar Modules for Labarde Project", "labels": -1.2561182175}, {"text": "First Solar Announces Pricing of Secondary Offering of Common Stock", "labels": -6.9311721122}, {"text": "First Solar Announces Secondary Offering of Common Stock", "labels": -15.2812480927}, {"text": "First Solar Power Plant in Chile is World\u2019s First to Deliver Grid Services", "labels": -1.1336086162}, {"text": "First Solar Signs Definitive Agreement to Sell North American O&M Business to NovaSource", "labels": 11.0654047183}, {"text": "First Solar, Inc. Announces Second Quarter 2020 Financial Results", "labels": 11.0654047183}, {"text": "First Solar Commits to Powering 100% of Global Operations with Renewable Energy by 2028", "labels": 11.0654047183}, {"text": "First Solar Announces COO Tymen deJong to Retire and Senior Leadership Changes", "labels": -0.5695144862}, {"text": "First Solar, Inc. to Announce Second Quarter 2020 Financial Results on August 6, 2020", "labels": 0.4182727191}, {"text": "Goldman Sachs Renewable Power LLC Acquires 123MW Project from First Solar", "labels": 0.4182727191}, {"text": "First Solar to Support Dow Gulf Coast Operations in Texas with Lowest Carbon Solar", "labels": 0.9561743724}, {"text": "First Solar, Inc. Announces First Quarter 2020 Financial Results", "labels": 1.2681190562}, {"text": "Geronimo Energy, First Solar Sign 415MW Series 6 Framework Supply Agreement", "labels": 2.4182669504}, {"text": "First Solar, Inc. to Announce First Quarter 2020 Financial Results on May 7, 2020", "labels": -5.9790427909}, {"text": "First Solar Signs Solar, Storage PPAs with California\u2019s Monterey Bay Community Power & Silicon Valley Clean Energy", "labels": 0.1739987463}, {"text": "COVID-19: First Solar Manufacturing Operations Update", "labels": 0.3929255836}, {"text": "Longroad Acquirer of Four California Projects from First Solar", "labels": -3.7774304868}, {"text": "First Solar, Inc. Announces Full-Year 2020 Guidance", "labels": -15.1610953663}, {"text": "First Solar, Inc. Announces Fourth Quarter & Full Year 2019 Financial Results", "labels": -15.1610953663}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results and 2020 Financial Guidance on February 20, 2020", "labels": -1.9634056652}, {"text": "First Solar, Inc. Reaches Agreement to Settle Pending Class Action Lawsuit", "labels": 1.1646371426}, {"text": "EDP Renewables, ConnectGen Complete Acquisition of Three First Solar Projects", "labels": 0.0531113349}, {"text": "Caroline Stockdale Joins First Solar as Chief Human Resources Officer", "labels": -1.7152614642}, {"text": "First Solar, Inc. Announces Third Quarter 2019 Financial Results", "labels": -5.6019763986}, {"text": "First Solar Becomes Largest PV Module Manufacturer in the Western Hemisphere", "labels": -5.6019763986}, {"text": "D. E. Shaw Renewable Investments Acquires Utah Projects from First Solar", "labels": -0.0178961108}, {"text": "First Solar, Inc. to Announce Third Quarter 2019 Financial Results on October 24, 2019", "labels": 0.2716434672}, {"text": "Intersect Power Selects First Solar for 1.7GW Multiyear Module Contract", "labels": -1.0283196082}, {"text": "On 20th Anniversary, First Solar Sets 25GW Milestone for Cleaner, Thin Film Solar", "labels": -2.6420214399}, {"text": "First Solar Evolves U.S. EPC Delivery Approach with Third-Party Execution Model", "labels": 1.049470735}, {"text": "First Solar, Inc. Announces Second Quarter 2019 Financial Results", "labels": 1.6659172386}, {"text": "First Solar, Microsoft Team-Up to Power Arizona Datacenters with Cleaner Solar", "labels": -1.2715145325}, {"text": "First Solar, Inc. to Announce Second Quarter 2019 Financial Results on August 1, 2019", "labels": -1.5379883907}, {"text": "First Solar, Rocky Mountain Power to Deliver Clean Energy for Facebook Data Center", "labels": -0.5168835843}, {"text": "Capital Dynamics, First Solar Celebrate Commissioning of the 280MWac California Flats Solar Project", "labels": 0.58762556}, {"text": "First Solar, Inc. Announces First Quarter 2019 Financial Results", "labels": 0.987689139}, {"text": "First Solar, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019", "labels": -0.2112402527}, {"text": "First Solar, Inc. Announces Fourth Quarter & Full Year 2018 Financial Results", "labels": 3.7595393169}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results on February 21, 2019", "labels": -0.8731850249}, {"text": "First Solar Series 6 Completes CSA C450 Test Protocol at CSA Group\u2019s PV Test Lab CFV Solar", "labels": -0.5207129484}, {"text": "First Solar Announces Full-Year 2019 Financial Guidance", "labels": -0.6422078069}, {"text": "First Solar, Inc. To Announce 2019 Financial Guidance on December 11, 2018", "labels": 4.8237937617}, {"text": "First Solar, Inc. Announces Third Quarter 2018 Financial Results", "labels": -9.9288972609}, {"text": "Study Shows Flexible Solar Can Have Significant Grid Benefits", "labels": -1.9301473891}, {"text": "First Solar Project Will Support PacifiCorp in Meeting Facebook Clean Energy Goals", "labels": -5.2321499051}, {"text": "D. E. Shaw Renewable Investments Acquires Willow Springs Project from First Solar", "labels": -2.1622825006}, {"text": "First Solar, Inc. to Announce Third Quarter 2018 Financial Results on October 25, 2018", "labels": -1.3397773484}, {"text": "First Solar, Inc. Announces Second Quarter 2018 Financial Results", "labels": -4.2207168263}, {"text": "First Solar, Inc. to Announce Second Quarter 2018 Financial Results on July 26, 2018", "labels": -2.2197501253}, {"text": "First Solar Receives Outstanding Project Award at InterSolar EU", "labels": -2.2197501253}, {"text": "First Solar Announces New U.S. Manufacturing Plant", "labels": 4.3361095391}, {"text": "First Solar, Inc. Announces First Quarter 2018 Financial Results", "labels": 4.3361095391}, {"text": "First Solar, Inc. To Announce First Quarter 2018 Financial Results on April 26, 2018", "labels": 2.2564658541}, {"text": "Vectren Selects Partner, Announces Location for 50 Megawatts of Renewable Energy in Southwestern Indiana", "labels": -1.3809073076}, {"text": "First Solar, Inc. Announces Fourth Quarter & Full Year 2017 Financial Results", "labels": -7.7844270712}, {"text": "First Solar to Build 200MWac Solar Plant in Twiggs County, Ga.", "labels": -1.4333201496}, {"text": "APS, First Solar Partner on Arizona\u2019s Largest Battery Storage Project", "labels": 4.609160453}, {"text": "First Solar, Inc. To Announce Fourth Quarter and Full Year 2017 Financial Results on February 22, 2018", "labels": -2.9728841204}, {"text": "8point3, the Joint-Venture Yieldco of First Solar and SunPower, Enters into a Definitive Agreement to be Acquired by Capital Dynamics", "labels": -0.834912725}, {"text": "First Solar Vietnam Celebrates Arrival of Series 6 Manufacturing Equipment", "labels": -0.1935460568}, {"text": "First Solar to Provide Power Electronics Warranty Services", "labels": -0.2584725829}, {"text": "First Solar to Power Zorlu Enerji\u2019s 100MW Solar Power Plant in Pakistan", "labels": -2.4603213742}, {"text": "First Solar Announces Full-Year 2018 Financial Guidance", "labels": 9.6457971646}, {"text": "First Solar and D. E. Shaw Renewable Investments Ink Module Deal", "labels": 9.6457971646}, {"text": "First Solar and Origis Energy Confirm Module Sale Agreement", "labels": 9.6457971646}, {"text": "First Solar Presents First Functional Series 6 Module", "labels": 9.6457971646}, {"text": "First Solar To Host Analyst Day on Tuesday, December 5th", "labels": 0.0644075714}, {"text": "PlantPredict\u2122 Energy Modeling Used as Basis for Project Performance Guarantees", "labels": 4.3373049384}, {"text": "First Solar, Inc. Announces Third Quarter 2017 Financial Results", "labels": 17.8428947937}, {"text": "First Solar, Inc. to Announce Third Quarter 2017 Financial Results on October 26, 2017", "labels": -0.9102380931}, {"text": "First Solar to Host Analyst Day on Tuesday, December 5", "labels": -2.2449842095}, {"text": "First Solar Sells California Flats Project to Capital Dynamics", "labels": 0.4302942446}, {"text": "D.\u00a0E. Shaw Renewable Investments Acquires Cuyama Solar Project from First Solar", "labels": -1.6437725307}, {"text": "First Solar Awarded 241MW Module Supply Contract for Edify Energy Solar Projects in Australia", "labels": 4.7063623641}, {"text": "First Solar Releases 2017 Sustainability Report", "labels": -0.564382226}, {"text": "First Solar, Inc. Announces Second Quarter 2017 Financial Results", "labels": 5.872721495}, {"text": "First Solar, Inc. to Announce Second Quarter 2017 Financial Results on July 27, 2017", "labels": -1.5503807853}, {"text": "EDF Renewable Energy Announces Acquisition of Solar Projects from First Solar", "labels": 2.4219774897}, {"text": "First Solar Appoints Molly Joseph to Board of Directors", "labels": -3.846147397}, {"text": "First Solar Secures Syndicated Development Loan Facility from Mizuho Bank for Utility-Scale Solar Projects in Japan", "labels": -3.846147397}, {"text": "First Solar, Inc. Announces First Quarter 2017 Financial Results", "labels": 12.1203203446}, {"text": "First Solar, Inc. to Announce First Quarter 2017 Financial Results on May 2, 2017", "labels": 0.9440821359}, {"text": "First Solar to Review Alternatives for the Sale of Its Interests in 8point3 Energy Partners", "labels": -1.4274949241}, {"text": "First Solar Sells Moapa Solar Project to Capital Dynamics", "labels": -2.9889278765}, {"text": "First Solar to Deliver 48.5MW Manildra Solar Farm in Australia", "labels": 0.5657703095}, {"text": "First Solar Begins Operation of 250 Megawatt Moapa Southern Paiute Solar Project", "labels": -8.7013822557}, {"text": "First Solar, Inc. Announces Fourth Quarter & Full Year 2016 Financial Results", "labels": -5.4215064384}, {"text": "First Solar Secures Syndicated Financing Arranged by Mizuho Bank for Utility-Scale Solar Project in Ishikawa, Japan", "labels": -5.4215064384}, {"text": "Photosol Selects First Solar Technology to Power Utility-Scale PV Plants in France", "labels": 1.8369672412}, {"text": "First Solar Signs Sales Collaboration Deal with Turkey's Zorlu Holding", "labels": 0.2052175127}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full Year 2016 Financial Results on February 21, 2017", "labels": 4.2614441743}, {"text": "First Solar Selected for 63MW Kidston Solar Project in Australia", "labels": 2.2700373957}, {"text": "First Solar Awarded 140MW Module Supply Contract for Australia's Largest Solar Project", "labels": 1.830593115}, {"text": "Prime Road Group and First Solar Complete 18MW of Solar Farms in Thailand", "labels": -1.8700480724}, {"text": "First Solar, Inc. Announces Acceleration of Series 6 Solar Module Production to 2018; Restructures Operations; Updates 2016 Guidance & Provides 2017 Guidance", "labels": -6.0012802986}, {"text": "First Solar to Announce 2017 Financial Guidance on November 16, 2016", "labels": -0.418033391}, {"text": "First Solar, Inc. Announces Third Quarter 2016 Financial Results", "labels": -18.2266045246}, {"text": "First Solar, MCE Sign Power Purchase Agreement", "labels": 0.0246479443}, {"text": "First Solar, Inc. To Announce Third Quarter Financial Results on November 2, 2016", "labels": 0.2918971786}, {"text": "First Solar Commissions 52.5MW Shams Ma'an Plant in Jordan", "labels": 1.2539173395}, {"text": "First Solar Announces Board Transition", "labels": 1.2570494344}, {"text": "First Solar Wins 160MW of Module Contracts in Turkey", "labels": -2.0623851977}, {"text": "First Solar Connects 130 MW of Utility-Scale Solar Power to the Grid in India", "labels": -3.332486818}, {"text": "First Solar, Inc. Announces Second Quarter 2016 Financial Results", "labels": -8.7145412905}, {"text": "D.\u00a0E.\u00a0Shaw\u00a0Renewable Investments Acquires Rancho Seco Solar Project from First Solar", "labels": -8.7145412905}, {"text": "First Solar Books 121MW in Community Solar Sales", "labels": -8.7145412905}, {"text": "First Solar, Inc. to Announce Second Quarter Financial Results on August 3, 2016", "labels": -4.0916877355}, {"text": "First Solar Recognizes NSG Vietnam Glass Industries with Supplier Award", "labels": 0.8276464116}, {"text": "First Solar Shifts Malaysian Production Capacity to Series 5 Assembly", "labels": 1.87258694}, {"text": "Neoen, First Solar To Deliver Lowest Cost Solar Electricity in Sub-Saharan Africa", "labels": -4.5406949725}, {"text": "First Solar Names Georges Antoun as Chief Commercial Officer", "labels": -0.9947304798}, {"text": "First Solar Announces Leadership Transition", "labels": -7.1729219918}, {"text": "First Solar, Inc. Announces First Quarter 2016 Financial Results", "labels": -7.1729219918}, {"text": "First Solar, Inc. to Announce First Quarter Financial Results on April 27, 2016", "labels": 1.8308506898}, {"text": "First Solar, Silicon Ranch Build on Strategic Partnership", "labels": -3.9356359169}, {"text": "First Solar Marks 1 Gigawatt Milestone in India", "labels": 1.0822510346}, {"text": "First Solar Reaches 5GW of O&M Assets", "labels": 2.8441410817}, {"text": "First Solar Publishes 2015 Sustainability Report", "labels": 2.8441410817}, {"text": "Skytron energy gains foothold in Japanese market with 20 MW win", "labels": -3.2108782764}, {"text": "First Solar, Thien Tan Group Sign MOU Targeting Utility Scale Project Development in Vietnam", "labels": -1.8255609932}, {"text": "First Solar, Inc. Announces Fourth Quarter & Full Year 2015 Financial Results", "labels": 8.1353462339}, {"text": "First Solar EPC Surpasses 6GW of Global Installed Capacity", "labels": 8.1353462339}, {"text": "First Solar Achieves Yet Another Cell Conversion Efficiency World Record", "labels": 8.1353462339}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full Year 2015 Financial Results", "labels": 2.3475683785}, {"text": "Skytron energy chosen for 86.2 MWp PV plant in South Africa", "labels": -3.2956193904}, {"text": "First Solar, Al Watania Agricultural Co. Pilot Solar-Powered Irrigation Project in Saudi Arabia", "labels": 1.3406417757}, {"text": "First Solar completes Australia's largest utility-scale solar plants", "labels": 4.4757204442}, {"text": "First Solar, California Utility Sign Agreements for 500MW", "labels": -1.5341906638}, {"text": "Skytron\u00ae energy partners with Strata Solar in the U.S.", "labels": -3.0783245329}, {"text": "First Solar, Inc. Announces Full Year 2016 Guidance", "labels": -9.402025306}, {"text": "First Solar to Announce 2016 Financial Guidance on December 9, 2015", "labels": 2.3545202367}, {"text": "First Solar, Inc. Announces Third Quarter 2015 Financial Results", "labels": -6.3361392218}, {"text": "First Solar, Inc. Announces Preliminary Third Quarter 2015 Financial Results", "labels": 10.0227812358}, {"text": "First Solar, Strata Sign 400MW Deal for 2017-18 Module Deliveries", "labels": 10.0227812358}, {"text": "First Solar, Austin Energy Ink 119MW Power Purchase Agreement", "labels": 10.0227812358}, {"text": "First Solar and SMUD Sign Rancho Seco 10.8MW Power Purchase Agreement", "labels": 10.0227812358}, {"text": "First Solar Connects Luz del Norte to Chilean Central Grid", "labels": 3.1378745561}, {"text": "First Solar, Indiana Michigan Power Break Ground on Twin Branch Solar Facility", "labels": 1.2979348421}, {"text": "First Solar, Inc. to Announce Third Quarter Financial Results on October 29, 2015", "labels": 0.1352128534}, {"text": "Community Solar Projects to Benefit from First Solar/CEC Supply Agreement", "labels": 2.8681456335}, {"text": "First Solar installs final modules at Broken Hill Solar Plant", "labels": -1.2455461262}, {"text": "\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30bd\u30fc\u30e9\u30fc\u3001\u307f\u305a\u307b\u9280\u884c\u3088\u308a \u4e8b\u696d\u8005\u898f\u6a21\u306e\u592a\u967d\u5149\u767a\u96fb\u6240\u306e\u5efa\u8a2d\u8cc7\u91d1\u878d\u8cc7\u3092\u7372\u5f97", "labels": 2.7881879527}, {"text": "First Solar receives Construction Loan Facility from Mizuho Bank for Utility-Scale Solar Generation", "labels": 2.7881879527}, {"text": "Australia's first commercial diesel displacement solar plant starts operation", "labels": 4.0701793648}, {"text": "First Solar, skytron energy Enhance PV Plant Performance with EMEA Operations Center", "labels": -2.3260949297}, {"text": "Southern Company subsidiary acquires system's largest solar project", "labels": 0.6005402983}, {"text": "First Solar, Inc. Announces Second Quarter 2015 Financial Results", "labels": 15.8320448688}, {"text": "First Solar, Inc. to Announce Second Quarter Financial Results on August 4, 2015", "labels": 0.9308855353}, {"text": "First Solar Modules to Power Landmark 200MW Solar Photovoltaic Project in Dubai", "labels": 0.1362922391}, {"text": "\u0648\u0623\u0644\u0627\u062d \"\u0641\u0631\u064a\u0633\u062a \u0648\u0633\u0627\u0644\u0631\" \u0633\u062a\u062a\u0645\u062f \u062e \u064a \u0641 \u0634\u0645\u0631\u0648\u0639 \u0636\u062e\u0645 \u0625\u0644\u0627\u0646 \u062a\u062c \u0627\u0644\u0637\u0642 \u0627\u0629 \u0627\u0644\u0634\u0629\u064a \u0633\u0645 \u0627\u0644\u0643\u0631 \u0647\u0648\u0636\u0648\u0626\u064a\u0629 \u0631\u062f\u0642\u0628\u0629 200 \u064a \u0645\u062c\u0627 \u0648\u0627\u0637 \u0641\u064a \u062f\u0628\u064a", "labels": 0.1362922391}, {"text": "8point3 Energy Partners LP, a YieldCo Formed by First Solar, Inc. and SunPower Corporation, Announces Pricing of its Initial Public Offering", "labels": -1.8196053494}, {"text": "First Solar Achieves World Record 18.6 % Thin Film Module Conversion Efficiency", "labels": 3.96931857}, {"text": "8point3 Energy Partners LP, a YieldCo Formed by First Solar, Inc. and SunPower Corporation, Announces Commencement of its Initial Public Offering", "labels": 1.8838008273}, {"text": "First Solar And OrionGroup Announce JV for Solar Development in Philippines", "labels": -2.2942501425}, {"text": "Silicon Ranch Selects First Solar Technology for Aerojet Rocketdyne Project", "labels": -2.1020517191}, {"text": "First Solar, Inc. Announces First Quarter 2015 Financial Results", "labels": -7.6560854168}, {"text": "Caterpillar Expands Renewable Power Generation Offerings in Conjunction with First Solar", "labels": -7.6560854168}, {"text": "Southern Company subsidiary tops 1,000 megawatts of renewable energy development with North Star solar acquisition", "labels": -7.6560854168}, {"text": "First Solar, Inc. To Announce First Quarter Financial Results on April 30, 2015", "labels": 2.0231681441}, {"text": "First Solar installs final module at Nyngan Solar Plant", "labels": -0.1445785584}, {"text": "Southern Company subsidiary acquires fourth California solar project; 32-megawatt Lost Hills-Blackwell", "labels": -2.8576049354}, {"text": "First Solar and UQ Launch Australia's Largest Solar Photovoltaic Systems Research Facility", "labels": 2.1255513759}, {"text": "Chilean Grid Operators Observe First Solar in Action", "labels": 3.9347393897}, {"text": "Representantes del CDEC-SIC y CDEC-SING Conocen Accionar de First Solar", "labels": 3.9347393897}, {"text": "First Solar and SunPower Announce Public Filing of Registration Statement for Proposed Initial Public Offering of a YieldCo", "labels": -1.72035831}, {"text": "First Solar, Inc. Announces Fourth Quarter and Full Year 2014 Financial Results", "labels": 2.9039985247}, {"text": "First Solar and SunPower Plan to Partner to Form Joint YieldCo Vehicle", "labels": 10.3290702872}, {"text": "First Solar Announces a 5 GW Green Energy Commitment at RE-INVEST", "labels": -0.6552000283}, {"text": "First Solar and Apple Strike Industry's Largest Commercial Power Deal", "labels": 4.2444118831}, {"text": "First Solar, Inc. to Announce Fourth Quarter Financial Results on February 24, 2015", "labels": 3.6258798991}, {"text": "One of the world's largest solar projects starts commercial operation", "labels": 3.6258798991}, {"text": "First Solar Achieves Efficiency, Durability Milestones", "labels": -0.7249469969}, {"text": "First Solar Launches Industry's First PV Project Assessment Application at WFES 2015", "labels": 1.7632930677}, {"text": "First Solar Marks New Milestone with 10 Gigawatts of Installed PV Capacity", "labels": 1.7632930677}, {"text": "First Solar Enters Residential Market with Strategic Investment in Clean Energy Collective", "labels": -4.2983235009}, {"text": "First Solar, Inc. Announces Third Quarter 2014 Financial Results", "labels": -12.2489555285}, {"text": "First Solar, BELECTRIC to Add 45 Million kWh of Clean Electricity to UK Generation Portfolio", "labels": -12.2489555285}, {"text": "First Solar, Inc. to Announce Third Quarter Financial Results on November 6, 2014", "labels": 2.3326235343}, {"text": "Southern Company subsidiary to top 300 MW of total solar generating capacity with acquisition of new California facility", "labels": 2.002121334}, {"text": "First Solar Installs Inaugural Panel at South America's Largest PV Plant", "labels": -1.8760354567}, {"text": "First Solar Completes Barilla Solar Project", "labels": -0.2238646005}, {"text": "Construction Begins On 250mw Silver State South Solar Project In Primm, Nevada", "labels": 2.5297066538}, {"text": "First Solar Builds the Highest Efficiency Thin Film PV Cell on Record", "labels": 2.5152404719}, {"text": "First Solar, Inc. Announces Second Quarter 2014 Financial Results", "labels": 2.5152404719}, {"text": "First Solar to Build, Operate and Maintain 54.5MW Shams Ma'an Power Plant in Jordan (Arabic)", "labels": 2.5152404719}, {"text": "First Solar to Build, Operate and Maintain 54.5MW Shams Ma'an Power Plant in Jordan (Japanese)", "labels": 2.5152404719}, {"text": "First Solar to develop 45 (MW)AC of utility scale solar projects in Telangana", "labels": 2.5152404719}, {"text": "First Solar To Build, Operate and Maintain 52.5MW Shams Ma'an Power Plant in Jordan", "labels": 2.5152404719}, {"text": "First Solar, Inc. to Announce Second Quarter Financial Results on August 5, 2014", "labels": -0.9454027141}, {"text": "First Solar, XSOL Establish Supply Agreement in Japan", "labels": 0.1223456672}, {"text": "First Solar Set to Build Largest PV Solar Power Plant in Latin America", "labels": 1.6666700504}, {"text": "BELECTRIC, First Solar Connect Three Utility-Scale Solar Power Plants to UK Grid", "labels": 4.1577082808}, {"text": "First Solar Selected by Tenaska to Build 150MW Solar Facility in Southern California", "labels": 4.7419569803}, {"text": "First Solar to Acquire Technology Provider skytron-energy from AEG Power Solutions", "labels": 3.9302641364}, {"text": "First Solar Launches Pre-Engineered PV Plant Solution, Next Generation Module", "labels": -0.3884779592}, {"text": "First Solar Completes Sale of 250MW Silver State South to NextEra Energy Resources", "labels": 1.0020994708}, {"text": "First Solar Sells Macho Springs Solar Project", "labels": 0.8978113812}, {"text": "First Solar to Deliver Diesel-PV Hybrid Solution to Rio Tinto in Australia", "labels": 2.3420781109}, {"text": "IXL Group Opens Structure Manufacturing Plant in Adelaide to Supply First Solar Australian Projects", "labels": -1.4238277787}, {"text": "First Solar, Inc. Announces First Quarter 2014 Financial Results", "labels": -7.9125354781}, {"text": "First Solar to Build 42.76MW for EDF Renewable Energy", "labels": -7.9125354781}, {"text": "First Solar, Inc. to Announce First Quarter Financial Results on May 6, 2014", "labels": -3.515392085}, {"text": "Moapa Paiute Tribe, LADWP and First Solar Break Ground on 250MW Solar Project", "labels": 5.2389367845}, {"text": "First Solar Announces Full-Year 2014 Financial Guidance", "labels": 18.9841149908}, {"text": "First Solar Sets Thin-Film Module Efficiency World Record of 17.0 Percent", "labels": 18.9841149908}, {"text": "First Solar and GE Shape Next-Generation PV Power Plant", "labels": 18.9841149908}, {"text": "First Solar, Shams Ma'an Consortium Secure 20-Year PPA for 52MW Jordan Project", "labels": 18.515853035}, {"text": "\u30d5\u30a1\u30fc\u30b9\u30c8\u30bd\u30fc\u30e9\u30fc\u3001\u5317\u4e5d\u5dde\u5e02\u30671.3MW DC\u306e\u592a\u967d\u5149\u767a\u96fb\u6240\u306e\u5efa\u8a2d\u5de5\u4e8b\u3092\u5b8c\u4e86 (Japanese)", "labels": 3.7873527678}, {"text": "First Solar Completes 1.3MW(DC) Solar PV Power Plant at Kitakyushu-shi in Japan", "labels": 3.7873527678}, {"text": "First Solar Sets World Record for CdTe Solar Cell Efficiency", "labels": -10.9214981764}, {"text": "First Solar, Inc. Announces Fourth Quarter and Full Year 2013 Financial Results", "labels": -10.9214981764}, {"text": "First Solar Names Paul Kaleta as General Counsel", "labels": -0.2503117985}, {"text": "First Solar Recognizes Top Suppliers with 2013 Achievement Awards", "labels": 4.0914791238}, {"text": "First Solar, Inc. to Announce Fourth Quarter and Full-Year 2013 Financial Results", "labels": 6.4368621318}, {"text": "First Solar Breaks Ground on 102 MW Nyngan Solar Project", "labels": 4.030974493}, {"text": "First Solar Starts Construction Activity on Barilla Solar Project", "labels": -3.2117422496}, {"text": "First Solar Modules Selected to Power Projects Totaling 48MW in France", "labels": 2.026070728}, {"text": "First Solar Starts Construction of Solar Power Plant in Kitakyushu-shi, Japan", "labels": -2.1559754371}, {"text": "First Solar Awards Major Supply Contract to IXL Group", "labels": 2.1619880001}, {"text": "First Solar to Invest $100 Million in Japan", "labels": -2.5449376746}, {"text": "First Solar and JX Nippon Partner to Deliver Next Generation Solar Power in Japan (Japanese)", "labels": -2.5449376746}, {"text": "First Solar to Invest $100 Million in Japan (Japanese)", "labels": -2.5449376746}, {"text": "First Solar and JX Nippon Partner to Deliver Next Generation Solar Power in Japan", "labels": -2.5449376746}, {"text": "First Solar Signs Power Purchase Agreements for 40MW Kingbird Solar Project", "labels": 2.1028014615}, {"text": "First Solar Sells 250MW Silver State South Project to a Subsidiary of NextEra Energy Resources", "labels": 15.2688516613}, {"text": "First Solar, Inc. Announces Third Quarter 2013 Financial Results", "labels": 15.2688516613}, {"text": "First Solar, Inc. to Announce Third Quarter 2013 Financial Results on Thursday, October 31, 2013", "labels": 1.9734409272}, {"text": "University of Queensland, First Solar to Build World-Leading Research Centre", "labels": 1.9734409272}, {"text": "First Solar Announces Completion of Dubai's Flagship 13MW Solar Power Plant", "labels": -4.3519168781}, {"text": "First Solar Announces Completion of Dubai's Flagship 13MW Solar Power Plant (Arabic)", "labels": -4.3519168781}, {"text": "First Solar to Build 250MW Power Plant in California for NextEra Energy Resources", "labels": 2.7191646004}, {"text": "First Solar Acquires 250MW Moapa Project in Nevada from K Road Power", "labels": -0.8351760261}, {"text": "First Solar Breaks Ground on Imperial Valley Solar Project", "labels": 2.4855677453}, {"text": "VDE Americas and First Solar Implement New Standards for Bankability and Quality Assurance", "labels": -3.2603025431}, {"text": "First Solar Strengthens Partnership with Belectric, Announces Joint Venture", "labels": 5.8142496851}, {"text": "First Solar Names Joe Kishkill as Chief Commercial Officer", "labels": 2.0255920228}, {"text": "First Solar Sells Canadian Power Plants to GE-Alterra Partnership", "labels": -6.2160719491}, {"text": "First Solar, Roseville Sign Contract for Lost Hills PPA", "labels": 3.2425422172}, {"text": "First Solar Highlights MENA Potential, Expands Business Development Capabilities", "labels": 0.597091224}, {"text": "First Solar Highlights MENA Potential, Expands Business Development Capabilities (Arabic)", "labels": 0.597091224}, {"text": "First Solar and Ingenero to Collaborate In the Delivery of Solar PV Projects", "labels": 0.597091224}, {"text": "First Solar Acquires US and Mexico Portfolio from Element Power", "labels": -19.100566615}, {"text": "GE, First Solar Announce Solar Technology and Commercial Partnership", "labels": -19.100566615}, {"text": "First Solar, Inc. Announces Second Quarter 2013 Financial Results", "labels": -19.100566615}, {"text": "First Solar Appoints Sharon Allen to Board of Directors", "labels": -0.3551988441}, {"text": "First Solar to Deliver 155MW of Solar Power Projects for AGL Energy", "labels": 3.7383179743}, {"text": "First Solar, Inc. to Announce Second Quarter 2013 Financial Results on Tuesday, August 6, 2013", "labels": 1.5352251397}, {"text": "First Solar to Build New Mexico Solar Projects Totaling 23MW for PNM", "labels": -3.0710960378}, {"text": "Macho Springs Solar Project Breaks Ground", "labels": -0.4649167759}, {"text": "First Solar Announces Closing of Common Stock Offering", "labels": -2.4023342452}, {"text": "First Solar Announces Pricing of Common Stock Offering", "labels": -8.0916096459}, {"text": "First Solar Announces Public Offering of Common Stock", "labels": -17.8739823829}, {"text": "50MW Power Purchase Agreement Approved for Largest Solar Power Plant in New Mexico", "labels": 3.1167853919}, {"text": "First Solar, Inc. Announces First Quarter 2013 Financial Results", "labels": -7.3681803833}, {"text": "First Solar Showcases Series 3 BlackTM Thin-Film Module at SNEC 2013 PV Power Expo", "labels": -7.3681803833}, {"text": "First Solar \u643a\u5168\u65b0Series 3 Black\u0099 \u8584\u819c\u5149\u4f0f\u7ec4\u4ef6\u4eae\u76f8SNEC", "labels": -7.3681803833}, {"text": "First Solar, Inc. to Announce First Quarter 2013 Financial Results on Monday, May 6, 2013", "labels": 3.7156346461}, {"text": "First Solar Sells 139-Megawatt Campo Verde Solar Project", "labels": 13.1899815616}, {"text": "First Solar Sets CdTe Module Efficiency World Record, Launches Series 3 Black Module", "labels": 4.139816503}, {"text": "First Solar Sets CdTe Module Efficiency World Record, Launches Series 3 Black Module (Thai)", "labels": 4.139816503}, {"text": "First Solar Acquires 60 MWAC North Star Project from NorthLight Power", "labels": 0.5108863504}, {"text": "First Solar to Acquire TetraSun to Expand Addressable Market Opportunity", "labels": 25.2753314491}, {"text": "First Solar Announces Full-Year 2013 Financial Guidance", "labels": 25.2753314491}, {"text": "First Solar Sets CdTe Module Efficiency World Record, Launches Series 3 Black Module", "labels": 25.2753314491}, {"text": "First Solar Sets CdTe Module Efficiency World Record, Launches Series 3 Black Module (Thai)", "labels": 25.2753314491}, {"text": "\u203b\u672c\u30ea\u30ea\u30fc\u30b9\u306f2013 \u5e744 \u67089 \u65e5\uff08\u73fe\u5730\u6642\u9593\uff09\u306b\u7c73\u56fd\u30a2\u30ea\u30be\u30ca\u5dde\u30c6\u30f3\u30d4\u3001\u304a\u3088\u3073\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30b5\u30f3\u30ce\u30bc\u3067\u767a\u8868\u3055\u308c\u305f\n\u30d7\u30ec\u30b9\u30ea\u30ea\u30fc\u30b9\u306e\u7ffb\u8a33\u7248\u3067\u3059\u3002", "labels": 25.2753314491}, {"text": "First Solar\u5237\u65b0\u78b2\u5316\u9549\u5149\u4f0f\u7ec4\u4ef6\u8f6c\u6362\u7387\u4e16\u754c\u7eaa\u5f55\uff0c\u63a8\u51faSeries 3 Black\u7ec4\u4ef6", "labels": 25.2753314491}, {"text": "First Solar Acquires 150 MWac Solar Gen 2 Photovoltaic Power Project", "labels": -3.8461546842}, {"text": "First Solar Donates Thin-Film Solar Modules to Inner Mongolia University of Technology Students for 2013 Solar Decathlon Competition", "labels": 6.3936805923}, {"text": "First Solar\u516c\u53f8\u5411\u5185\u8499\u53e4\u5de5\u4e1a\u5927\u5b66\u8d60\u9001\u8584\u819c\u592a\u9633\u80fd\u7ec4\u4ef6\uff0c\u652f\u6301\u8be5\u6821\u5b66\u751f\u53c2\u52a02013\u5e74\u56fd\u9645\u592a\u9633\u80fd\u5341\u9879\u5168\u80fd\u7ade\u8d5b", "labels": 6.3936805923}, {"text": "First Solar to Webcast Analyst Meeting on April 9, 2013", "labels": -1.1139964117}, {"text": "First Solar New Dii Shareholder", "labels": 4.3731805378}, {"text": "First Solar devient actionnaire de Dii", "labels": 4.3731805378}, {"text": "First Solar neuer Dii\u2010Gesellschafter", "labels": 4.3731805378}, {"text": "First Solar New Dii Shareholder (Arabic)", "labels": 4.3731805378}, {"text": "First Solar, Inc. Announces Fourth Quarter and Full-Year 2012 Financial Results", "labels": -22.0414159862}, {"text": "First Solar Sets New World Record for CdTe Solar Cell Efficiency", "labels": -22.0414159862}, {"text": "First Solar Sets New World Record for CdTe Solar Cell Efficiency (Arabic)", "labels": -22.0414159862}, {"text": "First Solar Sets New World Record for CdTe Solar Cell Efficiency (Thai)", "labels": -22.0414159862}, {"text": "First Solar\u78b2\u5316\u9549\u592a\u9633\u80fd\u7535\u6c60\u8f6c\u6362\u6548\u7387\u518d\u521b\u4e16\u754c\u7eaa\u5f55 \u7ecf\u7f8e\u56fd\u56fd\u5bb6\u53ef\u518d\u751f\u80fd\u6e90\u5b9e\u9a8c\u5ba4\uff08NREL\uff09\u8bc1\u5b9e\uff0c\u7814\u7a76\u6027\u7535\u6c60\u8f6c\u6362\u6548\u7387\u9ad8\u8fbe18.7%", "labels": -22.0414159862}, {"text": "AV Solar Ranch One Solar Power Plant Achieves 100 MW Milestone", "labels": -5.4925876142}, {"text": "First Solar Hiring Ahmed Nada as VP of Business Development for the Middle East", "labels": 2.8181088766}, {"text": "First Solar Hiring Ahmed Nada as VP of Business Development for the Middle East (Arabic version)", "labels": 2.8181088766}, {"text": "First Solar to Announce Fourth Quarter 2012 Financial Results on Tuesday, February 26, 2013", "labels": 5.4561472632}, {"text": "Azure Power commissions the largest solar PV project under JNNSM before the scheduled date", "labels": 5.4561472632}, {"text": "First Solar Acquires 50 MWAC Macho Springs Project from Element Power Solar", "labels": 1.4472285511}, {"text": "First Solar Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corp", "labels": -2.1548800445}, {"text": "First Solar Named \"Official Solar Provider\" of the 2013 Waste Management Phoenix Open", "labels": -2.0854057835}, {"text": "Solar PV power in harmony with nature - new WWF report says land requirements are insignificant", "labels": -2.8496525133}, {"text": "First Solar Begins Construction of Campo Verde Solar Project", "labels": -0.905969793}, {"text": "First Solar Acquires Chilean Project Developer Solar Chile", "labels": 1.6265203678}, {"text": "First Solar adquiere Solar Chile", "labels": 1.6265203678}, {"text": "First Solar Hires Tim Rebhorn as Senior Vice President, Project Development", "labels": 0.971480625}, {"text": "First Solar Extends and Expands Collaboration and Licensing Agreement with Intermolecular", "labels": -6.6408811828}, {"text": "First Solar Releases 92.5-Watt Thin-Film PV Module", "labels": 0.491400002}, {"text": "First Solar Named Military Friendly Employer by G.I. Jobs Magazine", "labels": 3.7966547879}, {"text": "First Solar Hires Johan Cilliers as Regional Director for Sub-Saharan Africa", "labels": 8.3166323537}, {"text": "First Solar Partners with Zhenfa on Thin-film PV Demonstration Project in China", "labels": 8.0378285007}, {"text": "First Solar\u643a\u624b\u632f\u53d1\u65b0\u80fd\u6e90\u5728\u4e2d\u56fd\u5f00\u5c55\u8584\u819c\u5149\u4f0f\u53d1\u7535\u793a\u8303\u9879\u76ee", "labels": 8.0378285007}, {"text": "First Solar Recognizes Top Suppliers with 2012 Achievement Awards", "labels": -6.5806481146}, {"text": "First Solar, Inc. Announces Third Quarter 2012 Financial Results", "labels": -8.6956477589}, {"text": "HCC Begins Collaboration with First Solar to Support Alternative Energy Technology Program", "labels": -8.6956477589}, {"text": "First Solar's Third Quarter 2012 Financial Results Moved to Thursday, Nov. 1, 2012", "labels": 2.2222191396}, {"text": "First Solar to Announce Third Quarter 2012 Financial Results on Wednesday, October 31, 2012", "labels": 1.54359175}, {"text": "Elementary School Students Participate in Environmental Stewardship Program at California Desert Parks: Mojave National Preserve and Joshua Tree National Park", "labels": 1.177958272}, {"text": "One Millionth Photovoltaic Solar Module Installed at MidAmerican Solar's Topaz Project by First Solar", "labels": 1.177958272}, {"text": "First Solar PV Modules Certified by UL for 1000-Volt Systems", "labels": 1.5839076608}, {"text": "First Solar recognized at the Inaugural Malaysia Greentech Awards", "labels": -2.0592083251}, {"text": "First Solar to Build 13MW Solar Power Plant for Dubai Electricity & Water Authority (Arabic version)", "labels": -2.0592083251}, {"text": "First Solar Launches New Advanced Global Power Plant Operations Center", "labels": -6.1597230212}, {"text": "First Solar to Build 13MW Solar Power Plant for Dubai Electricity & Water Authority", "labels": 2.1479674673}, {"text": "PJB Services & First Solar Sign Agreement on Development of Solar Power Plants in Indonesia", "labels": 11.0051666642}, {"text": "PJB Services & First Solar Menandatangani Kerjasama untuk Mengembangkan Pembangkit Listrik Tenaga Surya di Indonesia", "labels": 11.0051666642}, {"text": "Solar Power Gets Jolt of Energy as Western Australia Officially Flips Switch on Country's First Large-Scale Solar Project", "labels": 3.0418311271}, {"text": "First Solar Partners with Kiran Energy and Mahindra Solar One on 50 MWDC of PV Projects in Rajasthan", "labels": 2.0192312101}, {"text": "First Solar to Build New Mexico Solar Projects Totaling 20 Megawatts for PNM", "labels": 2.4830665758}, {"text": "First Solar Hires Bruce Yung as Managing Director & VP of Business Development, China", "labels": 2.4830665758}, {"text": "First Solar \u4efb\u547d\u5bb9\u4f2f\u5f3a\u4e3a\u4e2d\u56fd\u533a\u8463\u4e8b\u603b\u7ecf\u7406\u517c\u4e1a\u52a1\u62d3\u5c55\u526f\u603b\u88c1", "labels": 11.0774612968}, {"text": "First Solar, Sir Ratan Tata Trust Partner to Electrify Rural Communities in India", "labels": -2.4401925272}, {"text": "First Solar Installs PV Array at India's Ministry of New and Renewable Energy", "labels": 2.5210069856}, {"text": "First Solar and PG&E Sign Contracts for 72 Megawatts of Solar Photovoltaic Electricity", "labels": 4.0035571035}, {"text": "World's Largest Operational Solar PV Project, Agua Caliente, Achieves 250 Megawatts of Grid-Connected Power", "labels": 4.8623830415}, {"text": "First Solar Partners with Green Infra on 25MW(AC) Solar Power Project in Rajasthan", "labels": 7.0450122135}, {"text": "Constellation and Governor O'Malley Dedicate 16.1-Megawatt Grid Connected Solar Power System for State of Maryland", "labels": -30.1982740774}, {"text": "First Solar Establishes Thai Operating Subsidiary, Opens Bangkok Office (Thai)", "labels": 1.895732755}, {"text": "First Solar Establishes Thai Operating Subsidiary, Opens Bangkok Office", "labels": 1.895732755}, {"text": "First Solar Appoints CEO James Hughes to Board of Directors", "labels": 12.994979833}, {"text": "First Solar, Inc. Announces Second Quarter 2012 Financial Results", "labels": 12.994979833}, {"text": "First Solar to Develop 139 MW Campo Verde Solar Project", "labels": 12.994979833}, {"text": "First Solar to Announce Second Quarter 2012 Financial Results on Wednesday, August 1, 2012", "labels": -1.0714258466}, {"text": "Agua Caliente Reaches 200-Megawatt Milestone", "labels": 1.5905981695}, {"text": "Governor O'Malley Celebrates Groundbreaking on State's Largest Solar Power Project", "labels": -5.3596562683}, {"text": "First Solar Appoints Georges Antoun COO", "labels": -0.4581194354}, {"text": "Module Installation Begins at Antelope Valley Solar Ranch One", "labels": -1.2616173645}, {"text": "First Solar Installs 10 Millionth Power Plant PV Module", "labels": -4.5668189108}, {"text": "LA County Approves First Solar to Start Module Installation at AV Solar Ranch One", "labels": 0.5263152941}, {"text": "EnXco Announces Solar Module Supply Agreement With First Solar", "labels": -5.2269616979}, {"text": "First Solar to Provide 159 MW in Solar Power Projects for AGL Energy Under Australia's Solar Flagships Program", "labels": 11.772576932}, {"text": "First Solar and Intermolecular Announce Joint Program to Accelerate Solar PV Roadmap", "labels": 11.772576932}, {"text": "National Park Trust Awarded $48,000 Grant from First Solar to Implement Environmental Education Program in California and Nevada", "labels": -5.5468752154}, {"text": "First Solar Joins KAUST NEO Testing and Demonstration Program in Saudi Arabia", "labels": 6.4822112218}, {"text": "Frank Lloyd Wright Foundation, First Solar and Big Green Zero Energize Solar Power System at Taliesin West", "labels": -1.3956720888}, {"text": "First Photovoltaic Solar Panel Installed on Largest Solar Project in the World", "labels": -8.604486917}, {"text": "Enbridge and First Solar announce completion of 50-MW Silver State North Nevada Solar Project", "labels": -2.0556120098}, {"text": "First Solar Appoints Raffi Garabedian Chief Technology Officer; Dave Eaglesham Retires", "labels": -6.5525305077}, {"text": "First Solar Appoints James Hughes CEO", "labels": -6.5525305077}, {"text": "First Solar, Inc. Announces First Quarter 2012 Financial Results", "labels": -6.5525305077}, {"text": "MidAmerican Solar and First Solar Announce Start of Major Construction on Largest Solar Project in the World", "labels": -6.5525305077}, {"text": "First Solar Establishes Indian Operating Company, Appoints Sujoy Ghosh as Country Head, India", "labels": -6.5525305077}, {"text": "First Solar to Announce First Quarter 2012 Financial Results on Thursday, May 3, 2012", "labels": 0.2724857949}, {"text": "NRG Energy, MidAmerican Solar and First Solar Celebrate 100 MW Milestone for 290 MW Agua Caliente Solar Project", "labels": -3.0584456014}, {"text": "First Solar Marks First Anniversary of 3 MW Sai Sena PV Project in Thailand", "labels": -11.5324639655}, {"text": "First Solar Restructures Operations to Align With Sustainable Market Opportunities", "labels": -1.2640381213}, {"text": "First Solar richtet sich mit Restrukturierungsma\u00dfnahmen an den Chancen in nachhaltigen M\u00e4rkten aus", "labels": -1.2640381213}, {"text": "First Solar passt Produktion an ver\u00e4nderte Marktbedingungen an", "labels": -1.2640381213}, {"text": "Australia's Largest Solar PV Project Reaches Major Construction Milestone", "labels": -8.5933793667}, {"text": "First Solar to Expand Board of Directors", "labels": 1.3636328957}, {"text": "Antelope Valley Solar Ranch One Receives First Loan Advance", "labels": -7.2312978992}, {"text": "First Solar Powers 40 MW (AC) Solar Power Plant, One of India's Largest", "labels": -11.2389334748}, {"text": "First Solar Malaysia Supports Local Education", "labels": 0.8782407986}, {"text": "Enbridge Acquires 50-MW Nevada Solar Project from First Solar", "labels": -0.8425863968}, {"text": "BW EUROPE to Distribute First Solar Thin-Film PV Modules in Italy", "labels": 6.4993101603}, {"text": "James Hughes to Join First Solar as Chief Commercial Officer", "labels": -0.5747120924}, {"text": "First Solar Announces 20-Megawatt Maryland Solar Project", "labels": -0.5747120924}, {"text": "NextEra Energy Resources Completes Acquisition of Ontario Solar Projects from First Solar", "labels": -1.0248927151}, {"text": "First Solar to Build 26 Megawatt Avra Valley PV Solar Project for NRG", "labels": -1.0248927151}, {"text": "First Solar Begins Construction of Solar PV System for Frank Lloyd Wright Foundation's Energizing Taliesin WestTM Initiative", "labels": -1.0248927151}, {"text": "First Solar, Inc. Announces Fourth Quarter and 2011 Financial Results", "labels": -12.8483022412}, {"text": "Frank Lloyd Wright Foundation Announces Energizing Taliesin WestTM Initiative", "labels": 3.5714368057}, {"text": "First Solar to Announce Fourth Quarter 2011 and Year-End Financial Results on Tuesday, February 28, 2012", "labels": -4.4007752715}, {"text": "Sonnedix, First Solar Mark Completion of 7.5 MW Nakhon Ratchasima Solar Farm, Largest First Solar Plant in South-East Asia", "labels": -8.7970688374}, {"text": "Sonnedix, First Solar Mark Completion of 7.5 MW Nakhon Ratchasima Solar Farm, Largest First Solar Plant in South-East Asia (Thai)", "labels": -8.7970688374}, {"text": "Sonnedix y First Solar finalizan una planta solar de 7.5 MW en Nakhon Ratchasima, la primera de estas dimensiones en Tailandia", "labels": -8.7970688374}, {"text": "Agua Caliente Earns Solar Project of the Year Awards", "labels": -6.6996267821}, {"text": "CLP Names First Solar 2011 Safety Partner of the Year", "labels": -6.6996267821}, {"text": "MidAmerican Renewables, LLC Completes Acquisition of 550-MegawattAC Topaz Solar Farm from First Solar", "labels": -6.2792883927}, {"text": "Team Chipotle Becomes Team Chipotle-First Solar With Addition of First Solar As New Sponsor, Unveils 2012 Jersey and Roster", "labels": -5.2270647185}, {"text": "L'\u00c9quipe Chipotle Devient L'\u00c9quipe Chipotle-First Solar Avec L'arriv\u00e9e de First Solar en Tant Que Nouveau Sponsor, et D\u00e9voile son Maillot et sa Formation 2012", "labels": -5.2270647185}, {"text": "First Solar Sets Another World Record for CdTe Solar PV Efficiency", "labels": 4.1405036625}, {"text": "First Solar Named \"Official Solar Provider\"  Of The 2012 Waste Management Phoenix Open", "labels": 2.6368026456}, {"text": "First Solar Recognizes Top Suppliers with Achievement Awards", "labels": 2.0440240067}, {"text": "First Solar ernennt Christopher Burghardt zum europ\u00e4ischen Vertriebsleiter", "labels": 3.77129452}, {"text": "First Solar Names Christopher Burghardt Head of Sales Operations - Europe", "labels": 3.77129452}, {"text": "First Solar Updates 2011 Financial Guidance and Announces 2012 Financial Guidance", "labels": -18.6009485921}, {"text": "First Solar Appoints Jim Brown President, Global Business Development", "labels": -18.6009485921}, {"text": "MidAmerican Energy Holdings Company to Acquire 550-Megawatt (AC) Topaz Solar Farm from First Solar", "labels": -8.5454964951}, {"text": "First Solar Appoints David Brady to Lead Investor Relations", "labels": 3.5331237269}, {"text": "First Solar to Host 2012 Guidance Conference Call on Wed., Dec. 14", "labels": 3.5331237269}, {"text": "First Solar Signs 2\u02daC Challenge Communiqu\u00e9", "labels": 7.9607215309}, {"text": "First Solar unterzeichnet das \"2 \u02daC Challenge Communiqu\u00e9\" gegen Klimawandel", "labels": 7.9607215309}, {"text": "First Solar signe le \u00ab 2\u02daC Challenge Communiqu\u00e9 \u00bb", "labels": 7.9607215309}, {"text": "First Solar Achieves 5GW Photovoltaic Production Milestone", "labels": 3.1690111581}, {"text": "First Solar franchit le cap des 5 GW dans sa production photovolta\u00efque", "labels": 3.1690111581}, {"text": "First Solar erreicht Meilenstein von 5 GW bei Photovoltaikproduktion", "labels": 3.1690111581}, {"text": "First Solar Commences Construction on Australia's First Utility-Scale Solar Farm", "labels": -4.1009480425}, {"text": "First Solar to Build, Operate and Maintain 66 Megawatt Alpine Solar Project for NRG Energy", "labels": 2.2988493368}, {"text": "First Solar Consolidates Manufacturing, Increases Conversion Efficiency", "labels": 2.2988493368}, {"text": "First Solar Doubles Production in Germany", "labels": 2.2988493368}, {"text": "First Solar verdoppelt Produktion in Deutschland", "labels": 2.2988493368}, {"text": "First Solar double sa production en Allemagne", "labels": 2.2988493368}, {"text": "APS-Owned Paloma Solar Power Plant Now Online", "labels": 10.6686459662}, {"text": "First Solar Announces Third Quarter 2011 Financial Results", "labels": 10.1323260033}, {"text": "First Solar to Announce Third Quarter 2011 Financial Results on Thursday, November 3, 2011", "labels": -26.0247231428}, {"text": "First Solar Announces Chairman Michael Ahearn to Serve as Interim CEO", "labels": -26.0247231428}, {"text": "First Solar Measures and Reports Its Carbon Footprint", "labels": -0.4623904292}, {"text": "Solar Chile and First Solar Announce Strategic Alliance for Solar Development in Northern Chile", "labels": -3.1885067212}, {"text": "Land of Enchantment Welcomes New Mexico's Second-Largest Solar Facility", "labels": -8.4810970197}, {"text": "Topaz Solar Farm, North County Watch, and Carrizo Commons Reach Agreement on Topaz Solar Farm", "labels": -9.7927426935}, {"text": "First Solar Sells 550-Megawatt Desert Sunlight Solar Farm, Among World's Largest", "labels": -9.7927426935}, {"text": "Exelon to Expand its Clean Energy Fleet with Acquisition of 230-Megawatt Solar Photovoltaic Project from First Solar", "labels": -9.7927426935}, {"text": "Constellation Energy Begins Construction on Maryland's Largest Solar Photovoltaic Power System", "labels": -4.7302608876}, {"text": "Tenaska Solar Ventures Chooses First Solar to Construct Imperial Solar Energy Center South", "labels": -13.8378364239}, {"text": "Topaz Solar Farm Will Not Meet DOE Loan Guarantee Deadline", "labels": 1.8365617237}, {"text": "First Solar Modules to Power Ohio State University at Solar Decathlon Competition in Wash., D.C.", "labels": -7.6868033211}, {"text": "Enbridge and First Solar Celebrate the Completion of Two Ontario Solar Projects", "labels": -7.5612643964}, {"text": "First Solar Announces Agreement for 100MW Module Supply with Reliance Power", "labels": 3.2612339342}, {"text": "First Solar Extends Workmanship Warranty to Ten Years", "labels": 3.2612339342}, {"text": "Ex-Im Bank Announces Over $455 Million in Project Financing for First Solar's Exports to Canada", "labels": -8.3000394753}, {"text": "In Perrysburg, Brown Joins Head of Export-Import Bank at First Solar to Announce Funding to Support First Solar's Exports to Canada, Creating and Sustaining More than 500 Jobs", "labels": -8.3000394753}, {"text": "First Solar Modules \"Made in EU\" Qualify for Italian Feed-In Tariff Premium", "labels": -10.4328542565}, {"text": "I moduli First Solar certificati \"Made in EU\" ottengono la maggiorazione sulle tariffe incentivanti", "labels": -10.4328542565}, {"text": "NRG Solar Begins Operations at New Mexico's Roadrunner Facility", "labels": -5.6117130957}, {"text": "Australia's First Utility-Scale Solar PV Project Under Way in Western Australia", "labels": -1.6403274001}, {"text": "Five First Solar Executives Purchase Company Stock", "labels": 2.0727536991}, {"text": "First Solar Dedicates Mesa Factory Site", "labels": -6.5336414553}, {"text": "First Solar Announces Departure of Jens Meyerhoff", "labels": -5.0472595201}, {"text": "Secretary Salazar Approves 550 Megawatt Solar Project in Riverside County, California", "labels": 2.2903732428}, {"text": "Statement on Settlement Agreement between National Environmental Organizations and Solar Development Companies Regarding San Luis Obispo Solar Projects", "labels": -1.036270336}, {"text": "NRG Energy Acquires 290-Megawatt Agua Caliente Solar Project from First Solar", "labels": -5.6267550071}, {"text": "First Solar Announces Second Quarter 2011 Financial Results", "labels": -6.2885300524}, {"text": "PG&E and Sempra Generation Contract for 150 MW of Renewable Power", "labels": -6.2885300524}, {"text": "First Solar to Announce Second Quarter 2011 Financial Results on Thursday, August 4, 2011", "labels": -1.7254558036}, {"text": "First Solar PV Modules Receive New IEC Certification for Effectiveness in Coastal Environments", "labels": -1.7254558036}, {"text": "Les modules photovolta\u00efques First Solar obtiennent la nouvelle certification IEC en termes d'efficacit\u00e9 dans les milieux c\u00f4tiers", "labels": -1.7254558036}, {"text": "PV-Module von First Solar erhalten neue IEC-Zertifizierung f\u00fcr Wirkungsgrad in K\u00fcstengegenden", "labels": -1.7254558036}, {"text": "First Solar Sets World Record for CdTe Solar PV Efficiency", "labels": -4.0137224412}, {"text": "First Solar\u521b\u9020\u78b2\u5316\u9549\u592a\u9633\u80fd\u5149\u4f0f\u7535\u6c60\u8f6c\u6362\u6548\u7387\u4e16\u754c\u8bb0\u5f55", "labels": -4.0137224412}, {"text": "First Solar Sells 10MW Solar Power Plant near Zamora, Spain to KGAL", "labels": -2.6606840168}, {"text": "First Solar vend \u00e0 KGAL une centrale \u00e9lectrique solaire de 10 MW situ\u00e9e pr\u00e8s de Zamora en Espagne", "labels": -2.6606840168}, {"text": "First Solar verkauft 10-MW-Solarkraftanlage bei Zamora in Spanien an KGAL", "labels": -2.6606840168}, {"text": "Department of Energy Offers Conditional Loan Guarantee Commitments to Support Nearly $4.5 Billion in Loans for Three California Photovoltaic Solar Power Plants", "labels": -1.3602867818}, {"text": "First Solar Reaches 4 Gigawatt Manufacturing Milestone", "labels": -3.23514161}, {"text": "First Solar PV Modules Receive UK MCS Certification", "labels": -0.3478669868}, {"text": "IPCC Report Highlights Potential of Renewables and Advantages of PV Solar Electricity", "labels": 3.4045256641}, {"text": "First Solar & China Power International New Energy Announce International Cooperation Framework Agreement", "labels": -3.8938022679}, {"text": "First Solar Announces First Quarter 2011 Financial Results", "labels": -8.3841315356}, {"text": "First Solar to Announce First Quarter 2011 Financial Results on Tuesday, May 3, 2011", "labels": -0.8059131075}, {"text": "First Solar-PV-Module jetzt erh\u00e4ltlich f\u00fcr 10\u201330 kW gewerbliche Solaranlagen", "labels": -3.0802070864}, {"text": "First Solar Announces Departure of Bruce Sohn", "labels": -3.0802070864}, {"text": "Des panneaux solaires de First Solar d\u00e9sormais disponibles pour des syst\u00e8mes solaires commerciaux de 10 \u00e0 30 kW", "labels": -3.0802070864}, {"text": "First Solar PV Modules Now Available for 10-30 kW Commercial Solar Power Systems", "labels": -3.0802070864}, {"text": "First Solar and juwi solar Sponsor Road Cycling Team", "labels": 1.9605314728}, {"text": "First Solar Breaks Ground on Vietnam Factory", "labels": -1.3146487424}, {"text": "First Solar to Build Solar Module Factory in Mesa, Arizona", "labels": -4.4834901048}, {"text": "Mark Widmar to Join First Solar as Chief Financial Officer", "labels": 2.1021372636}, {"text": "First Solar als attraktiver Arbeitgeber ausgezeichnet", "labels": -9.5800225088}, {"text": "First Solar in Germany Recognized as Great Place to Work", "labels": -9.5800225088}, {"text": "First Solar, Inc. Announces Fourth Quarter and Year-end 2010 Financial Results", "labels": -5.4199861131}, {"text": "First Solar feiert Richtfest in Frankfurt (Oder): Zweites deutsches Werk nimmt im Sommer 2011 Produktion auf", "labels": 1.9730739554}, {"text": "First Solar Hosts Roof-Topping Ceremony in Frankfurt (Oder)", "labels": 1.9730739554}, {"text": "Moser Baer Clean Energy Ltd (MBCEL) to use First Solar Modules", "labels": 0.8240076762}, {"text": "Moser Baer Clean Energy Ltd (MBCEL) verwendet Module von First Solar", "labels": 0.8240076762}, {"text": "First Solar to Announce 2010 Fourth Quarter and Year End Financial Results on Thursday, February 24, 2011", "labels": 0.8240076762}, {"text": "Moser Baer Clean Energy Ltd (MBCEL) va utiliser des modules solaires de First Solar", "labels": 0.8240076762}, {"text": "First Solar, Southern California Edison Sign Contract for 250 Megawatts of Solar Photovoltaic Power", "labels": -1.2827867256}, {"text": "First Solar Acquires 15-Megawatt Amherstburg II Solar Project from Helios Energy Inc.", "labels": 5.1703164937}, {"text": "Enbridge to acquire 20 MW of solar energy from First Solar", "labels": 5.1703164937}, {"text": "Southern Company and Ted Turner Energize Cimarron Solar Facility", "labels": 0.2456480741}, {"text": "Department of Energy Offers Support for Arizona Solar Project", "labels": 3.6836088459}, {"text": "Environmental Permitting Final for AV Solar Ranch One", "labels": 2.5542861609}, {"text": "First Solar Acquires RayTracker Inc.", "labels": 0.6816629229}, {"text": "Plutonic Power Agrees to Buy 50 MW Portfolio from First Solar in Partnership with GE Energy Financial Services", "labels": 2.9807437324}, {"text": "First Solar and China Guangdong Nuclear to Develop Ordos Solar Project", "labels": 2.9807437324}, {"text": "Plutonic Power accepte d\u2019acqu\u00e9rir le portefeuille de 50 MW de First Solar en partenariat avec GE Energy Financial Services", "labels": 2.9807437324}, {"text": "Plutonic Power erwirbt gemeinsam mit GE Energy Financial Services 50-MW-Portfolio von First Solar", "labels": 2.9807437324}, {"text": "First Solar Receives Recognition from Canadian Solar Industries Association", "labels": -0.6915719592}, {"text": "NRG to Acquire 290-Megawatt Agua Caliente Solar Project from First Solar", "labels": -1.8275999499}, {"text": "First Solar, Inc. Announces 2011 Financial Guidance", "labels": -1.8275999499}, {"text": "Mike Ahearn Transitions from Executive Chairman to Chairman of the Board of First Solar", "labels": -1.4813296392}, {"text": "ACME Tele Power Ltd unterzeichnet Liefervereinbarung f\u00fcr Solarmodule von First Solar f\u00fcr Photovoltaik-Solarprojekte in Indien", "labels": 0.7356220677}, {"text": "ACME Tele Power Ltd Signs Module Supply Agreement With First Solar for Photovoltaic Solar Power Project in India", "labels": 0.7356220677}, {"text": "ACME Tele Power Ltd signe un accord de fourniture de panneaux solaires avec First Solar pour un projet solaire photovolta\u00efque en Inde", "labels": 0.7356220677}, {"text": "NextEra Energy Resources to purchase Canadian solar projects from First Solar", "labels": -0.7558448049}, {"text": "First Solar to Host Its 2011 Guidance Conference Call on Tuesday, December 14, 2010", "labels": -1.8115942474}, {"text": "First Solar\u2019s Cutting-Edge Photovoltaic Technology Seen by 1.5 Million Visitors to the Shanghai Expo", "labels": -0.1453043804}, {"text": "First Solar named one of the most family-friendly companies in Frankfurt (Oder)", "labels": -3.5034151812}, {"text": "First Solar als familienfreundliches Unternehmen ausgezeichnet", "labels": -3.5034151812}, {"text": "First Solar, Inc. Announces Third Quarter 2010 Financial Results", "labels": -10.3137804782}, {"text": "Sonnige Aussichten f\u00fcr die Kommunen", "labels": 0.8639884118}, {"text": "First Solar to Announce Third Quarter 2010 Financial Results on Thursday, October 28, 2010", "labels": -0.4254136362}, {"text": "First Solar Increases Revolving Credit Facility to $600 million", "labels": -0.0277991561}, {"text": "First Solar porte son instrument de cr\u00e9dit renouvelable \u00e0 600 millions de dollars", "labels": -0.0277991561}, {"text": "First Solar k\u00fcndigt Pl\u00e4ne f\u00fcr zwei neue Produktionsst\u00e4tten an", "labels": 4.3511299062}, {"text": "First Solar annonce deux nouveaux projets d\u2019usines de panneaux solaires", "labels": 4.3511299062}, {"text": "First Solar Announces Plans for Two New Manufacturing Facilities", "labels": 4.3511299062}, {"text": "First Solar gibt Anstieg der Auftr\u00e4ge f\u00fcr 2011 um 380 Megawatt bekannt", "labels": -3.1826805975}, {"text": "First Solar Announces 380 Megawatt Increase in Orders for 2011", "labels": -0.8821894669}, {"text": "First Solar annonce une augmentation de 380 m\u00e9gawatts de ses", "labels": -0.8821894669}, {"text": "Enbridge and First Solar Complete the Largest Photovoltaic Facility in the World", "labels": -2.4328690331}, {"text": "First Solar, Inc. Announces Second Quarter 2010 Financial Results", "labels": -9.8764445525}, {"text": "First Solar to Announce Second Quarter 2010 Financial Results on Thursday, July 29, 2010", "labels": 4.7964549915}, {"text": "First Solar schlie\u00dft Erwerb von NextLight Renewable Power ab", "labels": -0.7348489883}, {"text": "First Solar Completes Acquisition of NextLight Renewable Power", "labels": -0.7348489883}, {"text": "First Solar cl\u00f4ture l\u2019acquisition de NextLight Renewable Power", "labels": -0.7348489883}, {"text": "First Solar schlie\u00dft die solare Wertsch\u00f6pfungskette", "labels": 2.8060372875}, {"text": "First Solar Completes the Solar Value Chain", "labels": 2.8060372875}, {"text": "First Solar Creates Utility Systems Business", "labels": 5.7334850856}, {"text": "First Solar gr\u00fcndet Gesch\u00e4ftsbereich f\u00fcr Versorgungssysteme", "labels": 5.7334850856}, {"text": "First Solar cr\u00e9e une entreprise de syst\u00e8mes \u00e0 usage g\u00e9n\u00e9ral", "labels": 5.7334850856}, {"text": "First Solar Supports Solar Decathlon Europe 2010", "labels": -1.0106727013}, {"text": "First Solar Participa En El Solar Decathlon 2010 Con La Instalacion De Una Pergola Con Sus Modulos Fotovoltaicos De Capa Fina", "labels": -1.0106727013}, {"text": "First Solar Hosts Secretary for the Environment of Hong Kong Enhancing Dialogue on Sustainable Energy Solutions", "labels": 1.6553508784}, {"text": "First Solar Announces Intent to Expand German Manufacturing Plant", "labels": -2.1732782288}, {"text": "First Solar annonce son intention d\u2019agrandir son usine de fabrication en Allemagne Une mesure qui doublerait la capacit\u00e9 de production et cr\u00e9erait des centaines d\u2019emplois", "labels": -2.1732782288}, {"text": "First Solar will deutschen Produktionsstandort erweitern Ausbau w\u00fcrde Kapazit\u00e4t verdoppeln und hunderte neue Jobs schaffen", "labels": -2.1732782288}, {"text": "William J. Post Joins First Solar Board of Directors", "labels": -5.4129159557}, {"text": "First Solar Joins US Clean Energy Business Mission to China", "labels": 1.3409972486}, {"text": "First Solar Agrees to Acquire NextLight Renewable Power, LLC", "labels": 14.9002428946}, {"text": "First Solar, Inc. Announces First Quarter 2010 Financial Results", "labels": 14.9002428946}, {"text": "First Solar to Announce First Quarter 2010 Financial Results on Wednesday, April 28, 2010", "labels": -3.3642418613}, {"text": "The EREC Reports on Achieving a 100% Renewable Energy System by 2050", "labels": -3.9307237204}, {"text": "First Solar schliesst sich Desertec Industrial Initiative an", "labels": -1.1176100523}, {"text": "First Solar rejoint le projet DesertecUn partenariat fort pour renforcer l\u2019\u00e9nergie photovolta\u00efque dans le d\u00e9sert", "labels": -1.1176100523}, {"text": "First Solar Joins Desertec", "labels": -1.1176100523}, {"text": "First Solar Sells 30 Megawatt Solar Photovoltaic Power Project to Southern Company and Turner Renewable Energy", "labels": -0.2516495322}, {"text": "First Solar Becomes Thematic Partner of the Nicolas Hulot Foundation", "labels": 6.5441131864}, {"text": "First Solar, partenaire th\u00e9matique de la Fondation Nicolas Hulot", "labels": 6.5441131864}, {"text": "First Solar Signs Contract with PG&E for 300 MW Photovoltaic Solar Power Project", "labels": 4.5515958191}, {"text": "First Solar Officers Execute Company Stock Transactions", "labels": 0.340845106}, {"text": "First Solar Manufacturing GmbH - einer der attraktivsten Arbeitgeber Deutschlands", "labels": 4.9172547974}, {"text": "CORRECTING and REPLACING First Solar, Inc. Announces 2009 Fourth Quarter and Year-end Financial Results - Maintains Previously Issued 2010 Guidance", "labels": -3.1744664281}, {"text": "First Solar, Inc. Announces 2009 Fourth Quarter and Year-end Financial Results - Maintains Previously Issued 2010 Guidance", "labels": -8.3017217702}, {"text": "First Solar to Announce 2009 Fourth Quarter and Year End Financial Results on Thursday, February 18, 2010", "labels": 1.1563223127}, {"text": "PNM, First Solar Sign Contract for 22 Megawatts of Utility Scale Solar Power for New Mexico", "labels": -3.0376546054}, {"text": "First Solar Acquires Solar Project Development Pipeline from Edison Mission Group", "labels": -6.0046784847}, {"text": "First Solar and NRG Energy Open Largest Solar PV Power Plant in California", "labels": -0.1771258252}, {"text": "First Solar and EDF Energies Nouvelles in Exclusive Talks with Blanquefort", "labels": -0.1771258252}, {"text": "First Solar Announces 2010 Guidance and Capacity Expansion Plans", "labels": -2.9249254739}, {"text": "First Solar Becomes First PV Company to Produce 1GW in a Single Year", "labels": -0.906823303}, {"text": "First Solar Announces TK Kallenbach as EVP of Marketing and Product Management", "labels": 0.1128397416}, {"text": "Enbridge and First Solar Agree on 60 MW Renewable Energy Expansion at Sarnia", "labels": 0.8421981269}, {"text": "First Solar to Webcast Its 2010 Guidance on December 16, 2009", "labels": 4.3865090004}, {"text": "First Solar Sells California Solar Power Project to NRG", "labels": -3.6897287429}, {"text": "First Solar and Ordos Take Key Step Forward in 2GW China Project", "labels": -0.9625447945}, {"text": "First Solar, Inc. Announces 2009 Third Quarter Financial Results", "labels": -17.7433401003}, {"text": "First Solar to Announce Third Quarter 2009 Financial Results on Wednesday, October 28, 2009", "labels": 5.012259101}, {"text": "First Solar Added to the S&P 500 Index", "labels": 0.8476302807}, {"text": "Enbridge to Acquire Ontario Solar Project From First Solar", "labels": 0.3768996848}, {"text": "CORRECTING and REPLACING First Solar to Supply 27 Megawatts of Solar Modules to Juwi for U.S. Utility Installations", "labels": 3.5350555424}, {"text": "First Solar to Supply 27 Megawatts of Solar Modules to Juwi for U.S. Utility Installations", "labels": 3.5350555424}, {"text": "First Solar Secures $300 Million Revolving Credit Facility", "labels": 2.5329917571}, {"text": "First Solar und chinesische Regierung planen gr\u00f6\u00dftes Solarstrom-Kraftwerk der Welt in der chinesischen W\u00fcste", "labels": 9.3038569853}, {"text": "First Solar to Team With Ordos City on Major Solar Power Plant in China Desert", "labels": 9.3038569853}, {"text": "First Solar signe un protocole d\u2019accord avec la ville d\u2019Ordos (Chine) pour la construction d\u2019une importante centrale solaire dans le d\u00e9sert de Chine", "labels": 9.3038569853}, {"text": "First Solar Hosts Chinese National Leadership Delegation Seeking Sustainable Energy Solutions", "labels": 9.3038569853}, {"text": "First Solar annonce Robert J. Gillette au poste de PDG", "labels": 0.1811156816}, {"text": "First Solar k\u00fcndigt Robert J. Gillette als neuen Vorstandsvorsitzenden an", "labels": 0.1811156816}, {"text": "First Solar Announces Robert J. Gillette as CEO", "labels": 0.1811156816}, {"text": "Lieberose Solar Farm Becomes Germany's Biggest, World's Second-Biggest", "labels": -7.2568698604}, {"text": "First Solar, LADWP Contract for 55 Megawatts of Solar Electricity", "labels": -5.3945157055}, {"text": "First Solar, Southern California Edison Sign Contracts for 550 MW of Photovoltaic Solar Electricity", "labels": -5.3945157055}, {"text": "First Solar, Inc. Announces 2009 Second Quarter Financial Results", "labels": -13.2392010637}, {"text": "EDF Energies Nouvelles and First Solar Announce Venture to Build Largest Solar Manufacturing Plant in France", "labels": 8.7351640399}, {"text": "EDF Energies Nouvelles et First Solar s\u2019associent pour construire le plus grand site de fabrication de panneaux solaires en France", "labels": 8.7351640399}, {"text": "EDF Energies Nouvelles und First Solar errichten Frankreichs gr\u00f6\u00dfte Produktionsst\u00e4tte f\u00fcr Solarmodule", "labels": 8.7351640399}, {"text": "First Solar to Announce Second Quarter 2009 Financial Results on Thursday, July 30, 2009", "labels": 6.1776005288}, {"text": "First Solar Held 2009 Analyst and Investor Meeting", "labels": -4.3641879235}, {"text": "First Solar to Webcast Its Analyst/Investor Meeting on June 24, 2009", "labels": -7.1891190536}, {"text": "Lend Lease Collaborates With First Solar to Provide Solar Energy Solutions Across Its Australian Portfolio", "labels": -4.7721501013}, {"text": "First Solar Announces Multi-Year Supply Contract with Pfalzsolar", "labels": 1.6185325284}, {"text": "First Solar, Inc. Announces 2009 First Quarter Financial Results", "labels": 20.1131931867}, {"text": "First Solar Initiates Succession Process to Recruit Next CEO", "labels": 20.1131931867}, {"text": "First Solar to Supply Modules for Australia's Largest Solar PV Installation", "labels": -0.8571260417}, {"text": "First Solar Secures Financing for 53 Megawatt Solar Power Plant in Germany", "labels": 6.7662956383}, {"text": "First Solar sichert Finanzierung f\u00fcr das gr\u00f6\u00dfte Solarkraftwerk in Deutschland", "labels": 6.7662956383}, {"text": "First Solar, Inc. to Announce First Quarter 2009 Financial Results on Wednesday, April 29, 2009", "labels": -0.3567860726}, {"text": "First Solar to Build 48 Megawatt Photovoltaic Power Plant for Sempra Generation in Nevada", "labels": -3.0762978954}, {"text": "First Solar Completes Acquisition of OptiSolar's Photovoltaic Project Pipeline", "labels": 0.6441802013}, {"text": "First Solar Hires Dennis Fitzgibbons as Vice President, Federal Affairs", "labels": 7.0643347034}, {"text": "First Solar to Develop 30 Megawatt AC Solar Power Plant for Tri-State", "labels": 2.8437062846}, {"text": "First Solar Produces 1 Gigawatt of Clean Solar Electricity", "labels": 4.2131003606}, {"text": "First Solar Agrees to Acquire Multi Gigawatt Utility Scale Photovoltaic Pipeline", "labels": 6.2567941954}, {"text": "First Solar Passes $1 Per Watt Industry Milestone", "labels": -18.3372016572}, {"text": "First Solar, Inc. Announces 2008 Fourth Quarter and Year-end Financial Results", "labels": -18.3372016572}, {"text": "First Solar Applauds International Renewable Energy Initiative", "labels": 0.8434947732}, {"text": "First Solar begr\u00fc\u00dft internationale Initiative f\u00fcr erneuerbare Energien", "labels": 0.8434947732}, {"text": "First Solar, Inc. to Announce 2008 Fourth Quarter and Year End Financial Results on Tuesday, February 24, 2009", "labels": -6.6710241056}, {"text": "First Solar to Supply Modules for Masdar City Solar Power Project", "labels": 5.7832511126}, {"text": "First Solar Completes 10MW Thin Film Solar Power Plant for Sempra Generation", "labels": -2.6497776218}, {"text": "Global Solar Leaders and UNEP Outline Central Role for Solar in Climate Solution at United Nations Climate Change Conference in Poland", "labels": -16.2155284725}, {"text": "First Solar Announces Completion of 2MW Solar Power Plant for Southern California Edison", "labels": -2.2390616712}, {"text": "First Solar Announces New Long-Term Module Supply Agreements Totaling 525MW", "labels": 19.1434775167}, {"text": "First Solar and SolarCity Announce 100MW Module Supply Agreement to Serve U.S. Residential Segment", "labels": 19.1434775167}, {"text": "First Solar, Inc. Announces 2008 Third Quarter Financial Results", "labels": 19.1434775167}, {"text": "First Solar, Inc. to Announce 2008 Third Quarter Financial Results on Wednesday, October 29, 2008", "labels": 0.8926110321}, {"text": "First Solar Breaks Ground on Expansion of its Manufacturing and Development Facilities in Ohio", "labels": -19.9843764305}, {"text": "First Solar Management Enters into Pre-Arranged Stock Trading Plans", "labels": -9.4116672996}, {"text": "First Solar Announces Expansion of its Manufacturing and Development Facilities in Ohio", "labels": -2.9411827148}, {"text": "First Solar, Inc. Announces 2008 Second Quarter Financial Results", "labels": 2.1155663632}, {"text": "First Solar to Build 10 MW Solar PV Power Plant for Sempra Generation", "labels": -0.2057488998}, {"text": "First Solar, Inc. to Announce 2008 Second Quarter Financial Results on Wednesday, July 30, 2008", "labels": -5.1679445985}, {"text": "First Solar to Participate in Investor Conferences", "labels": -5.1679445985}, {"text": "First Solar Announces Two California Solar Projects with Southern California Edison", "labels": -4.5327183782}, {"text": "First Solar Announces Executive Management Appointments", "labels": -0.3064092982}, {"text": "First Solar, Inc. Announces 2008 First Quarter Financial Results", "labels": -12.9941144589}, {"text": "First Solar Hires Larry Polizzotto as Vice President, Investor Relations", "labels": -0.9159085269}, {"text": "First Solar, Inc. to Announce 2008 First Quarter Financial Results On Wednesday, April 30, 2008", "labels": 4.1740772715}, {"text": "First Solar, Inc. Announces 2007 Fourth Quarter and Year-end Financial Results", "labels": 4.2568351524}, {"text": "First Solar, Inc. to Announce 2007 Fourth Quarter and Year End Financial Results On Wednesday, February 13, 2008", "labels": 5.4950705962}, {"text": "First Solar Hires Kathy Weiss as Vice President, Government Relations", "labels": 6.9418492961}, {"text": "First Solar Hires John Gaffney as Executive Vice President and General Counsel", "labels": -2.0153766105}, {"text": "First Solar to Present At the Lehman Brothers Global Technology Conference", "labels": -2.0970704941}, {"text": "ADDING -- First Solar to Webcast Analyst Day", "labels": -10.8837544673}, {"text": "First Solar to Webcast Analyst Day", "labels": -10.8837544673}, {"text": "First Solar Announces Acquisition of Turner Renewable Energy", "labels": -7.9748707277}, {"text": "Bruce Sohn, President of First Solar, Inc. to Keynote Livingston Nanotechnology Conference", "labels": -2.0611787684}, {"text": "First Solar, Inc. Announces 2007 Third Quarter Financial Results", "labels": 24.0253085277}, {"text": "First Solar Announces Expansion", "labels": 14.9467423117}, {"text": "Additional Four Production Lines to Support New Long Term Module Supply Agreements Totalling 557MW", "labels": 14.9467423117}, {"text": "First Solar, Inc. to Announce 2007 Third Quarter Financial Results On Wednesday, November 7, 2007", "labels": -3.1555935112}, {"text": "First Solar Announces Expansion", "labels": 1.7241369255}, {"text": "First Solar Adds Two New Members to Board of Directors", "labels": -0.1581447071}, {"text": "First Solar Prices Offering", "labels": 0.3558760352}, {"text": "First Solar, Inc. Announces 2007 Second Quarter Financial Results", "labels": -14.4093003384}, {"text": "First Solar, Inc. to Announce 2007 Second Quarter Financial Results On Tuesday, July 31, 2007", "labels": 0.6068999192}, {"text": "First Solar, Inc. Announces Filing of Registration Statement", "labels": -0.9805718513}, {"text": "First Solar Announces Expansion", "labels": 8.2339621679}, {"text": "First Solar, Inc. Announces 2007 First Quarter Financial Results", "labels": 11.1244355449}, {"text": "First Solar Announces Groundbreaking of Malaysian Plant", "labels": 1.9322160793}, {"text": "First Solar, Inc. to Announce 2007 First Quarter Financial Results on Thursday, May 3, 2007", "labels": 0.5910369582}, {"text": "First Solar Management Enters Into Pre-Arranged Stock Trading Plans", "labels": -7.704504031}, {"text": "First Solar Appoints Bruce Sohn as President", "labels": 0.2593449983}, {"text": "First Solar to Supply Modules for 40 MW Solar Plant", "labels": 10.2267641639}, {"text": "First Solar liefert Module f\u00fcr 40 MW-Solarkraftwerk", "labels": 10.2267641639}, {"text": "First Solar ernennt Bruce Sohn zum Pr\u00e4sidenten", "labels": 10.2267641639}, {"text": "First Solar, Inc. Announces 2006 Fourth Quarter and Year-end Financial Results", "labels": 23.3302847167}, {"text": "First Solar, Inc. to Announce 2006 Fourth Quarter and Year End Financial Results On February 13, 2007", "labels": -0.3774900915}, {"text": "First Solar Announces 100MW Manufacturing Plant Expansion in Malaysia", "labels": -0.3774900915}, {"text": "First Solar gibt Expansion bekannt: Bau einer 100 MW-Produktionsanlage in Malaysia", "labels": 3.9451102353}, {"text": "First Solar Increases Volumes Under Long-Term Sales Contracts", "labels": 0.5486963246}, {"text": "First Solar Appoints Energy Industry Veteran, Paul H. Stebbins to Board of Directors", "labels": -0.7919341538}, {"text": "First Solar Exercises Options to Increase Sales Volumes and Extend Contracts Through 2012", "labels": -5.5055729719}, {"text": "First Solar Announces Closing of IPO and Exercise of Over-Allotment Option", "labels": 13.333335576}, {"text": "Photo Release -- First Solar's Initial Public Offering Priced at $20 Per Share", "labels": 2.0}, {"text": "Ford Re-Opens Orders for Mustang Mach-E with Higher EPA Est. Range, BlueCruise 1.2 Hands-Free Tech, Lower Pricing", "labels": -2.6571716693}, {"text": "Fords First-Quarter Volumes Sales Profits Cash Flow All Up; Distinct Segments Sharpen Focus Speed Accountability", "labels": -2.6571716693}, {"text": "Ford\u2019s Oakville, Ontario, Manufacturing Site Prepares to Build Next-Gen EVs; C$1.8 Billion Transformation Begins 2024", "labels": 0.1556396484}, {"text": "Ford Motor Company Board Declares Dividend for Q2 2023", "labels": 0.6959100742}, {"text": "Ford Becomes America\u2019s Best-Selling Brand in the First Quarter on Rising Sales for Trucks, Vans, Broncos, Large SUVs, EVs, Mustang", "labels": -1.4683821896}, {"text": "Road to Better: Ford Releases 2023 Integrated Sustainability and Financial Report, Details Progress Toward Carbon Neutrality and Commitment to Responsible EV Supply Chain", "labels": -1.1602593376}, {"text": "Ford Motor Company Issues 2023 Proxy Statement, Announces May 11 as Date for Virtual Annual Meeting", "labels": 0.384136167}, {"text": "PT Vale Indonesia and Huayou Sign Agreement with Ford Motor Co. Supporting Growth of the Global Sustainable EV Industry", "labels": 0.276265962}, {"text": "Ford to Build Next Electric Truck \u2013 \u2018Project T3\u2019 \u2013 at BlueOval City; BlueOval Learning Will Prepare Nearly 6,000 for Jobs", "labels": 2.2258599872}, {"text": "\u2018Refounded\u2019 Ford to Show How Customer-Focused Segments Will Drive Value and Growth, Changes in Financial Reporting", "labels": -2.393720713}, {"text": "Ford to Host March 23 \u2018Teach-In\u2019 About Financial Reporting, Strategic Implications of New Customer-Focused Segments", "labels": -0.1759084113}, {"text": "Ford\u2019s Sustainability Chief Bob Holycross to Speak at Deutsche Bank ESG Conference on March 9", "labels": 0.9172402673}, {"text": "Ford US February 2023 Sales Release", "labels": 0.9884407754}, {"text": "Ford China\u2019s Anning Chen Announces Intention to Retire; Sam Wu Will Follow Him as Company President and CEO", "labels": 1.5610566603}, {"text": "Ford, LG Energy Solution, and Ko\u00e7 Holding to Establish a Joint Venture to Produce Battery Cells as Ford Prepares to Bring More EVS to Customers In Europe", "labels": -1.5372443435}, {"text": "Ford Takes Next Steps to Transform European Business; Aligns Organization and Product Portfolio to Rapidly Changing Industry and Market Conditions", "labels": 0.9040269607}, {"text": "Ford Taps Michigan for New LFP Battery Plant; New Battery Chemistry Offers Customers Value, Durability, Fast Charging, Creates 2,500 More New American Jobs", "labels": 1.3268166993}, {"text": "People, Plan, Products Position Ford Well for \u2018Pivotal\u2019 2023 Despite Effect of Volume Shortfall on Q4, Full-Year 2022 Results", "labels": 0.7725451558}, {"text": "Ford to Significantly Increase Production of Mustang Mach-E in 2023, Reduces Prices Across the Board", "labels": 0.5215806917}, {"text": "Ford Releases First Sustainable Financing Report, Update on Allocation and Impact of Green Bond Investments", "labels": 0.9004263737}, {"text": "F-150 Lightning Wins MotorTrend Truck of the Year for 2023, Setting Precedent with Unanimous Vote by Judges", "labels": -2.6085012272}, {"text": "Ford, SK On Make Significant Construction Progress at BlueOval SK Battery Park, On-Plan to Train 5,000 Employees at On-Site Training Center", "labels": -1.4372599548}, {"text": "Ford to Increase Investment at Halewood to Scale Up Electric Vehicle Portfolio", "labels": -2.2343701076}, {"text": "Ford produces 150,000th Mustang Mach-E", "labels": 0.1101064156}, {"text": "Ford Credit Earns Sixth J.D. Power Top Ranking Since 2015", "labels": -1.3991221057}, {"text": "Ford's Jim Baumbick to Oversee Quality; Armstrong, Rowley, Falotico to Retire; Craig to lead Global Lincoln Business", "labels": -0.3537706647}, {"text": "Ford Strengthens Position As America\u2019s No. 2 EV Brand; All-New Super Duty Off to Hot Start \u2013Orders Exceed 50,000 in Five Days", "labels": -0.3537706647}, {"text": "Doug Field to Discuss Ford\u2019s Focus on Software-Defined Vehicles and Services at Bernstein Conference on Nov. 7", "labels": 0.0787539617}, {"text": "Ford Credit CFO Schaaf to retire; Eliane Okamura named CFO", "labels": 1.9118169016}, {"text": "Ford Fulfills Earnings Guidance, Has Strong Cash Flow in Q3; Will Accelerate Development of L2+/L3 ADAS Technology", "labels": 1.2841102578}, {"text": "Ford China Sells 133,000 Vehicles in Third Quarter; Strengthens Sales Rebound with Quarter-over-Quarter Growth", "labels": -4.6783011839}, {"text": "All-New Ford F-Series Super Duty Is Built Like Never Before With Next-Level Capability, Connectivity and Technology", "labels": 0.2222533624}, {"text": "Ford Announces New Manufacturing Investment and Jobs Commitment in Kentucky", "labels": 0.2222533624}, {"text": "Ford Announces Leadership Changes to Strengthen Product Creation and Transform Global Supply Chain Management", "labels": -3.8849120822}, {"text": "Ford Previews Effect of Parts Shortages on Q3 Performance, Reaffirms Full-Year Adjusted EBIT Guidance of $11.5-$12.5B", "labels": -0.1467608623}, {"text": "Benchmark for Street and Track, Ford Introduces Mustang Dark Horse and New Family of Track-Only Race Ponies", "labels": 0.9926258915}, {"text": "All-New Ford Mustang Redefines Driving Freedom with Immersive Digital Cockpit, Advanced Engines and Bold Style", "labels": 0.9926258915}, {"text": "Ford Pro Launches All-New Fleet Management Suite, Offers Bundled Solutions for Small Businesses", "labels": -1.6792886583}, {"text": "All-New, All-Electric E-Transit Custom from Ford Pro is Set to Spark the EV Revolution for Small Businesses", "labels": 3.2642365456}, {"text": "BlueCruise Adds Hands-Free Lane Changing, Tech to Make Road-Sharing Easy with Bigger Vehicles on Key 2023 Models", "labels": 3.2642365456}, {"text": "Bill Ford Statement On The Passing Of Queen Elizabeth II", "labels": 3.2642365456}, {"text": "Ford Motor Company and DTE Energy Announce the Largest Renewable Energy Purchase From a Utility in U.S. History", "labels": 1.8145518912}, {"text": "BlueCruise Ford Power-Up Software Update Transforms F-150, Mustang Mach-E Models for Hands-Free Driving", "labels": 0.0953506632}, {"text": "Ford Achieves Solid Second-Quarter 2022 Operating Results, While Organizing, Deploying Toward Ambitious Ford+ Future", "labels": 0.696804934}, {"text": "Ford Releases New Battery Capacity Plan, Raw Materials Details to Scale EVs; On Track to Ramp to 600K Run Rate by \u201923 and 2M+ by \u201926, Leveraging Global Relationships", "labels": 0.2788381403}, {"text": "Ford to Provide Electric Vehicle Plan Update Thursday", "labels": 1.0579257256}, {"text": "700 Horsepower! New Ford F-150 Raptor R Is Most Powerful Raptor Ever for High-Performance Off-Roading", "labels": -0.1833111857}, {"text": "Ford Execs to Discuss Ford+ Plan, Q2 Results, 2022 Outlook During July 28 Fireside Chat with BNP Paribas Exane Analyst", "labels": 4.3913309987}, {"text": "Ford\u2019s Thai-Tang and Toney to Retire After Stellar Careers; Dave Bozeman Joins Ford to Lead FCSD, Enthusiast Vehicles", "labels": 4.3913309987}, {"text": "Ford Motor Company Announces Details for Q2 2022 Earnings Conference Call", "labels": 4.3913309987}, {"text": "Ford Speeds Toward All-Electric, Connected Future in Europe; Chooses Valencia Plant, Spain, for Next-Gen EV Architecture", "labels": -0.8426999452}, {"text": "Ford Credit Announces Expiration of Its Tender Offers for Certain Outstanding Debt Securities Maturing in 2022 and 2023; Increases Maximum Purchase Amount", "labels": 1.9770334619}, {"text": "Ford Credit Commences Cash Tender Offers for Certain Outstanding Debt Securities Maturing in 2022 and 2023", "labels": -2.4548580545}, {"text": "Ford To Invest $3.7B and Add 6,200 UAW Jobs To Help Deliver Ford+ Plan", "labels": 0.1997657994}, {"text": "Ford US May 2022 Sales Release", "labels": 0.1997657994}, {"text": "John Lawler to Discuss Continued Execution of Ford+ Plan at Deutsche Bank 2022 Global Automotive Conference", "labels": 1.5654437808}, {"text": "Jim Farley to Discuss Ford+ Plan for Growth, Value Creation, Shift to Digital EVs at Bernstein Conference on June 1", "labels": 4.6692006663}, {"text": "Ford Pro Reveals Exciting Next Phase of Electrification Journey with All-New, All-Electric E-Transit Custom", "labels": -2.7083840406}, {"text": "Ford US April 2022 Sales Release", "labels": 0.9038038547}, {"text": "How Ford F-150 Lightning Software Accurately Estimates Range to Give Customers Confidence While Towing", "labels": 2.5603627023}, {"text": "Ford\u2019s Q1 Demand Strong, Supplies Limit Product Shipments; Affirms Full-Year Adjusted EBIT Guidance of $11.5-$12.5 Billion", "labels": 0.8188675783}, {"text": "America\u2019s Best-Selling Vehicle Now Electric: Production Begins for F-150 Lightning Trucks", "labels": -2.6519495617}, {"text": "Leading From the Front: Ford Pro Open for Business to Drive Productivity for Europe\u2019s Commercial Fleets", "labels": -2.4305068996}, {"text": "Ford Motor Company Announces Details for Q1 2022 Earnings Conference Call", "labels": 2.3787838331}, {"text": "Ford China Sells 125,000 Vehicles in First Quarter, Accelerating Localization and Delivery of Ford+ Growth Plan", "labels": 1.5257707719}, {"text": "Lake Resources and Ford Sign Non-binding MoU to Negotiate for Lithium Offtake From the Kachi Project", "labels": -1.1099263643}, {"text": "Lake Resources and Ford Motor Company sign non-binding MoU to negotiate for lithium offtake from the Kachi Project", "labels": -1.1099263643}, {"text": "Ford Takes In Record 50,000 F-Series Retail Vehicle Orders in March; Ford Electrified Vehicle Sales Post Record; Ford Pro Continues Strong Momentum; Ford Bronco Family Achieves Record March Sales; Lincoln SUV Demand Strengthens", "labels": 0.1551252001}, {"text": "Ford to Hold 2022 Virtual Annual Shareholder Meeting on May 12", "labels": -1.0963034463}, {"text": "Ford Releases Inaugural Human Rights Report, Increases Climate Risk Disclosure in 2022 Integrated Report As It Transitions to Electric Future", "labels": -3.3404923236}, {"text": "Kiersten Robinson Selected for Ford Blue Operating Position; Jennifer Waldo, Christopher Smith Join as New Ford Leaders", "labels": 1.5916300321}, {"text": "Ford Takes Bold Steps Toward All-Electric Future in Europe; 7 New Connected EVs Support Plans to Sell 600K+ EVs Annually by 2026", "labels": 2.2795708215}, {"text": "Ford, SK and Ko\u00e7 Set to Create a Joint Venture to Accelerate Ford\u2019s Electrification Revolution in Europe", "labels": 2.2795708215}, {"text": "Ford Strengthens Further its Electric Vehicle Product Range and Commercial Vehicle Growth Capability in Craiova, Romania", "labels": 2.2795708215}, {"text": "Jim Farley to Discuss the Auto Industry\u2019s Shift to Electrification at CERAWeek Annual Conference", "labels": -0.7887110334}, {"text": "Hans Schep to Discuss How Ford Pro Drives European Leadership at Jefferies Spring Automotive Conference", "labels": -4.0476051061}, {"text": "Ford Accelerating Transformation: Forming Distinct Auto Units to Scale EVs, Strengthen Operations, Unlock Value", "labels": 0.7231043707}, {"text": "Ford Takes In Over 72,000 New Retail Vehicle Orders In February; Record Start For Ford Brand SUV Retail Sales; Ford Electrified Sales Charge Ahead Conquesting From Competitors At 54 Percent; Lincoln SUVs Post Strong Sales Gains", "labels": 0.7231043707}, {"text": "Ford Plans Wednesday Announcement About Acceleration of Ambitious Ford+ Plan for Growth and Value Creation", "labels": -0.5456431974}, {"text": "Ford to Webcast Fireside Chats with Company Leaders on Feb. 23 & Feb. 24", "labels": 0.3161466485}, {"text": "Built for America, Ready for Work: Ford Pro\u2122 Begins Shipping Electric E-Transit to Customers, Works to Boost Production", "labels": 1.0217113773}, {"text": "Strategic Progress of Ford+ Growth Plan, Solid Financials in \u201921 Position Company for Connected EV Leadership in 2022, Beyond", "labels": 1.6780381068}, {"text": "Ford Begins 2022 With Record Electrified and SUV Sales Momentum; Electrified Vehicle Sales Expand At Almost 4 Times Rate Of Overall Industry Segment; F Series Hits 40 Millionth Sale; January New Retail Vehicle Orders Hit 90,000 A New Record", "labels": -1.2105035804}, {"text": "Ford and JMC Launch Passenger Vehicle Joint Venture in China", "labels": -2.3467013764}, {"text": "Farming of the Future: Ford Pro, Sonoma County Winegrowers Join Forces to Electrify Business of Farming", "labels": -2.3467013764}, {"text": "Productivity Accelerated: Ford Pro Announces New Partners, Services; Demand Strong with Orders for 10,000 E-Transits", "labels": -2.3467013764}, {"text": "Ford of Europe Q4 2021 Sales", "labels": 2.8866882379}, {"text": "Desert-Racing, Rock-Crawling 2022 Ford Bronco Raptor Debuts as Most Powerful Street-Legal Bronco Ever", "labels": 2.9004254094}, {"text": "Ford Provides Update on Certain Special Items for FY2021 Results", "labels": -4.5994780492}, {"text": "Ford Motor Company Announces Details For Q4 2021 Earnings Conference Call", "labels": -4.5994780492}, {"text": "Ford and ADT to Form Joint Venture to Fortify Vehicle Security With Breakthrough Technology", "labels": -4.5994780492}, {"text": "Ford-Stripe Agreement to Accelerate Easy Payment Experiences for Customers, Dealers", "labels": -4.5994780492}, {"text": "Ford China Full-Year 2021 Sales Increase with Significant Lincoln Gains, Building Foundation for Growth in Electric Vehicle Segment", "labels": -6.6185433556}, {"text": "Ford Motor Company Board Declares Dividend for First-Quarter 2022", "labels": -0.9433333269}, {"text": "Ford Best-Selling Automaker in Q4; Becomes No. 2 for Electric Vehicle Sales for 2021; F-Series Best-Selling Truck for 45thYear In Row and Best-Selling Vehicle for 40th straight year; SUV Share Expands", "labels": -1.3895764557}, {"text": "Full Speed Ahead: Ford Planning to Nearly Double All-Electric F-150 Lightning Production to 150,000 Units Annually; First Wave of Reservation Holders Invited to Order", "labels": 0.2741692231}, {"text": "Lend a Hand \u2013 and a Few Miles \u2013 to Your Friends Using Vehicle-to-Vehicle Charging on F-150 Lightning, F-150 Hybrid", "labels": 0.8232239555}, {"text": "Ford Pro Charging Launches to Help Businesses of All Sizes Overcome the Hurdle to Seamless Electrification", "labels": -2.315643754}, {"text": "John C. May, Chairman and CEO of Deere & Co., Named to Ford Board", "labels": 0.1063703538}, {"text": "Ford Invests US$900 Million to Modernize Thailand Manufacturing for Next-Gen Ranger and Everest; Adds 1250 New Jobs", "labels": -1.3710515767}, {"text": "Ford Launches VIIZR, a Technology Built on Salesforce to Help Small Businesses and Tradespeople Thrive", "labels": -0.7280340783}, {"text": "Ford F-Series Best-Selling Truck for 45th Year In Row; Ford Brand SUVs Post Record November Retail Sales; Ford Electrified Vehicle Sales Hit New Record, Grow More Than 3 Times Faster Than Segment; November New Vehicle Orders Hit 74,000", "labels": -0.9728983284}, {"text": "Ford to Present Updates on Its Electric Vehicle Leadership at Dec. 3 Goldman Sachs, Credit Suisse Conferences", "labels": -0.8043645249}, {"text": "GlobalFoundries, Ford to Address Auto Chip Supply and Meet Growing Demand", "labels": -2.1563556867}, {"text": "Ford Pro CEO Ted Cannis to Discuss Electrification, Commercial Vehicles, Digital Connectivity at Barclays Global Automotive and Mobility Tech Conference", "labels": -1.118770611}, {"text": "Ford and Purdue Patent Charging Station Cable for Research That Could Lead to Recharging EVs as Quickly as Gas Fill-Ups", "labels": 0.0954751685}, {"text": "Ford Pro Readies American Businesses; All-Electric E-Transit Customer Pilot Vehicles Debut Nationwide", "labels": 0.0946218491}, {"text": "Ford Motor Company Commences Cash Tender Offers for Outstanding Debt Securities", "labels": -1.1603563915}, {"text": "Ford Ford Credit Introduce Sustainable Financing Framework Prioritizing EV Clean Production Community Investments", "labels": -1.1603563915}, {"text": "New Products, Strong Inventory Make Ford America\u2019s Top-Selling Automaker For Second Straight Month; Ford Brand SUVs Post Best October Results in 21 Years; F-Series Expands Lead; October New Vehicle Orders Hit 77,000; Lincoln Brand SUV Sales Continue to Climb", "labels": -1.0933598729}, {"text": "Ford Achieves Strong Q3 Results, Raises Full-Year 2021 Guidance; Says Financial Flexibility Enables Ample Investment in Ford+ Plan", "labels": 0.0234778708}, {"text": "Ford of Europe Q3 2021 Sales", "labels": 0.5323508579}, {"text": "Mustang Mach-E Rolls Off Assembly Line in China for Delivery to Local Customers by Year End; Sold Through Network of Direct-to-Customer EV Stores", "labels": 1.2398529197}, {"text": "Ford to Invest \u00a3230 Million to Transform Halewood Operations in U.K. to Build its First Electric Vehicle Components in Europe", "labels": 1.2398529197}, {"text": "Ford China Year-to-Date Sales Grow 11%, Driven by Record Lincoln Sales", "labels": 2.9169934034}, {"text": "New Products, Improved Inventory Propels Ford To Top-Selling Automaker in September with Retail Sales Up 34.3 Percent Compared to August; 52,000 New Vehicle Orders Placed; Lincoln Brand Retail Sales Increase 52.6 Percent Over August as Nautilus Sales Soar", "labels": 1.5950105241}, {"text": "Ford Renews $15.5 Billion in Revolving Corporate Credit Lines, Aligning Them With Sustainability Priorities in Ford+ Strategic Plan", "labels": -1.5395028697}, {"text": "Ford to Lead America\u2019s Shift to Electric Vehicles with New Mega Campus in Tennessee and Twin Battery Plants in Kentucky; $11.4B Investment to Create 11,000 Jobs and Power New Lineup of Advanced EVs", "labels": 0.650278285}, {"text": "Ford Motor Company Announces Details For Q3 2021 Earnings Conference Call", "labels": 3.0912689699}, {"text": "Ford, Redwood Materials Teaming Up on Closed-Loop Battery Recycling, U.S. Supply Chain", "labels": 3.7101223804}, {"text": "New Ford Expedition Raises Bar Among Full-Size SUVs with Most Off-Road Capable, Most Powerful, Smartest Expedition Ever", "labels": 1.5265276357}, {"text": "Ford Begins Pre-Production of All-Electric F-150 Lightning Truck, Boosts Investment, Adds Jobs in Michigan", "labels": -1.0971777584}, {"text": "Ford, Argo AI, and Walmart to Launch Autonomous Vehicle Delivery Service in Three U.S. Cities", "labels": 0.8666159903}, {"text": "Mike Amend Brings Multi-Industry Record of Growth, Value Creation To New Assignment as Ford\u2019s Chief Digital and Information Officer", "labels": -0.9295272707}, {"text": "Ford Pro Builds Accomplished Leadership Team Focused on Success of Commercial and Government Customers", "labels": -0.578320865}, {"text": "Ford Restructures India Operations: Plans to Grow Ford Business Solutions; Serve Customers with Iconic Global Vehicles; Cease Local Vehicle Manufacturing", "labels": -0.578320865}, {"text": "Lisa Drake to Discuss Ford\u2019s Plans to Lead in the Electric Revolution at Morgan Stanley Virtual Laguna Conference", "labels": 0.1884812194}, {"text": "Ford Names Doug Field Chief Advanced Technology and Embedded Systems Officer", "labels": -0.9400691953}, {"text": "Ford Retail Sales Grow 6.5 Percent From Last Month Due To Production and Inventory Improvements; 41,000 New Retail Orders, Up 4-Fold; F-Series Has Best Performance Since Semiconductor Chip Shortage Began, Up 11 Percent From July; F-150 Lightning Tops 130,000 Reservations", "labels": -0.3323068958}, {"text": "Ford Credit CFO Brian Schaaf to Speak August 12 at J.P. Morgan Automotive Conference", "labels": -1.1876630579}, {"text": "Ford Mustang Mach-E Sales Grew 15.8 Percent in July, Second Largest In Electric SUV Segment; New Vehicle Launches of F-150 Hybrid, Bronco, Mustang Mach-E Expand Ford\u2019s Competitive Conquest Rate; Ford Accessory Business Climbs 23 percent, On Track To Post New Record", "labels": 1.2406154833}, {"text": "Hau Thai-Tang to Discuss Ford+, Winning in Electrification At J.P. Morgan Virtual Automotive Conference Next Week", "labels": -0.4694675069}, {"text": "Ford\u2019s Expectations for Better Full-Year 2021 Operating Results Driven by Strong Order Bank, Improving Semiconductor Supplies", "labels": 0.4640572106}, {"text": "Argo AI and Ford to Launch Self-Driving Vehicles on Lyft Network by End of 2021", "labels": -0.7420550661}, {"text": "Ford of Europe Q2 2021 Sales", "labels": -0.7420550661}, {"text": "Ford Provides Details on Three Safety Recalls in North America", "labels": -6.1168933094}, {"text": "Ford China First-Half Sales Grow 24%, Driven by Doubling of Lincoln Sales and Double-Digit Growth in SUV and Commercial Vehicle Sales", "labels": 2.6706113852}, {"text": "Mustang Mach-E Takes Top Spot in Car and Driver\u2019s Inaugural Electric Vehicle of the Year Award 2021", "labels": -0.7088952798}, {"text": "Ford Names Steven Croley Chief Policy Officer, General Counsel, As Company Organizes to Support Ford+ Plan for Growth", "labels": -0.7088952798}, {"text": "Ford Motor Company Announces Details For Q2 2021 Earnings Conference Call", "labels": -1.4258690456}, {"text": "Ford Electrified Vehicle Sales Up 117 Percent in June \u2013 Delivering New First Half Record - Mustang Mach-E Sales Up 27 Percent Over May; Ford SUVs Post Best First Half Retail Sales In 20 Years On Strength From New Products; Lincoln SUVs Set New Record, Retail Sales Up 23 Percent", "labels": -1.6557083416}, {"text": "Ford Motor Company Issues Safety Recall for Certain 2015-2020 Ford Transit Vehicles in Canadian Corrosion Provinces", "labels": 1.1274590182}, {"text": "Ford Says Q2 2021 Adjusted EBIT Will Exceed Its Expectations", "labels": -6.2060782063}, {"text": "Ford Acquires Electriphi to Provide Ford Pro Commercial Customers with Seamless Charging and Energy Management", "labels": -6.2060782063}, {"text": "Lincoln Accelerates Brand Transformation; Plans to Deliver a Full Portfolio of Connected and Electrified Vehicles by 2030", "labels": -1.9570478256}, {"text": "Ford Motor Company Issues Safety Recall for Select 2021 Super Duty Vehicles", "labels": -3.2027237021}, {"text": "40 MPG City. Standard Hybrid. Seats Five. Starts Under $20K. All-New 2022 Ford Maverick: Did We Mention It\u2019s a Truck?", "labels": -0.9512844893}, {"text": "Ford CEO Jim Farley to Speak at Deutsche Bank Virtual Global Auto Industry Conference on June 17", "labels": -0.9512844893}, {"text": "Record Ford Electrified Vehicle Sales Run Continues \u2013 Up 184 Percent On Strength of F-150 PowerBoost Hybrid, Mustang Mach-E, Escape and Explorer Hybrid; Ford SUVs Post Best May Retail Sales Since 2003; Record SUV Sales for Lincoln on Gains From Entire Lineup", "labels": 0.6188429468}, {"text": "New \u2018Ford Pro\u2019 Vehicle Services and Distribution Business Redefining Transportation Value for Commercial Customers", "labels": 0.4745979231}, {"text": "Superior Value From EVs, Commercial Business, Connected Services Is Strategic Focus of Today\u2019s \u2018Delivering Ford+\u2019 Capital Markets Day", "labels": 0.4745979231}, {"text": "Ford Introduces All-Electric F-150 Lightning Pro, Built for Work with Next-Generation Technology, Seamless Overnight Charging", "labels": -0.9329457621}, {"text": "Ford Commits to Manufacturing Batteries, to Form New Joint Venture with SK Innovation to Scale NA Battery Deliveries", "labels": 1.1250451074}, {"text": "Ford Motor Company to Host Capital Markets Day on May 26", "labels": -2.3054624863}, {"text": "Ford to Reveal All-Electric F-150 Lightning May 19 with Livestreamed Event at Ford HQ", "labels": -1.8670733295}, {"text": "Ford Motor Company Issues Safety Recall", "labels": -1.8670733295}, {"text": "Ford Electrified Vehicle Sales Post Best Sales Month Ever \u2013 Up 262 Percent on Mustang Mach-E and F-150 PowerBoost Hybrid; F-Series Up 31.8 Percent; Ford Brand SUVs Achieve Record April Sales On Higher Bronco Sport Sales; Lincoln SUVs \u2013 Deliver Record April Sales", "labels": 2.9520160669}, {"text": "Ford Boosts Investment in Solid Power, Aiming to Accelerate Solid-State Vehicle Battery Development for Customers", "labels": 0.4051674911}, {"text": "Ford Announces New Roles for Armstrong, Watters As Company Speeds Turnarounds of Key Regional Units", "labels": 1.7784841677}, {"text": "Enhanced Execution, Fresh Portfolio of Exciting Vehicles Drive Ford\u2019s Strong Q1 Profitability, As Trust in Company Rises", "labels": 1.7784841677}, {"text": "Ford Accelerates Battery R&D with Dedicated Team, New Global Battery Center of Excellence Named Ford Ion Park", "labels": 1.136440131}, {"text": "Ford to Build New Light Commercial Vehicle in Romania in 2023; All-Electric Model Debuts Following Year", "labels": 1.136440131}, {"text": "Ford of Europe Q1 2021 Sales", "labels": -0.7992221532}, {"text": "Ford: Virtual Annual Shareholder Meeting Details", "labels": 1.3372541953}, {"text": "Ford Director Jon Huntsman to Join Company as Vice Chair, Policy", "labels": 0.4600051998}, {"text": "Starting from RMB 265,000, Mustang Mach-E Manufactured in China Opens for Pre-order; Ford China Launches Direct Sales Model for Electric Vehicles", "labels": -2.3411184457}, {"text": "Ford Motor Company Announces Details For Q1 2021 Earnings Conference Call", "labels": 1.4589116376}, {"text": "Ford China First-Quarter Sales Grow 73.3 Percent, Marking Fourth Consecutive Quarter of Year-Over-Year Growth", "labels": 1.3022182202}, {"text": "Ford Electrified Vehicle Sales Up 74 Percent on Strong Sales of Mustang Mach-E and F-150 PowerBoost Hybrid; F-Series Up 9.2 Percent; Ford Bronco Sport Powers Ford Brand SUVs To Best Retail Start in 20 Years; Lincoln SUVs \u2013 Best Retail Start Since 2001", "labels": 1.6986107212}, {"text": "Ford\u2019s New Science-Based, Interim Carbon-Neutral Targets Highlight First Integrated Sustainability, Financial Report", "labels": 0.2797535713}, {"text": "Ford Continues to Go All-In on Electrification with New Hybrid Engine and Increased Battery Pack Assembly in Spain; Continuing to Evolve Passenger Vehicle Range", "labels": 3.2819604976}, {"text": "Ford Announces FORDLiive \u2013 a New Commercial Vehicle Uptime Accelerator to Maximise Productivity for Businesses", "labels": -2.2346944396}, {"text": "Ford Motor Company Announces Pricing of $2.0 Billion Convertible Notes Offering", "labels": 1.4652684646}, {"text": "Next Generation Ford Transit Custom All-Electric Coming in 2023; New Vehicle Built in Turkey by Ford Otosan", "labels": 0.6447824966}, {"text": "Ford Motor Company Announces $2.0 Billion Convertible Notes Offering", "labels": 0.6447824966}, {"text": "Ford Motor Company Provides Details on Two Safety Recalls in North America", "labels": -0.9590281087}, {"text": "Ford Nominates Alexandra Ford English and Henry Ford III for Election to Board; Edsel B. Ford II to Retire After 33 Years as Director", "labels": -0.9590281087}, {"text": "Ford Senior Leaders to Describe Opportunities in Europe at Jefferies Conference on March 10", "labels": -0.2027338012}, {"text": "Ford Posts Record February Electrified Vehicle Sales on First Full Month of Mustang Mach-E and Strong F-150 PowerBoost Hybrid Sales; F-Series Expands Retail Sales and Share; Lincoln Navigator Delivers Best February Sales Since 2007", "labels": -0.4450285996}, {"text": "Ford Credit CFO Brian Schaaf to Speak March 2 at J.P. Morgan Global High Yield & Leveraged Finance Conference", "labels": 0.7077466273}, {"text": "Ford\u2019s Chief Sustainability, Environment & Safety Officer Bob Holycross to Speak at RBC Global ESG Conference on Feb. 25", "labels": 2.483233186}, {"text": "Ford Motor Company Issues Safety Compliance and Safety Recalls in North America", "labels": 2.483233186}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": 2.7158380461}, {"text": "Ford CEO Jim Farley to Speak at Wolfe Research Virtual Global Auto, Auto Tech, and Mobility Conference on Feb. 24", "labels": 1.1264629512}, {"text": "Ford Europe Goes All-In on EVs on Road to Sustainable Profitability; Cologne Site Begins $1 Billion Transformation", "labels": 1.1264629512}, {"text": "Ford Raises Planned Investment in EV, AV Leadership to $29 Billion; Further Advances Turnaround of Global Automotive Business in Q4", "labels": 1.8190889158}, {"text": "Ford January Retail Sales Outpaced Overall Industry Retail by Four Percentage Points on Strong Truck and SUV Sales; F-Series Starts The Year As America\u2019s Best-Selling Truck; Ford Brand SUVs Post Record January Start; Lincoln SUVs Post Best Retail Sales In 20 Years", "labels": 3.3273028687}, {"text": "Ford Invests $1 Billion (R15.8) to Modernize, Expand South African Manufacturing for All-New Ranger; Adds 1,200 Jobs", "labels": 2.3679041141}, {"text": "Ford and Google to Accelerate Auto Innovation, Reinvent Connected Vehicle Experience", "labels": 3.1509806564}, {"text": "Ford to Manufacture Mustang Mach-E in China for Local Customers", "labels": 0.3996676432}, {"text": "Ford Motor Company Issues Safety Compliance Recall for 286 Ford Explorer Police Interceptor and Lincoln Aviator Vehicles in North America", "labels": -2.217625859}, {"text": "Ford Europe 2020 Sales: Sixth Consecutive Year of Commercial Vehicle Leadership, Mustang Mach-E Ready to Accelerate Electrification", "labels": 0.4419214974}, {"text": "Ford China Fourth Quarter 2020 Sales Results", "labels": 0.6483727139}, {"text": "Ford Advances South America Restructuring; Will Cease Manufacturing in Brazil, Serve Customers With New Lineup", "labels": 4.022253326}, {"text": "Ford Motor Company Announces Details for Q4 2020 Earnings Conference Call", "labels": 1.5067019539}, {"text": "Truck Customers Make F-Series America\u2019s Best-Selling Pickup For 44 Straight Years; Ford Brand Achieves 11 Straight Years as America\u2019s Best-Selling Brand; Ford Explorer Claims Top Spot in 2020; Luxury Customers Propel Lincoln SUVs to Highest Sales in 17 Years", "labels": 4.4086232323}, {"text": "Ford\u2019s Ted Cannis to Discuss Commercial Vehicles, Electrification at Morgan Stanley Auto 2.0 Conference Jan. 11", "labels": 4.9867068493}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": -0.5976968667}, {"text": "Ford Motor Company Issues Safety Recall for Select 2017-19 Ford Super Duty SuperCrew Vehicles", "labels": -0.4441283845}, {"text": "Ford Motor Company Issues Two Safety Recalls in North America", "labels": -0.2083406566}, {"text": "Ford Executive Marion Harris To Address Connectivity At Deutsche Bank\u2019s 2019 AutoTech Conference", "labels": 1.9419569646}, {"text": "Changing How We Work: Ford\u2019s Leader of Product Line Management To Participate In The Credit Suisse Industrials Conference", "labels": 0.1817188152}, {"text": "Ford Motor Company Issues Safety Recall for Select 2019 Ford Ranger Vehicles for Tail Lamp Function", "labels": 0.3189724473}, {"text": "Ford Mustang Expands Family: All-Electric Mustang Mach-E Delivers Power, Style, and Freedom For New Generation", "labels": 0.7811424154}, {"text": "New UAW-Ford Collective Bargaining Agreement to Increase Manufacturing Competitiveness, Protect U.S. Jobs", "labels": 1.0641560831}, {"text": "Ford Motor Company Issues Two Safety Recalls and a Safety Compliance Recall", "labels": 1.3973591624}, {"text": "Electric and Untamed: Ford\u2019s Electric-Vehicles Leader To Address Barclays 2019 Global Automotive Conference", "labels": 1.3973591624}, {"text": "Ford Announces New Executive Leaders For Sustainability/Safety, AV, Strategy, and Ford Credit", "labels": -0.0383274793}, {"text": "Ford Motor Company Announces Planned 2020 Quarterly Earnings Dates", "labels": 0.0154823284}, {"text": "Ford Motor Company Issues Three Safety Recalls in North America", "labels": -0.2624599942}, {"text": "Improvement in Key Automotive Markets, Ford Credit Contribute to Ford\u2019s Q3, YTD Operating Results", "labels": 0.6638476816}, {"text": "Ford Europe Third Quarter 2019 Sales Results", "labels": 3.4261425337}, {"text": "Ford China Third Quarter 2019 Sales Results", "labels": 0.3606614995}, {"text": "Ford Motor Company Declares Dividend for Fourth Quarter 2019", "labels": 2.5830994174}, {"text": "Ford U.S. Third Quarter Sales Results", "labels": -1.5220408267}, {"text": "Mahindra and Ford Announce a Joint Venture To Drive Profitable Growth in India and Emerging Markets", "labels": -4.5474773733}, {"text": "Ford Motor Company and Changan Automobile Strengthen Strategic Partnership; Changan Ford Unveils Acceleration Plan with China Speed, China Design and Intelligent Manufacturing in Chinese Market", "labels": -0.1359198078}, {"text": "Details of Ford Motor Company\u2019s Briefing on 2019 Third Quarter Results", "labels": -0.6355724921}, {"text": "Details of Ford Motor Company\u2019s Third Quarter 2019 U.S. Sales Conference Call", "labels": 1.1188943665}, {"text": "Ford Reveals Electrified Vehicle Line-Up that will Surpass Conventional Petrol and Diesel by 2022", "labels": 0.7594525505}, {"text": "Ford Goes Electric In Europe", "labels": 0.7594525505}, {"text": "The Tipping Point \u2013 Ford\u2019s New Breed Of Electrified Vehicles To Surpass Combined Diesel And Petrol Models By 2022", "labels": 0.7594525505}, {"text": "Avis Budget Group and Ford Team Up to Connect Cars, Reinventing the Rental Experience in Europe", "labels": 0.8100450455}, {"text": "Ford Announces Leadership Changes; Steven Armstrong to Succeed Nigel Harris as President, Changan Ford China JV", "labels": -2.2165574991}, {"text": "Ford Motor Company to Participate in the J.P. Morgan 2019 Auto Conference", "labels": -1.869873162}, {"text": "Underlying Progress From Ford\u2019s Global Redesign Evident in Q2; New Explorer, Aviator Fortify Company\u2019s U.S. Strength in SUVs", "labels": 0.1123341471}, {"text": "Europe Second Quarter Sales Release", "labels": 0.4474036162}, {"text": "Details of Ford Motor Company Briefing on 2019 Second Quarter Results", "labels": -0.3648333515}, {"text": "Ford \u2013 Volkswagen expand their global collaboration to advance autonomous driving, electrification and better serve customers", "labels": -0.2019278198}, {"text": "Ford Motor Company Declares Dividend for Third Quarter 2019", "labels": 1.6738811038}, {"text": "Ford - Volkswagen AG Providing Update on Global Collaboration", "labels": 1.6738811038}, {"text": "Beth Mooney, Keycorp Chairman and CEO, Joins Ford Board of Directors", "labels": 0.6398132018}, {"text": "China Second Quarter Sales Release", "labels": -0.5670202979}, {"text": "Ford Looks to the Future in Europe: Business Redesigned for Profitability, Efficiency, More New EVs and SUVs", "labels": 2.6475800259}, {"text": "Details of Ford Motor Company\u2019s Second Quarter 2019 U.S. Sales Conference Call", "labels": -0.5717433791}, {"text": "Ford, Lincoln Rank Among Top Five Brands in J.D. Power 2019 U.S. Initial Quality Study", "labels": -0.5717433791}, {"text": "Ford Confirms Start of Consultation on Potential Closure of Bridgend Engine Plant in Support of Business Redesign", "labels": -0.9069413955}, {"text": "Innovating for Smart Vehicles in a Smart World", "labels": 2.0702800546}, {"text": "Ford Motor Company to Participate in UBS Global Industrials and Transportation Conference", "labels": -0.3642733587}, {"text": "Ford Motor Company To Participate In Goldman Sachs Industrials & Materials Conference 2019", "labels": -0.1244238534}, {"text": "Details of Ford Motor Company\u2019s 2019 annual Meeting of Shareholders", "labels": -0.1244238534}, {"text": "Ford Motor Company to Share Details on Mobility Business at Citi\u2019s 2019 Car of the Future Symposium", "labels": -0.2686094885}, {"text": "Ford Motor Company Reports First Quarter 2019 Results", "labels": 1.2754442163}, {"text": "Rivian Announces $500 Million Investment from Ford; Partnership to Deliver All-New Ford Battery Electric Vehicle", "labels": 0.3080664461}, {"text": "Ford Motor Company, Autonomic, and Amazon Web Services Collaborate to Advance Vehicle Connectivity and Mobility Experiences", "labels": 0.4843720785}, {"text": "Mahindra and Ford Sign Agreement to Co-Develop a Midsize Sports Utility Vehicle", "labels": -0.8186729107}, {"text": "Bank of America Merrill Lynch 2019 Auto Summit", "labels": 1.5512260549}, {"text": "Europe First Quarter Sales Release", "labels": 0.1620157463}, {"text": "China First Quarter Sales Release", "labels": 0.4548031082}, {"text": "Details of Ford Motor Company Briefing on 2019 First Quarter Results", "labels": 4.945603351}, {"text": "Ford Makes Leadership Changes as it Speeds Transformation", "labels": 1.0354794546}, {"text": "Ford Motor Company to Participate at Bank of America Merrill Lynch 2019 Auto Summit", "labels": 0.2468067822}, {"text": "Ford China Names Song Yang as President of National Distribution Services Division", "labels": -0.2288292087}, {"text": "Ford Motor Company Declares Dividend for Second Quarter 2019", "labels": -0.2288292087}, {"text": "First Quarter Sales Release", "labels": 0.7217024043}, {"text": "Ford China 2.0\u201d Combines \u201cBest of Ford, Best of China\u201d: Marks Acceleration of Company\u2019s Transformation in World\u2019s Largest Auto Market; Supports Global Redesign", "labels": 0.5243438319}, {"text": "Ford Motor Company Participates in J.P. Morgan 2019 Europe Autos Tour", "labels": 2.9625286256}, {"text": "Details of Ford Motor Company\u2019s First Quarter 2019 U.S. Sales Conference Call", "labels": 1.2150728821}, {"text": "Ford Announces Key Changes to Global Leadership Team; Tim Stone to Succeed Bob Shanks as CFO", "labels": -3.7389775425}, {"text": "Ford Adds 2nd North American Site to Build Battery Electrics; Michigan Workers to Make Its First Autonomous Vehicles", "labels": -3.460663434}, {"text": "Ford Releases 2019 Preliminary Proxy Statement and Announces Virtual Annual Meeting Date", "labels": 1.6606215102}, {"text": "Ford Investigating Process for U.S. Emissions Certification Concerning Road Load", "labels": -0.4285796077}, {"text": "Ford Exits Heavy Truck Business in South America; Key Milestone in Global Redesign of Company", "labels": 0.738019555}, {"text": "Ford Invests $1 Billion in Chicago Plants; Creates 500 New Jobs to Launch Explorer, Police Interceptor, Lincoln Aviator", "labels": -1.8646503077}, {"text": "Ford Motor Company Reports Fourth Quarter and Full Year 2018 Results", "labels": -0.6813582444}, {"text": "Ford Details Commitment to Global Redesign \u2013 Reshaping Overseas Operations and Strengthening North America", "labels": 0.6509803878}, {"text": "Volkswagen AG and Ford Motor Company Launch Global Alliance", "labels": 0.6509803878}, {"text": "Ford Europe December Sales", "labels": 3.5219418223}, {"text": "Volkswagen AG and Ford Motor Company to Provide Update on Alliance Talks on Tuesday Conference Call", "labels": 2.7635878505}, {"text": "Ford China December Sales", "labels": 1.0402271991}, {"text": "Ford to Strengthen European Competitive Position and Profitability; Sets Vision for the Future", "labels": -0.1100862445}, {"text": "Details of Ford Motor Company Briefing on 2018 Fourth Quarter and Full Year Results", "labels": -0.4183935066}, {"text": "Ford Motor Company to Present at Wolfe Research Global Auto Industry Conference and Deutsche Bank Global Auto Industry Conference", "labels": 0.1392198559}, {"text": "Ford Recommends Shareholders Reject Below-Market Mini-Tender Offer by Baker Mills", "labels": 2.0359491553}, {"text": "Ford U.S. December Sales", "labels": 2.0359491553}, {"text": "Details of Ford Motor Company\u2019s December 2017 U.S. Sales Conference Call", "labels": 0.2133090299}, {"text": "Ford Fiesta UK and Germany\u2019s No.1 Small Car in November; Total Ford Vehicle Sales Up 4.0 Percent", "labels": -1.9491480457}, {"text": "Ford Sells Nearly 118,000 Vehicles in China in November Lincoln Sets Another Monthly Sales Record in China", "labels": 1.0575280383}, {"text": "Ford Motor Company Announces 2018 Earnings Dates", "labels": 0.8237026576}, {"text": "Ford Intensifies China Growth Plan: More Smart Vehicles, Expanded Local Production, Leaner Business Structure", "labels": -0.6194517563}, {"text": "Ford Sales up 6.7 Percent in November; F-Series Achieves Best Sales in 16 Years", "labels": 1.9167847277}, {"text": "Details of Ford Motor Company\u2019s November 2017 U.S. Sales Conference Call", "labels": -1.1232800875}, {"text": "Ford Names John Veihmeyer to Board of Directors", "labels": -0.3973986827}, {"text": "Ford Europe SUV Sales Up 28.5 Percent in October; Total Vehicle Sales Grow 5.4 Percent", "labels": 0.8656569141}, {"text": "Ford to Participate in Barclays 2017 Global Automotive Conference", "labels": -0.6555538366}, {"text": "Ford and Zotye Sign Definitive JV Agreement in China to Meet Growing Demand for All-Electric Vehicles", "labels": -0.6555538366}, {"text": "Ford to Participate in Goldman Sachs Industrials Conference 2017", "labels": -2.9905820143}, {"text": "Ford Sells Nearly 106,000 Vehicles in China in October; Best October Sales for Lincoln and JMC", "labels": -2.9905820143}, {"text": "Ford Posts 6.2 Percent October Sales Gain, Marks Best F-Series Sales in 13 Years; Ford Brand SUV Sales Up 4.6 Percent, While Strong Customer Demand Lifts Lincoln SUV Sales 13.1 Percent", "labels": 0.482333501}, {"text": "Ford Motor Company Third Quarter Results: Improved Growth, Profitability and Cash Flow, Supported by Fitness Actions", "labels": 0.4126740345}, {"text": "Details of Ford Motor Company\u2019s October 2017 U.S. Sales Conference Call", "labels": 0.48163761}, {"text": "Ford of Europe Customer Order Bank at Record Level As New Fiesta Production Ramp-Up Continues", "labels": 2.4121107594}, {"text": "Ford Sells Nearly 113,000 Vehicles in China in September Lincoln Sales Up 79 Percent Year Over Year", "labels": -1.5021940679}, {"text": "Ford Motor Company Declares Dividend for Fourth Quarter 2017", "labels": -1.5021940679}, {"text": "Details of Ford Motor Company Briefing on 2017 Third Quarter Results", "labels": -1.5021940679}, {"text": "Ford\u2019s Future: Evolving to Become Most Trusted Mobility Company, Designing Smart Vehicles for a Smart World", "labels": -0.4877832011}, {"text": "Ford Sales up 8.7 Percent in September; F-Series Trucks up 21.4 Percent", "labels": -0.4877832011}, {"text": "Ford Hires Lynn Antipas Tyson To Lead Investor Relations", "labels": 1.6230178327}, {"text": "How Ford and Lyft Are Teaming Up to Take Self-Driving Cars Mainstream", "labels": 0.4298499249}, {"text": "Ford Motor Company to Host CEO Strategic Update", "labels": 1.4708973348}, {"text": "Mahindra and Ford to Explore Strategic Cooperation to Drive Profitable Growth in India and other Emerging Markets", "labels": 2.1396597079}, {"text": "Ford Europe SUV Sales Grow By 21.3% in August; Total Sales Up 2.2% in First Eight Months of 2017", "labels": 1.980213827}, {"text": "Ford China sales down one percent in August; big gains for Lincoln, JMC, Ford Mondeo and Ford EcoSport", "labels": -1.9113317479}, {"text": "Ford F-Series Pickup Truck Sales Rise 15.0 Percent in August", "labels": -1.943891874}, {"text": "Ford Provides More Than $3.5M To Hurricane Relief; Offers 'Texas is Family' Package To Aid Victims", "labels": -1.943891874}, {"text": "Ford Reports its Environmental Progress Across Business", "labels": -0.3056885496}, {"text": "Ford Motor Company to Host CEO Strategic Update", "labels": -0.04353376}, {"text": "Ford Names New Chairman and CEO for Ford China; New Vice President of Powertrain Engineering", "labels": 0.7102265489}, {"text": "Ford Names Sarah-Jayne Williams As Its First Director of Smart Mobility In Europe", "labels": 0.7102265489}, {"text": "Ford Furthers Global Electrification Expansion; Signs MOU in China with Zotye Auto to Explore New All-Electric Vehicle JV", "labels": 0.654507092}, {"text": "Ford of Europe Sales Up 2.6% in First Seven Months of 2017; CV Sales Up Nearly 10%", "labels": 0.3882273247}, {"text": "Ford Sells More Than 84,000 Vehicles in China in July; Lincoln Sales Up 68 Percent Year Over Year", "labels": 0.5530524857}, {"text": "Ford Overall Sales Down 7.5 Percent in July, Driven Largely by Lower Fleet Sales", "labels": 0.6658765366}, {"text": "Ford Delivers Second Quarter Net Income of $2.0B; $2.5B Adjusted Pre-Tax Profit; Total Company Revenue of $39.9B", "labels": -1.6930494976}, {"text": "Ford of Europe Sales Up 3.7 Percent in First Half; SUV and CV Sales Continue to Grow in June", "labels": 0.6346400294}, {"text": "Ford Motor Company Declares Dividend for Third Quarter 2017", "labels": -0.4769578412}, {"text": "Ford Achieves June Sales Record in China; Up 15 percent Year Over Year", "labels": 0.3303208816}, {"text": "Ford Motor Company\u2019s June 2017 U.S. Sales", "labels": 1.9490410419}, {"text": "Ford Invests in Ky. Plant to Build New Expedition, Navigator; Smart, Spacious New Focus for N.A. to be Globally Sourced", "labels": -0.72310378}, {"text": "Ford Sales in Europe Rise 6% in May; SUVs Up 17% and Commercial Vehicles Up 16%", "labels": -0.5281653119}, {"text": "Lincoln Voted Most Satisfying Premium Brand Among Owners in AutoPacific Survey", "labels": 1.93053255}, {"text": "Best Start Ever For Ford Escape and Lincoln MKC SalesDrives More Production At Louisville SUV Plant", "labels": 1.93053255}, {"text": "Ford of China Sells Nearly 88,000 Vehicles in May; Best-Ever May Sales for JMC, Lincoln", "labels": 1.93053255}, {"text": "Ford Motor Company\u2019s May 2017 U.S. Retail Sales", "labels": 0.2178356778}, {"text": "Details of Ford Motor Company\u2019s May 2017 U.S. Sales Conference Call", "labels": -1.4421887637}, {"text": "Ford Announces Global Leadership Team Appointments", "labels": -0.7380629682}, {"text": "Ford Motor Company News Conference", "labels": 0.6763068576}, {"text": "Ford Appoints Jim Hackett as CEO to Strengthen Operations, Transform for Future; Farley, Hinrichs, Klevorn Take on New Roles", "labels": 0.6763068576}, {"text": "Ford of Europe SUV Sales Grow 17% in April; Brand Builds Market Share in 3 Key Markets", "labels": 0.5821229295}, {"text": "Details of Ford Motor Company\u2019s 2017 Annual Meeting of Shareholders", "labels": -0.1721972998}, {"text": "Ford F-Series Surpasses the 70,000 Mark; Ford Brand SUVs Set Record; Company\u2019s Overall U.S. Sales Down 7.2 Percent", "labels": 0.3333229315}, {"text": "Ford Delivers First Quarter Revenue of $39.1B; $1.6B Net Income; $2.2B Adjusted Pre-Tax Profit", "labels": -1.574730431}, {"text": "Details of Ford Motor Company\u2019s April 2017 U.S. Sales Conference Call", "labels": -0.1357300608}, {"text": "Details of Ford Motor Company Briefing on 2017 First Quarter Results", "labels": 0.4192949482}, {"text": "Ford Motor Company Declares Dividend for Second Quarter 2017", "labels": -0.4082709124}, {"text": "Ford Continues Drive to Be Global Electric Vehicle Leader, Reveals Industry\u2019s First Pursuit-Rated Hybrid Police Car", "labels": -0.4082709124}, {"text": "Ford Releases 2016 Annual Report, 2017 Proxy Statement; Announces Virtual Annual Meeting Details", "labels": -1.3597003866}, {"text": "Ford Investing $1.2 Billion in Three Michigan Facilities, Further Bolstering Leadership in Trucks, SUVs, Mobility", "labels": 1.4161133015}, {"text": "Corporate Responsibility Puts Ford Among World\u2019s Most Ethical Companies", "labels": 0.2185814969}, {"text": "Ford names Lynn Vojvodich to Board of Directors", "labels": -0.6458079914}, {"text": "Ford invests in Argo AI, a new artificial intelligence company, in drive for autonomous vehicle leadership", "labels": 0.7600840173}, {"text": "New Ford Commercial Center program keeps fleet and commercial customers on the road", "labels": -1.1230701106}, {"text": "London trials new plug-in hybrid vans that could help deliver cleaner air; supports push for EV leadership", "labels": 0.33451101}, {"text": "Ford to close 2016 strong; declares regular and supplemental dividends; highlights progress in auto and mobility expansion", "labels": 1.1598495241}, {"text": "Ford reveals new F-150; Bronco is back; all-new Ranger coming to North America; company presents vision for City of Tomorrow", "labels": 0.8098915464}, {"text": "Unprecedented: Ford F-Series achieves 40 consecutive years as America's best-selling truck", "labels": -0.9870818986}, {"text": "Alexa in the car: Ford, Amazon to provide access to shop, search and control smart home features on the road", "labels": -0.9870818986}, {"text": "Ford and Toyota establish SmartDeviceLink Consortium to accelerate industry- driven standard for in-vehicle apps", "labels": -0.9870818986}, {"text": "Ford adding electrified F-150, Mustang, Transit by 2020 in major EV push; Expanded U.S. plant to add 700 jobs to make EVs, autonomous cars", "labels": 0.0582288003}, {"text": "Ford debuts Next-Generation Fusion Hybrid autonomous development vehicle; Car to first appear at CES and North American International Auto Show in January", "labels": -1.4786267377}, {"text": "Ford announces senior leadership team changes", "labels": -1.0066566008}, {"text": "Ford tops industry for US patents granted in 2016", "labels": -0.3422914792}, {"text": "Ford Motor Company announces 2017 Earnings dates", "labels": 1.6608848276}, {"text": "BMW Group, Daimler AG, Ford Motor Company and Volkswagen Group with Audi and Porsche plan a joint venture for ultra-fast, high-power charging along major highways in Europe", "labels": 2.2202688384}, {"text": "Mark Fields: Ford focused on creating the City of Tomorrow", "labels": -1.2532683189}, {"text": "2017 Ford Super Duty named Motor Trend Truck of the Year", "labels": 2.6587962005}, {"text": "Global Leadership: How Ford Transit became the best-selling cargo van nameplate on Earth", "labels": 0.0888768134}, {"text": "Ford Motor Company declares dividend for Fourth Quarter 2016", "labels": 0.0888768134}, {"text": "Ford, University of Michigan accelerate autonomous vehicle research with Ford researchers in-house at new robotics lab on U-M campus", "labels": -0.7140589307}, {"text": "Ford outlines growth plan: Fortify profit pillars; Transform underperforming operations; Invest in emerging opportunities to be a leader in electrification, autonomy and mobility", "labels": 0.5552043915}, {"text": "Ford partnering with global cities on new transportation; Chariot Shuttle to beacquired, Ford GoBike to launch in San Francisco", "labels": 0.0447170213}, {"text": "Ford names John S. Weinberg to Board of Directors", "labels": -0.8552151316}, {"text": "Ford Credit chairman and CEO Bernard Silverstone to retire after 37 years; Joy Falotico named as successor", "labels": 0.8148193359}, {"text": "Ford targets fully autonomous vehicle for ride sharing in 2021; Invests in new tech companies, doubles Silicon Valley team", "labels": 0.8043427576}, {"text": "Ford announces senior leadership team changes", "labels": -0.4227909032}, {"text": "Ford Motor Company declares dividend for Third Quarter 2016", "labels": -0.8725448864}, {"text": "Ford Sustainability Report unveils pilot program in South Africa to deliver healthcare, education, improve lives", "labels": -0.3053654263}, {"text": "Ford leaders honored among 100 Most Influential Women in Michigan", "labels": 0.6455373898}, {"text": "Ford invests in Pivotal to accelerate cloud-based software development; New labs drive Ford Smart Mobility innovation", "labels": 8.5449e-06}, {"text": "Fearless, ferocious and fun; Ford introduces F-150 Raptor SuperCrew to China", "labels": -0.0628916943}, {"text": "Ford Smart Mobility LLC established to develop, invest in mobility services; Jim Hackett named subsidiary chairman", "labels": -0.4567016193}, {"text": "Lilly to Divest BAQSIMI to Amphastar", "labels": -0.1039377145}, {"text": "Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities", "labels": -1.3760093773}, {"text": "U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab", "labels": 0.5630762969}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement", "labels": 0.5630762969}, {"text": "Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting", "labels": 1.6450703881}, {"text": "Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease", "labels": 2.0041047755}, {"text": "US FDA accepts supplemental New Drug Application for Jardiance\u00ae for children 10 years and older with type 2 diabetes", "labels": 2.0041047755}, {"text": "Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study", "labels": -2.0313548142}, {"text": "U.S. FDA Broadens Indication for Verzenio\u00ae (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer", "labels": 0.8120129193}, {"text": "Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month", "labels": 1.6029163589}, {"text": "Lilly to Participate in Cowen's 43rd Annual Health Care Conference", "labels": 0.5834665527}, {"text": "Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh", "labels": 0.6350924742}, {"text": "Lilly to Participate in SVB Securities Global Biopharma Conference", "labels": 1.3735279522}, {"text": "Lilly to Participate in Guggenheim Oncology Conference", "labels": 1.3948912301}, {"text": "Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook", "labels": 1.4981634905}, {"text": "U.S. FDA Approves Jaypirca\u2122 (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor", "labels": -1.6475735097}, {"text": "Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity", "labels": -2.6015724346}, {"text": "Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park", "labels": 1.0665396894}, {"text": "US FDA accepts supplemental New Drug Application for Jardiance\u00ae for adults with chronic kidney disease", "labels": -1.39972701}, {"text": "U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab", "labels": -1.8204412063}, {"text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement", "labels": -1.8204412063}, {"text": "Lilly to Participate in the J.P. Morgan Healthcare Conference", "labels": -1.5936676997}, {"text": "Lilly and ProQR to Expand RNA Editing Collaboration", "labels": 0.157653679}, {"text": "Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa", "labels": 0.2777633001}, {"text": "Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines", "labels": 0.5144454379}, {"text": "Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting", "labels": -1.1905372928}, {"text": "Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend", "labels": -1.1905372928}, {"text": "Phase III trial demonstrated Jardiance\u00ae is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes", "labels": 0.6643536801}, {"text": "Lilly Announces Updated Data from the Verzenio\u00ae (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology", "labels": 1.3361333183}, {"text": "Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases", "labels": -0.0080036922}, {"text": "Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease", "labels": 1.4203471926}, {"text": "Lilly and Akouos Announce Expiration of Akouos Tender Offer", "labels": 1.4203471926}, {"text": "Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement", "labels": 1.7408659271}, {"text": "Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium", "labels": 0.1357710242}, {"text": "Lilly to Participate in Evercore ISI HealthCONx Conference", "labels": 2.985274181}, {"text": "Lilly to begin rollout of Tempo\u00ae Personalized Diabetes Management Platform", "labels": 2.3618660686}, {"text": "Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance\u00ae in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease", "labels": -0.0356071896}, {"text": "Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting", "labels": 0.9372989552}, {"text": "Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress", "labels": 2.5721200947}, {"text": "Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration", "labels": 0.2528543809}, {"text": "Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement", "labels": -1.8780198619}, {"text": "Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss", "labels": -1.4728685276}, {"text": "Lilly Declares Fourth-Quarter 2022 Dividend", "labels": 0.6685950725}, {"text": "Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities", "labels": -0.3918460678}, {"text": "FDA Approves Lilly's Retevmo\u00ae (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type", "labels": 3.1749600452}, {"text": "Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials", "labels": 1.8098775272}, {"text": "Lilly Announces Details of Presentations at ESMO Congress 2022", "labels": 2.1331204531}, {"text": "Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference", "labels": 0.6437349274}, {"text": "Lilly to Participate in Citi's 17th Annual BioPharma Conference", "labels": -1.5971604336}, {"text": "Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly", "labels": 2.6063141498}, {"text": "Lilly's Taltz\u00ae (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience", "labels": 0.7821281011}, {"text": "Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results", "labels": -2.9470372984}, {"text": "Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements", "labels": -2.9470372984}, {"text": "Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement", "labels": 2.2205249675}, {"text": "Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options", "labels": 1.8721403246}, {"text": "Lilly Declares Third-Quarter 2022 Dividend", "labels": -2.0811210534}, {"text": "FDA Approves Lilly and Incyte's OLUMIANT\u00ae (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata", "labels": 0.1238036822}, {"text": "Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials", "labels": 3.0303949843}, {"text": "New analyses of Mounjaro\u2122 (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's\u00ae 82nd Scientific Sessions\u00ae", "labels": -0.9708420917}, {"text": "Jardiance\u00ae decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study", "labels": -0.9708420917}, {"text": "Lilly's AWARD-PEDS trial investigating use of Trulicity\u00ae (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo", "labels": -0.9708420917}, {"text": "Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight", "labels": -0.9708420917}, {"text": "Lilly to Participate in Goldman Sachs Global Healthcare Conference", "labels": 0.3955666954}, {"text": "Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting", "labels": 5.6417728784}, {"text": "Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana", "labels": 2.0608687988}, {"text": "Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study", "labels": 1.0748959843}, {"text": "Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA", "labels": 1.7518429844}, {"text": "CHMP Recommends Approval of Lilly and Incyte's OLUMIANT\u00ae (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)", "labels": 3.9226728871}, {"text": "Lilly to Participate in UBS Global Healthcare Conference 2022", "labels": 3.0822963829}, {"text": "FDA approves Lilly's Mounjaro\u2122 (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes", "labels": 2.2546548908}, {"text": "FDA Approves Lilly and Incyte's OLUMIANT\u00ae (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19", "labels": 2.786146515}, {"text": "Mary Lynne Hedley Elected to Lilly Board of Directors", "labels": -0.3250081532}, {"text": "Lilly to Participate in Bank of America Securities 2022 Healthcare Conference", "labels": 2.1261397452}, {"text": "Lilly Declares Second-Quarter 2022 Dividend", "labels": -1.0969591057}, {"text": "Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022", "labels": -1.321317938}, {"text": "Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1", "labels": -1.321317938}, {"text": "Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care", "labels": -2.5586283902}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement", "labels": -1.874231089}, {"text": "Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis", "labels": -1.6262161297}, {"text": "Lilly Presents Updated Data on Retevmo\u00ae (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress", "labels": 1.8083989239}, {"text": "Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT\u00ae 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies", "labels": -1.0194299382}, {"text": "Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies", "labels": -1.0194299382}, {"text": "Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer", "labels": 0.9445790087}, {"text": "Jardiance\u00ae phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease", "labels": 2.6829068169}, {"text": "Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)", "labels": 1.0883280405}, {"text": "Lilly to Participate in Barclays Global Healthcare Conference", "labels": 3.0585535397}, {"text": "Jardiance\u00ae provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial", "labels": 2.6006214354}, {"text": "Lilly to Participate in Cowen Health Care Conference", "labels": 1.3466851104}, {"text": "US FDA approves Jardiance\u00ae (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction", "labels": 6.2467636126}, {"text": "Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site", "labels": -0.3776629053}, {"text": "Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study", "labels": 0.4641812291}, {"text": "Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence", "labels": -0.6681303056}, {"text": "Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19", "labels": -1.51071586}, {"text": "Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options", "labels": -1.7646463262}, {"text": "Cynthia Cardona Elected as President of the Lilly Foundation", "labels": -1.7646463262}, {"text": "Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients", "labels": -2.1587402223}, {"text": "UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents", "labels": -0.2205929067}, {"text": "Lilly to Participate in Guggenheim Oncology Conference", "labels": 1.507001967}, {"text": "Lilly announces $1 billion investment in new manufacturing facility in North Carolina", "labels": 3.21936084}, {"text": "Updates on OLUMIANT\u00ae (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis", "labels": 3.21936084}, {"text": "Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement", "labels": -1.0367793069}, {"text": "Lilly to Participate in the J.P. Morgan Healthcare Conference", "labels": -0.2312121649}, {"text": "Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications", "labels": -0.2312121649}, {"text": "Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study", "labels": 0.9380935079}, {"text": "Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting", "labels": 6.0815466649}, {"text": "Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022", "labels": 10.0043670332}, {"text": "Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend", "labels": 1.5518607821}, {"text": "Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control\u00ae Platform", "labels": 1.5518607821}, {"text": "Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting", "labels": 1.5518607821}, {"text": "Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders", "labels": 2.9493456516}, {"text": "New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients", "labels": -0.1433740686}, {"text": "Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12", "labels": -2.3545656128}, {"text": "Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting", "labels": -0.6293304916}, {"text": "Emgality\u00ae Versus Nurtec\u00ae ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients", "labels": -0.4986647973}, {"text": "Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference", "labels": 1.7296086892}, {"text": "US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance\u00ae for adults with heart failure independent of left ventricular ejection fraction", "labels": -0.7013581695}, {"text": "Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care", "labels": -0.7013581695}, {"text": "Lilly to Participate in Wolfe Research Virtual Healthcare Conference", "labels": 1.5567529497}, {"text": "OLUMIANT\u00ae Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis", "labels": 1.5567529497}, {"text": "Jardiance\u00ae shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status", "labels": -3.2472244}, {"text": "Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting", "labels": -0.1811489473}, {"text": "Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19", "labels": 5.6373647542}, {"text": "Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference", "labels": 0.677442145}, {"text": "Additional Verzenio\u00ae (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology", "labels": 1.8056172416}, {"text": "Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential", "labels": 2.2664532641}, {"text": "Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk", "labels": 1.9120379195}, {"text": "Lilly Declares Fourth-Quarter 2021 Dividend", "labels": 1.7993503793}, {"text": "Lilly Announces Updated Verzenio\u00ae (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology", "labels": 0.3657339169}, {"text": "FDA Approves Verzenio\u00ae (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer", "labels": 1.1069256752}, {"text": "Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement", "labels": 0.7359221143}, {"text": "Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics", "labels": 2.0603640326}, {"text": "Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals", "labels": 1.3553794926}, {"text": "At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study", "labels": -2.7351490839}, {"text": "OLUMIANT\u00ae Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata", "labels": -1.3894414773}, {"text": "Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study", "labels": -1.3894414773}, {"text": "Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study", "labels": -1.3894414773}, {"text": "Lilly and Susan G. Komen\u00ae Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women", "labels": 2.4410395675}, {"text": "FDA Expands Lilly's ERBITUX\u00ae (cetuximab) Label with Combination of BRAFTOVI\u00ae (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy", "labels": 1.7233841568}, {"text": "Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options", "labels": 1.7233841568}, {"text": "New Data from Verzenio\u00ae (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary", "labels": -3.7770759407}, {"text": "Eli Lilly and Company\u202fIssues Voluntary\u202fNationwide Recall of\u202fOne Lot of GLUCAGON\u00ae Emergency Kit Due\u202fto Loss of Potency", "labels": -2.8136067119}, {"text": "Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities", "labels": -1.646948548}, {"text": "Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19", "labels": -1.646948548}, {"text": "Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059", "labels": -1.646948548}, {"text": "Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19", "labels": -1.7296920926}, {"text": "Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19", "labels": -1.0993728266}, {"text": "Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference", "labels": -2.9816824576}, {"text": "Lilly to Present New Data from Oncology Portfolio at ESMO Congress", "labels": -2.9816824576}, {"text": "Lilly Prices First Sustainability Bond to Advance Global ESG Strategy", "labels": -5.7578215384}, {"text": "FDA grants Jardiance\u00ae Breakthrough Therapy designation for heart failure with preserved ejection fraction", "labels": -5.7578215384}, {"text": "Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to \"Type 1 Diabetes Camps Initiative\"", "labels": -1.6324043478}, {"text": "Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities", "labels": -1.6324043478}, {"text": "Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference", "labels": -2.3665512071}, {"text": "Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference", "labels": -2.11344706}, {"text": "Landmark trial demonstrates Jardiance\u00ae (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction", "labels": -0.0800439962}, {"text": "Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders", "labels": -0.5587151793}, {"text": "Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors", "labels": -0.5587151793}, {"text": "US FDA approves Jardiance\u00ae (empagliflozin) to treat adults living with heart failure with reduced ejection fraction", "labels": -0.5954008397}, {"text": "Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units", "labels": -0.9831721215}, {"text": "FDA approves Lyumjev\u00ae (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps", "labels": 2.871182194}, {"text": "Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials", "labels": 2.871182194}, {"text": "Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance", "labels": 6.7512437022}, {"text": "Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation", "labels": 6.7512437022}, {"text": "Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline", "labels": -1.6427080177}, {"text": "FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen", "labels": -1.6427080177}, {"text": "Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses", "labels": -1.6427080177}, {"text": "Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement", "labels": 2.8138361769}, {"text": "Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis", "labels": 0.7004319632}, {"text": "Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab", "labels": -1.0969551}, {"text": "Lilly Announces Acquisition of Protomer Technologies", "labels": -1.8663312301}, {"text": "Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study", "labels": -0.4915023646}, {"text": "Breakthrough results for Jardiance\u00ae (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction", "labels": 0.9286753464}, {"text": "Lilly Declares Third-Quarter 2021 Dividend", "labels": 0.5533314133}, {"text": "Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes", "labels": 0.1613061791}, {"text": "Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes", "labels": -2.1470475154}, {"text": "Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin", "labels": -2.0415203984}, {"text": "Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease", "labels": -2.0415203984}, {"text": "Lilly Launches Think Talk Treat Migraine\u2122 to Help Improve Diagnosis and Treatment of Migraine", "labels": -0.7870074788}, {"text": "Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality\u00ae with Every-Other-Day Nurtec\u00ae ODT for the Preventive Treatment of Migraine", "labels": -2.4189256734}, {"text": "Lilly to Participate in Guggenheim Biopharma Strategy Series", "labels": -0.3176424167}, {"text": "Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA", "labels": -0.4113194636}, {"text": "Lilly Announces New Clinical Data from Verzenio and Oral SERD Programs at the American Society of Clinical Oncology Annual Meeting", "labels": 8.8666338466}, {"text": "Lilly to Participate in Goldman Sachs Healthcare Conference", "labels": 1.4998504737}, {"text": "Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021", "labels": 1.4998504737}, {"text": "OLUMIANT\u00ae Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses", "labels": -0.5975984683}, {"text": "Taltz\u00ae Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study", "labels": -0.5975984683}, {"text": "Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial", "labels": -0.893471318}, {"text": "Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial", "labels": 1.3608218003}, {"text": "Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting", "labels": 2.9669752088}, {"text": "U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer", "labels": 0.7684058062}, {"text": "Lilly to Participate in UBS Global Healthcare Virtual Conference", "labels": 2.0182291937}, {"text": "Lilly and MiNA Therapeutics Announce saRNA Research Collaboration", "labels": -0.0983463512}, {"text": "Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes", "labels": 1.9803584497}, {"text": "Lilly to Participate in Bank of America Securities 2021 Health Care Conference", "labels": 2.7025604359}, {"text": "Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries", "labels": 2.7384460474}, {"text": "Lilly Outlines Robust Plans to Strengthen ESG Commitments Across the Globe", "labels": 2.7384460474}, {"text": "Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements", "labels": 2.7384460474}, {"text": "Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization", "labels": 2.7683207931}, {"text": "Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity", "labels": 2.7683207931}, {"text": "Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance", "labels": -1.910834954}, {"text": "OLUMIANT\u00ae Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses", "labels": 0.1014885818}, {"text": "Taltz\u00ae Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis", "labels": 0.1014885818}, {"text": "Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study", "labels": 0.2827873066}, {"text": "Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.", "labels": 1.1917514179}, {"text": "Diogo Rau to join Lilly as Senior Vice-President and Chief Information and Digital Officer", "labels": 0.9945301529}, {"text": "Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together", "labels": -0.4930552692}, {"text": "Lilly Presents New Data on Retevmo\u00ae (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting", "labels": -0.4930552692}, {"text": "Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients", "labels": 0.8347431135}, {"text": "Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis", "labels": -1.2999162882}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement", "labels": -1.2999162882}, {"text": "Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts", "labels": -1.0438785657}, {"text": "Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care", "labels": -0.1781300262}, {"text": "Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19", "labels": 0.4528208947}, {"text": "Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain", "labels": 2.3258385222}, {"text": "Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio\u00ae at St. Gallen Virtual Congress 2021", "labels": -3.1533719275}, {"text": "Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study", "labels": -2.5759166533}, {"text": "Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD\u2122 2021 and published in NEJM", "labels": -1.1052987316}, {"text": "Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)", "labels": -0.8186728585}, {"text": "Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19", "labels": -0.8186728585}, {"text": "Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021\u2122 (AD/PD\u2122 2021) to Showcase Clinical Advances in Alzheimer's Disease Research", "labels": -1.4066899289}, {"text": "Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations", "labels": -1.4066899289}, {"text": "Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes", "labels": -0.4317774728}, {"text": "Lilly to Participate in Barclays Global Healthcare Conference", "labels": -0.4317774728}, {"text": "EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union", "labels": 2.902949507}, {"text": "Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet", "labels": 2.902949507}, {"text": "Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes", "labels": 1.51266987}, {"text": "Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial", "labels": -1.4112077809}, {"text": "Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19", "labels": -0.1114031004}, {"text": "Welldoc and Lilly collaborate to integrate BlueStar\u00ae app capabilities into Lilly's connected insulin solutions", "labels": 0.6442393756}, {"text": "Lilly to Participate in Cowen Health Care Conference", "labels": 1.0548690139}, {"text": "Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases", "labels": -2.1799651782}, {"text": "Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program", "labels": -1.9341607032}, {"text": "Kimberly H. Johnson Elected to Lilly Board of Directors", "labels": -1.9341607032}, {"text": "Lilly To Participate in SVB Leerink Global Healthcare Conference", "labels": 2.1322762381}, {"text": "Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19", "labels": 0.3131215836}, {"text": "Lilly Appoints Anat Ashkenazi Chief Financial Officer", "labels": 0.3131215836}, {"text": "Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference", "labels": 2.4582490023}, {"text": "Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day", "labels": 1.8896906233}, {"text": "Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients", "labels": -6.0234718793}, {"text": "Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results", "labels": -4.3418449228}, {"text": "Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate", "labels": -0.0144291498}, {"text": "Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19", "labels": -0.45212622}, {"text": "New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death  by 70 percent", "labels": -2.3991910173}, {"text": "Lilly Completes Acquisition of Prevail Therapeutics", "labels": 4.8551969026}, {"text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents", "labels": 1.1836594969}, {"text": "Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies", "labels": 2.6135152356}, {"text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement", "labels": 5.8847218184}, {"text": "Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund", "labels": 5.8847218184}, {"text": "Gabrielle Sulzberger Elected to Lilly Board of Directors", "labels": 2.8830472242}, {"text": "US FDA accepts supplemental New Drug Application for Jardiance\u00ae (empagliflozin) for adults with heart failure with reduced ejection fraction", "labels": -3.4675536856}, {"text": "Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial", "labels": -3.4675536856}, {"text": "Lilly to Participate in J.P. Morgan Healthcare Conference", "labels": -1.6233892673}, {"text": "Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico", "labels": -2.2159256914}, {"text": "Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance", "labels": 7.3350797485}, {"text": "Lilly Announces Agreement to Acquire Prevail Therapeutics", "labels": 7.3350797485}, {"text": "Lilly Announces 15 Percent Dividend Increase", "labels": 4.025570449}, {"text": "Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study", "labels": 4.025570449}, {"text": "Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine", "labels": -1.1462262978}, {"text": "Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio\u00ae", "labels": 3.9813850857}, {"text": "Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes", "labels": 3.9813850857}, {"text": "Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement", "labels": 6.9746856713}, {"text": "Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting", "labels": 1.3396057159}, {"text": "Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting", "labels": 1.3396057159}, {"text": "Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19", "labels": 2.2723932065}, {"text": "Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19", "labels": -0.8673925409}, {"text": "Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference", "labels": 0.9395608027}, {"text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19", "labels": 0.3766226739}, {"text": "Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement", "labels": 0.3766226739}, {"text": "Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19", "labels": 3.6016343995}, {"text": "Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes", "labels": 3.6016343995}, {"text": "Jardiance\u00ae reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME\u00ae trial", "labels": 1.0529181591}, {"text": "Lilly to Participate in Wolfe Research Virtual Healthcare Conference", "labels": -0.386290045}, {"text": "Lilly to Participate in Bernstein Operational Decisions Conference", "labels": -0.386290045}, {"text": "Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program", "labels": -4.2364441318}, {"text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19", "labels": 2.7428979301}, {"text": "Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting", "labels": -3.4608169059}, {"text": "Aarti Shah to Retire as Lilly Chief Information and Digital Officer", "labels": -3.4608169059}, {"text": "ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant\u00ae in Rheumatoid Arthritis", "labels": -1.1910101306}, {"text": "EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis", "labels": -1.1910101306}, {"text": "Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata", "labels": -0.098752001}, {"text": "New Data at EADV 2020 Confirm Taltz\u00ae (ixekizumab) Demonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis", "labels": -1.1804405775}, {"text": "Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine", "labels": 1.5767686867}, {"text": "Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19", "labels": 1.5767686867}, {"text": "Lilly Reports Third-Quarter Financial Results, Updates Guidance", "labels": -1.3022847399}, {"text": "New Jardiance\u00ae findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status", "labels": -0.3810993062}, {"text": "Lilly Declares Fourth-Quarter 2020 Dividend", "labels": -2.3748174245}, {"text": "Lilly Announces Agreement to Acquire Disarm Therapeutics", "labels": -0.2669142464}, {"text": "Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial", "labels": -4.4976050878}, {"text": "Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment", "labels": 0.2589199313}, {"text": "Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement", "labels": 2.8556850027}, {"text": "Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen", "labels": 2.8556850027}, {"text": "Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity", "labels": 2.8556850027}, {"text": "Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries", "labels": 2.8556850027}, {"text": "Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs", "labels": 3.2443229612}, {"text": "Lilly and Dexcom team up on new program to help improve diabetes management", "labels": 3.2443229612}, {"text": "REYVOW\u00ae (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study", "labels": 1.36277481}, {"text": "Verzenio\u00ae Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer", "labels": -2.2087258202}, {"text": "CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis", "labels": -0.5688431217}, {"text": "Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies", "labels": 2.6204885688}, {"text": "Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting", "labels": 0.4918888639}, {"text": "Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care", "labels": 0.6624304844}, {"text": "US FDA grants Fast Track designation to Jardiance\u00ae (empagliflozin) to improve outcomes following a heart attack", "labels": 0.6624304844}, {"text": "Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial", "labels": 0.6596314675}, {"text": "Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference", "labels": 0.9664728918}, {"text": "Lilly to Participate in Morgan Stanley Global Healthcare Conference", "labels": 0.9664728918}, {"text": "REYVOW\u00ae (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study", "labels": 0.9664728918}, {"text": "Lilly Announces Webcast to Discuss ESMO 2020 Presentations", "labels": -1.2087380299}, {"text": "Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes", "labels": -1.2087380299}, {"text": "Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020", "labels": -1.2087380299}, {"text": "Lilly Announces Leadership Changes", "labels": -3.0091697104}, {"text": "FDA approves additional doses of Trulicity\u00ae (dulaglutide) for the treatment of type 2 diabetes", "labels": -0.8481990586}, {"text": "Jardiance\u00ae reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction", "labels": -0.0339232366}, {"text": "New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo\u2122 (selpercatinib) in Advanced RET-Driven Lung and Thyroid Cancers", "labels": -2.1989926231}, {"text": "Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement", "labels": 0.0919336193}, {"text": "Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)", "labels": 1.3238957634}, {"text": "Lilly Reports Second-Quarter Financial Results, Raises EPS Guidance", "labels": -5.4295023427}, {"text": "Jardiance\u00ae meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes", "labels": -5.4295023427}, {"text": "Lilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA", "labels": 0.0494347346}, {"text": "Data from Lilly at Alzheimer's Association International Conference 2020\u00ae (AAIC\u00ae 2020) to Showcase Clinical Advances in Alzheimer's Research", "labels": -1.2314982339}, {"text": "Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement", "labels": 0.5986675784}, {"text": "Lilly's Mirikizumab Superior to Cosentyx\u00ae (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis", "labels": 0.5986675784}, {"text": "Lilly Declares Third-Quarter 2020 Dividend", "labels": -0.1151366189}, {"text": "Central Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments", "labels": 3.1873885074}, {"text": "Lilly launches program about what people with diabetes should \u201cKnow Before the Low\u201d", "labels": 2.6464269042}, {"text": "Full results from EMPERIAL exercise ability trials presented", "labels": -1.1093550411}, {"text": "Emgality\u00ae Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine", "labels": -1.9618963692}, {"text": "Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications", "labels": 2.2816991646}, {"text": "Verzenio\u00ae (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer", "labels": 2.2816991646}, {"text": "Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients", "labels": 13.261229824}, {"text": "Once-weekly Trulicity\u00ae (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections", "labels": 13.261229824}, {"text": "Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice", "labels": 13.261229824}, {"text": "Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life", "labels": -2.8405446687}, {"text": "Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)", "labels": -2.8405446687}, {"text": "Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event", "labels": -2.8405446687}, {"text": "First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial", "labels": 0.8278163914}, {"text": "Lilly to Participate in Goldman Sachs Global Healthcare Conference", "labels": 1.5959386757}, {"text": "Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment", "labels": 1.5959386757}, {"text": "EULAR 2020: Lilly Shares New Data for Olumiant\u00ae in Rheumatoid Arthritis and Systemic Lupus Erythematosus", "labels": -1.7450762046}, {"text": "EULAR 2020: Lilly's Taltz\u00ae (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis", "labels": -1.7450762046}, {"text": "Lilly's Taltz\u00ae (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)", "labels": -0.3964643673}, {"text": "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans", "labels": -0.3964643673}, {"text": "Lilly's CYRAMZA\u00ae (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer", "labels": 0.5182028334}, {"text": "Lilly Receives U.S. FDA Approval of TAUVID\u2122 (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease", "labels": 3.6090233632}, {"text": "Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model", "labels": -3.7131389804}, {"text": "Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's\u00ae effects following an acute myocardial infarction", "labels": -3.7131389804}, {"text": "Emgality\u00ae Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure", "labels": -3.7131389804}, {"text": "Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease", "labels": -2.4292974}, {"text": "Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020", "labels": 1.3169392695}, {"text": "Lilly Receives U.S. FDA Approval for Retevmo\u2122 (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers", "labels": 2.7436311458}, {"text": "Higher investigational doses of Trulicity\u00ae (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes", "labels": 2.7436311458}, {"text": "Lilly to Participate in UBS Virtual Global Healthcare Conference", "labels": 1.8381312294}, {"text": "Lilly Declares Second-Quarter 2020 Dividend", "labels": 2.0520657984}, {"text": "Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19", "labels": 2.0520657984}, {"text": "Lilly to Participate in Bank of America Securities Health Care Conference", "labels": -1.0219453072}, {"text": "Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance", "labels": 3.5291409476}, {"text": "Lower-priced versions of Humalog\u00ae Mix75/25\u2122 KwikPen\u00ae and Humalog\u00ae Junior KwikPen\u00ae now available", "labels": 2.7973751616}, {"text": "Lilly Begins Clinical Testing of Therapies for COVID-19", "labels": 4.0632817835}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2020 Financial Results Announcement", "labels": 2.5252018675}, {"text": "Eli Lilly and Company to Hold 2020 Annual Meeting of Shareholders Virtually", "labels": 2.1132577473}, {"text": "New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.", "labels": 2.1132577473}, {"text": "Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic", "labels": 5.7532614635}, {"text": "Governor Holcomb and Mayor Hogsett announce coalition to flatten the COVID-19 curve across state, public invited to make commitment", "labels": 5.7532614635}, {"text": "Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines", "labels": -0.3958442674}, {"text": "Lilly's Taltz\u00ae (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis", "labels": 3.4962701877}, {"text": "Updates from Lilly about insulin supply and affordability", "labels": -1.0660829313}, {"text": "Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic", "labels": 1.5786400074}, {"text": "Lilly to Provide Drive-Through COVID-19 Testing for Indianapolis Health Care Workers", "labels": 1.5786400074}, {"text": "US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes", "labels": -11.0121835098}, {"text": "Kathryn Beiser to join Lilly as Vice President, Global Communications", "labels": -11.0121835098}, {"text": "Lilly, Indiana State Department of Health Partner to Accelerate COVID-19 Testing Using Lilly Research Laboratories", "labels": -2.4419531058}, {"text": "Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata", "labels": 8.5195587273}, {"text": "AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19", "labels": 6.1562816507}, {"text": "US FDA grants Fast Track designation to Jardiance\u00ae for the treatment of chronic kidney disease", "labels": 6.1562816507}, {"text": "Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D", "labels": -10.6649731359}, {"text": "Lilly to Participate in Barclays Global Healthcare Conference", "labels": 5.0782456507}, {"text": "Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines", "labels": 5.0577080789}, {"text": "U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis", "labels": 1.9722442017}, {"text": "Eli Lilly and Company Statement on ICER Final Report for Acute Treatments for Migraine: Effectiveness and Value", "labels": 4.8629727828}, {"text": "FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA\u00ae (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer", "labels": -5.2945382001}, {"text": "Trulicity\u00ae (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease", "labels": -2.3091183316}, {"text": "Lilly to Participate in Cowen Health Care Conference", "labels": -2.3091183316}, {"text": "Lilly To Participate in SVB Leerink Global Healthcare Conference", "labels": -2.3091183316}, {"text": "Lilly Completes Acquisition of Dermira", "labels": 0.2886560076}, {"text": "Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study", "labels": 1.9064370316}, {"text": "Lilly to Participate in Guggenheim Healthcare Talks Idea Forum", "labels": -1.1752039365}, {"text": "Lilly's REYVOW\u2122 (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription", "labels": -1.3120380674}, {"text": "CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes", "labels": -1.3120380674}, {"text": "Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition", "labels": 1.0455320288}, {"text": "Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis", "labels": 1.0455320288}, {"text": "Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application", "labels": 2.2149042734}, {"text": "Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities", "labels": 0.8790987982}, {"text": "US FDA approves only triple-combination tablet with Jardiance\u00ae for adults with type 2 diabetes", "labels": 1.3786928614}, {"text": "Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine", "labels": 1.3786928614}, {"text": "Anat Hakim to join Lilly as General Counsel", "labels": -2.5594823477}, {"text": "Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant", "labels": 1.4552386444}, {"text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement", "labels": -1.6119673683}, {"text": "Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease", "labels": 0.6009939124}, {"text": "Lilly expands insulin affordability options with lower-priced versions of Humalog\u00ae Mix75/25\u2122 KwikPen\u00ae and Humalog\u00ae Junior KwikPen\u00ae", "labels": 1.5023596464}, {"text": "Tyvyt\u00ae (Sintilimab Injection) Combined with ALIMTA\u00ae (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC", "labels": 1.7419298237}, {"text": "Lilly Announces Agreement to Acquire Dermira", "labels": 2.2743550647}, {"text": "Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab", "labels": 2.5000042195}, {"text": "Lilly to Participate in J.P. Morgan Healthcare Conference", "labels": -1.19071e-05}, {"text": "U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit", "labels": -0.0684832927}, {"text": "Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer", "labels": -0.0684832927}, {"text": "Lilly Launches Campaign to Increase Awareness of Insulin Cost-Saving Options", "labels": 2.5296186927}, {"text": "Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality\u00ae (galcanezumab-gnlm)", "labels": 2.2697755534}, {"text": "Lilly Announces 2020 Financial Guidance, Updates 2019 Guidance", "labels": 4.232323613}, {"text": "Lilly Announces 15 Percent Dividend Increase", "labels": 1.8032405172}, {"text": "Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System", "labels": 1.8032405172}, {"text": "Boehringer Ingelheim and Lilly provide update on Jardiance\u00ae phase III exercise ability studies in chronic heart failure", "labels": 0.7081753609}, {"text": "CHMP Issues Positive Opinion to Expand CYRAMZA\u00ae (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer", "labels": 0.7081753609}, {"text": "Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Na\u00efve RET Fusion-Positive Non-Small Cell Lung Cancer", "labels": 0.9367490681}, {"text": "Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting", "labels": 0.9282862854}, {"text": "Lilly Announces New Leadership and Strategy in Oncology Research and Development", "labels": 1.0364438602}, {"text": "Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference", "labels": 0.0765399962}, {"text": "Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco", "labels": 0.0765399962}, {"text": "Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)", "labels": 0.0765399962}, {"text": "Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis", "labels": -0.1830084709}, {"text": "Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement", "labels": 0.5060716359}, {"text": "Interim analysis from EMPRISE real-world study shows Jardiance\u00ae decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists", "labels": 1.8071087036}, {"text": "Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes", "labels": -0.7492162766}, {"text": "Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance\u00ae in people hospitalized for acute heart failure who have been stabilized", "labels": 0.0177278484}, {"text": "ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz\u00ae (ixekizumab) Versus Humira\u00ae (adalimumab) Trial in Psoriatic Arthritis", "labels": 0.0177278484}, {"text": "ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz\u00ae (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis", "labels": 0.0177278484}, {"text": "Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting", "labels": 0.133003057}, {"text": "Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities", "labels": -0.6166004784}, {"text": "Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities", "labels": -0.6166004784}, {"text": "Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019", "labels": 1.0641171699}, {"text": "Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference", "labels": -1.7887553287}, {"text": "Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance\u00ae", "labels": -1.7887553287}, {"text": "Lilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities", "labels": 2.4500962637}, {"text": "Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance", "labels": 1.7062212665}, {"text": "Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno", "labels": 1.7062212665}, {"text": "Lilly Declares Fourth-Quarter 2019 Dividend", "labels": 0.8831053169}, {"text": "Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival", "labels": -0.6638308508}, {"text": "Lilly Presents Positive Results for Taltz\u00ae (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress", "labels": 1.0756762115}, {"text": "Lilly's REYVOW\u2122 (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval", "labels": 0.1390083851}, {"text": "Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress", "labels": 0.3821080174}, {"text": "Lilly's CYRAMZA\u00ae (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology", "labels": -1.0448716045}, {"text": "Lilly Announces Voluntary Delisting from Euronext Paris", "labels": 1.0258761552}, {"text": "New Head-to-Head Data Show Taltz\u00ae (ixekizumab) Superiority versus TREMFYA\u00ae (guselkumab) in People with Moderate to Severe Plaque Psoriasis", "labels": 1.0258761552}, {"text": "Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement", "labels": -2.8334297709}, {"text": "Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers", "labels": -1.2977751798}, {"text": "Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019", "labels": -2.4282636563}, {"text": "CHMP Issues Positive Opinion to Expand Trulicity\u00ae (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial", "labels": -1.5326750313}, {"text": "Lilly Announces Webcast to Discuss ESMO 2019 Presentations", "labels": 2.8409135844}, {"text": "Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer", "labels": -3.0782951601}, {"text": "Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program", "labels": 0.0789313523}, {"text": "Lilly to Participate in Morgan Stanley Global Healthcare Conference", "labels": 0.1919719288}, {"text": "Lilly Receives U.S. FDA Approval for Taltz\u00ae (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)", "labels": 0.1083673359}, {"text": "Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis", "labels": 0.2862739295}, {"text": "Arbitration panel rules in favor of Lilly in complaint filed by Adocia", "labels": -1.7623958615}, {"text": "Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation", "labels": -0.0360374892}, {"text": "Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health", "labels": -4.2003130949}, {"text": "Lilly Announces Superiority of Taltz\u00ae (ixekizumab) versus TREMFYA\u00ae (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis", "labels": -2.3638393521}, {"text": "U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit", "labels": 0.3168804529}, {"text": "Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia", "labels": 1.5909532941}, {"text": "Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services", "labels": 3.1587057857}, {"text": "Lilly Announces Positive Results for Emgality\u00ae (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments", "labels": 0.0179746647}, {"text": "Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance", "labels": 0.5965874986}, {"text": "Lilly's Verzenio\u00ae (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2", "labels": 0.5965874986}, {"text": "BAQSIMI\u2122 (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA", "labels": -0.4915605926}, {"text": "Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study", "labels": 0.477858532}, {"text": "Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine", "labels": -0.9219283016}, {"text": "AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality\u00ae (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine", "labels": -0.9219283016}, {"text": "Lilly Announces Changes in Senior Leadership", "labels": -2.9919431281}, {"text": "New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality\u00ae (galcanezumab-gnlm) in Episodic Cluster Headache", "labels": -2.9919431281}, {"text": "Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment", "labels": -3.1415135268}, {"text": "Lilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement", "labels": 2.3400109994}, {"text": "Lilly's AWARD-11 trial studying higher investigational doses of Trulicity\u00ae (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes", "labels": -2.9963123249}, {"text": "U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure", "labels": -2.9963123249}, {"text": "Lilly Declares Third-Quarter 2019 Dividend", "labels": 0.4673112454}, {"text": "Lilly Presents Positive Results for Taltz\u00ae (ixekizumab) vs. Humira\u00ae (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology", "labels": 1.1199268424}, {"text": "Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz\u00ae (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology", "labels": 0.399154598}, {"text": "Detailed findings from CAROLINA\u00ae outcome trial support long-term cardiovascular safety profile of Tradjenta\u00ae", "labels": -3.3775922441}, {"text": "New analysis shows cardiorenal risk reductions of Jardiance\u00ae are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria", "labels": -3.3775922441}, {"text": "Trulicity\u00ae (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes", "labels": -3.3775922441}, {"text": "Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog\u00ae (insulin lispro), with superior post-meal blood glucose reductions", "labels": -3.3775922441}, {"text": "Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's\u00ae 79\u1d57\u02b0 Scientific Sessions\u00ae", "labels": -3.3775922441}, {"text": "Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology", "labels": 0.7012985392}, {"text": "Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology", "labels": -0.4510492906}, {"text": "FDA Approves Emgality\u00ae (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks", "labels": -0.9058345347}, {"text": "U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes", "labels": -0.9058345347}, {"text": "Hurricane Season is Almost Here. Are You Ready?", "labels": 1.2246161171}, {"text": "Lilly to Participate in Goldman Sachs Global Healthcare Conference", "labels": 0.388130496}, {"text": "Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio", "labels": 0.2502130941}, {"text": "Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics", "labels": -1.385390578}, {"text": "Lilly's Lower-Priced Insulin Now Available", "labels": 0.5906904921}, {"text": "Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions", "labels": 0.7967507721}, {"text": "Lilly to Participate in UBS Global Healthcare Conference", "labels": 1.2412717379}, {"text": "Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer", "labels": 1.8186764382}, {"text": "Lilly to Participate in Bank of America Merrill Lynch Health Care Conference", "labels": 1.8186764382}, {"text": "Lilly's CYRAMZA\u00ae (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma", "labels": 0.0696087414}, {"text": "AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience", "labels": -0.0431714833}, {"text": "Lilly Declares Second-Quarter 2019 Dividend", "labels": -0.7656099264}, {"text": "AAN 2019: Pooled Analyses of Two Emgality\u00ae (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups", "labels": -0.7656099264}, {"text": "Lilly to Present New Data at AAN 2019 on Emgality\u00ae (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio", "labels": -1.3087015345}, {"text": "Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health", "labels": 1.3284719541}, {"text": "U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit", "labels": 0.6438231598}, {"text": "Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market", "labels": 1.7685707172}, {"text": "Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China", "labels": 2.0852540277}, {"text": "Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz\u00ae (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis", "labels": 2.0852540277}, {"text": "Lilly and Avidity Biosciences Announce Licensing and Research Collaboration", "labels": 2.0852540277}, {"text": "Pfizer and Lilly Announce Top-Line Results from Long-Term Phase 3 Study of Tanezumab in Patients with Osteoarthritis", "labels": -0.6581669233}, {"text": "Lilly and ImmuNext Announce Licensing and Research Collaboration", "labels": -1.1415864007}, {"text": "Survey Reveals Genital Psoriasis May Reduce Patients\u2019 Self-Confidence and Hinder Them from Having Close Relationships", "labels": 1.1067673474}, {"text": "NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology", "labels": 0.6001308119}, {"text": "Lilly Announces Final Results of Elanco Exchange Offer", "labels": -1.2349722267}, {"text": "Lilly's CYRAMZA\u00ae (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer", "labels": 0.6516013757}, {"text": "Lilly Announces Preliminary Results of Elanco Exchange Offer", "labels": 0.5667991484}, {"text": "Lilly to Participate in Barclays Global Healthcare Conference", "labels": -2.3238911252}, {"text": "Lilly to Participate in Cowen Health Care Conference", "labels": 0.2288776204}, {"text": "Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer", "labels": 0.2288776204}, {"text": "Lilly Receives FDA Priority Review Designation for Emgality\u00ae (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults", "labels": -1.3577317444}, {"text": "Lilly to Introduce Lower-Priced Insulin", "labels": -1.5721081631}, {"text": "Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting", "labels": 0.1647581958}, {"text": "Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain", "labels": 1.1006091687}, {"text": "Lilly Completes Acquisition of Loxo Oncology", "labels": 0.777860697}, {"text": "Lilly To Participate in Leerink Partners Global Healthcare Conference", "labels": 2.8902636041}, {"text": "Boehringer Ingelheim and Lilly announce the CAROLINA\u00ae cardiovascular outcome trial of Tradjenta\u00ae met its primary endpoint of non-inferiority compared with glimepiride", "labels": 2.8902636041}, {"text": "Lilly to Participate in Guggenheim Healthcare Talks Idea Forum", "labels": 0.2372589207}, {"text": "Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health", "labels": 0.2372589207}, {"text": "Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology", "labels": -0.995740103}, {"text": "Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis", "labels": -0.6476738301}, {"text": "Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction", "labels": -0.1248359529}, {"text": "FDA Expands Lilly's ALIMTA\u00ae (pemetrexed) Label with Combination of KEYTRUDA\u00ae (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer", "labels": 3.2674365208}, {"text": "Lilly Revises Date for Fourth-Quarter 2018 Financial Results Announcement", "labels": 3.6125344465}, {"text": "Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain", "labels": 2.1806105801}, {"text": "Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin", "labels": -1.8436473544}, {"text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2018 Financial Results Announcement", "labels": 2.6096323031}, {"text": "Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA\u00ae (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients", "labels": 1.2896166259}, {"text": "Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO\u00ae", "labels": 1.2896166259}, {"text": "Lilly Announces Agreement To Acquire Loxo Oncology", "labels": 3.4124232735}, {"text": "Lilly to Participate in J.P. Morgan Healthcare Conference", "labels": -0.0523166878}, {"text": "Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting", "labels": -2.0587395342}, {"text": "Lilly Announces 15 Percent Dividend Increase", "labels": -2.0587395342}, {"text": "Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies", "labels": -0.2932771365}, {"text": "Lilly announces publication of analyses showing benefit of the addition of Verzenio\u00ae (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis", "labels": -0.2932771365}, {"text": "Lilly Announces Positive Top-Line Results for Taltz\u00ae (ixekizumab) vs. Humira\u00ae (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis", "labels": -4.4225529919}, {"text": "Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences", "labels": -5.4724897774}, {"text": "Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors", "labels": -5.4724897774}, {"text": "FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)", "labels": -2.403284977}, {"text": "Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease", "labels": -2.403284977}, {"text": "Lilly and AC Immune Announce License and Collaboration Agreement", "labels": -0.5398025745}, {"text": "NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment", "labels": -1.8194300949}, {"text": "Lilly to Present Clinical Data for Verzenio\u00ae (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS", "labels": 2.8152484678}, {"text": "Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting", "labels": 2.8131188199}, {"text": "Jardiance\u00ae Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway", "labels": 2.5914985768}, {"text": "Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality\u2122 (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache", "labels": -0.142620499}, {"text": "Lilly to Participate in Credit Suisse 27th Annual Healthcare Conference", "labels": 2.4240342183}, {"text": "Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance", "labels": 0.6562099002}, {"text": "Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines", "labels": -4.2776200136}, {"text": "Trulicity\u00ae (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes", "labels": -4.2776200136}, {"text": "Initial results from EMPRISE real-world evidence study show Jardiance\u00ae was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease", "labels": -4.2776200136}, {"text": "Lilly and Dicerna Announce RNAi Licensing and Research Collaboration", "labels": 0.8215046914}, {"text": "Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients", "labels": -4.1196170543}, {"text": "ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz\u00ae (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)", "labels": -1.4584793884}, {"text": "ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT\u00ae (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis", "labels": -1.4584793884}, {"text": "Karen Walker Elected to Lilly Board of Directors", "labels": 2.4209937817}, {"text": "Lilly Declares Fourth-Quarter 2018 Dividend", "labels": 0.477357794}, {"text": "New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting", "labels": 0.477357794}, {"text": "Lilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC", "labels": 1.4644730859}, {"text": "New analysis estimates the positive impact of Jardiance\u00ae on life expectancy in adults with type 2 diabetes and established cardiovascular disease", "labels": -6.5332170162}, {"text": "Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care", "labels": 0.5196925115}, {"text": "Boehringer Ingelheim and Lilly present full results of Tradjenta\u00ae's CARMELINA\u00ae cardiovascular outcome trial", "labels": 1.217159807}, {"text": "Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes", "labels": 1.217159807}, {"text": "Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes", "labels": 1.217159807}, {"text": "Lilly Confirms Date and Conference Call for Third-Quarter 2018 Financial Results Announcement", "labels": 4.00034462}, {"text": "Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes", "labels": 1.0311427474}, {"text": "Lilly's Emgality\u2122 (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults", "labels": 0.7641365891}, {"text": "Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833", "labels": 0.5905129554}, {"text": "Lilly Receives Positive CHMP Opinion for Emgality\u2122 (galcanezumab) for the Prophylaxis of Migraine in Adults", "labels": -0.6061323828}, {"text": "New Lilly Diabetes Center of Excellence Established at the Indiana Biosciences Research Institute", "labels": -0.3687338453}, {"text": "NCCN and Lilly Support Quality Improvements for Gastric Cancer Care", "labels": 0.7224572709}, {"text": "Lilly to Showcase New Data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, Furthering Innovation for Patients with Complex Dermatological Conditions", "labels": -1.7607004089}, {"text": "Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz\u00ae and Tremfya\u00ae in Patients with Moderate-to-Severe Plaque Psoriasis", "labels": -1.7607004089}, {"text": "Lilly Announces Webcast to Discuss EASD Presentations", "labels": 1.2706876457}, {"text": "Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent", "labels": 0.4935053826}, {"text": "Anne White Promoted to President of Lilly Oncology", "labels": 0.4448548333}, {"text": "Lilly to Participate in Morgan Stanley Global Healthcare Conference", "labels": -0.9222190777}, {"text": "Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes", "labels": 1.5097488181}, {"text": "Elanco Animal Health Files IPO Registration Statement", "labels": 2.6148363998}, {"text": "Lilly Diabetes Solution Center Now Open to Help People with Insulin Affordability", "labels": 0.7339125276}, {"text": "Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute", "labels": 2.4592564111}, {"text": "Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance", "labels": 5.568811469}, {"text": "Lilly to Separate Elanco Animal Health with Initial Public Offering", "labels": 5.568811469}, {"text": "Highlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference\u00ae 2018 (AAIC\u00ae 2018)", "labels": -0.1575310371}, {"text": "Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)", "labels": -1.5372310941}, {"text": "Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA\u00ae cardiovascular outcome trial meets primary endpoint", "labels": -1.5372310941}, {"text": "Lilly's Once-Weekly Trulicity\u00ae (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease", "labels": -1.5372310941}, {"text": "Pfizer and Lilly Announce Positive Top-Line Results from Phase 3 Trial of Tanezumab for the Treatment of Osteoarthritis (OA) Pain", "labels": -0.1900869018}, {"text": "New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability", "labels": 1.7946458497}, {"text": "Lilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine", "labels": 0.0233050685}, {"text": "Lilly Confirms Date and Conference Call for Second-Quarter 2018 Financial Results Announcement", "labels": 0.5625221609}, {"text": "Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz\u00ae (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients", "labels": 0.5625221609}, {"text": "AHS 2018: Lilly's Emgality\u2122 (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX\u00ae* (onabotulinumtoxinA)", "labels": 0.6784224096}, {"text": "AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache", "labels": 0.6784224096}, {"text": "Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes", "labels": -1.0457266235}, {"text": "First-ever Study of Lilly's Humulin\u00ae R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes", "labels": -1.0457266235}, {"text": "Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache", "labels": -1.0457266235}, {"text": "Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity\u00ae (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW", "labels": -1.0457266235}, {"text": "New Data Presented at the American Diabetes Association 78th Scientific Sessions\u00ae Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes", "labels": -1.0457266235}, {"text": "Jardiance\u00ae reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors", "labels": -1.0457266235}, {"text": "Investigational Doses of Lilly's Once-Weekly Trulicity\u00ae (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes", "labels": -1.0457266235}, {"text": "U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit", "labels": -0.2914691216}, {"text": "Lilly Completes Acquisition of ARMO BioSciences", "labels": -0.2914691216}, {"text": "Lilly Declares Third-Quarter 2018 Dividend", "labels": 0.967520917}, {"text": "Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease", "labels": -0.0466607358}, {"text": "Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology", "labels": -0.9591788081}, {"text": "Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp.", "labels": 0.7913394642}, {"text": "DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial", "labels": 0.7913394642}, {"text": "FDA Expands Lilly's ALIMTA\u00ae (pemetrexed) Label to Include Combination with KEYTRUDA\u00ae (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression", "labels": 0.7913394642}, {"text": "FDA Approves OLUMIANT\u00ae (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis", "labels": -0.1527817647}, {"text": "Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis", "labels": -0.1527817647}, {"text": "Lilly to Participate in Goldman Sachs Global Healthcare Conference", "labels": 1.1432022222}, {"text": "Lilly to Participate in Jefferies Global Healthcare Conference", "labels": 2.4929253095}, {"text": "Sue Mahony to Retire as President of Lilly Oncology", "labels": 1.2090418508}, {"text": "Lilly's Taltz\u00ae (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area", "labels": 0.6530987502}, {"text": "Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care", "labels": -0.1714692099}, {"text": "Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache", "labels": -1.1991625615}, {"text": "Lilly to Acquire AurKa Pharma", "labels": -0.4744162312}, {"text": "Lilly to Participate in UBS Global Healthcare Conference", "labels": 2.3113073445}, {"text": "Lilly Announces Agreement To Acquire ARMO BioSciences", "labels": 3.6264623234}, {"text": "Lilly Declares Second-Quarter 2018 Dividend", "labels": 0.595824495}, {"text": "Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis", "labels": -2.3468374134}, {"text": "Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development", "labels": -5.0840770227}, {"text": "Lilly to Participate in Bank of America Merrill Lynch Health Care Conference", "labels": -1.7639518193}, {"text": "Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease", "labels": 2.7619510997}, {"text": "Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance", "labels": -0.0369594954}, {"text": "AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies", "labels": -0.0369594954}, {"text": "FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis", "labels": 0.8240598993}, {"text": "Lilly Reports Additional Top-Line Results from CYRAMZA\u00ae (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer", "labels": 0.6982602781}, {"text": "Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine", "labels": 0.6982602781}, {"text": "Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance\u00ae in adults with chronic kidney disease", "labels": -0.6756931765}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement", "labels": 2.2894778188}, {"text": "Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes", "labels": 2.2894778188}, {"text": "Lilly Announces CYRAMZA\u00ae (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint", "labels": 2.2894778188}, {"text": "Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology", "labels": -0.3036297643}, {"text": "EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research", "labels": 2.4619787283}, {"text": "Boehringer Ingelheim and Lilly expand heart failure program for Jardiance\u00ae with new exercise capacity trials", "labels": -0.5423624699}, {"text": "Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer", "labels": -0.3684550311}, {"text": "New Data Show Lilly's Trulicity\u00ae (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes", "labels": -0.3684550311}, {"text": "Lilly to Participate in Barclays Global Healthcare Conference", "labels": -0.5181929334}, {"text": "Lilly to Participate in Cowen Health Care Conference", "labels": -0.8123755366}, {"text": "Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month", "labels": -0.8123755366}, {"text": "AAD 2018: Treatment with Lilly's Taltz\u00ae (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity", "labels": -0.8123755366}, {"text": "Lilly to Showcase New Data for Taltz\u00ae (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting", "labels": 3.3452971946}, {"text": "Lilly Announces Positive Top-Line Phase 3 Results for Taltz\u00ae (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)", "labels": 2.0402777022}, {"text": "Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance", "labels": -4.96299782}, {"text": "Lilly To Present At Leerink Partners Global Healthcare Conference", "labels": 3.2420122708}, {"text": "Livongo and Lilly Collaborate on Real-World Diabetes Research", "labels": -0.7320583233}, {"text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement", "labels": 0.0464429408}, {"text": "Lilly to Present at J.P. Morgan Healthcare Conference", "labels": 0.7986715226}, {"text": "Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference", "labels": -0.0576594295}, {"text": "Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin", "labels": -1.941324361}, {"text": "Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020", "labels": 0.1040486558}, {"text": "Lilly Announces 8 Percent Dividend Increase", "labels": 0.1153296519}, {"text": "FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults", "labels": 0.1153296519}, {"text": "Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology", "labels": 0.1153296519}, {"text": "Lilly Reports Top-Line Results from CYRAMZA\u00ae (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer", "labels": 1.1653236649}, {"text": "Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System", "labels": -0.3164394711}, {"text": "Lilly's Taltz\u00ae (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis", "labels": 0.7010715096}, {"text": "Lilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement", "labels": 0.502940351}, {"text": "Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference", "labels": 0.2164036626}, {"text": "Jardiance\u00ae reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease", "labels": -0.3844067234}, {"text": "Lilly Appoints Philip Johnson to Senior Vice President and Treasurer", "labels": -0.3844067234}, {"text": "New Data on FORTEO\u00ae (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis", "labels": -0.6363386401}, {"text": "ACR/ARHP 2017: Long-Term Use of Lilly's Taltz\u00ae (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors", "labels": 1.1787124007}, {"text": "ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo", "labels": -0.0120447927}, {"text": "Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting", "labels": -2.2211026167}, {"text": "Lilly To Participate In Credit Suisse 26th Annual Healthcare Conference", "labels": -2.0793423873}, {"text": "Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health", "labels": -3.0288949894}, {"text": "Lilly announces $72 million investment in diabetes manufacturing in Indianapolis", "labels": -2.7004900707}, {"text": "Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines", "labels": 0.0347291006}, {"text": "Lilly Declares Fourth-Quarter 2017 Dividend", "labels": -0.4880586054}, {"text": "Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA\u00ae (ramucirumab) Phase 3 Subgroup Analysis", "labels": -0.4880586054}, {"text": "FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio\u2122 (abemaciclib) as Initial Treatment of Advanced Breast Cancer", "labels": 0.5199437184}, {"text": "Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio\u2122 (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer", "labels": 0.7901349304}, {"text": "Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio\u2122 (abemaciclib) Plus NSAI in Advanced Breast Cancer", "labels": -0.2986865102}, {"text": "U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent", "labels": 0.3559969153}, {"text": "Additional Delivery of Insulin Ready for Distribution in Puerto Rico", "labels": 0.3559969153}, {"text": "Lilly Receives U.S. FDA Approval of Verzenio\u2122 (abemaciclib)", "labels": 1.312020536}, {"text": "Humalog\u00ae Junior KwikPen\u00ae Now Available in the U.S. for People with Diabetes", "labels": 1.312020536}, {"text": "Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement", "labels": 0.774994026}, {"text": "Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing", "labels": 1.3665207591}, {"text": "Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death", "labels": 0.4155850899}, {"text": "Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis", "labels": 0.1334597651}, {"text": "Jardiance\u00ae (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control", "labels": -0.2062212416}, {"text": "Lilly to Present New Data for Olumiant\u00ae (baricitinib) and Taltz\u00ae (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress", "labels": -0.9370807327}, {"text": "Lilly Builds Upon Body of Clinical Evidence for CYRAMZA\u00ae (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer", "labels": -0.9370807327}, {"text": "IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine", "labels": -0.9370807327}, {"text": "IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine", "labels": 1.2344083755}, {"text": "Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth", "labels": 2.7737545872}, {"text": "Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC)", "labels": 1.6311115097}, {"text": "Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018", "labels": 2.6940624153}, {"text": "New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress", "labels": 2.4226651696}, {"text": "Lilly to Participate in Morgan Stanley Global Healthcare Conference", "labels": -0.7001905554}, {"text": "Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine", "labels": 0.2071280621}, {"text": "Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes", "labels": -1.1776206178}, {"text": "Lilly Reports Second-Quarter Results", "labels": -2.321618644}, {"text": "Lilly and Incyte Provide Update on Baricitinib", "labels": -2.321618644}, {"text": "Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy", "labels": -3.0052139859}, {"text": "Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation", "labels": 1.5353517197}, {"text": "Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference\u00ae 2017 (AAIC\u00ae 2017)", "labels": 1.5353517197}, {"text": "Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment", "labels": 0.0243035784}, {"text": "FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer", "labels": 0.0243035784}, {"text": "UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents", "labels": 0.8021309286}, {"text": "Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement", "labels": -0.0364953913}, {"text": "Lilly and Purdue University Announce Strategic Research Collaboration", "labels": -0.0364953913}, {"text": "Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant\u00ae (baricitinib) for the Treatment of Rheumatoid Arthritis", "labels": -0.9926322717}, {"text": "Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour", "labels": -1.2996649991}, {"text": "Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego", "labels": 1.4351644444}, {"text": "Lilly Declares Third-Quarter 2017 Dividend", "labels": 0.8821893608}, {"text": "EULAR 2017: Lilly's Taltz\u00ae (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks", "labels": 0.1214601524}, {"text": "New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017", "labels": 0.1214601524}, {"text": "EULAR 2017: Lilly's Taltz\u00ae (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors", "labels": 0.5984234838}, {"text": "Lilly to Present New Data on Olumiant\u00ae (baricitinib) in Rheumatoid Arthritis and Taltz\u00ae (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)", "labels": 0.4779629756}, {"text": "U.S. FDA Approves Humalog\u00ae Junior KwikPen\u00ae for the Treatment of Diabetes", "labels": 0.4779629756}, {"text": "Jardiance\u00ae (empagliflozin) analysis reinforces established safety profile", "labels": 0.4779629756}, {"text": "Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab", "labels": 0.4779629756}, {"text": "Jardiance\u00ae (empagliflozin) tablets to be studied in chronic kidney disease", "labels": 0.3569469646}, {"text": "Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS", "labels": 0.3569469646}, {"text": "IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention", "labels": 0.9888573332}, {"text": "Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting", "labels": 2.0360480132}, {"text": "Lilly Announces Webcast to Discuss Pain Management Portfolio", "labels": 2.0360480132}, {"text": "Lilly Announces Strategic Collaboration with KeyBioscience AG", "labels": 2.0360480132}, {"text": "Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer", "labels": -1.1505991512}, {"text": "Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions\u00ae", "labels": 0.6614032531}, {"text": "Derica Rice to Retire as Lilly Chief Financial Officer", "labels": 0.6614032531}, {"text": "Lilly to Participate in Goldman Sachs Global Healthcare Conference", "labels": 1.8877418084}, {"text": "Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA\u00ae (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival", "labels": 1.8877418084}, {"text": "Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017", "labels": -0.8811785903}, {"text": "Actress Angela Bassett joins For Your SweetHeart\u2122 to urge people with diabetes to know their heart disease risk -- in honor of her mom", "labels": -2.6747109378}, {"text": "Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine", "labels": -0.0373135856}, {"text": "Lilly to Participate in Bernstein Strategic Decisions Conference", "labels": -0.1263359477}, {"text": "Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications", "labels": -0.1263359477}, {"text": "Lilly to Participate in UBS Global Healthcare Conference", "labels": 2.1435392195}, {"text": "Lilly Announces Webcast to Discuss Oncology Pipeline", "labels": -0.8984184143}, {"text": "Lilly Declares Second-Quarter 2017 Dividend", "labels": -0.4773744605}, {"text": "Lilly Reports First-Quarter 2017 Results", "labels": -2.161577378}, {"text": "Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis", "labels": -1.9950830629}, {"text": "Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting", "labels": 0.8548211404}, {"text": "U.S. FDA Issues Complete Response Letter for Baricitinib", "labels": -0.1231493802}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement", "labels": 0.9043762561}, {"text": "Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences", "labels": 0.1521181138}, {"text": "Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students", "labels": 1.2845909231}, {"text": "Lilly and the William Sansum Diabetes Center announce a five-year research collaboration", "labels": 0.3088291214}, {"text": "Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival", "labels": -1.0390559392}, {"text": "First dedicated outcome trials of empagliflozin in chronic heart failure initiated", "labels": -0.4520422283}, {"text": "New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz\u00ae (ixekizumab) Compared to Stelara\u00ae (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis", "labels": -0.6163984107}, {"text": "Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR\u00ae'", "labels": 1.3479629193}, {"text": "Lilly Announces Changes in Senior Management", "labels": -0.1074014063}, {"text": "Lilly Completes Acquisition of CoLucid Pharmaceuticals", "labels": -0.639260024}, {"text": "Lilly to Present New Data for Taltz\u00ae (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting", "labels": 1.2283782644}, {"text": "Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo", "labels": 2.1239430262}, {"text": "European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis", "labels": 1.5733865406}, {"text": "Lilly To Present At Leerink Partners Global Healthcare Conference", "labels": -0.4113583372}, {"text": "Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors", "labels": -0.4113583372}, {"text": "Lilly to Present at Cowen Health Care Conference", "labels": 0.3345727249}, {"text": "Lilly's Trulicity\u00ae (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes", "labels": 0.3345727249}, {"text": "Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents", "labels": 0.3107499837}, {"text": "Lilly Reports Fourth-Quarter and Full-Year 2016 Results", "labels": 4.3169785583}, {"text": "Lilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement", "labels": 2.5185119094}, {"text": "Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid", "labels": -0.6246841212}, {"text": "U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment", "labels": -0.0911205898}, {"text": "U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent", "labels": 3.2945775905}, {"text": "Lilly and Merck Expand Immuno-Oncology Collaboration", "labels": 0.8295456236}, {"text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement", "labels": 0.9779257643}, {"text": "Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities", "labels": 0.9779257643}, {"text": "U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy\u00ae (empagliflozin/metformin hydrochloride), Synjardy\u00ae XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi\u00ae (empagliflozin/linag", "labels": 0.8466622579}, {"text": "Lilly to Present at J.P. Morgan Healthcare Conference", "labels": 1.0438983563}, {"text": "Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance\u00ae (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards", "labels": 0.7627154071}, {"text": "CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)", "labels": 0.7627154071}, {"text": "BASAGLAR\u00ae (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.", "labels": 4.0103929077}, {"text": "Lilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade", "labels": 4.0103929077}, {"text": "Lilly Announces Program to Provide Insulin at Discounted Prices", "labels": -0.4729302263}, {"text": "Lilly Announces Dividend Increase", "labels": 0.9615614004}, {"text": "U.S. FDA approves Synjardy\u00ae XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes", "labels": 0.9615614004}, {"text": "Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease", "labels": 0.3401739076}, {"text": "Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting", "labels": 1.1790843263}, {"text": "Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer", "labels": 1.1790843263}, {"text": "U.S. FDA approves Jardiance\u00ae (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease", "labels": -0.5309561698}, {"text": "Lilly Confirms Date and Conference Call for 2017 Financial Guidance Announcement", "labels": 1.4273213711}, {"text": "Lilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students", "labels": -2.0160977486}, {"text": "Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial", "labels": 4.2559221228}, {"text": "Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes", "labels": -14.426432736}, {"text": "New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients", "labels": -0.892386427}, {"text": "Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes", "labels": -0.892386427}, {"text": "Jardiance\u00ae (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline", "labels": -0.892386427}, {"text": "Lilly Presents Clinical Efficacy, Safety and Patient-Reported Outcomes Data of Baricitinib in Patients with Rheumatoid Arthritis at 2016 American College of Rheumatology Annual Meeting", "labels": -0.4414357792}, {"text": "New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo", "labels": -1.4421991025}, {"text": "New Edition of Online Tool to Measure Cancer Progress to Launch at World Cancer Congress", "labels": -2.2608357304}, {"text": "Lilly Reports Third-Quarter 2016 Results", "labels": -0.1563326984}, {"text": "FDA Approves Lilly's LARTRUVO\u2122 (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma", "labels": -0.2794207629}, {"text": "Lilly Declares Fourth-Quarter 2016 Dividend", "labels": -0.964847715}, {"text": "Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative", "labels": -0.964847715}, {"text": "Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community", "labels": -2.2625144227}, {"text": "Lilly to Participate in Credit Suisse 2016 Healthcare Conference", "labels": -2.5959308086}, {"text": "Leading Experts Warn Global Goal to Cure or Treat Alzheimer's Disease By 2025 is at Risk, Offer Solutions to Adjust Course", "labels": -2.5959308086}, {"text": "New Data on the Combination of Lilly's ALIMTA\u00ae (pemetrexed) and Merck's KEYTRUDA\u00ae (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer", "labels": -0.3911292984}, {"text": "Lilly Highlights Advancements in its Oncology Portfolio with New Data at ESMO 2016", "labels": 0.1473120263}, {"text": "Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio", "labels": 0.1473120263}, {"text": "Lilly Confirms Date And Conference Call For Third-Quarter 2016 Financial Results Announcement", "labels": 0.8440419206}, {"text": "Lilly to Present Latest Data for Taltz\u00ae (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress", "labels": 0.1114934264}, {"text": "CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma", "labels": 0.581116936}, {"text": "Boston Mayor Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter, Receive Alzheimer's Readiness Award", "labels": 0.862931357}, {"text": "Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career", "labels": 0.1903065091}, {"text": "Jamere Jackson Elected to Lilly Board of Directors", "labels": -0.8545807016}, {"text": "Lilly to Participate in Morgan Stanley Global Healthcare Conference", "labels": -2.1663996503}, {"text": "Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease", "labels": 0.3141949956}, {"text": "Lilly announces Joshua Smiley, Anat Ashkenazi appointed to new roles, Thomas Grein retires", "labels": 1.1758684606}, {"text": "Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib", "labels": 1.1758684606}, {"text": "New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease", "labels": 0.8199778229}, {"text": "John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor", "labels": 0.8199778229}, {"text": "Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through the Remainder of the Decade", "labels": 0.7793299527}, {"text": "Diversity of Lilly's Alzheimer's Disease Pipeline Showcased at the Alzheimer's Association International Conference\u00ae 2016 (AAIC\u00ae 2016)", "labels": 1.7036640151}, {"text": "U.S. FDA expands indication for type 2 diabetes treatment Synjardy\u00ae (empagliflozin/metformin hydrochloride) to include treatment-na\u00efve adults", "labels": 0.5356211081}, {"text": "Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer", "labels": 0.8437570441}, {"text": "Lilly and Howard University partner on summer Medical Scientific Fellowship", "labels": -0.3402238495}, {"text": "Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox as Newest Spokesperson", "labels": 1.73055e-05}, {"text": "FDA Advisory Committee recommends approval of Jardiance\u00ae (empagliflozin) for cardiovascular indication in 12-11 vote", "labels": 3.8643588321}, {"text": "Lilly Confirms Date And Conference Call For Second-Quarter 2016 Financial Results Announcement", "labels": 3.8643588321}, {"text": "Lilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities", "labels": 1.4504678516}, {"text": "Diabetes Scholars Foundation Announces 2016 Scholarship Recipients", "labels": 0.9955895229}, {"text": "Lilly Declares Third-Quarter 2016 Dividend", "labels": -2.5906524511}, {"text": "German Supreme Court Grants Lilly Appeal in Alimta\u00ae Vitamin Regimen Patent Lawsuit", "labels": 0.2305739421}, {"text": "Aarti Shah named chief information officer", "labels": 0.3229450351}, {"text": "New Data Show Lilly's Once-Weekly Trulicity\u00ae (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes", "labels": 0.3229450351}, {"text": "New Jardiance\u00ae (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes", "labels": 0.3229450351}, {"text": "New study results show Tradjenta\u00ae (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment", "labels": 0.3229450351}, {"text": "New Study Findings Underscore Importance of Physician/Patient Communication on Insulin Adherence and Outcomes", "labels": 0.3229450351}, {"text": "Data in The Lancet Show Olaratumab Plus Doxorubicin Offered 11.8-Month Increase in Overall Survival in Patients with Advanced Soft Tissue Sarcoma, as Reported by Lilly and Memorial Sloan Kettering Researchers", "labels": -1.1088640376}, {"text": "Lilly and American Migraine Foundation Announce $1 Million Grant for Launch of First Patient Registry to Advance Research and Development in Migraine", "labels": -1.1088640376}, {"text": "Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)", "labels": -1.1088640376}, {"text": "Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs", "labels": -1.1088640376}, {"text": "Studies Demonstrate Lilly's Taltz\u00ae (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine", "labels": -0.3090148914}, {"text": "Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)", "labels": 0.3871167887}, {"text": "Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA\u00ae (pemetrexed) and CYRAMZA\u00ae (ramucirumab) with Merck's KEYTRUDA\u00ae (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer", "labels": -0.5488633398}, {"text": "Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy", "labels": -0.8818686542}, {"text": "Lilly Announces Diabetes Commercial Update Investor Call", "labels": 0.7421477358}, {"text": "Lilly Announces Webcast to Discuss Abemaciclib Data", "labels": -0.0934380557}, {"text": "U.S. FDA Approves Once-daily Jentadueto\u00ae XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes", "labels": -0.0934380557}, {"text": "Lilly to Participate in Goldman Sachs 37th Annual Global Healthcare Conference", "labels": 0.0397090989}, {"text": "Lilly Details Robust R&D Pipeline to Investment Community", "labels": -0.0133981526}, {"text": "Lilly to Participate in Bernstein Strategic Decisions Conference", "labels": -0.0133381775}, {"text": "Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana", "labels": -0.4143623896}, {"text": "Lilly partners with Washington University School of Medicine and Meharry Medical College on unique summer research program", "labels": -2.812562848}, {"text": "ASCO Data Underscore Lilly's Diverse Oncology Pipeline and Portfolio", "labels": -2.812562848}, {"text": "FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma", "labels": 0.132868101}, {"text": "Lilly Releases First-Ever Integrated Report", "labels": 0.393467062}, {"text": "Lilly Declares Second-Quarter 2016 Dividend", "labels": 0.393467062}, {"text": "Lilly's Taltz\u00ae (ixekizumab) Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis", "labels": 0.393467062}, {"text": "Lilly to Participate in Bank of America Merrill Lynch 2016 Health Care Conference", "labels": -0.781135304}, {"text": "Lilly Reports First-Quarter 2016 Results, Revises 2016 Financial Guidance", "labels": -0.1437991214}, {"text": "Jardiance\u00ae (empagliflozin) to be studied for the treatment of people with chronic heart failure", "labels": -0.6487193035}, {"text": "Lilly to Provide Detailed Update of Pipeline and R&D Strategy at Upcoming Investment Community Meeting", "labels": 1.8361145642}, {"text": "Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease", "labels": -1.7984832816}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2016 Financial Results Announcement", "labels": -0.7119798836}, {"text": "New 2016 ACC/AHA Guideline Focused Update States that it is Reasonable to Choose Effient\u00ae (prasugrel) Over Clopidogrel for Certain ACS-PCI Patients with ST-Elevation Myocardial Infarction and NSTE-ACS", "labels": 2.2473258343}, {"text": "Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics", "labels": 2.2473258343}, {"text": "Lilly's Taltz\u00ae (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis", "labels": 1.3488894142}, {"text": "Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study", "labels": 1.1451728233}, {"text": "Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis: Results Published in JAMA Dermatology", "labels": -0.232879176}, {"text": "Ixekizumab Demonstrates High Levels of Skin Clearance among Patients with Moderate-to-Severe Plaque Psoriasis Who Did Not Respond to Treatment with Etanercept", "labels": -0.232879176}, {"text": "Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis", "labels": 0.0408925527}, {"text": "Lilly to Participate in Barclays Global Healthcare Conference", "labels": 0.7098482894}, {"text": "Lilly to Present Phase 3 Data at the American Academy of Dermatology (AAD) Annual Meeting for Ixekizumab in Psoriasis and Psoriatic Arthritis", "labels": 1.8778937734}, {"text": "Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis", "labels": -4.7499724533}, {"text": "Lilly to Present at Cowen Health Care Conference", "labels": -0.9103197396}, {"text": "Eli Lilly and Company and United Way Announced Global Partnership Agreement", "labels": 0.4382945759}, {"text": "UK Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit", "labels": 2.4001295462}, {"text": "Lilly Diabetes Helps Inspiring Students with Type 1 Diabetes Attend College Through Scholarship Donation", "labels": -1.3049261333}, {"text": "American Diabetes Association\u00ae Survey Shows Summer Camp Can Positively Impact Children's Disease Management Skills, Confidence and Stress", "labels": -2.9348378976}, {"text": "Lilly Reports Fourth-Quarter and Full-Year 2015 Results", "labels": -3.5018696731}, {"text": "Lilly To Present At Leerink Partners Global Healthcare Conference", "labels": -6.2492297357}, {"text": "Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool", "labels": -6.2492297357}, {"text": "U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance\u00ae (empagliflozin)", "labels": -0.6588392616}, {"text": "U.S. Food and Drug Administration Approves Humulin\u00ae R U-500 KwikPen\u00ae", "labels": -0.0969648984}, {"text": "Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis", "labels": 0.3752520717}, {"text": "Lilly Announces 2016 Financial Guidance, Updates 2015 Expectations", "labels": 0.8136014051}, {"text": "Lilly to Present at J.P. Morgan Healthcare Conference", "labels": 0.8441022033}, {"text": "FDA Approves Basaglar\u00ae (insulin glargine injection), a Long-Acting Insulin Treatment", "labels": 0.2551849937}, {"text": "Lilly Sets Dates and Conference Calls for 2016 Financial Guidance and Fourth-Quarter 2015 Financial Results", "labels": 1.2863726799}, {"text": "Juan R. Luciano elected to Lilly board of directors", "labels": 1.2863726799}, {"text": "Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA\u00ae Combination Trial", "labels": -1.1285783404}, {"text": "Lilly Announces Dividend Increase", "labels": -2.0987003879}, {"text": "Lilly Ends Basal Insulin Peglispro Development Program", "labels": 3.3688399381}, {"text": "New Data Show Lilly's Once-Weekly Trulicity\u00ae (dulaglutide) is Effective as Add-on Treatment to Sulfonylurea", "labels": 0.4139306587}, {"text": "FDA Approves Portrazza\u2122 (necitumumab) for Specific Type of Lung Cancer", "labels": 0.2149973839}, {"text": "Lilly to Provide Detailed Review of Elanco Animal Health and Alzheimer's R&D Strategy at Investment Community Meeting", "labels": 0.5192336253}, {"text": "Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial", "labels": 1.5035022322}, {"text": "New Jardiance\u00ae (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline", "labels": 0.6672179916}, {"text": "Patients Show Significant Improvement in Signs and Symptoms of Psoriatic Arthritis, Less Progression of Structural Joint Damage When Treated with Ixekizumab for 24 Weeks", "labels": 0.6672179916}, {"text": "Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate", "labels": 0.6672179916}, {"text": "Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis", "labels": 0.6672179916}, {"text": "EMPA-REG OUTCOME\u00ae: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015", "labels": -1.1845074134}, {"text": "Lilly and United Way Celebrate Deepening Partnership, Community Impact", "labels": -0.6711310581}, {"text": "Lilly to Participate in Credit Suisse 2015 Healthcare Conference", "labels": -1.9104123568}, {"text": "Results of Two Pivotal Baricitinib Trials to be Presented at 2015 American College of Rheumatology Annual Meeting", "labels": -1.9104123568}, {"text": "Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Announce Winners of the My Diabetes Pit Crew Sweepstakes", "labels": -1.4558664751}, {"text": "Eli Lilly and Company Announces Expansion of Indianapolis R&D Headquarters", "labels": 0.6489130654}, {"text": "Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data", "labels": 4.297583564}, {"text": "Lilly Reports Third-Quarter 2015 Results, Revises 2015 Financial Guidance", "labels": 1.3919552614}, {"text": "Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations", "labels": 1.3919552614}, {"text": "Lilly supports global Dementia Discovery Fund", "labels": -1.6238310273}, {"text": "Lilly Declares Fourth-Quarter 2015 Dividend", "labels": -4.2935642277}, {"text": "New Type 2 Diabetes Treatment Synjardy\u00ae (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies", "labels": -1.3899003274}, {"text": "Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study", "labels": -1.3899003274}, {"text": "Lilly brings drug development to the classroom with new college course offering", "labels": -0.6813615537}, {"text": "Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration", "labels": -0.6813615537}, {"text": "Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease", "labels": 1.3062033151}, {"text": "Lilly and Innovent Biologics Expand Their Strategic Alliance to Include Immuno-Oncology Bispecific Antibodies in China and Globally", "labels": 1.3062033151}, {"text": "Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions", "labels": -7.4144432396}, {"text": "Eli Lilly and Company Expands New York City Research and Development Site", "labels": -7.4144432396}, {"text": "Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer", "labels": 3.4711221129}, {"text": "Lilly Confirms Date and Conference Call for Third-Quarter 2015 Financial Results Announcement", "labels": -0.6326875102}, {"text": "Lilly Joins the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study", "labels": -0.6326875102}, {"text": "Lilly to Showcase Data for Investigational Psoriasis Treatment at 24th European Academy of Dermatology and Venereology Congress", "labels": -2.8575154255}, {"text": "Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis", "labels": 3.967033157}, {"text": "Lilly and Sanofi Reach Settlement Agreement in U.S. Insulin Glargine Litigation", "labels": -4.2352442318}, {"text": "Lilly's CYRAMZA\u00ae (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial", "labels": -4.2352442318}, {"text": "Jardiance\u00ae (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial", "labels": 4.5428725396}, {"text": "Lilly Announces Webcast to Discuss EMPA-REG OUTCOME\u00ae Data", "labels": 2.3919429946}, {"text": "Lilly to Participate in Morgan Stanley Global Healthcare Conference", "labels": 1.682904786}, {"text": "U.S. FDA approves Synjardy\u00ae (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes", "labels": 1.682904786}, {"text": "U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent", "labels": -1.3440268315}, {"text": "Lilly, AACE Mark 10th Anniversary of Hurricane Katrina with Reminder of \"My Diabetes Emergency Plan\" Checklist", "labels": -1.3440268315}, {"text": "Jardiance\u00ae demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events", "labels": -2.7564744567}, {"text": "Lilly's Humalog\u00ae 200 units/mL KwikPen\u00ae Now Available in U.S. Pharmacies", "labels": -0.0716481428}, {"text": "Lilly to End Contract with the University of California, San Diego for A4 Alzheimer's Study", "labels": 0.2832927375}, {"text": "Lilly Provides Update on Evacetrapib Phase 3 Trial", "labels": 1.3771973435}, {"text": "Lilly Diabetes and NASCAR XFINITY Series Driver Ryan Reed Want You to Think About Your Diabetes Pit Crew", "labels": -5.1227694253}, {"text": "Eli Lilly and Company Announces Expansion of San Diego Biotechnology Center", "labels": -5.1227694253}, {"text": "Lilly Reports Second-Quarter 2015 Results, Revises 2015 Financial Guidance", "labels": -5.1227694253}, {"text": "New Study Shows Florbetapir F 18 Injection Scans Led to Change in Diagnosis and Management of Patients Being Evaluated for Cognitive Decline", "labels": 3.9649556574}, {"text": "Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease", "labels": 3.9649556574}, {"text": "Lilly Diabetes Launches Android Version of Glucagon Mobile Application for Those Who Support People with Diabetes", "labels": -3.0909699843}, {"text": "Lilly Statement on FDA Advisory Committee Review of Necitumumab", "labels": 0.3284778317}, {"text": "Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement", "labels": 2.7165435385}, {"text": "Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma", "labels": -2.2277952272}, {"text": "Diabetes Scholars Foundation Announces 2015 Scholarship Recipients", "labels": 1.9685698119}, {"text": "UK Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit", "labels": 1.9685698119}, {"text": "CYRAMZA\u00ae (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology", "labels": 0.5427358546}, {"text": "Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study", "labels": -1.9749516093}, {"text": "Eli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy", "labels": -1.9749516093}, {"text": "Lilly and Dana-Farber Cancer Institute Announce Research Collaboration", "labels": -1.9749516093}, {"text": "Lilly Declares Third-Quarter 2015 Dividend", "labels": 1.4272472071}, {"text": "Lilly Announces Webcast to Discuss Ixekizumab Phase III Data", "labels": 1.3062463111}, {"text": "Studies Show Psoriasis Patients Achieved Significant Levels of Skin Clearance and Improved Quality of Life after 12 Weeks of Ixekizumab Treatment", "labels": 5.3123930941}, {"text": "Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis", "labels": 5.3123930941}, {"text": "Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes", "labels": 5.7871203737}, {"text": "New Data Show Superiority of Lilly's Once-Weekly Trulicity\u2122 (dulaglutide) to Lantus\u00ae (insulin glargine) in Patients with Type 2 Diabetes", "labels": 5.7871203737}, {"text": "Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes", "labels": 5.7871203737}, {"text": "Lilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes", "labels": 5.7871203737}, {"text": "Study: Once-Weekly Trulicity\u2122 (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza\u00ae (liraglutide) in Japanese Patients after 52 weeks", "labels": 5.7871203737}, {"text": "Lilly commits 780,000 additional vials of insulin to Life for a Child", "labels": 0.9984603133}, {"text": "Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology", "labels": 0.9984603133}, {"text": "Lilly to Participate in Goldman Sachs Global Healthcare Conference", "labels": 3.6075745294}, {"text": "Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors", "labels": 3.6075745294}, {"text": "Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities", "labels": 5.1964708038}, {"text": "Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data", "labels": 5.1964708038}, {"text": "PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting", "labels": 5.1964708038}, {"text": "Lilly Announces the Early Results of Its Cash Tender Offer", "labels": 5.1964708038}, {"text": "Lilly to Present CYRAMZA\u00ae (ramucirumab) Data at 2015 ASCO Annual Meeting", "labels": 5.1964708038}, {"text": "Lilly Sends Employees to Serve in Vulnerable Communities around the World", "labels": 2.6828857658}, {"text": "U.S. Food and Drug Administration Approves Humalog\u00ae 200 units/mL KwikPen\u00ae", "labels": 2.6828857658}, {"text": "Lilly to Present New Clinical Data at 75th American Diabetes Association\u00ae Scientific Sessions", "labels": 2.6828857658}, {"text": "Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association's 75th Scientific Sessions\u00ae", "labels": 2.6828857658}, {"text": "Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies", "labels": 0.3017471853}, {"text": "Lilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016", "labels": -0.46702076}, {"text": "Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies", "labels": -1.1319802897}, {"text": "Eli Lilly and Company Reveals Plan for Innovation Center in Cambridge, Massachusetts", "labels": -0.2088575503}, {"text": "Lilly Declares Second-Quarter 2015 Dividend", "labels": -1.8634205317}, {"text": "Lilly Releases Corporate Responsibility, Global Health Reports", "labels": -1.8634205317}, {"text": "Lilly to Participate in Bank of America Merrill Lynch Health Care Conference", "labels": 1.0814467569}, {"text": "Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed", "labels": 2.2966273294}, {"text": "Lilly's CYRAMZA\u00ae (ramucirumab) Receives Fourth FDA Approval", "labels": -1.8761597047}, {"text": "Lilly Reports First-Quarter 2015 Results", "labels": -1.8161550492}, {"text": "Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015", "labels": -1.094072818}, {"text": "Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis", "labels": -1.094072818}, {"text": "Lilly, Bristol-Myers Squibb Restructure Erbitux\u00ae (cetuximab) Collaboration in North America", "labels": -1.5731132759}, {"text": "Lilly Confirms Date and Conference Call for First-Quarter 2015 Financial Results Announcement", "labels": -2.3582084269}, {"text": "Preparation Is Personal for Those with Chronic Illnesses", "labels": -1.8582236461}, {"text": "Lilly Announces Date for Diabetes Investor Meeting", "labels": -1.8582236461}, {"text": "First-in-class type 2 diabetes treatment Glyxambi\u00ae (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies", "labels": -0.6088337402}, {"text": "Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab", "labels": -0.6088337402}, {"text": "Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World", "labels": 1.4929351883}, {"text": "Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy", "labels": 3.757227813}, {"text": "German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit", "labels": -0.9772774885}, {"text": "Lilly and IU School of Medicine Partner on Rotation Program for Medical Students", "labels": 0.8216407079}, {"text": "Lilly to Participate in Barclays Global Healthcare Conference", "labels": -0.6652555381}, {"text": "Lilly to Present at Cowen Health Care Conference", "labels": -0.9096017025}, {"text": "Lilly Announces Update on Regulatory Submission Timing for Basal Insulin Peglispro", "labels": -1.2834884052}, {"text": "Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study", "labels": -1.2834884052}, {"text": "NASCAR Driver Ryan Reed Takes First Place At Daytona International Speedway", "labels": -1.2834884052}, {"text": "Lilly Provides Update on Evacetrapib Phase 3 Trial", "labels": 1.4607878589}, {"text": "Students with Type 1 Diabetes Get a Boost from Lilly Diabetes to Attend College", "labels": 0.7514610896}, {"text": "Lilly to Present at Leerink Global Healthcare Conference", "labels": -2.2267018611}, {"text": "The Lilly Foundation Commits $1 Million to Support AMPATH Oncology Institute in Kenya", "labels": 1.652452395}, {"text": "Lilly Diabetes Donates $92,000 in Camp Scholarships to the American Diabetes Association", "labels": -1.9510169027}, {"text": "U.S. FDA approves first-in-class Glyxambi\u00ae (empagliflozin/linagliptin) tablets for adults with type 2 diabetes", "labels": -1.3824362557}, {"text": "Lilly Reports Fourth-Quarter and Full-Year 2014 Results, Updates 2015 Guidance", "labels": -1.8552359254}, {"text": "Scoring Progress Against Cancer: New Tool Measures Cancer Progress to Help Inform Research and Policy Decisions", "labels": 1.4305934344}, {"text": "Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer", "labels": -0.4444148902}, {"text": "Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors", "labels": -0.4444148902}, {"text": "Lilly Provides Update on Strategy and Announces 2015 Financial Guidance", "labels": 1.1852685194}, {"text": "Lilly to Present at J.P. Morgan Healthcare Conference", "labels": -0.0143638954}, {"text": "Lilly Announces Promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development", "labels": -0.0143638954}, {"text": "Lilly Finalizes Novartis Animal Health Acquisition", "labels": -0.5765977999}, {"text": "XTANDI\u00ae (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide", "labels": 0.1536133415}, {"text": "U.S. FDA Approves PREVNAR 20\u00ae, Pfizer\u2019s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children", "labels": 0.6942670661}, {"text": "Pfizer Announces 2023 Shareholder Meeting Preliminary Results", "labels": 0.6942670661}, {"text": "Pfizer Declares Second-Quarter 2023 Dividend", "labels": -1.0841459751}, {"text": "Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27", "labels": -0.8254434667}, {"text": "FDA Accepts Pfizer\u2019s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI", "labels": 0.2647427494}, {"text": "Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts", "labels": -2.1244746925}, {"text": "Phase 3 Study Shows XTANDI\u00ae (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer", "labels": 0.0997433974}, {"text": "FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer\u2019s PAXLOVID\u2122", "labels": 0.0997433974}, {"text": "Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years", "labels": 0.57100186}, {"text": "Pfizer Invests $43 Billion to Battle Cancer", "labels": 1.6040179947}, {"text": "Pfizer\u2019s ZAVZPRET\u2122 (zavegepant) Migraine Nasal Spray Receives FDA Approval", "labels": 1.43000423}, {"text": "Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years", "labels": 0.147704481}, {"text": "Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults", "labels": -0.7964153619}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -2.1444390891}, {"text": "Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster", "labels": -3.0652281447}, {"text": "Pfizer\u2019s Elranatamab Receives FDA and EMA Filing Acceptance", "labels": -0.9929125088}, {"text": "U.S. FDA Accepts Biologics License Application for Pfizer\u2019s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review", "labels": -1.0146302368}, {"text": "Pfizer Announces Positive TALZENNA\u00ae and XTANDI\u00ae Combination Data from Phase 3 TALAPRO-2 Study", "labels": 0.138851099}, {"text": "Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults", "labels": 0.138851099}, {"text": "FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO\u00ae (abrocitinib)", "labels": 1.1138932934}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -0.5469413353}, {"text": "PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE", "labels": 2.2060522942}, {"text": "Pfizer Expands \u2018An Accord for a Healthier World\u2019 Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries", "labels": -3.4222198706}, {"text": "U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children", "labels": -3.2858060169}, {"text": "Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases", "labels": -3.2858060169}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -1.7554282618}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate", "labels": 0.4293572369}, {"text": "U.S. FDA Accepts for Review the Biologics License Application for Pfizer\u2019s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents", "labels": 0.5454943307}, {"text": "Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis", "labels": 0.0580944049}, {"text": "Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts", "labels": 0.8710801879}, {"text": "Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial", "labels": 1.7900906865}, {"text": "Pfizer Declares First-Quarter 2023 Dividend", "labels": 0.7860446748}, {"text": "Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years", "labels": 2.9775726785}, {"text": "U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer\u2019s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults", "labels": 3.9204264168}, {"text": "Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease", "labels": -0.8558854536}, {"text": "Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years", "labels": -2.4139981751}, {"text": "Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day", "labels": 1.1785443595}, {"text": "Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases", "labels": 1.1785443595}, {"text": "Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate", "labels": 1.1785443595}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.6263936735}, {"text": "Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages", "labels": -0.9547529919}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 4.4069897684}, {"text": "Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union", "labels": 0.1470552156}, {"text": "Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center Collaborate with Pfizer\u2019s Institute of Translational Equitable Medicine to Identify Novel Genetic Drivers of Cancer Disparities in African Ancestry Populations", "labels": 0.1470552156}, {"text": "Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine", "labels": -0.8069677732}, {"text": "Pfizer\u2019s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma", "labels": 1.8212639502}, {"text": "PFIZER REPORTS STRONG\u00a0THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK", "labels": -1.9757864005}, {"text": "Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate", "labels": -1.9757864005}, {"text": "Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022", "labels": -2.1804681799}, {"text": "Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older", "labels": 2.5665004169}, {"text": "Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age", "labels": 2.0707339929}, {"text": "Pfizer Completes Acquisition of Global Blood Therapeutics", "labels": -2.3903329546}, {"text": "Voyager Therapeutics Announces Pfizer License of  Next-Generation AAV Capsid for Rare Neurologic Disease Target", "labels": -0.2946563087}, {"text": "Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial", "labels": -0.2946563087}, {"text": "Pfizer Completes Acquisition of Biohaven Pharmaceuticals", "labels": 0.8771871522}, {"text": "Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age", "labels": 0.6350614464}, {"text": "Pfizer Declares Fourth-Quarter 2022 Dividend", "labels": 0.9301427954}, {"text": "Pfizer to Supply Global Fund Up to 6 Million PAXLOVID\u2122 Treatment Courses for Low-and-Middle-Income Countries", "labels": 0.9301427954}, {"text": "Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts", "labels": -2.4590147449}, {"text": "CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development", "labels": -2.4590147449}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union", "labels": -2.0326172023}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents", "labels": -0.1738011985}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022", "labels": -0.5659548729}, {"text": "Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine", "labels": -0.5659548729}, {"text": "Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union", "labels": -4.0918074085}, {"text": "FDA and EMA Accept Regulatory Submission for Pfizer\u2019s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata", "labels": 1.1725292267}, {"text": "FDA Grants Breakthrough Therapy Designation to Pfizer\u2019s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women", "labels": 2.9311793431}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.3685288828}, {"text": "Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action", "labels": 0.3685288828}, {"text": "Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences", "labels": 1.2253801953}, {"text": "Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union", "labels": 1.2253801953}, {"text": "Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older", "labels": 1.3296218867}, {"text": "Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine", "labels": -3.0067074557}, {"text": "Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate", "labels": -1.4950934848}, {"text": "Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age", "labels": -2.0872855572}, {"text": "Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine", "labels": -2.4994728747}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.1227019009}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants", "labels": 2.4120605235}, {"text": "Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15", "labels": 0.7834486196}, {"text": "Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology", "labels": 0.7834486196}, {"text": "Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE\u00ae, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis", "labels": -0.1412088088}, {"text": "PFIZER REPORTS SECOND-QUARTER 2022 RESULTS", "labels": -0.6731371532}, {"text": "Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID\u2122", "labels": 1.1852469002}, {"text": "Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine", "labels": 3.2424131721}, {"text": "Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus", "labels": -1.7471516019}, {"text": "Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron", "labels": -1.6186394496}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts", "labels": 2.3708535384}, {"text": "Valneva and Pfizer Announce Closing of Equity Investment", "labels": 4.5745297198}, {"text": "Pfizer Declares Third-Quarter 2022 Dividend", "labels": 4.5745297198}, {"text": "Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time", "labels": 3.566327744}, {"text": "Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15", "labels": 3.566327744}, {"text": "Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age", "labels": 1.5173539699}, {"text": "Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain", "labels": 1.5173539699}, {"text": "Pfizer Reports Additional Data on PAXLOVID\u2122 Supporting Upcoming New Drug Application Submission to U.S. FDA", "labels": 1.5666869445}, {"text": "Pfizer Completes Acquisition of ReViral", "labels": -6.6039618264}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -6.6039618264}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -4.4032583317}, {"text": "Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.", "labels": 1.426988608}, {"text": "Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory           Multiple Myeloma", "labels": 1.426988608}, {"text": "Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE\u00ae (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer", "labels": 1.426988608}, {"text": "Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE\u00ae", "labels": 1.5601546747}, {"text": "Annaliesa Anderson, Ph.D., Will Lead Pfizer\u2019s Vaccine Research & Development", "labels": -1.0820090331}, {"text": "Pfizer Provides Update on Ownership Interest in Haleon", "labels": -1.0820090331}, {"text": "Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability", "labels": -1.8140051871}, {"text": "Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)", "labels": -0.2782518374}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 1.4632361419}, {"text": "Pfizer Launches \u2018An Accord for a Healthier World\u2019 to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries", "labels": 1.4632361419}, {"text": "Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod\u2019s Potentially Best-in-Class Profile in Ulcerative Colitis", "labels": 1.8618475525}, {"text": "Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose", "labels": 1.554011326}, {"text": "NetVation DL Medicine Announces Research Collaboration with Pfizer Inc.", "labels": 3.0446364739}, {"text": "Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age", "labels": -1.0912658081}, {"text": "Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission", "labels": 0.5723205785}, {"text": "Pfizer to Acquire Biohaven Pharmaceuticals", "labels": 0.8291223087}, {"text": "Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE\u00ae for the Management of Moderate to Severe Pain Associated With Endometriosis", "labels": 1.13076282}, {"text": "Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE\u00ae (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022", "labels": -0.9081451873}, {"text": "Pfizer Reports First-Quarter 2022 Results", "labels": 1.5908250716}, {"text": "Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID\u2122 for Post-Exposure Prophylactic Use", "labels": -3.1650783865}, {"text": "Pfizer Announces 2022 Shareholder Meeting Preliminary Results", "labels": -2.7919293713}, {"text": "Pfizer Declares Second-Quarter 2022 Dividend", "labels": -2.7919293713}, {"text": "Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy", "labels": -2.7919293713}, {"text": "Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer", "labels": 2.7717293379}, {"text": "Pfizer and Biohaven\u2019s VYDURA\u00ae (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine", "labels": 2.7717293379}, {"text": "Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age", "labels": 1.5078344993}, {"text": "Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate", "labels": 1.5078344993}, {"text": "Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL\u00ae (Quinapril HCl) Due to N-Nitroso-Quinapril Content", "labels": -1.0288e-06}, {"text": "Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28", "labels": -3.8391898206}, {"text": "Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age", "labels": -3.0092573799}, {"text": "Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE\u00ae for the Management of Moderate to Severe Pain Associated with Endometriosis", "labels": -0.3766600454}, {"text": "Pfizer Names David M. Denton Chief Financial Officer", "labels": -4.4247670118}, {"text": "Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer\u2019s LORBRENA\u00ae (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer", "labels": -1.705916789}, {"text": "Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates", "labels": 4.8395863675}, {"text": "Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older", "labels": -2.9748216612}, {"text": "Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential", "labels": -2.9748216612}, {"text": "Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults", "labels": 0.4547215937}, {"text": "Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients", "labels": -0.8176387439}, {"text": "Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts", "labels": -3.8513257921}, {"text": "Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries", "labels": -3.8513257921}, {"text": "Pfizer Voluntary Nationwide Recall of Lots of ACCURETIC\u2122 (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide Tablets, and quinapril HCl/hydrochlorothiazide Tablets Due to N-Nitroso- Quinapril Content", "labels": -2.2624438884}, {"text": "Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults", "labels": 0.5668859376}, {"text": "Pfizer Updates Company Position in Russia", "labels": 2.8538501742}, {"text": "Pfizer Completes Acquisition of Arena Pharmaceuticals", "labels": 5.9521628409}, {"text": "Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants", "labels": 2.1747972076}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 2.3999939481}, {"text": "Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women", "labels": 3.5960760907}, {"text": "Phase 3 CLOVER Trial for Pfizer\u2019s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints", "labels": 2.1174041211}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -2.3387849294}, {"text": "FDA Accepts for Review Pfizer\u2019s Supplemental Application for ABRILADA\u2122 (adalimumab-afzb) Interchangeability", "labels": 2.4073129888}, {"text": "Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment", "labels": 2.4073129888}, {"text": "Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union", "labels": 3.897728502}, {"text": "CDC Advisory Committee on Immunization Practices Votes to Recommend TicoVac\u2122, Pfizer\u2019s Tick-Borne Encephalitis (TBE) Vaccine, For Those at Risk of Virus Exposure", "labels": -3.5465617285}, {"text": "Pfizer Statement on Results of Third Annual Pay Equity Study Among Colleagues Worldwide", "labels": -1.4294820723}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference", "labels": -1.4294820723}, {"text": "Pfizer and OPKO\u2019s Once-Weekly NGENLA\u2122 (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency", "labels": -0.2415412135}, {"text": "European Medicines Agency Approves Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults", "labels": -0.2415412135}, {"text": "Pfizer joins the Open Targets consortium", "labels": -0.0602538651}, {"text": "Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea", "labels": -0.0602538651}, {"text": "Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age", "labels": -1.0642595526}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -2.055345855}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2021 Results", "labels": 1.612595079}, {"text": "Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate", "labels": 0.3570725651}, {"text": "Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA", "labels": 2.0794676173}, {"text": "Pfizer Announces New Chief Development Officer", "labels": 2.0794676173}, {"text": "Pfizer Invites Public to View and Listen to a Webcast with Pfizer Director Joseph Echevarria to Discuss Board Oversight of ESG", "labels": 2.0794676173}, {"text": "Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program", "labels": -1.7524170119}, {"text": "European Commission Approves LORVIQUA\u00ae (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer", "labels": -2.0497188346}, {"text": "Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment", "labels": 2.4111921774}, {"text": "Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age", "labels": 3.1126160712}, {"text": "Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant", "labels": 1.5036133462}, {"text": "Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency", "labels": -5.5878892023}, {"text": "Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform", "labels": -1.7930619484}, {"text": "Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant", "labels": -1.7930619484}, {"text": "U.S. FDA Approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis", "labels": -1.6078303053}, {"text": "Positive Top-Line Results of Pfizer\u2019s Phase 3 Study Exploring Coadministration of PREVNAR 20\u2122 With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released", "labels": -1.4404126053}, {"text": "Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer", "labels": -0.1765211035}, {"text": "Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics", "labels": 1.728705328}, {"text": "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases", "labels": 1.728705328}, {"text": "Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States", "labels": -1.8234700945}, {"text": "Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine", "labels": -1.8234700945}, {"text": "Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19", "labels": -1.0605866961}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -1.0605866961}, {"text": "Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older", "labels": -7.2804018264}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 2.2015227477}, {"text": "Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts", "labels": -2.5529565548}, {"text": "Pfizer and BioNTech Submit Updated Longer-Term Follow-Up Data of COMIRNATY\u00ae in Adolescents 12 Through 15 Years of Age to EMA", "labels": -1.0472943985}, {"text": "Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment", "labels": -0.9197803106}, {"text": "Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19", "labels": -0.9197803106}, {"text": "Pfizer\u2019s VYNDAQEL\u00ae/VYNDAMAX\u00ae Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate", "labels": -2.7989828259}, {"text": "Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY\u00ae to Help Meet Continued Need for Vaccine Supply", "labels": -2.7989828259}, {"text": "Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine", "labels": 1.7862952999}, {"text": "EMA Adopts a Positive CHMP Opinion for Pfizer\u2019s and OPKO\u2019s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency", "labels": 1.7862952999}, {"text": "CHMP Issues Positive Opinion for Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults", "labels": 1.7862952999}, {"text": "Pfizer Receives Positive CHMP Opinion for LORVIQUA\u00ae (lorlatinib) as First-Line Treatment for ALK-Positive Advanced Lung Cancer", "labels": 1.7862952999}, {"text": "Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY\u00ae in Adolescents 12 Through 15 Years of Age", "labels": 1.8829839212}, {"text": "EMA Issues Advice for Potential Early Use of Pfizer\u2019s Novel COVID-19 Oral Antiviral Candidate", "labels": 1.8829839212}, {"text": "Anaveon to raise CHF 110 million in oversubscribed Series B financing", "labels": 1.8829839212}, {"text": "Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities", "labels": 8.3918338065}, {"text": "U.S. FDA Approves Pfizer\u2019s XELJANZ\u00ae (tofacitinib) for the Treatment of Active Ankylosing Spondylitis", "labels": 6.853749525}, {"text": "Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death", "labels": 6.853749525}, {"text": "Pfizer to Acquire Arena Pharmaceuticals", "labels": 3.7810547048}, {"text": "Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy", "labels": 3.7810547048}, {"text": "Pfizer Declares First-Quarter 2022 Dividend", "labels": 7.2463700144}, {"text": "European Commission Approves Pfizer\u2019s Cibinqo\u00ae (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis", "labels": 7.2463700144}, {"text": "Arvinas and Pfizer Announce PROTAC\u00ae Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer", "labels": 7.2463700144}, {"text": "Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older", "labels": 2.4062207704}, {"text": "Pfizer and BioNTech Provide Update on Omicron Variant", "labels": -1.2864736131}, {"text": "Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer\u2019s Novel COVID-19 Oral Antiviral Treatment Candidate", "labels": 0.2918262275}, {"text": "FDA Issues Update to XELJANZ\u00ae Prescribing Information in the United States", "labels": -4.3317748298}, {"text": "AWS Helps Pfizer Accelerate Drug Development And Clinical Manufacturing", "labels": 0.8291822881}, {"text": "Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation", "labels": -2.642850325}, {"text": "Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY\u00ae in Children 5 to under 12 Years of Age in the European Union", "labels": -3.1297666552}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 2.3282438545}, {"text": "Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia", "labels": 2.3282438545}, {"text": "Important Update on EpiPen\u00ae (epinephrine injection, USP) 0.3 mg  Auto-Injectors", "labels": 0.6091479853}, {"text": "Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age", "labels": 0.2545154128}, {"text": "Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium", "labels": -1.4843623911}, {"text": "Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older", "labels": -1.4843623911}, {"text": "Pfizer\u2019s XELJANZ\u00ae (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis", "labels": -0.5905715317}, {"text": "Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative", "labels": -0.5905715317}, {"text": "Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19", "labels": -0.5905715317}, {"text": "Pfizer Completes Acquisition of Trillium Therapeutics", "labels": 2.8593827127}, {"text": "Pfizer Announces Retirement of Chief Financial Officer Frank D\u2019Amelio", "labels": 2.8593827127}, {"text": "Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate", "labels": 2.7521037864}, {"text": "Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries", "labels": 2.7521037864}, {"text": "Pfizer Names Bill Sessa, Ph.D., Chief Scientific Officer to Lead Internal Medicine Research", "labels": -1.5508443947}, {"text": "Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana", "labels": 1.0054141333}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 5.5400626519}, {"text": "Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older", "labels": 1.4075882103}, {"text": "Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States", "labels": 1.4075882103}, {"text": "Pfizer\u2019s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study", "labels": 0.4965935716}, {"text": "PFIZER REPORTS THIRD-QUARTER 2021 RESULTS", "labels": -0.5801125588}, {"text": "Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years", "labels": 1.2603145615}, {"text": "Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs", "labels": 1.806128983}, {"text": "FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years", "labels": -0.8378072325}, {"text": "Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine", "labels": 0.2316864772}, {"text": "Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer\u2019s PREVNAR 20\u2122 (Pneumococcal 20-valent Conjugate Vaccine) in Adults", "labels": 1.7265710131}, {"text": "Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress", "labels": 2.803736816}, {"text": "New Formulation of COMIRNATY\u00ae Receives Positive Opinion from CHMP", "labels": 1.5205432993}, {"text": "Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12 Years of Age with COMIRNATY\u00ae", "labels": -1.4036791239}, {"text": "Pfizer\u2019s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis", "labels": -1.4036791239}, {"text": "AION Labs, Biotech Innovation Lab Launched by Top Pharma, Tech and Investment Leaders", "labels": -0.1919973729}, {"text": "Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union", "labels": -1.4413949209}, {"text": "Japan\u2019s MHLW Approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis", "labels": -2.003258152}, {"text": "Positive Top-line Results of Pfizer\u2019s Phase 3 Study Exploring Coadministration of Prevnar 20\u2122 With Seasonal Flu Vaccine in Older Adults Released", "labels": -0.4882577422}, {"text": "Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate", "labels": 1.0567295447}, {"text": "Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age", "labels": 1.0567295447}, {"text": "Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program", "labels": -2.0445995103}, {"text": "Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults", "labels": -2.0445995103}, {"text": "Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency", "labels": -1.1475830295}, {"text": "Pfizer Declares Fourth-Quarter 2021 Dividend", "labels": -0.7737840848}, {"text": "Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries", "labels": 0.452581165}, {"text": "Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years", "labels": 1.2067232117}, {"text": "FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY\u00ae Booster for Emergency Use in People 65 and Older and Certain High-risk Populations", "labels": 0.0678867223}, {"text": "Astellas\u2019 and Pfizer\u2019s XTANDI\u00ae (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study", "labels": 0.0678867223}, {"text": "Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX\u00ae (varenicline) Tablets Due to N-Nitroso Varenicline Content", "labels": 0.0678867223}, {"text": "Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies", "labels": -2.2556417704}, {"text": "Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE\u00ae for the Management of Moderate to Severe Pain Associated With Endometriosis", "labels": -1.9302287473}, {"text": "UK\u2019s MHRA Grants Marketing Authorisation for Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis", "labels": -1.9302287473}, {"text": "Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences", "labels": -1.0320409374}, {"text": "Pfizer and BioNTech Submit a Variation to EMA with the Data in  Support of a Booster Dose of COMIRNATY\u00ae", "labels": -1.0320409374}, {"text": "The Bristol-Myers Squibb-Pfizer Alliance is pleased with the decision by the U.S.  Court of Appeals for the Federal Circuit upholding the Eliquis\u00aePatents", "labels": -0.3208589985}, {"text": "Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)", "labels": 0.768575169}, {"text": "FDA Issues Drug Safety Communication Related to Current XELJANZ\u00ae Label", "labels": 1.3877030832}, {"text": "First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate  in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of  Severe Illness", "labels": 1.3877030832}, {"text": "Positive Top-Line Results From Pfizer\u2019s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis", "labels": -0.2821792975}, {"text": "Pfizer Announces New Chief Business Innovation Officer", "labels": -2.3605357359}, {"text": "Pfizer and BioNTech Announce Collaboration With Brazil\u2019s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America", "labels": -2.3605357359}, {"text": "Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY\u00ae in Individuals 16 and Older", "labels": -1.3929903917}, {"text": "Pfizer-BioNTech COVID-19 Vaccine COMIRNATY\u00ae Receives Full U.S. FDA Approval for Individuals 16 Years and Older", "labels": -3.9479041433}, {"text": "Pfizer to Acquire Trillium Therapeutics Inc.", "labels": -3.9479041433}, {"text": "XELJANZ\u00ae (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis", "labels": 1.9026485576}, {"text": "Pfizer Prices $1.0 Billion Sustainability Bond", "labels": 4.3435140567}, {"text": "Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine", "labels": 4.3435140567}, {"text": "U.S. FDA Approves TICOVAC\u2122, Pfizer\u2019s Tick-Borne Encephalitis (TBE) Vaccine", "labels": 3.0668668806}, {"text": "Pfizer Expands Voluntary Nationwide Recall to include Four  Additional Lots of CHANTIX\u00ae (varenicline) Tablets Due to N-Nitroso Varenicline Content", "labels": 3.0668668806}, {"text": "VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease", "labels": 4.0841434391}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata", "labels": -0.6435687599}, {"text": "Pfizer and BioNTech Share Detailed Update to the Results from 6 Month Safety and  Efficacy Data Analysis of Landmark COVID-19 Vaccine Study", "labels": 1.91663523}, {"text": "PFIZER REPORTS SECOND-QUARTER 2021 RESULTS", "labels": 1.91663523}, {"text": "Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.", "labels": 0.8371240577}, {"text": "Arvinas And Pfizer Announce Global Collaboration To Develop And Commercialize Protac\u00ae Protein Degrader Arv-471", "labels": 1.3435776188}, {"text": "Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC\u00ae Protein Degrader ARV-471", "labels": 1.3435776188}, {"text": "Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ\u00ae Filings", "labels": 0.5546110479}, {"text": "Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa", "labels": 0.5546110479}, {"text": "Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate", "labels": 2.3873294263}, {"text": "Pfizer Announces New Investor Relations Leader", "labels": 2.3873294263}, {"text": "Pfizer Issues A Voluntary Nationwide Recall for Twelve Lots of  CHANTIX\u00ae (varenicline) Tablets Due to N-Nitroso Varenicline  Content", "labels": 0.0249261368}, {"text": "U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine", "labels": 0.0249261368}, {"text": "Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant", "labels": 1.5400160343}, {"text": "Newly Published Expert Opinion Article Details Evidence for Classifying Aging Immune System as a High-Risk Condition for Pneumococcal Vaccine Policy", "labels": 1.5400160343}, {"text": "Collaboration Between Abbvie, Biogen And Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants To Human Health And Disease.", "labels": 1.5400160343}, {"text": "Collaboration Between Abbvie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease", "labels": 1.5400160343}, {"text": "Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206", "labels": 1.0616965092}, {"text": "Pfizer Declares Third-Quarter 2021 Dividend", "labels": -0.4104503628}, {"text": "First Participant Dosed in Pfizer\u2019s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)", "labels": -1.1227455039}, {"text": "SVI announces collaboration with Pfizer", "labels": -0.9219026142}, {"text": "Data Published in New England Journal of Medicine Shows Pfizer\u2019s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia", "labels": -0.3546189538}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts", "labels": -0.3546189538}, {"text": "XELJANZ\u00ae Safety Review Recommendation Issued in the European Union", "labels": -2.5990509524}, {"text": "Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations", "labels": 0.6226744249}, {"text": "U.S. FDA Approves PREVNAR 20\u2122, Pfizer\u2019s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older", "labels": 1.858842403}, {"text": "IMI SOPHIA PARTNERS WITH MACCABI\u2019S RESEARCH AND INNOVATION CENTER (KSM), PFIZER, AND LAUSANNE UNIVERSITY HOSPITAL TO IMPROVE OBESITY TREATMENT", "labels": -0.3866903036}, {"text": "Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents", "labels": -0.6493729606}, {"text": "Pfizer Colleagues to Mentor Veterans in Transition to Civilian Life", "labels": -0.6493729606}, {"text": "RefleXion Announces New Additions to Board of Directors and Appoints Audit Committee Chair", "labels": -0.6196514216}, {"text": "Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE\u00ae, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids", "labels": -1.6559099687}, {"text": "The Foundation for the NIH Announces a New Research Initiative to Find Integrated Treatments Across Common Metabolic Diseases", "labels": -1.6559099687}, {"text": "Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults", "labels": -1.9069506383}, {"text": "Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY\u00ae", "labels": 0.5507003872}, {"text": "Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials", "labels": 0.5483491948}, {"text": "Pfizer\u2019s Novel Prediction Model, Derived from Machine Learning, Shows Robust Performance for Identifying Heart Failure Patients At-Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, a Rare and Life-Threatening Condition", "labels": 0.0251835472}, {"text": "Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents", "labels": -1.2198247949}, {"text": "Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine", "labels": 2.0321184226}, {"text": "Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games", "labels": 2.7791918314}, {"text": "Hospira Issues A Voluntary Nationwide Recall for One Lot of  0.5% Bupivacaine Hydrochloride Injection, USP and One Lot of 1%  Lidocaine HCl Injection, USP Due to Mislabeling", "labels": -0.0750542248}, {"text": "Hospira Issues A Voluntary Nationwide Recall for One Lot of  Sterile Water for Injection, USP, Due to the Potential Presence of Visible Particulate", "labels": -0.0750542248}, {"text": "PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS", "labels": -0.0750542248}, {"text": "Pfizer Ventures' Barbara Dalton Appointed as AMRA Medical's Newest Board Member", "labels": -0.8797027835}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.155445173}, {"text": "Pfizer Acquires Amplyx Pharmaceuticals", "labels": 0.155445173}, {"text": "Pfizer Acquires Amplyx Pharmaceuticals", "labels": 0.155445173}, {"text": "Pfizer Announces 2021 Shareholder Meeting Results", "labels": -2.1210664141}, {"text": "Pfizer Declares Second-Quarter 2021 Dividend", "labels": -2.1210664141}, {"text": "Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY\u00ae", "labels": 1.1017117711}, {"text": "Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22", "labels": 3.3964457913}, {"text": "AMRA Medical Generates Largest Imaging Dataset on Body Composition Profiling", "labels": 1.1436044496}, {"text": "Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet", "labels": 1.829925252}, {"text": "Pfizer and BioNTech Request Regulatory Agencies Expand  Emergency Use of Their COVID-19 Vaccine to Adolescents", "labels": 2.8942496401}, {"text": "Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis", "labels": -0.1946402213}, {"text": "Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021", "labels": -1.0818153766}, {"text": "Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study", "labels": -0.0551607636}, {"text": "Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents", "labels": 0.4132351097}, {"text": "EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union", "labels": 2.5669110959}, {"text": "Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain", "labels": 1.6551682929}, {"text": "Results from Pfizer\u2019s Phase 3 Jade Compare Study of Abrocitinib in Moderate to Severe Atopic Dermatitis Published in New England Journal of Medicine", "labels": 1.6551682929}, {"text": "Real-World Evidence Supports Effectiveness of First-line IBRANCE\u00ae (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer", "labels": 1.6551682929}, {"text": "Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids", "labels": 0.5326526217}, {"text": "Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2", "labels": -0.5897229625}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts", "labels": -0.5897229625}, {"text": "Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments", "labels": -0.1677639439}, {"text": "Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared", "labels": -0.3720719034}, {"text": "Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate", "labels": -0.0870730596}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.3780079242}, {"text": "U.S. FDA Expands Approval of Pfizer\u2019s LORBRENA\u00ae as First-Line Treatment for ALK-Positive Metastatic Lung Cancer", "labels": 2.0175628086}, {"text": "Pfizer-BioNTech\u2019s COVID-19 Vaccine Arrives in Rwanda", "labels": 2.0175628086}, {"text": "European Medicines Agency Accepts Pfizer\u2019s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older", "labels": -0.4452356296}, {"text": "EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency", "labels": -0.4452356296}, {"text": "Pfizer Statement on Results of Second Annual Pay Equity Study  Among Colleagues Worldwide", "labels": -0.9853535321}, {"text": "Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants", "labels": -0.9853535321}, {"text": "U.S. FDA Accepts for Priority Review Pfizer\u2019s Application for TicoVac\u2122 (Tick-borne Encephalitis Vaccine)", "labels": -0.7407426902}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -1.2385742185}, {"text": "President Biden Visits Pfizer\u2019s Kalamazoo Manufacturing Facility", "labels": -1.1675596167}, {"text": "Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA", "labels": -1.1675596167}, {"text": "Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women", "labels": -0.9872057431}, {"text": "Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids", "labels": -0.028933215}, {"text": "Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder", "labels": -0.028933215}, {"text": "Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma", "labels": -0.028933215}, {"text": "Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY\u00ae", "labels": -0.028933215}, {"text": "In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer- BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations", "labels": -0.028933215}, {"text": "U.S. FDA Approves PANZYGA\u00ae for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "labels": 0.7206701206}, {"text": "Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine", "labels": 0.7206701206}, {"text": "Pfizer And Ida Foundation Partner To Expand Access To Essential Cancer Treatments In  70 Low-And Lower-Middle-Income Countries New Partnership Broadens Access To Oncology Treatments Across Latin America, Asia, Africa And The  Western Pacific.", "labels": -0.1727373083}, {"text": "Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries", "labels": -0.1727373083}, {"text": "Palleon Pharmaceuticals Appoints Nikola Trbovic to its Board of Directors", "labels": 0.0286282912}, {"text": "Pfizer and BioNTech Publish Data from In Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants", "labels": 0.0286282912}, {"text": "Pfizer Confirms U.S. Patent Term Extension for IBRANCE\u00ae (palbociclib) Until March 2027", "labels": -0.287192213}, {"text": "PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS", "labels": -2.6406526209}, {"text": "Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine  Program in Nature", "labels": -2.6864745227}, {"text": "Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies\u2019 Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science", "labels": -3.0167592985}, {"text": "Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ\u00ae (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)", "labels": -2.0410903353}, {"text": "In Vitro Studies Demonstrate Pfizer and BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants", "labels": -2.0410903353}, {"text": "Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis", "labels": -2.8421678167}, {"text": "Statement on ATMI Ranking", "labels": -2.8421678167}, {"text": "European Commission Approves BAVENCIO\u00ae (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma", "labels": 2.0369921016}, {"text": "Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19", "labels": 2.5750930784}, {"text": "Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform", "labels": 2.5750930784}, {"text": "Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors", "labels": 0.4377786245}, {"text": "Pfizer and BioNTech Publish Results of Study Showing COVID-19  Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the  SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture", "labels": -0.8498025442}, {"text": "Statement by Pfizer Chairman and CEO Albert Bourla", "labels": 0.136135812}, {"text": "Statement on European Upscaling as well as Impact on Deliveries", "labels": 0.136135812}, {"text": "Pfizer\u2019s XALKORI\u00ae (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults", "labels": -0.2179829491}, {"text": "Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.", "labels": -2.2788840563}, {"text": "Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative", "labels": -2.2788840563}, {"text": "Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to FurtherDevelop CodexDNA\u2019s Novel Enzymatic DNA Synthesis Technology for Pfizer\u2019s use in its Research and  Development ofmRNA-based Vaccines and Biotherapies", "labels": -0.1076083661}, {"text": "An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission", "labels": 1.6150435079}, {"text": "Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy", "labels": 0.2423919985}, {"text": "Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference", "labels": 0.4068379283}, {"text": "US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency", "labels": 0.8604437595}, {"text": "Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY\u00ae", "labels": -0.4355240597}, {"text": "LORBRENA\u00ae (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA", "labels": -0.8366931037}, {"text": "Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health", "labels": -0.8366931037}, {"text": "Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine", "labels": 0.6976195537}, {"text": "Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts", "labels": 0.6143262212}, {"text": "Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine", "labels": -1.4697948477}, {"text": "Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine", "labels": -1.4697948477}, {"text": "Pfizer COVID-19 Vaccine Production and Distribution Working Well", "labels": -0.3981042368}, {"text": "Pfizer Doses First Participants as Part of Global Achondroplasia Phase 2 Development Program", "labels": -3.224092846}, {"text": "Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2", "labels": -7.5174524339}, {"text": "U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older", "labels": -7.5174524339}, {"text": "Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19", "labels": -7.0390128333}, {"text": "BAVENCIO\u00ae (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma", "labels": -7.0390128333}, {"text": "BAVENCIO\u00ae (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma", "labels": -7.0390128333}, {"text": "Pfizer Declares First-Quarter 2021 Dividend", "labels": -7.0390128333}, {"text": "Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.", "labels": -1.7023417382}, {"text": "Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine", "labels": -1.7023417382}, {"text": "Statement on EMA Cyberattack", "labels": -3.2111339719}, {"text": "U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer\u2019s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older", "labels": 1.075267324}, {"text": "PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine  learning for Drug Discovery", "labels": 4.4642755563}, {"text": "Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma", "labels": 4.4642755563}, {"text": "Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10\u00b9\u00b3 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy", "labels": 4.4642755563}, {"text": "Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19", "labels": -0.9478837376}, {"text": "Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA", "labels": 3.4313752468}, {"text": "Pfizer and BioNTech Submitted Application for Conditional Marketing  Authorization for COVID-19 Vaccine to the EMA", "labels": 3.4313752468}, {"text": "Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors", "labels": -1.1748727906}, {"text": "Pfizer Receives European Approval for Oncology Supportive Care Biosimilar, NYVEPRIATM (pegfilgrastim)", "labels": -0.4928833262}, {"text": "Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine", "labels": -0.4928833262}, {"text": "Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China", "labels": 0.2725047072}, {"text": "Results from Phase 3 CROWN Trial of Pfizer\u2019s LORBRENA\u00ae (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine", "labels": 0.2725047072}, {"text": "Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints", "labels": -2.0447772091}, {"text": "PFIZER UPDATE ON OUR U.S. COVID-19 VACCINE CANDIDATE  DISTRIBUTION PREPAREDNESS", "labels": 0.3321210481}, {"text": "Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness", "labels": 0.3321210481}, {"text": "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan", "labels": 0.3321210481}, {"text": "Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL\u00ae 80 mg/VYNDAMAX\u00ae 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg", "labels": 0.8803855623}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -3.5419498083}, {"text": "Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens", "labels": -3.5419498083}, {"text": "Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2", "labels": -3.5419498083}, {"text": "Pfizer Statement on Geodon (ziprasidone) Trial Closure in the  United States", "labels": -5.0649133954}, {"text": "Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.", "labels": -8.2213207267}, {"text": "Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study", "labels": -8.2213207267}, {"text": "Pfizer Announces Positive Phase 3 Study Results for XELJANZ \u00ae (tofacitinib) in Ankylosing Spondylitis (AS)", "labels": 7.1683754825}, {"text": "Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock", "labels": -2.335164689}, {"text": "Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn", "labels": 2.7325400548}, {"text": "New Report Identifies Need for More Effective Policy Responses and Investment to Prevent Strokes in Europe", "labels": -9.975e-06}, {"text": "FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer\u2019s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis", "labels": -4.4851831651}, {"text": "PFIZER REPORTS THIRD-QUARTER 2020 RESULTS", "labels": -4.4851831651}, {"text": "Data From Pfizer\u2019s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020", "labels": 0.2137342664}, {"text": "Pfizer and BioNTech Announce New England Journal of Medicine Publication of Phase 1 Data on Lead mRNA Vaccine Candidate  BNT162b2 Against COVID-19", "labels": -1.2585677887}, {"text": "PENELOPE-B Trial of IBRANCE\u00ae (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint", "labels": -0.0271494316}, {"text": "Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency", "labels": 0.5164488358}, {"text": "Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment", "labels": 1.7077885713}, {"text": "BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2", "labels": -1.453238409}, {"text": "SpringWorks Therapeutics Announces Clinical Collaboration with PfizerInc. to  Evaluate Nirogacestat in Combination with PF\u201006863135 in Patients with Relapsed  or Refractory Multiple Myeloma", "labels": -0.9953165712}, {"text": "Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy", "labels": -1.4568318833}, {"text": "BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2", "labels": 0.2749366445}, {"text": "U.S. FDA Approves Pfizer\u2019s XELJANZ\u00ae (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis", "labels": 0.027633653}, {"text": "Pfizer Declares Fourth-Quarter 2020 Dividend", "labels": 0.2774347734}, {"text": "Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet\u2019s  Investigational Gene Therapy for Wilson Disease", "labels": -1.6219495306}, {"text": "FDA Accepts Supplemental New Drug Application for Pfizer\u2019s XALKORI\u00ae (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma", "labels": -1.6219495306}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts", "labels": 0.5277925886}, {"text": "Javelin Biotech Aims to Develop Industry-Leading \u201cOrgan-on-a-Chip\u201d Predictive  Pharmacokinetics Platform in Collaboration with Pfizer Inc.", "labels": 0.5277925886}, {"text": "BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine", "labels": -2.1099601067}, {"text": "Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas", "labels": -1.1147162458}, {"text": "Pfizer Hosts Virtual Investor Day", "labels": 1.6233631716}, {"text": "Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial", "labels": 1.6233631716}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 3.4315078191}, {"text": "Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020", "labels": -0.3603922705}, {"text": "Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19", "labels": -1.7952387348}, {"text": "Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2", "labels": -1.7952387348}, {"text": "Biopharma Leaders Unite To Stand With Science", "labels": -0.9673862624}, {"text": "Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020", "labels": -2.7777596874}, {"text": "Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19", "labels": 1.8004120835}, {"text": "Pfizer Statement on Lyrica (Pregabalin) Patent Infringement  in Japan", "labels": 0.8342148989}, {"text": "Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARSCoV-2 in Nature", "labels": 0.8907511975}, {"text": "Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19", "labels": 0.2344170526}, {"text": "Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020", "labels": -0.8322543249}, {"text": "Pfizer signs on to The Hispanic Promise further strengthening its ties and commitment to Hispanics in the workplace", "labels": -0.8322543249}, {"text": "The Bristol-Myers Squibb-Pfizer Alliance is pleased with the U.S. District Court decision to uphold both the composition of matter (COM) patent (US 6,967,208) and formulation patent (US 9,326,945) covering Eliquis\u00ae.", "labels": -0.5225873635}, {"text": "Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate", "labels": -0.5225873635}, {"text": "LORBRENA\u00ae (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer", "labels": -0.5225873635}, {"text": "Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate", "labels": 0.1825385129}, {"text": "Pfizer Reports Second-Quarter 2020 Results", "labels": 1.8339415192}, {"text": "Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study", "labels": 4.254208283}, {"text": "Pfizer Shares Pre-Clinical Data Updates on COVID-19 Antiviral Research Program", "labels": 0.4686092458}, {"text": "Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2", "labels": 0.4686092458}, {"text": "Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data", "labels": -2.1804473147}, {"text": "Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2", "labels": -2.1804473147}, {"text": "Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2", "labels": 1.4192342631}, {"text": "Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance", "labels": 0.295609952}, {"text": "Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2", "labels": -0.0869199611}, {"text": "FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma", "labels": 3.5862543682}, {"text": "European Commission Approves DAURISMO\u2122 (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)", "labels": 3.5862543682}, {"text": "Pfizer Statement on Facebook Advertising Boycott", "labels": 0.7339214106}, {"text": "Pfizer Declares Third-Quarter 2020 Dividend", "labels": -0.2184662047}, {"text": "Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa", "labels": -1.2066940972}, {"text": "NEW DATA ON THE BURDEN OF EMERGING S. PNEUMONIAE SEROTYPES  PUBLISHED IN ISPPD 2020 ONLINE DIGITAL LIBRARY", "labels": -3.1376212493}, {"text": "European Medicines Agency Validates Application for BAVENCIO\u00ae (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma", "labels": -1.7088814229}, {"text": "Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines", "labels": -1.7088814229}, {"text": "European Medicines Agency Validates Application for BAVENCIO\u00ae (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma", "labels": -1.7088814229}, {"text": "Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy", "labels": 0.4488327547}, {"text": "Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn", "labels": 0.4488327547}, {"text": "Merck and Pfizer\u2019s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary  Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and  Atherosclerotic Cardiovascular Disease", "labels": -0.0893913764}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts", "labels": -0.0893913764}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th", "labels": -2.1582811901}, {"text": "FDA Approves Pfizer\u2019s Oncology Supportive Care Biosimilar, NYVEPRIA\u2122 (pegfilgrastim-apgf)", "labels": -5.481471388}, {"text": "Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis", "labels": -9.1892008577}, {"text": "Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology", "labels": -0.7775611265}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 1.7422512467}, {"text": "Pfizer Establishes New Program to Support Continued Biotechnology Innovation", "labels": 1.7422512467}, {"text": "Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE\u00ae (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer", "labels": -7.9243938083}, {"text": "Final PROSPER Results Show XTANDI\u00ae (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer", "labels": -7.9243938083}, {"text": "Corning and Pfizer Announce Supply Agreement for Corning Valor\u00ae Glass  Packaging", "labels": 0.9164559276}, {"text": "Corning and Pfizer Announce Supply Agreement for Corning Valor\u00ae Glass Packaging", "labels": 0.9164559276}, {"text": "Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC", "labels": 1.013609352}, {"text": "Pfizer Prices $4,000,000,000 Debt Offering", "labels": -1.7515720136}, {"text": "Pfizer\u2019s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study", "labels": 0.2889455982}, {"text": "Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age", "labels": 2.5423775515}, {"text": "Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day", "labels": 1.6086563372}, {"text": "New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program", "labels": -2.8880126931}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -2.8880126931}, {"text": "Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting", "labels": 2.2309798065}, {"text": "Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program", "labels": -0.7790179867}, {"text": "New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized", "labels": 2.3630422625}, {"text": "Pfizer Receives Positive CHMP Opinion for DAURISMO\u00ae(glasdegib)for Certain Adult Patients with Newly Diagnosed or Secondary Acute Myeloid Leukemia (AML)", "labels": -0.6113727799}, {"text": "Pfizer Receives Positive CHMP Opinion for DAURISMOTM (glasdegib)for  Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia  (AML)", "labels": -0.6113727799}, {"text": "Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15", "labels": -0.9564756443}, {"text": "AMRA Medical renews collaboration with Pfizer Inc.  aiming to generate the world\u2019s  largest imaging dataset on body  composition profiling", "labels": -0.9564756443}, {"text": "BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany", "labels": -0.2606467737}, {"text": "PFIZER REPORTS FIRST-QUARTER 2020 RESULTS", "labels": -2.4396662803}, {"text": "Pfizer Hosts Virtual-Only Annual Meeting of Shareholders", "labels": 2.9427743096}, {"text": "FoRx Therapeutics AG Raises EUR 10 Million Seed Round to Develop a Pipeline  of Drugs Targeting DNA Replication Stress for Cancer", "labels": -0.735905966}, {"text": "BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates", "labels": -0.735905966}, {"text": "Valneva Receives FDA Fast Track Designation for its Lyme Disease  Vaccine Candidate VLA15", "labels": -2.1336390039}, {"text": "Pfizer Advances Battle Against COVID-19 on Multiple Fronts", "labels": 0.3130224119}, {"text": "Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development", "labels": 0.3130224119}, {"text": "EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO\u00ae for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma", "labels": 0.3130224119}, {"text": "U.S. FDA Approves BRAFTOVI\u00ae (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy", "labels": 3.955923944}, {"text": "Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders", "labels": -1.1560851751}, {"text": "Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic", "labels": -0.9223289721}, {"text": "Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE\u2122 (rituximab)", "labels": 5.1724263045}, {"text": "Susan Desmond-Hellmann Elected to Pfizer\u2019s Board of Directors", "labels": 5.1724263045}, {"text": "Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic", "labels": 2.8901644279}, {"text": "Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact", "labels": 5.7238885516}, {"text": "Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn", "labels": 3.2686209366}, {"text": "U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA\u00ae (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis", "labels": 0.8067219305}, {"text": "Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Na\u00efve Adults Aged 18 Years or Older", "labels": -1.1505512587}, {"text": "Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch", "labels": -1.1505512587}, {"text": "Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns", "labels": -1.1505512587}, {"text": "Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch", "labels": -1.1505512587}, {"text": "Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts", "labels": 2.224988915}, {"text": "Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine", "labels": 2.224988915}, {"text": "Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine", "labels": 2.224988915}, {"text": "Pfizer Outlines Five-Point Plan to Battle COVID-19", "labels": -3.6116782049}, {"text": "EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study", "labels": -3.6116782049}, {"text": "Susan Hockfield Elected to Pfizer\u2019s Board of Directors", "labels": 1.0152283707}, {"text": "Pfizer Provides Comment on COVID-19 White House Meeting", "labels": 1.1370122693}, {"text": "U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis", "labels": 1.1370122693}, {"text": "James Quincey Elected to Pfizer\u2019s Board of Directors", "labels": -3.0520632249}, {"text": "Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer", "labels": -3.0520632249}, {"text": "Mylan and Pfizer Finalize Appointments to Viatris Board of Directors", "labels": -3.0520632249}, {"text": "Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer", "labels": -3.0520632249}, {"text": "Mylan and Pfizer Finalize Appointments to Viatris Board of Directors", "labels": -3.0520632249}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.1152156035}, {"text": "Montis Biosciences launched with \u20ac8,4 million seed financing and a novel  approach to immune-oncology", "labels": 0.0280029646}, {"text": "European Commission Approves VYNDAQEL\u00ae, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)", "labels": -0.883251132}, {"text": "European Commission Approves VYNDAQEL\u00ae, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)", "labels": -0.883251132}, {"text": "XTANDI\u00ae (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC", "labels": -0.3974578679}, {"text": "Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE\u2122 (rituximab)", "labels": 1.5195649055}, {"text": "PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS", "labels": -4.6301109691}, {"text": "Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults", "labels": -0.9291909169}, {"text": "Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial  Discounts", "labels": -0.9291909169}, {"text": "Pfizer\u2019s Greenstone and Digital Men\u2019s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra\u00ae (sildenafil citrate)", "labels": -0.9291909169}, {"text": "Insilico enters into research collaboration with Pfizer Inc. to explore novel data  and artificial intelligence system for potential therapeutic targets", "labels": 3.0489414721}, {"text": "Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer\u2019s Disease  and Parkinson\u2019s Disease from Pfizer Inc.", "labels": 1.123032391}, {"text": "Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer\u2019s Reboxetine  Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate", "labels": 1.123032391}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -0.1536288611}, {"text": "BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma", "labels": -0.1806499127}, {"text": "Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program", "labels": -0.3308709891}, {"text": "BioInvent announces selection of second target and extension of the research  collaboration and license agreement with Pfizer Inc.", "labels": -0.3308709891}, {"text": "U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI\u00ae (encorafenib) in Combination with ERBITUX\u00ae (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy", "labels": -0.1026311826}, {"text": "Pfizer and Mylan Announce Two Future Viatris Board Members", "labels": -0.1026311826}, {"text": "Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts", "labels": -1.4142311928}, {"text": "Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of  Transformative Treatments for Triplet Repeat Disorders", "labels": -1.4142311928}, {"text": "XTANDI\u00ae (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer", "labels": 0.5141052399}, {"text": "Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline", "labels": 0.5141052399}, {"text": "Pfizer Receives Positive CHMP Opinion for VYNDAQEL\u00ae for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease", "labels": 1.5840482856}, {"text": "FDA Approves XELJANZ\u00ae XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis", "labels": 0.4174168161}, {"text": "ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and  BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials", "labels": -0.1308321033}, {"text": "Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer", "labels": 0.9875229969}, {"text": "Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment", "labels": 0.9875229969}, {"text": "ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel  Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases", "labels": -0.5258922836}, {"text": "CeMM enters into research collaboration on expanding the druggable proteome  with Pfizer Inc.", "labels": 2.3009228929}, {"text": "FDA Approves Pfizer\u2019s Biosimilar, ABRILADA\u2122 (adalimumab-afzb) for Multiple Inflammatory Conditions", "labels": 0.7169452316}, {"text": "Pfizer Announces CHMP Opinion for XELJANZ\u00ae (tofacitinib) in the European Union Related to Ongoing Review of the Product", "labels": 1.5851279894}, {"text": "Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals", "labels": 1.5851279894}, {"text": "CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.", "labels": -1.0943846609}, {"text": "Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination", "labels": -0.6284283276}, {"text": "Pfizer Announces Results of Phase 3 Study for XELJANZ\u00ae (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting", "labels": -0.6284283276}, {"text": "EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial", "labels": 0.1353998994}, {"text": "PFIZER REPORTS THIRD-QUARTER 2019 RESULTS", "labels": 1.2474039043}, {"text": "European Commission Approves BAVENCIO\u00ae (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma", "labels": 3.5331026916}, {"text": "OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency", "labels": -0.6039218049}, {"text": "Pfizer Statement on Vincristine Sulfate Injection, USP Supply in the United States", "labels": 0.0822774976}, {"text": "Pfizer Statement on Results of Pay Equity Study and  Opportunity Parity Among Colleagues Worldwide", "labels": -0.0822885253}, {"text": "The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis", "labels": -0.0822885253}, {"text": "ImaginAb signs multi-party collaboration agreement with three global  pharmaceutical companies to help further develop company\u2019s CD8  ImmunoPET technology", "labels": 0.931494303}, {"text": "Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis", "labels": 0.931494303}, {"text": "Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx", "labels": -1.1007867139}, {"text": "Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI\u00ae (Encorafenib), MEKTOVI\u00ae (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer", "labels": -2.3991194565}, {"text": "Ian Read to Retire as Executive Chairman of Pfizer\u2019s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman", "labels": 0.1948008469}, {"text": "Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis", "labels": 0.1948008469}, {"text": "New Data for BAVENCIO\u00ae (avelumab) for Advanced Cancers to Be Presented at ESMO 2019", "labels": 0.1948008469}, {"text": "Pfizer Declares Fourth-Quarter 2019 Dividend", "labels": -1.0306508675}, {"text": "Pfizer Presents New Evidence of IBRANCE\u00ae (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019", "labels": -1.0306508675}, {"text": "Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology", "labels": -1.0306508675}, {"text": "CHMP Adopts Positive Opinion for BAVENCIO\u00ae (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma", "labels": -1.7936159896}, {"text": "Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio", "labels": 0.7359122444}, {"text": "TrialSpark and Pfizer collaborating to improve speed and access to clinical trials", "labels": -1.1269625326}, {"text": "Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococcal Pneumonia and the Importance of Vaccination", "labels": -1.1269625326}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts", "labels": -1.1269625326}, {"text": "Catalia Health and Pfizer collaborate to better understand patient journeys using artificial intelligence and via robot wellness coach", "labels": -1.78813777}, {"text": "Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants", "labels": 2.1134188903}, {"text": "Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance", "labels": 1.2761544519}, {"text": "Findings Released from NAXOS, a French Real-World Data Analysis and the Largest Real-World  Data Analysis on Oral Anticoagulant Effectiveness and Safety in Europe Among Patients with Non-Valvular Atrial Fibrillation", "labels": 0.6140068474}, {"text": "U.S. FDA Grants XTANDI\u00ae (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer", "labels": 0.3990684761}, {"text": "Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina", "labels": 0.3990684761}, {"text": "The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance", "labels": -0.6596052593}, {"text": "Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of  RELPAX\u00ae (eletriptan hydrobromide) 40 mg Tablets Due to Potential  Microbiological Contamination of Non-Sterile Products", "labels": -1.3051001943}, {"text": "Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis", "labels": -3.490244527}, {"text": "Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company", "labels": -0.8157762755}, {"text": "BioInvent announces selection of first target discovered by BioInvent\u2019s  proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc.", "labels": 0.0203089565}, {"text": "Pfizer Completes Acquisition of Array Biopharma", "labels": -2.5489166132}, {"text": "Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT", "labels": -8.7135694712}, {"text": "PFIZER REPORTS SECOND-QUARTER 2019 RESULTS", "labels": -8.7135694712}, {"text": "Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World\u2019s Need for Medicine", "labels": -8.7135694712}, {"text": "Pfizer Statement on Update to XELJANZ\u00ae (tofacitinib) Prescribing Information in the United States", "labels": -2.91918292}, {"text": "FDA Approves Pfizer\u2019s Biosimilar, RUXIENCE\u2122 (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions", "labels": 0.0932841468}, {"text": "Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels", "labels": -2.332568242}, {"text": "Pfizer Completes Acquisition of Therachon", "labels": 1.6056368545}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis", "labels": 1.6056368545}, {"text": "Pfizer Announces Results from Phase 3 Trial of Revatio\u00ae (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension", "labels": 0.7310836892}, {"text": "Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)", "labels": 0.7310836892}, {"text": "Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV\u2122 (bevacizumab-bvzr)", "labels": 0.7310836892}, {"text": "Scott Gottlieb Elected to Pfizer\u2019s Board of Directors", "labels": 0.6925188493}, {"text": "Pfizer Declares Third-Quarter 2019 Dividend", "labels": 0.6925188493}, {"text": "European Commission Approves TALZENNA\u00ae (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer", "labels": 0.4798937073}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts", "labels": 1.5631988051}, {"text": "Pfizer to Acquire Array BioPharma", "labels": 0.8590949703}, {"text": "Pfizer Announces Results from XELJANZ\u00ae XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor", "labels": 0.0705656629}, {"text": "Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development", "labels": 0.2575568102}, {"text": "Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA\u00ae (pregabalin) in Primary Generalized Tonic-Clonic Seizures", "labels": -0.3818792352}, {"text": "Pfizer confirms initiation of EU review of Tofacitinib with interim recommendations", "labels": 0.6972694604}, {"text": "Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting", "labels": 1.8732003456}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis", "labels": 1.8732003456}, {"text": "FDA Approves BAVENCIO\u00ae (avelumab) Plus INLYTA\u00ae (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma", "labels": 1.3608535868}, {"text": "Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts", "labels": 1.031420722}, {"text": "Pfizer Acquires Clinical-Stage Biotech Therachon", "labels": 0.4888600033}, {"text": "European Commission Approves LORVIQUA\u00ae (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": -1.074444006}, {"text": "U.S. FDA Approves VYNDAQEL\u00ae and VYNDAMAX\u2122 for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease", "labels": -0.1959604788}, {"text": "PFIZER REPORTS FIRST-QUARTER 2019 RESULTS", "labels": 0.9075371934}, {"text": "Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of One Lot of ThermaCare\u00ae Back Pain Therapy HeatWraps, up to 16HR pain relief, Due To Out of Specification Results for  High Cell Temperature", "labels": -0.2020806816}, {"text": "Pfizer Receives Positive CHMP Opinion for TALZENNA\u00ae (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer", "labels": -0.2020806816}, {"text": "Pfizer Hosts Annual Meeting of Shareholders", "labels": 1.8013390177}, {"text": "Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis", "labels": -2.4371392873}, {"text": "Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders", "labels": -2.4371392873}, {"text": "Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older", "labels": -2.2971624148}, {"text": "U.S. FDA Approves IBRANCE\u00ae (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer", "labels": 0.4652598181}, {"text": "VIZIMPRO\u00ae (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer", "labels": -0.5849612397}, {"text": "Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy", "labels": -0.2567657528}, {"text": "Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics", "labels": 0.3542011419}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer", "labels": 0.4742752149}, {"text": "Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts", "labels": 0.4742752149}, {"text": "Hospira, Inc. Issues A Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP Due To The Presence of Particulate  Matter", "labels": 1.2529380029}, {"text": "AUGUSTUS Demonstrates Favorable Safety Results of Eliquis\u00ae Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention", "labels": 1.2529380029}, {"text": "U.S. FDA Approves Pfizer\u2019s Oncology Biosimilar TRAZIMERA\u2122 (trastuzumab-qyyp), a Biosimilar to Herceptin\u00ae1", "labels": 1.5096987811}, {"text": "European Medicines Agency Validates Application for BAVENCIO\u00ae (avelumab) Plus INLYTA\u00ae (axitinib) for the Treatment of Advanced Renal Cell Carcinoma", "labels": 0.4096323716}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -2.9383591701}, {"text": "Pfizer Prices $5,000,000,000 Debt Offering", "labels": -1.2823768134}, {"text": "Pfizer Receives Positive CHMP Opinion for LORVIQUA\u00ae (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": -1.253762958}, {"text": "Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older", "labels": 0.9455839704}, {"text": "Pfizer Announces Modification To Ongoing Tofacitinib FDA Post-Marketing Requirement Study In Patients With Rheumatoid Arthritis", "labels": -0.0947821429}, {"text": "Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials", "labels": -0.0947821429}, {"text": "Pfizer Receives European Approval for ZIRABEV\u2122 (bevacizumab), a Biosimilar to Avastin\u00ae*", "labels": -0.0947821429}, {"text": "Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain", "labels": -0.0947821429}, {"text": "Pivotal Phase III Data for BAVENCIO\u00ae (avelumab) Plus INLYTA\u00ae (axitinib) in Advanced Renal Cell Carcinoma Published in The New England Journal of Medicine", "labels": -0.0947821429}, {"text": "G-CON Manufacturing Delivers New PCMM POD\u00ae With Tablet Coating Capability to Pfizer Inc.\u2019s  Groton, Conn. Site", "labels": -0.0239817064}, {"text": "FDA Accepts sBLA and Grants Priority Review for BAVENCIO\u00ae (avelumab) Plus INLYTA\u00ae (axitinib) for the Treatment of Advanced Renal Cell Carcinoma", "labels": -0.9792218811}, {"text": "Phase 3 ARCHES Trial Shows XTANDI\u00ae (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer", "labels": -0.9792218811}, {"text": "The Union For International Cancer Control And Pfizer Announce New Phase Of Global Grants Initiative Supporting Metastatic Breast Cancer Patients", "labels": -1.7335672132}, {"text": "Pfizer Receives Positive CHMP Opinion for Vizimpro\u00ae (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations", "labels": -1.0132040104}, {"text": "PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS", "labels": 5.0024279823}, {"text": "Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain", "labels": 5.0024279823}, {"text": "US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy", "labels": 0.4212522819}, {"text": "eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-inClass Inhibitors of eIF4E to Treat Multiple Cancer Types", "labels": -2.7180525723}, {"text": "CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason\u2019s Machine Learning Model  of the Immune System for Drug Discovery", "labels": 0.8289299446}, {"text": "Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata", "labels": -0.5581693953}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer", "labels": -2.6880406227}, {"text": "Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis", "labels": 0.5246694662}, {"text": "Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI\u00ae (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer", "labels": 0.5246694662}, {"text": "Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company", "labels": -3.5740014658}, {"text": "Pfizer Invites Public to View and Listen to Webcast of January 29 Conference Call with Analysts", "labels": -3.5740014658}, {"text": "Kineta Enters Research Collaboration and License Agreement  with Pfizer to Develop New Cancer Immunotherapies", "labels": -2.5943226634}, {"text": "Pfizer Declares First-Quarter 2019 Dividend", "labels": -2.2500778628}, {"text": "Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV\u2122 (bevacizumab)", "labels": -2.2500778628}, {"text": "Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older", "labels": -2.2500778628}, {"text": "Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting", "labels": -2.7248807603}, {"text": "Pfizer Reaches a Global Agreement with AbbVie", "labels": 1.3915956022}, {"text": "Pfizer Receives Six Months Pediatric Exclusivity for LYRICA\u00ae (pregabalin)", "labels": 3.7861771879}, {"text": "Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall Of Six Lots Of ThermaCare\u00ae HeatWraps Due To Leaking Wraps with  the Potential For Skin Injuries", "labels": 1.7018228411}, {"text": "U.S. FDA Approves DAURISMO\u2122 (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option", "labels": -0.3691676439}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer", "labels": -0.2067845976}, {"text": "Pfizer Provides Transparency On Drug Prices In The U.S. 90 Percent Of Company\u2019s Prices Will Remain Unchanged", "labels": 2.4445663483}, {"text": "Real-World Evidence on Patients Aged 80 and Older Presented From ARISTOPHANES,  the Largest Real-World Data Study Evaluating Oral Anticoagulants Among Patients with  Non-Valvular Atrial Fibrillation", "labels": -1.7463526145}, {"text": "Data From Phase 2 PALLET Study of IBRANCE\u00ae (palbociclib)in Early Breast  Cancer to be Presented at San Antonio Breast Cancer Symposium", "labels": 0.8841796676}, {"text": "U.S. FDA Approves LORBRENA\u00ae (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC", "labels": -0.5514837771}, {"text": "PFIZER REPORTS THIRD-QUARTER 2018 RESULTS", "labels": 2.5777897572}, {"text": "Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH", "labels": -0.1398758703}, {"text": "CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL  CANCER DRUGS", "labels": 0.4929477626}, {"text": "Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients", "labels": -3.3192106138}, {"text": "Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company", "labels": -3.3192106138}, {"text": "Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE\u00ae (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer", "labels": -0.7709796551}, {"text": "Pfizer Announces Initiation of Phase 3 Trial of Tofacitinib in  Patients with Ankylosing Spondylitis", "labels": 0.3595594376}, {"text": "U.S. FDA Approves TALZENNA\u00ae (talazoparib)", "labels": 2.7372919427}, {"text": "Pfizer Announces Executive Leadership Team", "labels": -1.0784066048}, {"text": "Pfizer to Award More Than $3 Million in Grants to Further Breast Cancer Research", "labels": 0.8461580826}, {"text": "Pfizer Announces CEO Succession", "labels": 0.429658264}, {"text": "U.S. FDA Approves VIZIMPRO\u00ae (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer", "labels": 0.6353367325}, {"text": "Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend", "labels": 0.6353367325}, {"text": "Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older", "labels": 1.5660640472}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts", "labels": 0.6010109056}, {"text": "New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting", "labels": 0.6010109056}, {"text": "ATOMWISE ENTERS INTO AN EVALUATION AGREEMENT WITH PFIZER", "labels": 1.126161324}, {"text": "Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress", "labels": 0.6045311695}, {"text": "System1 Announces a $25 Million Series A Funding to Advance  Integrated Technology Platform for Neurotherapeutics Discovery", "labels": 1.2835458236}, {"text": "Terry Bradshaw and Pfizer Encourage Boomers to Understand Their Risk  for Pneumococcal Pneumonia and Take Action to Help Prevent It", "labels": 1.2835458236}, {"text": "BAVENCIO\u00ae (avelumab) Plus INLYTA\u00ae (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study", "labels": 0.9667456138}, {"text": "CYTOO enters into Research and Option Agreement with Pfizer to develop a  target discovery platform for Duchenne Muscular Dystrophy", "labels": 0.8293898718}, {"text": "4D Molecular Therapeutics Raises $90 Million Series B Financing", "labels": 1.1728318622}, {"text": "Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata", "labels": 1.1728318622}, {"text": "Pfizer Prices $5,000,000,000 Debt Offering", "labels": 0.8840787008}, {"text": "Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy", "labels": 0.6984472986}, {"text": "Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children\u2019s Advil\u00ae Suspension Bubble Gum Flavored 4 FL OZ Bottle", "labels": -2.4578436741}, {"text": "Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018", "labels": -2.4578436741}, {"text": "Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer", "labels": 0.1184899256}, {"text": "Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard\u00ae", "labels": 0.1184899256}, {"text": "Important Notice Regarding EpiPen Auto-Injector U.S. supply", "labels": -0.6180388374}, {"text": "Bristol-Myers Squibb-Pfizer Alliance ACROPOLIS\u2122 Real-World Data Program Grows to Sample  Size of Nearly One Million Lives Worldwide", "labels": -0.0948490499}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018", "labels": -0.0948490499}, {"text": "BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza", "labels": 2.0432367338}, {"text": "SANGAMO ANNOUNCES POSITIVE PRELIMINARY DATA FROM THE PHASE 1/2  ALTA STUDY EVALUATING SB-525 GENE THERAPY FOR HEMOPHILIA A", "labels": 0.7073197996}, {"text": "XELJANZ\u00ae (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis", "labels": 0.8943352561}, {"text": "PFIZER REPORTS SECOND-QUARTER 2018 RESULTS", "labels": 5.115468673}, {"text": "Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA\u2122 (trastuzumab)", "labels": 5.115468673}, {"text": "Pfizer Clarifies Incorrect Media Reports Regarding Amsterdam UMC Clinical Trial", "labels": 1.2840698628}, {"text": "Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs", "labels": 1.6320155635}, {"text": "Dr. Seng Hing Cheng Appointed Chief Scientific Officer of Pfizer Rare Disease Research Unit", "labels": 0.9549187848}, {"text": "U.S. FDA Approves Pfizer\u2019s Biosimilar NIVESTYM\u2122 (filgrastim-aafi)", "labels": 0.0268820965}, {"text": "Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain", "labels": -0.6156390739}, {"text": "Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy", "labels": 0.4515214175}, {"text": "U.S. FDA Approves XTANDI\u00ae (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)", "labels": -0.3210290068}, {"text": "Pfizer to Organize for Future Growth", "labels": 0.7196234576}, {"text": "Pfizer Announces it Will Defer Company\u2019s Price Increases", "labels": -0.2418854008}, {"text": "RESOLUTE:13 academic & industry partners join forces to unlock SLCs for new therapies", "labels": 1.9401945462}, {"text": "Hospira Issues Voluntary Nationwide Recall Of Daptomycin For  Injection Lyophilized Powder For Solution, Due to Infusion Reactions", "labels": -0.3302906839}, {"text": "XELJANZ\u00ae (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis", "labels": 0.4685793587}, {"text": "Pfizer Declares 34-Cent Third-Quarter 2018 Dividend", "labels": 0.4685793587}, {"text": "U.S. FDA Grants Priority Review for Pfizer\u2019s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia", "labels": 0.1650207303}, {"text": "Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE\u00ae (Palbociclib) in HR+, HER2- Metastatic Breast Cancer", "labels": 0.1649279039}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts", "labels": 1.5633272053}, {"text": "Pfizer Announces Extension of Zithromax\u00ae Antibiotic Donation Program through 2025 to Help Eliminate World\u2019s Leading Infectious Cause of Blindness", "labels": -0.469350302}, {"text": "U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation", "labels": 0.4908341015}, {"text": "Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures", "labels": 0.2466580537}, {"text": "Hospira Issues A Voluntary Nationwide Recall For Two Lots of  Naloxone Hydrochloride Injection, USP, in the Carpuject\u2122 Syringe  System Due To The Potential Presence of Particulate Matter.", "labels": 0.0822992288}, {"text": "Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations", "labels": 0.0822992288}, {"text": "Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO\u00ae (avelumab)", "labels": 0.0822992288}, {"text": "Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, TRAZIMERA\u2122 (trastuzumab)", "labels": 0.5212853038}, {"text": "Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress", "labels": 0.827584344}, {"text": "Pfizer Announces U.S. FDA Approves XELJANZ\u00ae (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis", "labels": -0.0556645921}, {"text": "The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families", "labels": -0.0556645921}, {"text": "Pfizer\u2019s XALKORI\u00ae (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications", "labels": 1.8862595064}, {"text": "Pfizer Reaches $23.85 Million Settlement Agreement To Resolve  Allegations Related To Patient Assistance Charities", "labels": -0.784756608}, {"text": "FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy", "labels": 0.5851168436}, {"text": "A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar\u00ae 13 in Adults Age 65+", "labels": 0.4726288101}, {"text": "Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine", "labels": 0.4726288101}, {"text": "Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events", "labels": 0.028001038}, {"text": "Around the World, People Living with Ulcerative Colitis Share Common Perspectives and Experiences", "labels": 0.0280477191}, {"text": "LYRICA\u00ae (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint", "labels": 0.0280477191}, {"text": "Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO", "labels": -0.0559853803}, {"text": "Pfizer\u2019s Biosimilar RETACRIT\u00ae (epoetin alfa-epbx) Approved by U.S. FDA", "labels": 0.4764548674}, {"text": "Important Notice Regarding EpiPen auto-injector supply", "labels": 1.0232612057}, {"text": "XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop  Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery", "labels": 0.7392730071}, {"text": "New project to enhance nanomedicine development", "labels": 0.7392730071}, {"text": "Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer", "labels": 0.5431517133}, {"text": "HUB Announces Collaboration with Pfizer Inc. on Human Gut Organoids for  IBD", "labels": -1.9776431531}, {"text": "Pfizer Reports First-Quarter 2018 Results", "labels": -1.9776431531}, {"text": "Dawn Rogers Appointed Executive Vice President of Pfizer Worldwide Human Resources", "labels": -4.8869987428}, {"text": "Pfizer Hosts Annual Meeting of Shareholders", "labels": 0.5405561289}, {"text": "Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA\u00ae (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years", "labels": 1.0523742636}, {"text": "Pfizer Provides Update on Proposed Trastuzumab Biosimilar", "labels": 1.0523742636}, {"text": "MYLOTARG\u2122 Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy", "labels": 1.0523742636}, {"text": "Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders", "labels": 0.6551976558}, {"text": "Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy", "labels": 0.7984592074}, {"text": "Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery", "labels": -0.5867487608}, {"text": "Pfizer Signs Lease for The Spiral at Hudson Yards in Manhattan", "labels": -0.5867487608}, {"text": "U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations", "labels": 1.1475132846}, {"text": "Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer\u2019s Allogeneic CAR T Immuno-oncology Portfolio", "labels": 2.8231394835}, {"text": "Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy", "labels": -1.3409535581}, {"text": "Pfizer Reports Top-Line Results from a Study of CHANTIX\u00ae/CHAMPIX\u00ae (varenicline) in Adolescent Smokers", "labels": -1.2842276162}, {"text": "U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI\u00ae (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)", "labels": -1.2936929164}, {"text": "BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable  Fluorosulfation Reagent", "labels": -1.2936929164}, {"text": "BIOGEN TO ACQUIRE FROM PFIZER FIRST-IN-CLASS PHASE 2b READY ASSET  FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA", "labels": -0.4625917579}, {"text": "Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants", "labels": -0.4625917579}, {"text": "AM\u2010Pharma announces Phase II study results of recAP in sepsis\u2010associated Acute  Kidney Injury", "labels": 9.0623e-06}, {"text": "Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ\u00ae (tofacitinib) for Moderately to Severely Active Ulcerative Colitis", "labels": 2.1212801123}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 2.4657523373}, {"text": "Hospira Issues A Voluntary Nationwide Recall For Hydromorphone HCL Injection, USP CII Due To The Potential For Empty Or Cracked Glass Vials", "labels": 0.167236684}, {"text": "Dan R. Littman Elected to Pfizer\u2019s Board of Directors", "labels": 0.167236684}, {"text": "Neofluidics Announces Collaboration with Pfizer Inc.", "labels": 1.5780899234}, {"text": "Inserm announces research agreement with Pfizer Inc. to study rare neuromuscular  disease", "labels": -3.9292679436}, {"text": "Hospira Issues A Voluntary Nationwide Recall For Labetalol  Hydrochloride Injection, USP, Due To The Potential Of Cracked  Glass At The Rim Surface Of The Vials", "labels": 3.1275545941}, {"text": "Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG\u2122 and BOSULIF\u00ae", "labels": 3.1275545941}, {"text": "Pfizer Announces Update on European Marketing Authorization Application for SUTENT\u00ae (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma", "labels": 3.1275545941}, {"text": "Albert Bourla Elected to Pfizer\u2019s Board of Directors", "labels": 3.1275545941}, {"text": "Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis", "labels": 2.8283399645}, {"text": "U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer\u2019s Third-Generation ALK Inhibitor Lorlatinib", "labels": 1.4024018587}, {"text": "Phase 3 PROSPER Trial Shows XTANDI\u00ae (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer", "labels": -3.4013823162}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2017 Results", "labels": -3.1587363776}, {"text": "Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan\u00ae/MabThera\u00ae", "labels": 0.6446376576}, {"text": "MINDIMMUNE THERAPEUTICS TO CONDUCT RESEARCH ON SPECIALIZED IMMUNE CELLS WITH PFIZER INC.", "labels": -0.19010856}, {"text": "Survey of Ulcerative Colitis Patients and Gastroenterologists Indicates that Symptoms May Create a New Reality for Patients", "labels": -0.7040167127}, {"text": "Circle Pharma announces publication in Journal of Medicinal Chemistry of results from  collaboration with Pfizer Inc.", "labels": 0.4595515635}, {"text": "Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Products  Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.", "labels": 0.0822266246}, {"text": "Imcyse announces a research collaboration with  Pfizer Inc. in rheumatoid arthritis (RA)", "labels": -0.8514091026}, {"text": "Regeneron Forms Consortium of Leading Life Sciences Companies to  Accelerate Largest Widely-Available \u2018Big Data\u2019 Human Sequencing Resource with UK Biobank", "labels": -0.8514091026}, {"text": "Alexandria Venture Investments Launches the Alexandria Seed Capital Platform, a Novel  and Innovative Seed-Stage Life Science Funding Model and a Natural Extension of  Alexandria LaunchLabs", "labels": -0.8514091026}, {"text": "Pfizer Inc. Announces Expiration and Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents", "labels": -0.8514091026}, {"text": "Pfizer Establishes New Partnering Model for Early-Stage Academic Research", "labels": -0.8514091026}, {"text": "Distributed Bio Announces SuperHuman  Platform License Agreement with Pfizer Inc.", "labels": -1.0150842776}, {"text": "Distributed Bio Announces SuperHuman  Platform License Agreement with Pfizer Inc.", "labels": -1.0150842776}, {"text": "Berkeley Lights Announces Research Collaboration and License Agreement with Pfizer", "labels": 0.4069398747}, {"text": "Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS", "labels": 0.9241644767}, {"text": "FDA Approves SGLT2 Inhibitor STEGLATRO\u2122 (ertugliflozin) and Fixed-Dose Combination STEGLUJAN\u2122 (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes", "labels": -0.1657141215}, {"text": "FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA\u00ae in Advanced Renal Cell Carcinoma", "labels": -1.1067930738}, {"text": "U.S. FDA Approves Pfizer\u2019s BOSULIF\u00ae (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)", "labels": -2.0296319238}, {"text": "CMAC Medicines Manufacturing Consortium Welcomes Pfizer as  Newest Partner", "labels": -0.7579780597}, {"text": "Pfizer Declares First-Quarter 2018 Dividend", "labels": -0.7579780597}, {"text": "Pfizer Inc. Announces Expiration and Results of its Private Exchange Offer for its 6.500 per cent. Notes due 2038 and Related Tender Offer", "labels": 0.9426377465}, {"text": "Pfizer Announces FDA Approval of XELJANZ\u00ae (tofacitinib) and XELJANZ\u00ae XR for the Treatment of Active Psoriatic Arthritis", "labels": 1.2634361256}, {"text": "Pfizer Inc. Announces Pricing Terms of Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors", "labels": 1.2634361256}, {"text": "Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis", "labels": 1.2634361256}, {"text": "FDA Approves New Pfizer Biosimilar", "labels": -0.3017349635}, {"text": "Phase 3 TRUMENBA\u00ae (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccine\u2019s Immunogenicity", "labels": -0.3017349635}, {"text": "U.S. Food And Drug Administration Extends Action Date For XELJANZ\u00ae (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months", "labels": 0.7642348676}, {"text": "Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition", "labels": 1.47622066}, {"text": "Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer", "labels": 2.4578539577}, {"text": "Pfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent.", "labels": 0.5036670717}, {"text": "Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B", "labels": -0.2253794155}, {"text": "Updated Data from Phase 3 Trial of IBRANCE\u00ae (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival", "labels": -0.2253794155}, {"text": "Bristol-Myers Squibb and Pfizer Alliance Urge People to \u2018Tune in to AFib, Take Note of Stroke Risk\u2019", "labels": -1.0123767207}, {"text": "Pfizer Unveils 2017 ASPIRE Oncology/Hematology Clinical Research Awards Winners; Grants Totaling More than $6M in 2017", "labels": -1.0123767207}, {"text": "Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA\u00ae (isavuconazole) in China and Asia Pacific Region", "labels": 0.38512885}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer", "labels": 1.7122232966}, {"text": "Ground-breaking \u20ac34 million project to develop better test for liver disease", "labels": 0.0846756904}, {"text": "Pfizer Receives FDA Approval for SUTENT\u00ae (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma", "labels": 0.0848238555}, {"text": "COMBACTE Adds a New Project to its Consortium: COMBACTE-CDI", "labels": 0.7874147686}, {"text": "UC San Diego Center for Microbiome Innovation Announces Pfizer as Corporate Member", "labels": 0.7874147686}, {"text": "Pfizer Names Albert Bourla Chief Operating Officer", "labels": 0.4522060934}, {"text": "BMS-Pfizer Alliance To Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation", "labels": 0.5665976526}, {"text": "Pfizer Sells Its 49% Equity Share in Hisun-Pfizer Pharmaceuticals", "labels": 0.5665976526}, {"text": "Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B", "labels": 0.1132032246}, {"text": "Encycle\tTherapeutics\tannounces discovery\tcollaboration with\tPfizer\tInc.", "labels": 1.2690396894}, {"text": "Pfizer Reports Third-Quarter 2017 Results", "labels": 0.5955826677}, {"text": "One Year Maintenance and Switching Data in Patients with Crohn\u2019s Disease Support the Use of INFLECTRA\u00ae* (infliximab CT-P13) in IBD1", "labels": -1.0553671878}, {"text": "New Ulcerative Colitis Data for XELJANZ\u00ae (tofacitinib) at Upcoming Gastroenterology Congresses", "labels": -0.4143685968}, {"text": "Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer", "labels": -0.4143685968}, {"text": "The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries to address the needs of metastatic breast cancer patients worldwide", "labels": -1.0839489615}, {"text": "U.S. FDA Approves LYRICA\u00ae CR (pregabalin) Extended-Release Tablets CV", "labels": -0.3852471202}, {"text": "Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business", "labels": 0.192051364}, {"text": "Pfizer Launches Novel Programs to Put Important Support Services at the Fingertips of Cancer Patients", "labels": 0.4715820807}, {"text": "AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program", "labels": -0.5000222877}, {"text": "Pfizer Declares 32-Cent Fourth-Quarter 2017 Dividend", "labels": 0.983147103}, {"text": "Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan", "labels": 0.983147103}, {"text": "Patti LaBelle and Pfizer Work Together to Educate Baby Boomers About the Risk of Pneumococcal Pneumonia", "labels": -0.1692594103}, {"text": "LabCentral to Open Next-Stage Facility for Growing Life Science Companies, Supported by Pfizer", "labels": -0.2780782851}, {"text": "National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views", "labels": -0.2780782851}, {"text": "New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors", "labels": -0.2780782851}, {"text": "European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma", "labels": 0.1112044125}, {"text": "Pfizer Goes To Court To Allow Competition For Biologics And Expand Options For Patients", "labels": 0.1112044125}, {"text": "Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT\u00ae in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery", "labels": 0.9169167345}, {"text": "Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer", "labels": 0.876687501}, {"text": "Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": 3.6188958491}, {"text": "Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin\u00ae (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress", "labels": 3.6188958491}, {"text": "Pfizer Receives FDA Approval for MYLOTARG\u2122 (gemtuzumab ozogamicin)", "labels": -0.4141980909}, {"text": "Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease", "labels": 1.3545431656}, {"text": "Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valvular Atrial Fibrillation", "labels": 0.0598166884}, {"text": "U.S. FDA and European Medicines Agency Accept Regulatory Submissions for BOSULIF\u00ae (bosutinib) for the Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia", "labels": 0.0598166884}, {"text": "Bristol-Myers Squibb and Pfizer Present Investigational Eliquis\u00ae (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion", "labels": -1.33799e-05}, {"text": "Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis\u00ae (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation", "labels": -1.33799e-05}, {"text": "Pfizer Rare Disease Launches Two First-of-Its-Kind Innovative Technologies for People Living with Hemophilia at National Hemophilia Foundation Annual Meeting", "labels": 0.0598950449}, {"text": "Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer", "labels": 1.4440620801}, {"text": "Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at...", "labels": -0.4578938463}, {"text": "Pfizer Receives U.S. FDA Approval for BESPONSA\u00ae (inotuzumab ozogamicin)", "labels": -1.8977728397}, {"text": "FDA Advisory Committee Votes in Favor of XELJANZ\u00ae (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis", "labels": 2.0511179123}, {"text": "Pfizer Reports Second-Quarter 2017 Results", "labels": 0.606385597}, {"text": "CONSORTIUM ESTABLISHED TO SUPPORT ICH M7 COMPLIANCE", "labels": -1.4898302801}, {"text": "Interest from startups in the BaseLaunch healthcare accelerator exceeds  expectations", "labels": -1.4898302801}, {"text": "Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin\u00ae1 (bevacizumab)", "labels": -0.8458951361}, {"text": "EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma", "labels": -0.4501892093}, {"text": "Merck and Pfizer Collaborate with Corning", "labels": 0.0298544623}, {"text": "Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole)", "labels": 0.5068590771}, {"text": "Pfizer Announces FDA Accepts Supplemental New Drug Application for XELJANZ\u00ae (tofacitinib citrate) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis", "labels": 0.6281916754}, {"text": "FDA Advisory Committee Votes in Favor of Pfizer\u2019s MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia", "labels": -0.5418598061}, {"text": "Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting  Consistent and Sustained Response at the International Society on Thrombosis  and Haemostasis (ISTH) 2017 Congress", "labels": -0.5728014716}, {"text": "BESPONSA\u00ae Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia", "labels": 0.2661258329}, {"text": "Alcyone Lifesciences Enters into a Feasibility Study Agreement with Pfizer to  Evaluate Alcyone\u2019s proprietary PulsarTM Advanced Intrathecal Precision Delivery  Platform Technology for use in Gene Therapy Targeting Central Nervous System  Disorders", "labels": -0.4763590824}, {"text": "Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri", "labels": -1.1259054271}, {"text": "Pfizer Declares 32-Cent Third-Quarter 2017 Dividend", "labels": 0.6438348768}, {"text": "Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine", "labels": 1.847463477}, {"text": "Pfizer Announces Results from XELJANZ\u00ae (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress", "labels": 0.7224260195}, {"text": "Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients", "labels": 0.6705291883}, {"text": "Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey", "labels": -0.0611952292}, {"text": "Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab", "labels": -0.0611952292}, {"text": "Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies", "labels": -0.5831576852}, {"text": "Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer", "labels": 2.7216949015}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -1.0393637148}, {"text": "Sangamo Therapeutics And Pfizer Announce That Sb-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency", "labels": -1.0393637148}, {"text": "Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy", "labels": -0.9375105077}, {"text": "Spark Therapeutics Presents Updated Preliminary Data From Hemophilia B Phase 1/2 Trial Suggesting Consistent And Sustained Levels Of Factor IX Activity At The Hemostasis And Thrombosis Research Society (HTRS) 2017 Scientific Symposium", "labels": -1.3720201382}, {"text": "Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer", "labels": -1.3720201382}, {"text": "Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT\u00ae (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery", "labels": 1.3145828727}, {"text": "European Commission Approves Pfizer\u2019s TRUMENBA\u00ae to Help Prevent Meningococcal Group B Disease in Adolescents and Adults", "labels": 1.8070375896}, {"text": "FDA Advisory Committee Recommends Approval of Pfizer\u2019s Proposed Biosimilar to Epogen\u00ae/Procrit\u00ae Across All Indications", "labels": 0.2489206035}, {"text": "Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation", "labels": -0.0311046155}, {"text": "Pharma Completes Patient Recruitment Of Recombinant Human Alkaline  Phosphatase (Recap) Phase II Trial In Acute Kidney Injury", "labels": -1.1201199681}, {"text": "Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting", "labels": -1.1793894867}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017", "labels": -1.1793894867}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations", "labels": -1.1793894867}, {"text": "Sangamo Receives Fast Track Designation From The Fda For Sb-525 Investigational Hemophilia A Gene Therapy", "labels": -1.0238860216}, {"text": "Sangamo Receives Fast Track Designation From The Fda For Sb-525 Investigational Hemophilia A Gene Therapy", "labels": -1.0238860216}, {"text": "TNO Starts Research Initiative With Industrial Partners To Combat Obesity-Associated Liver Disease", "labels": 0.694445405}, {"text": "SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY", "labels": 0.1210702862}, {"text": "FDA Grants BAVENCIO\u00ae (avelumab) Approval for a Common Type of Advanced Bladder Cancer", "labels": -0.3007052738}, {"text": "FDA Grants Second Approval for BAVENCIO\u00ae (avelumab)", "labels": -0.3007052738}, {"text": "New Smartphone App May Enable Lupus Patients to Report Symptoms More Easily and Accurately", "labels": -0.3007052738}, {"text": "Collaboration Helps Broaden Access to Pfizer\u2019s Contraceptive, Sayana\u00ae Press (medroxyprogesterone acetate), for Women in Some of the World\u2019s Poorest Countries", "labels": -0.0599190093}, {"text": "Phase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of Medicine", "labels": -0.0896868473}, {"text": "Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ\u00ae (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis", "labels": -0.0896868473}, {"text": "Pfizer Reports First-Quarter 2017 Results", "labels": -0.3286604397}, {"text": "Pfizer Hosts Annual Meeting of Shareholders", "labels": -0.117895665}, {"text": "Insphero Announces Agreement With Pfizer To Develop Novel Assays For Predicting Drug-Induced Liver Injury", "labels": -0.117895665}, {"text": "Pfizer\u2019s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer", "labels": -0.117895665}, {"text": "Aquinnah Pharmaceuticals Receives $10 Million Investment  from Pfizer and AbbVie to Research Breakthrough Approach to  Neurodegenerative Disease", "labels": 0.0886197596}, {"text": "Circle Pharma Announces Expansion Of Series A Financing And Appointment Of James C. Lu To Its Board", "labels": 0.0886197596}, {"text": "Domain Therapeutics And Pfizer Inc. Enter Into Collaboration Agreement On Biosensall\u2122", "labels": 0.0886197596}, {"text": "Pivotal Phase III Study Underscores Efficacy Of Zavicefta\u2122 (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals", "labels": -0.6516834656}, {"text": "Pfizer Receives Positive CHMP Opinion for BESPONSA\u00ae (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia", "labels": 0.2964106131}, {"text": "Pfizer Unveils ATLAS\u00ae, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries", "labels": 0.2964106131}, {"text": "Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders", "labels": 0.0297061203}, {"text": "PSI And Pfizer Partner To Address Hypertension In Vietnam And Myanmar", "labels": 0.0297061203}, {"text": "IBRANCE\u00ae (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer", "labels": 0.0876129632}, {"text": "XELJANZ\u00ae (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)", "labels": 1.2295211599}, {"text": "Pfizer Receives Positive CHMP Opinion for TRUMENBA\u00ae for Prevention of Meningococcal Group B Disease", "labels": -0.2633099176}, {"text": "FDA Grants Approval for BAVENCIO\u00ae (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma", "labels": -0.9411760308}, {"text": "NephCure Kidney International\u00ae Launches the NephCure Accelerating Cures Institute\u00ae Aims to accelerate treatments and a cure for glomerular kidney diseases", "labels": -0.0290134313}, {"text": "New drug strategy: target the ribosome to halt protein production", "labels": -0.0290134313}, {"text": "DILIsym Services, Inc. Evaluates Prospective NAFLD Treatment,  Utilizing Its Flagship Technology in Collaboration with Pfizer, Inc.", "labels": -0.2326878461}, {"text": "Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation", "labels": -0.2326878461}, {"text": "Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ\u00ae, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis", "labels": 0.6099476503}, {"text": "Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia", "labels": 0.4111836179}, {"text": "The Union for International Cancer Control and Pfizer Announce Next Phase of Global Grants Initiative Supporting Metastatic Breast Cancer Patients", "labels": 0.4111836179}, {"text": "Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis\u2122 (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session", "labels": -1.0002907818}, {"text": "Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes", "labels": -1.0002907818}, {"text": "Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational  Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines  (PRIME) Program by the European Medicines Agency", "labels": 0.6954389516}, {"text": "Pfizer Prices \u20ac4,000,000,000 Debt Offering", "labels": 0.9297131682}, {"text": "Pfizer Commits $4M to North Carolina Biotechnology Center Gene Therapy  Fellowship Program", "labels": 0.9297131682}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 0.9297131682}, {"text": "FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review", "labels": 0.9297131682}, {"text": "Arrakis Therapeutics Announces $38M Series A Financing To Target RNA with  Small-Molecule Medicines And Names Michael Gilman Chairman and CEO", "labels": -0.3223916161}, {"text": "Pfizer Prices $1,065,000,000 Debt Offering", "labels": 0.3208837712}, {"text": "Ronald E. Blaylock Elected to Pfizer\u2019s Board of Directors", "labels": 1.634562098}, {"text": "Startup accelerator BaseLaunch aims to attract promising  healthcare ventures to Basel, Europe\u2019s leading life sciences hub.", "labels": 1.4386595719}, {"text": "Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration", "labels": 0.0595210216}, {"text": "New Data in Crohn\u2019s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA\u00ae and REMICADE\u00aea", "labels": 0.0892337451}, {"text": "Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ\u00ae (tofacitinib citrate) Compared to Humira\u00ae (adalimumab)", "labels": 0.5056539022}, {"text": "Pfizer Receives FDA Approval for EUCRISA\u2122 (crisaborole)", "labels": 1.4206288918}, {"text": "Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases", "labels": 1.4206288918}, {"text": "Edelris Announces Research Collaboration Agreement with Pfizer Inc.", "labels": 3.0714877842}, {"text": "PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2016 RESULTS", "labels": 3.0714877842}, {"text": "Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ\u00ae (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis", "labels": -0.5110311958}, {"text": "Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection", "labels": 0.0636722267}, {"text": "Milner Therapeutics Institute announces new partnership with US pharmaceutical company Pfizer", "labels": -0.912812285}, {"text": "The Scripps Research Institute Signs Collaboration Agreement with Pfizer to Advance DNA-Encoded Library  Technology", "labels": -2.3149601352}, {"text": "Guardant Health to create a new 500-plus-gene liquid biopsy panel with several leading  pharmaceutical companies to accelerate clinical trials and drug development", "labels": -0.567691961}, {"text": "Iterum Announces Sulopenem in Development for Treatment of  Gram-Negative, Multi-drug Resistant Infections", "labels": 0.3285825313}, {"text": "Molecular Stethoscope Completes $8.2M Seed Financing to Advance Circulating Cell-Free RNA Liquid  Biopsy Platform; Announces Research Collaboration with Pfizer", "labels": 0.3285825313}, {"text": "AbCellera Announces Multi-Target Research Collaboration with Pfizer", "labels": 0.3285825313}, {"text": "Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira\u00ae1 (adalimumab)", "labels": 0.3285825313}, {"text": "Arvinas Announces Research Collaboration and License Agreement  with Pfizer Inc. for the Discovery and Development of Protein  Degradation Drug Candidates", "labels": 1.4281144632}, {"text": "Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer  for Progress in Hemophilia B Gene Therapy Program", "labels": 1.4281144632}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts", "labels": 1.7723233784}, {"text": "Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca", "labels": 0.5849896127}, {"text": "BioInvent announces Cancer Immunotherapy Research Collaboration and  License Agreement with Pfizer and issues new shares to Pfizer", "labels": -1.205950405}, {"text": "Circle Pharma, developer of macrocyclic peptide therapeutics, announces Series A financing and  appoints Walter H. Moos, Ph.D., to its board", "labels": -1.205950405}, {"text": "FDA Accepts Supplemental New Drug Application for Pfizer\u2019s IBRANCE\u00ae (palbociclib) in HR+, HER2- Metastatic Breast Cancer", "labels": -1.205950405}, {"text": "Draper to Build Preclinical Microphysiological Systems with Pfizer to Help Predict Clinical Outcomes", "labels": -1.1728359848}, {"text": "Pfizer Presents Data from PALOMA-2 Phase 3 Study Demonstrating Clinical Benefit of IBRANCE\u00ae (palbociclib) in Asian Women with ER+, HER2- Metastatic Breast Cancer at ESMO Asia Congress", "labels": 0.2739569523}, {"text": "Pfizer Receives Approval in the European Union for Nimenrix\u2122 (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older", "labels": 0.2739569523}, {"text": "FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX\u00ae (varenicline) Labeling", "labels": -0.1522794694}, {"text": "Pfizer Receives FDA Approval for EUCRISA\u2122 (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema)", "labels": -0.5190630483}, {"text": "Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI\u00ae (enzalutamide) Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer", "labels": -0.5190630483}, {"text": "Pfizer Announces FDA Approval of EUCRISA\u2122 (crisaborole)", "labels": -0.5190630483}, {"text": "Pediatric Open Innovation Challenge Grantees Awarded $50,000 by the Institute for  Pediatric Innovation and Pfizer", "labels": 0.0304301686}, {"text": "Ab\tInitio\tAnnounces\tStrategic\tCollaboration with\tPfizer\tto\tDiscover\tGPCR\tActivating\tAntibodies", "labels": 0.0304301686}, {"text": "Pfizer Declares First-Quarter 2017 Dividend", "labels": 0.0304301686}, {"text": "Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation  of IGNITE Immunotherapy Inc., a Company Focused on Oncolytic Cancer  Vaccine Discovery and Development", "labels": 3.441987793}, {"text": "Akili and Pfizer Present Positive Data from Digital Biomarker Study to Detect Subtle Cognitive Changes  in Healthy Subjects at Risk of Developing Alzheimer\u2019s Disease", "labels": 3.9814863443}, {"text": "Pfizer Announces Expansion of ASPIRE Awards Program for 2017 to Include $5.5M in Funding for Breast and Hematologic Cancers", "labels": -1.4748118835}, {"text": "Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia", "labels": -0.5703605379}, {"text": "Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase  1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at  Annual ASH Meeting", "labels": -0.5703605379}, {"text": "New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome", "labels": -0.5703605379}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -1.9601672651}, {"text": "IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery", "labels": -1.9601672651}, {"text": "LYRICA\u00ae (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint", "labels": -1.9601672651}, {"text": "Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin\u00ae1 (trastuzumab)", "labels": -1.6528919666}, {"text": "FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review", "labels": 0.9023157326}, {"text": "Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire", "labels": -0.574530613}, {"text": "Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019", "labels": -0.574530613}, {"text": "Pfizer Announces Pricing of Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019", "labels": -1.2036852485}, {"text": "PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer\u2019s IBRANCE\u00ae (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer", "labels": -1.4812275802}, {"text": "Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ\u00ae (Tofacitinib Citrate) for Psoriatic Arthritis", "labels": -2.5031415817}, {"text": "Pfizer Prices $6,000,000,000 Debt Offering", "labels": -1.9236737712}, {"text": "Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019", "labels": -1.9236737712}, {"text": "Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers", "labels": -1.9236737712}, {"text": "Landmark Study Demonstrates Pfizer\u2019s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen", "labels": -1.9236737712}, {"text": "Pfizer Announces Major Expansion of Humanitarian Assistance Program", "labels": -2.5941874597}, {"text": "Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis\u00ae (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016", "labels": -2.2399815205}, {"text": "IBRANCE\u00ae (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer", "labels": 1.4332857456}, {"text": "Pfizer to Present Additional Research For XELJANZ\u00ae (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis", "labels": 0.2283998451}, {"text": "Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity", "labels": -2.333334212}, {"text": "Pfizer\u2019s Prevenar 13\u00ae Receives Approval For Use in Infants and Children in China", "labels": -3.6801481806}, {"text": "Pfizer Reports Third-Quarter 2016 Results", "labels": -1.0120998185}, {"text": "Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor", "labels": -1.0120998185}, {"text": "European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma", "labels": -3.121971284}, {"text": "FDA Approves Supplemental New Drug Application for XTANDI\u00ae (enzalutamide) Capsules in Advanced Prostate Cancer", "labels": -0.9025834403}, {"text": "CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA\u00ae (Meningococcal Group B Vaccine)", "labels": -0.6453503337}, {"text": "DILIsym Services, Inc. Utilizes Flagship Technology to Evaluate Prospective NAFLD Treatments in  Collaboration with Pfizer Inc.", "labels": -0.6453503337}, {"text": "Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection", "labels": -0.6453503337}, {"text": "Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA\u00ae (infliximab-dyyb)", "labels": 0.3364880385}, {"text": "Pfizer to Present New Data on XELJANZ\u00ae (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016", "labels": 0.3364880385}, {"text": "First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT\u00ae (sunitinib) Extended Disease Free Survival After Surgical Removal", "labels": -1.5695578762}, {"text": "Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA\u00ae (axitinib) In Advanced Renal Cell Carcinoma (RCC)", "labels": -1.5695578762}, {"text": "ICU Medical Inc. To Acquire The Hospira Infusion Systems Business From Pfizer Inc. For $1 Billion In Cash And Stock", "labels": -0.6555492183}, {"text": "iTeos Announces Initiation of Phase 1 Clinical Trial of IDO1 inhibitor", "labels": -1.590611763}, {"text": "Pfizer Completes Acquisition of Medivation", "labels": -1.590611763}, {"text": "Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress", "labels": -1.590611763}, {"text": "Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation", "labels": -0.2660247339}, {"text": "Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation", "labels": -1.5457678744}, {"text": "Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend", "labels": -0.2042980614}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts", "labels": 1.2835851523}, {"text": "Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade\u00ae (infliximab)", "labels": -1.6047458884}, {"text": "Pfizer Receives Positive CHMP Opinion For IBRANCE\u00ae (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe", "labels": -1.6047458884}, {"text": "OncoImmune Announces Option and License Agreement with Pfizer Inc.", "labels": 0.1473102631}, {"text": "Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes", "labels": 0.1473102631}, {"text": "FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer\u2019s Smoking Cessation Therapy, CHANTIX\u00ae (varenicline)", "labels": 0.0585796941}, {"text": "Pfizer Launches New \u201cMoodivator\u201d App to Help Support, Encourage and Motivate People with Depression", "labels": -1.4731816326}, {"text": "Circle Pharma enters into an agreement with Pfizer to build screening library of macrocyclic  peptides", "labels": 0.1175031299}, {"text": "AnTolRx, Inc. Announces Series A Equity Funding from Pfizer,  JDRF and Orion Equity Partners, LLC to Develop Targeted  Nanoparticle Tolerance Therapeutics", "labels": -1.7888550348}, {"text": "Pfizer Appoints Chief Scientific Officer for Neuroscience Research", "labels": 2.1573e-06}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Morgan Stanley Global Healthcare Conference", "labels": -0.1148140022}, {"text": "XALKORI\u00ae (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer", "labels": -0.5189869938}, {"text": "Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca", "labels": -0.516931287}, {"text": "Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016", "labels": -0.516931287}, {"text": "Pfizer To Acquire Medivation", "labels": 0.8264470037}, {"text": "FDA Approves TROXYCA\u00ae ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain", "labels": -0.6314696572}, {"text": "Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease", "labels": -0.5701275336}, {"text": "PFIZER REPORTS SECOND-QUARTER 2016 RESULTS", "labels": -3.3067524289}, {"text": "PFIZER AIMS TO BECOME INDUSTRY LEADER IN GENE THERAPY WITH AQUISITION OF BAMBOO THERAPEUTICS, INC.", "labels": -1.7312290481}, {"text": "Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ\u00ae (Tofacitinib Citrate) in Ulcerative Colitis", "labels": 0.0271091497}, {"text": "Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology", "labels": 0.0271091497}, {"text": "BIND Therapeutics Determines Pfizer\u2019s $40 Million Bid Is Highest and Best in 363 Auction for  Substantially All of BIND\u2019s Assets", "labels": 0.0542705863}, {"text": "Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2  Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity", "labels": 0.0814285279}, {"text": "Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B", "labels": 0.1905137968}, {"text": "Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13\u00ae", "labels": 0.0272461473}, {"text": "Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis", "labels": 1.7334781575}, {"text": "Pfizer Receives FDA Approval for Prevnar 13\u00ae in Adults Age 18 Through 49", "labels": 0.4406634895}, {"text": "Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT\u00ae (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma", "labels": 0.7468911438}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer", "labels": -0.1397645146}, {"text": "BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.", "labels": 1.8430317781}, {"text": "Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results", "labels": 2.4564614634}, {"text": "Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China", "labels": 1.8582964012}, {"text": "Pfizer Completes Acquisition of Anacor", "labels": 1.047e-05}, {"text": "Pfizer Declares 30-Cent Third-Quarter 2016 Dividend", "labels": -2.1489449321}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts", "labels": -0.1160529301}, {"text": "Help Pfizer Change The Future Of Healthy Aging", "labels": -1.344247803}, {"text": "Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts", "labels": -1.344247803}, {"text": "Shire to License PF-00547659 from Pfizer, Adding to Established and  Leading Gastrointestinal Portfolio", "labels": 0.5461385179}, {"text": "Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia", "labels": -0.0857507977}, {"text": "Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes", "labels": -0.0857507977}, {"text": "Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination", "labels": 0.6800668768}, {"text": "Pfizer Announces FDA Advisory Committees\u2019 Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval", "labels": 1.5293070212}, {"text": "Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ\u00ae) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA", "labels": 1.5293070212}, {"text": "A Mother\u2019s Mission to Help Prevent Another Life Lost to MenB", "labels": 1.1631474811}, {"text": "Pfizer Announces Positive Top-Line Results from Second Phase 3 Trial of Oral XELJANZ\u00ae (Tofacitinib Citrate) in Adults with Psoriatic Arthritis", "labels": 1.1631474811}, {"text": "ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma", "labels": 0.4018377495}, {"text": "Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer", "labels": 0.4018377495}, {"text": "Weizmann Institute of Science Announces Visiting Scientist Agreement with Pfizer Inc.", "labels": 0.4018377495}, {"text": "Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor", "labels": 0.4018377495}, {"text": "BioRap Technologies to enter strategic collaboration with Pfizer Inc. to research and develop novel  immunomodulators", "labels": 0.2302092697}, {"text": "CHAMPIX\u00ae (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP", "labels": 0.7917637738}, {"text": "Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA\u00ae (Meningococcal Group B Vaccine)", "labels": 0.5643198125}, {"text": "Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression", "labels": 1.7190145617}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting", "labels": 1.1084442026}, {"text": "Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting", "labels": 1.1084442026}, {"text": "Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)", "labels": -0.3015001484}, {"text": "Pfizer to Acquire Anacor", "labels": 0.3027760097}, {"text": "Pfizer Presents Results from Two Phase 3 TRUMENBA\u00ae (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting", "labels": 0.1497734978}, {"text": "Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative", "labels": -0.8134721015}, {"text": "AM\u2010Pharma publishes safety and pharmacokinetic data from Phase I recAP trial", "labels": -1.1150022169}, {"text": "First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers  Milestone Payment to MacroGenics", "labels": -1.1150022169}, {"text": "WAVE Life Sciences Enters Collaboration with Pfizer to Develop  Genetically Targeted Therapies for the Treatment of Metabolic Diseases", "labels": 0.625362095}, {"text": "PFIZER REPORTS FIRST-QUARTER 2016 RESULTS", "labels": -0.7485379764}, {"text": "Pfizer Hosts Annual Meeting of Shareholders", "labels": -0.7948532643}, {"text": "AM\u2010Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and  reports completion of first stage in Phase II trial", "labels": -0.6060606661}, {"text": "Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled", "labels": -0.6060606661}, {"text": "CHANTIX\u00ae/CHAMPIX\u00ae (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet", "labels": -0.1204447742}, {"text": "Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders", "labels": 0.6311661608}, {"text": "AM-Pharma STOP-AKI Phase II trial nominated for  \u201cMost Innovative Clinical Trial Design\u201d in 2016 CARE Awards", "labels": 1.2939936559}, {"text": "Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE\u00ae (palbociclib)", "labels": 1.2939936559}, {"text": "Pfizer Taps IBM for Research Collaboration to Transform Parkinson\u2019s Disease Care", "labels": -0.153831022}, {"text": "Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13\u00ae", "labels": 3.7240699141}, {"text": "Pfizer Announces Termination of Proposed Combination with Allergan", "labels": 3.7240699141}, {"text": "FDA Approves INFLECTRA\u2122 (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications", "labels": 5.2232048983}, {"text": "Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA\u00ae in Renal Cell Carcinom", "labels": 5.2232048983}, {"text": "Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis", "labels": 5.2232048983}, {"text": "Pfizer and Allergan Issue Statement", "labels": 4.0497229904}, {"text": "Cancer Metabolism Company Metabomed Completes $18 Million Series A  Financing", "labels": 4.0497229904}, {"text": "Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab", "labels": 4.1666807983}, {"text": "Pfizer Inc. (NYSE: PFE) today issued the following statement:", "labels": -0.0665644913}, {"text": "Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination", "labels": -1.7206548285}, {"text": "Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology\u2019s 65th Annual Scientific Session", "labels": -1.7206548285}, {"text": "Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ\u00ae (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis", "labels": -1.1635805542}, {"text": "Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts", "labels": 0.529991629}, {"text": "Pfizer Joins The Human Vaccines Project To Help Decode The Immune System", "labels": 0.529991629}, {"text": "Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials", "labels": 1.8955626207}, {"text": "Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO", "labels": -0.613522319}, {"text": "Pfizer Celebrates a Year of Achievements in 2015 Annual Review", "labels": -2.8925640117}, {"text": "XALKORI\u00ae (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer", "labels": 1.0630991445}, {"text": "New Survey Reveals Many Living with Symptoms of Diabetic Nerve Pain Are Undiagnosed Despite Severe and Constant Pain", "labels": -0.4393333954}, {"text": "Pfizer Commences $5 Billion Accelerated Share Repurchase", "labels": -0.4393333954}, {"text": "Pfizer Announces Publication of Study Results of BeneFIX\u00ae Coagulation Factor IX (Recombinant) Once-Weekly Prophylaxis for Hemophilia B", "labels": -0.0336136081}, {"text": "Pfizer Consumer Healthcare and frog Launch Design Collaborative", "labels": -0.0336136081}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 0.6337554864}, {"text": "Pfizer Announces FDA Approval of XELJANZ\u00ae XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis", "labels": 2.5498366877}, {"text": "Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer", "labels": 1.4975069091}, {"text": "WYETH REACHES AGREEMENT IN PRINCIPLE TO RESOLVE MEDICAID DRUG REBATE CLAIMS FOR 2001-2006 PERIOD FOR PROTONIX", "labels": 0.2699990004}, {"text": "Pfizer Commends The FDA Advisory Committee\u2019s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications", "labels": 3.4588088627}, {"text": "Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan Transaction", "labels": 1.4432772551}, {"text": "UI strikes agreement with Pfizer Inc. to develop potential cystic fibrosis gene  therapy", "labels": -1.5845858176}, {"text": "PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2015 RESULTS PROVIDES 2016 FINANCIAL GUIDANCE", "labels": -0.6730634307}, {"text": "Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan", "labels": -0.6635685962}, {"text": "La Jolla Institute receives $5 million gift from Pfizer", "labels": -0.5217038638}, {"text": "King\u2019s College London signs licence and research agreement with Pfizer Inc. in the field of gene therapy", "labels": 1.2099484095}, {"text": "California Institute for Biomedical Research (Calibr) Enters Worldwide Strategic Collaboration with Pfizer Inc.", "labels": 0.0642794553}, {"text": "Schr\u00f6dinger Announces Research Collaboration with Pfizer Inc.", "labels": -0.4838490444}, {"text": "HemoShear Therapeutics Announces Next Stage of Safety  Collaboration with Pfizer Inc.", "labels": -0.4838490444}, {"text": "Pfizer Expands R&D Equity Investment Strategy to Access Early-Stage Scientific Innovations", "labels": -1.5449209544}, {"text": "Pfizer Enters into Translational Research Collaboration with Adaptive Biotechnologies to Help Advance Novel Immuno-Oncology Solutions", "labels": -1.5449209544}, {"text": "PHILOGEN ANNOUNCES EXERCISE OF OPTIONS WITHIN THE LICENSE AGREEMENT  WITH PFIZER INC. FOR THE DEVELOPMENT AND POTENTIAL COMMERCIALIZATION  OF MULTIPLE ANTIBODY DRUG CONJUGATES (ADCs) AND TARGETED  TECHNOLOGIES", "labels": -0.5161104995}, {"text": "4D Molecular Therapeutics Announces Collaboration with Pfizer Inc. for  Cardiac Gene Therapy Vector Discovery and Development", "labels": -0.5161104995}, {"text": "Cortexyme Raises $15 Million Series A", "labels": -1.0509339442}, {"text": "NextCure, Inc., New Immuno-Oncology Firm Announces $67 Million Series A Financing", "labels": -1.0509339442}, {"text": "KineMed Enters Into Strategic Proteomic Biomarker Discovery Collaboration with Pfizer Inc.", "labels": 1.0254725949}, {"text": "Absorption Systems Licenses Cell Line to Pfizer", "labels": 1.0254725949}, {"text": "Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer", "labels": 1.0254725949}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of February 2 Conference Call With Analysts", "labels": -0.1842768865}, {"text": "Merck KGaA, Darmstadt, Germany and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab", "labels": -0.1842768865}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 0.8369656005}, {"text": "Pfizer Declares First-Quarter 2016 Dividend", "labels": 0.8369656005}, {"text": "AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy", "labels": -1.1541047484}, {"text": "Pfizer Announces FDA Acceptance of IBRANCE\u00ae (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer", "labels": -1.1541047484}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers", "labels": -0.1853984349}, {"text": "BIOATLA ENTERS INTO STRATEGIC LICENSE AND OPTION AGREEMENT WITH PFIZER  FOR A NEW CLASS OF ANTIBODY THERAPEUTICS", "labels": -0.1858324662}, {"text": "Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for  Progress in Hemophilia B Gene Therapy Program", "labels": -0.1858324662}, {"text": "Pfizer Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for XALKORI\u00ae (crizotinib) for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer", "labels": -0.1858324662}, {"text": "Pfizer Awards More Than $4 Million in Grants to Further Clinical Research in Advanced Breast Cancer for 2015", "labels": -0.1858324662}, {"text": "Pfizer Receives U.S. FDA Approval of New QuilliChew ER\u2122 (methylphenidate hydrochloride) extended-release chewable tablets CII", "labels": -0.6455292384}, {"text": "HEPTARES ENTERS STRATEGIC DRUG DISCOVERY COLLABORATION WITH PFIZER INC. FOCUSED ON GPCR TARGETS ACROSS MULTIPLE THERAPEUTIC AREAS", "labels": 2.1118055095}, {"text": "Sosei Subsidiary Heptares Enters Strategic Drug Discovery  Collaboration with Pfizer Inc. Focused on GPCR Targets Across  Multiple Therapeutic Areas", "labels": 2.1118055095}, {"text": "Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA\u00ae (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain", "labels": 1.251192836}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products", "labels": 4.5330079964}, {"text": "Pfizer Receives European Approval to Expand Use of XALKORI\u00ae (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": 4.5330079964}, {"text": "Pfizer And Allergan To Combine", "labels": 1.7203298276}, {"text": "Thermo Fisher Scientific Signs Development Agreement for Next-Generation  Sequencing-Based Companion Diagnostic", "labels": -2.4465698102}, {"text": "Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI\u00ae (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)", "labels": -2.4465698102}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma", "labels": -2.4465698102}, {"text": "Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma", "labels": -1.2777793529}, {"text": "Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM\u2019s Board of Directors", "labels": -0.2667553376}, {"text": "Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association (AHA) Scientific Sessions 2015", "labels": -0.8023803542}, {"text": "Pfizer Expands its Patient Assistance Program, Doubling the Income Eligibility Limit to Benefit Even More Patients Taking Pfizer Medicines", "labels": -0.8841656545}, {"text": "Global Analysis Of Metastatic Breast Cancer Landscape Reveals Gaps In Patient Care And Support", "labels": -0.8841656545}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer", "labels": -2.2547837981}, {"text": "New Data Continue to Characterize the Safety and Efficacy of XELJANZ\u00ae (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis", "labels": 2.2876452906}, {"text": "GLYCOMIMETICS, INC. ANNOUNCES INITIATION OF FIRST CLINICAL TRIAL  EVALUATING SUBCUTANEOUS ADMINISTRATION OF RIVIPANSEL", "labels": -1.2714349309}, {"text": "HALOZYME ANNOUNCES FIRST CLINICAL DOSING OF PFIZER\u2019S  RIVIPANSEL USING ENHANZE\u2122TECHNOLOGY", "labels": -1.2714349309}, {"text": "Announcement Regarding Allergan plc", "labels": -1.2714349309}, {"text": "Pfizer Announces Collaboration with GSK on Next-Generation Design of Portable, Continuous, Miniature and Modular (PCMM) Oral Solid Dose Development and Manufacturing Units", "labels": -1.2714349309}, {"text": "PFIZER REPORTS THIRD-QUARTER 2015 RESULTS", "labels": 1.2411717236}, {"text": "Pfizer\u2019s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL)", "labels": -1.2058957172}, {"text": "Pfizer Receives Complete Response Letter from FDA for Oral XELJANZ\u00ae (tofacitinib citrate) Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis", "labels": 3.0516418255}, {"text": "Pelago Bioscience grants Pfizer Inc. license to the CETSA\u2122 method", "labels": -0.4237179955}, {"text": "Pfizer and the Union for International Cancer Control Award 20 Grants Totaling $760,000 to Address the Needs of Metastatic Breast Cancer Patients Worldwide", "labels": -0.4237179955}, {"text": "Pfizer\u2019s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA\u00ae When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents", "labels": 0.4816383394}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma", "labels": -0.0302386332}, {"text": "Pfizer Inc. Announces Final Results of Exchange Offers", "labels": 4.5101659434}, {"text": "Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline", "labels": 5.3808994077}, {"text": "Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers", "labels": 1.2248715808}, {"text": "Pfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results From September 3, 2015 Through Year-End 2015", "labels": 1.2248715808}, {"text": "Is 50 Really the New 30? Your Immune System May Not Think So", "labels": 1.2248715808}, {"text": "Pfizer Declares 28-Cent Fourth-Quarter 2015 Dividend", "labels": -6.9435431437}, {"text": "BIND\tTherapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors", "labels": -1.4738226765}, {"text": "Pfizer\u2019s Sayana\u00ae Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection", "labels": 1.4678917774}, {"text": "New Centrum\u00ae VitaMints\u00ae Offer a Refreshingly New Way to Take a Multivitamin", "labels": 1.9619854757}, {"text": "Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Oral Tofacitinib in Adults with Moderate-to-Severe Ulcerative Colitis", "labels": -2.6038407687}, {"text": "Pfizer Inc. Announces Results of Early Tenders and Consents in Exchange Offers", "labels": -2.0357821084}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts", "labels": 1.4934362648}, {"text": "Merck KGaA, Darmstadt, Germany and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015", "labels": 0.428019393}, {"text": "Evotec enters into licence and  collaboration agreement with  Pfizer Inc. in tissue fibrosis", "labels": -1.1648998481}, {"text": "GPCR Consortium Exceeds Goal with Addition of Four New Pharma Members", "labels": -1.1648998481}, {"text": "GPCR Consortium Exceeds Goal with Addition of Four New Pharma Members", "labels": -1.1648998481}, {"text": "Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention", "labels": -1.1648998481}, {"text": "AMRA announces collaboration with Pfizer to use imaging to potentially help  identify those most at risk from metabolic disease and comorbidities", "labels": 0.4067145563}, {"text": "Pfizer Inc. Commences Exchange Offers for Hospira Notes", "labels": -2.8689939501}, {"text": "Pfizer Completes Acquisition of Hospira", "labels": -2.8689939501}, {"text": "Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE\u00ae (palbociclib), for Patients with Hormone Receptor\u2013Positive Early Breast Cancer", "labels": 3.5477919224}, {"text": "Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015", "labels": -2.0102200911}, {"text": "Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition", "labels": -2.0102200911}, {"text": "Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA\u00ae (Meningococcal Group B Vaccine)", "labels": -6.5670582567}, {"text": "Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE\u00ae (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer", "labels": -4.1144929267}, {"text": "Pfizer Granted Approval From The Canadian Competition Bureau For Hospira Acquisition", "labels": 0.366187122}, {"text": "HiFiBiO SAS Achieves Milestone in Antibody Research Collaboration with Pfizer Inc.", "labels": -0.1698614922}, {"text": "Pfizer Receives Approval from the Australian Competition and Consumer Commission for Pending Acquisition of Hospira", "labels": -0.1698614922}, {"text": "Pfizer Receives Approval From European Commission For Pending Acquisition Of Hospira", "labels": -0.3326330076}, {"text": "Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis", "labels": -0.4984502732}, {"text": "PFIZER REPORTS SECOND-QUARTER 2015 RESULTS", "labels": 2.2930938617}, {"text": "Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility", "labels": -0.805094898}, {"text": "Pfizer\u2019s Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announce Collaboration to Help Advance Immunological Research", "labels": 0.9155150594}, {"text": "Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery", "labels": 0.328854289}, {"text": "Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ\u00ae (tofacitinib citrate) Modified Release Tablets", "labels": -1.4736801361}, {"text": "Joseph J. Echevarria Elected To Pfizer\u2019s Board Of Directors", "labels": -0.8549589422}, {"text": "Pfizer Declares 28-Cent Third-Quarter 2015 Dividend", "labels": -0.8549589422}, {"text": "CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA\u00ae for Adolescents and Young Adults 16 through 23 Years of Age", "labels": -0.940649195}, {"text": "Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease", "labels": -0.5258599445}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of July 28 Conference Call With Analysts", "labels": -0.5258599445}, {"text": "New Online Community, Quitter\u2019s Circle, Helps Smokers Trade Cigarettes for Real-Time Support", "labels": -0.5258599445}, {"text": "Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline", "labels": 0.4637835505}, {"text": "Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder", "labels": -0.321548022}, {"text": "Pfizer Builds Upon Robust Body Of Knowledge For XELJANZ\u00ae (tofacitinib citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015)", "labels": 1.10273941}, {"text": "Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology", "labels": 0.1176025042}, {"text": "Get Ready. Get Set. Get Old. Pfizer Challenges Conventional Views of Aging Through New Campaign", "labels": -0.3227025093}, {"text": "Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy", "labels": -0.8118289676}, {"text": "Pfizer\u2019s RAPAMUNE\u00ae (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease", "labels": 0.2314864864}, {"text": "Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer", "labels": 0.8345402958}, {"text": "Pfizer Global Survey Finds Adults with Rheumatoid Arthritis Who Feel Comfortable Speaking Up About Their Concerns Have a More Positive View of Their Health", "labels": 0.8345402958}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations", "labels": 1.2536630116}, {"text": "Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira", "labels": 0.823767082}, {"text": "Bar Ilan University to work with Pfizer Inc. to evaluate  drug delivery via DNA Nanorobots", "labels": 0.823767082}, {"text": "Marc Tessier-Lavigne, Ph.D. to Leave Pfizer Board of Directors", "labels": 0.823767082}, {"text": "Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody", "labels": 0.5008787132}, {"text": "Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company", "labels": -0.9176905655}, {"text": "Pfizer Appoints New Leaders for  BioTherapeutics Research & Development and Rinat", "labels": -0.506240949}, {"text": "23andMe Launches Lupus Research Community in Collaboration with  Pfizer Inc.", "labels": -1.8767079907}, {"text": "PFIZER REPORTS FIRST-QUARTER 2015 RESULTS", "labels": -1.3123463666}, {"text": "Pfizer Hosts Annual Meeting Of Shareholders", "labels": 1.0774086435}, {"text": "Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI\u00ae (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer", "labels": -0.486710301}, {"text": "Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia", "labels": -0.486710301}, {"text": "Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer", "labels": -0.4299332541}, {"text": "Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders", "labels": -0.0856252592}, {"text": "Pfizer Launches 2014 Integrated Annual Review", "labels": -0.0856252592}, {"text": "Pfizer Announces PALOMA-3 Trial For IBRANCE\u00ae (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy", "labels": -0.5967283409}, {"text": "REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes  Prevention and Treatment Promoting Regulatory T-Cells", "labels": 0.4544003168}, {"text": "Pfizer Launches First Annual PCSK9 Competitive Grants Program to Advance Cardiovascular Disease Research", "labels": 2.2573437039}, {"text": "Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI\u00ae (crizotinib)", "labels": 0.0288616545}, {"text": "Kathrin U. Jansen, Ph.D., to Lead Pfizer\u2019s Vaccine Research and Development Unit", "labels": 0.3474332419}, {"text": "Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit", "labels": 0.5461354891}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 1.2163337278}, {"text": "Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab", "labels": 0.0289705703}, {"text": "Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials", "labels": 2.6248190105}, {"text": "Results of Pfizer\u2019s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine", "labels": 0.351367772}, {"text": "Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA\u00ae Capsules CV As A Treatment For Adolescents With Fibromyalgia", "labels": 0.5588169141}, {"text": "Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults", "labels": -0.3175637191}, {"text": "CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk", "labels": -0.4370601523}, {"text": "Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA\u00ae (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diphtheria And Pertussis (Tdap) Vaccines In Adolescents", "labels": 1.2694686781}, {"text": "FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE\u00ae (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)", "labels": 0.3489133019}, {"text": "Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)", "labels": -0.3470080434}, {"text": "Safety and Efficacy of ELELYSO\u00ae (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015", "labels": 1.0392394506}, {"text": "Pfizer Commences $5 Billion Accelerated Share Repurchase", "labels": 3.4260423974}, {"text": "Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Investor Conference", "labels": 3.4260423974}, {"text": "University of Dundee signs agreement with Pfizer Inc. to research potential new therapies  for the treatment of Cystic Fibrosis.", "labels": 0.3919182614}, {"text": "Pfizer to Acquire Hospira", "labels": 0.3919182614}, {"text": "Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Pfizer's Proposed Acquisition of Hospira", "labels": 0.3919182614}, {"text": "Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ\u00ae (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis", "labels": 3.0918521808}, {"text": "Pfizer Marks World Cancer Day With Grant To Union For International Cancer Control To Address The Needs Of Metastatic Breast Cancer Patients", "labels": 3.0918521808}, {"text": "Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE\u00ae (palbociclib)", "labels": 1.585378367}, {"text": "PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE", "labels": -1.2206755086}, {"text": "Pfizer Commits to Further Reduce Price for Prevenar 13 in the World\u2019s Poorest Countries Through 2025", "labels": 0.3987815946}, {"text": "SANIONA RECEIVES A RESEARCH MILESTONE PAYMENT IN  PFIZER INC. COLLABORATION", "labels": 0.3987815946}, {"text": "Prevenar 13\u00ae* Receives CHMP Positive Opinion For Prevention Of Vaccine-Type Pneumococcal Pneumonia in Adults", "labels": -0.6779788386}, {"text": "Pfizer and the Avon Foundation for Women Award 23 Grants Totaling $1 Million in Funding to Support Patients Living With Metastatic Breast Cancer", "labels": -0.3352582877}, {"text": "HemoShear\tAnnounces\tCollaboration\twith\tPfizer\tInc. To Help\tIdentify and\tPredict Drug-Induced\tVascular\tInjury for\t Early\tStage\tCompounds", "labels": -0.7089813896}, {"text": "23andMe Announces Collaboration with Pfizer Inc. to Perform Genetic Research Through 23andMe\u2019s Research Platform", "labels": -0.7089813896}, {"text": "Repligen Receives Milestone Payment from Pfizer", "labels": 0.9494520136}, {"text": "Pfizer Provides Update on IBRANCE\u00ae (palbociclib)", "labels": 0.9494520136}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference", "labels": 1.8210520045}, {"text": "Pfizer Acquires Redvax GmbH", "labels": 0.2227882922}, {"text": "Pfizer Acquires Redvax GmbH", "labels": 0.2227882922}, {"text": "Kissei Announces Licensing Agreement with Pfizer Inc. for KUX-1151, a  Novel Investigational Therapy for Gout and Hyperuricemia", "labels": -0.1592639827}, {"text": "PHILOGEN\tANNOUNCES OPTION AND LICENSE AGREEMENT WITH PFIZER INC. TO DEVELOP AND COMMERCIALIZE MULTIPLE ANTIBODY DRUG CONJUGATES AND TARGETED NANOPARTICLES", "labels": -1.303656302}, {"text": "Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia", "labels": 1.3149915457}, {"text": "Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy", "labels": 3.9724390008}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of January 27 Conference Call With Analysts", "labels": 0.931879372}, {"text": "Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against Meningitis", "labels": 0.931879372}, {"text": "Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology", "labels": -1.4998278007}, {"text": "Pfizer Declares First-Quarter 2015 Dividend", "labels": -1.4998278007}, {"text": "OPKO and Pfizer Enter into Global Agreement for OPKO\u2019s Long-Acting Human Growth Hormone (hGH-CTP)", "labels": -1.4998278007}, {"text": "Pfizer employees join the movement to end hunger; Partnering with Stop Hunger Now, Pfizer is slated to package more than 50,000 meals", "labels": -1.1058694801}, {"text": "Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause", "labels": -1.1058694801}, {"text": "New Data at ASH 2014 Highlight Progress of Pfizer\u2019s Growing Portfolio in Blood Cancers", "labels": 0.9730300295}, {"text": "Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects", "labels": 0.5321042306}, {"text": "iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for  Discovery and Development of Cancer Immunosuppression Targets", "labels": 0.5321042306}, {"text": "Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B with Pfizer Inc.", "labels": 0.5321042306}, {"text": "Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform", "labels": 0.5321042306}, {"text": "Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer\u2019s XALKORI\u00ae (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": 0.5367547696}, {"text": "WADA Signs a Global Collaboration Agreement with Pfizer  Inc.", "labels": 0.5367547696}, {"text": "Lpath Completes Enrollment in its Phase 2 Clinical Trial of iSONEP for Wet Age-Related Macular Degeneration", "labels": 0.9764051571}, {"text": "New Survey Finds Majority of Women with Breast Cancer Who Work Want to Do So Even While Undergoing Treatment", "labels": 0.9764051571}, {"text": "Pfizer Completes Acquisition of Baxter\u2019s Marketed Vaccines", "labels": 2.1856150144}, {"text": "Sanguine\u2019s Mobile Application to Assist Recruitment for Pfizer Inc. Chronic  Pain Research", "labels": -0.1642535436}, {"text": "TRUMENBA\u00ae (Meningococcal Group B Vaccine) is Now Available", "labels": -0.1642535436}, {"text": "Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)", "labels": 2.2229506982}, {"text": "Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology", "labels": 2.2229506982}, {"text": "Novel Agreement Expands Access to Pfizer\u2019s Contraceptive,  Sayana\u00ae Press, for Women Most in Need  in the World\u2019s Poorest Countries", "labels": -0.5932520154}, {"text": "Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting", "labels": 0.6245948909}, {"text": "Cedric \u201cThe Entertainer\u201d Urges People with Diabetic Nerve Pain to \u201cStep On Up\u201d and Seek Relief", "labels": -0.5347450233}, {"text": "Pfizer Receives FDA Accelerated Approval for TRUMENBA\u00ae (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults", "labels": 2.3123284309}, {"text": "Pfizer\u2019s PRISTIQ\u00ae (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder", "labels": 2.3123284309}, {"text": "PFIZER REPORTS THIRD-QUARTER 2014 RESULTS", "labels": 1.085125827}, {"text": "Pfizer to Discontinue Agreement on REMOXY\u2122 (oxycodone) Extended-Release Capsules CII", "labels": -7.0584e-06}, {"text": "Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend", "labels": 1.5802062987}, {"text": "Pfizer Wins SUTENT\u00ae Patent Case In Delaware District Court", "labels": 1.5802062987}, {"text": "FDA Approves Abuse Deterrent Labeling for EMBEDA\u00ae (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII", "labels": 0.4296543075}, {"text": "Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review", "labels": -2.4595978356}, {"text": "Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014\u2122", "labels": -2.2480049256}, {"text": "Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer", "labels": 0.620926836}, {"text": "Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine", "labels": 0.620926836}, {"text": "Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study", "labels": -0.338170393}, {"text": "Pfizer Completes Acquisition Of InnoPharma", "labels": -2.0524651589}, {"text": "Pfizer Completes Acquisition Of InnoPharma", "labels": -2.0524651589}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts", "labels": 1.5835907976}, {"text": "Kim Cattrall Encourages Women to Embrace Menopause with Style", "labels": 1.5835907976}, {"text": "Circle\tPharma\tAnnounces Receipt\tof Seed\tFunding\tand\tInitiation\tof\tTwo\tCollaborations", "labels": -0.698800584}, {"text": "Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers", "labels": -0.698800584}, {"text": "MedGenesis Enters Into Agreement with Pfizer Inc. for Potential Treatments for Parkinson\u2019s Disease", "labels": 1.3179405467}, {"text": "Pfizer Invites the Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": -0.2723915637}, {"text": "Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)", "labels": 0.6462868506}, {"text": "Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO\u2122 (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease", "labels": -0.136067975}, {"text": "Pfizer\u2019s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation", "labels": -0.136067975}, {"text": "Pfizer And Merck To Collaborate On Study Evaluating Novel AntiCancer Combination Regim", "labels": 1.5598438917}, {"text": "Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen", "labels": 1.5598438917}, {"text": "U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy", "labels": 1.01107e-05}, {"text": "Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer", "labels": 1.01107e-05}, {"text": "Expanding IBD Research Through Collaboration", "labels": -0.0347288557}, {"text": "Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis\u00ae (apixaban) at the ESC Congress 2014", "labels": -0.0347288557}, {"text": "Pfizer Announces Submission of Palbociclib New Drug Application to the FDA", "labels": 0.6565424777}, {"text": "Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine", "labels": 1.3268716953}, {"text": "Advisory Committee on Immunization Practices Votes to Recommend Pfizer\u2019s Prevnar 13\u00ae Vaccine in Adults Aged 65 Years and Older", "labels": 1.6707215326}, {"text": "Pfizer Reports Top-line Results From Postherpetic Neuralgia And Painful Diabetic Peripheral Neuropathy Lyrica\u00ae Studies Conducted In China", "labels": -0.1772497767}, {"text": "23andMe Announces Agreement with Pfizer Inc. to  Research Genetics of Ulcerative Colitis and Crohn\u2019s Disease", "labels": -0.1772497767}, {"text": "Epilepsy Foundation Collaborating On Personalized Drug Discovery Platform For Epilepsy With Intellimedix And Pfizer Inc.", "labels": 0.6017932752}, {"text": "European Medicines Agency Accepts Application Seeking New Indication For Prevenar 13\u00ae1 For Prevention Of Pneumococcal Pneumonia In Adults", "labels": -0.3528556676}, {"text": "Rascal Flatts Joins the Thousands of People Who Choose Nexium\u00ae 24HR Every Day for Their Frequent Heartburn", "labels": -1.9007236884}, {"text": "Pfizer Enters Into Agreement To Acquire Baxter\u2019s Portfolio Of  Marketed Vaccines", "labels": -2.8223075451}, {"text": "Pfizer Enters Into Agreement To Acquire Baxter\u2019s Portfolio Of Marketed Vaccines", "labels": -2.8223075451}, {"text": "European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE", "labels": -2.7503441635}, {"text": "PFIZER REPORTS SECOND-QUARTER 2014 RESULTS", "labels": -2.7503441635}, {"text": "ViiV Healthcare presents phase III data comparing once-daily  maraviroc in combination with darunavir/ritonavir with  emtricitabine/tenofovir plus darunavir/ritonavir in treatment-na\u00efve  adults with HIV-1", "labels": -0.5264682528}, {"text": "Seven pharma companies offer up compounds to UK researchers", "labels": -0.5264682528}, {"text": "Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis\u00ae (apixaban) in Patients with NVAF Undergoing Cardioversion", "labels": -0.2277748982}, {"text": "Pfizer to Acquire InnoPharma, Inc.", "labels": 0.1309327638}, {"text": "#FOGO? \u2013 New Survey Reveals 87% of Americans have a Fear of Getting Old (FOGO) \u2013 Results Show Top Fear is Decline in Physical Ability1", "labels": 0.1309327638}, {"text": "Pfizer to Acquire InnoPharma, Inc.", "labels": 0.1309327638}, {"text": "Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX\u00ae) Once-Weekly Prophylaxis For Hemophilia B", "labels": 0.1309327638}, {"text": "Absorption Systems Announces License Agreement with Pfizer Inc.", "labels": 2.454802432}, {"text": "Pfizer Inc. Receives Kosher Certification for Elelyso\u2122 (taliglucerase alfa) for Injection, for the Treatment of Type 1 Gaucher Disease", "labels": 2.5024772768}, {"text": "Eliquis\u00ae (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE", "labels": 0.0336575519}, {"text": "Pfizer Declares 26-Cent Third-Quarter 2014 Dividend", "labels": -0.1684888544}, {"text": "James C. Smith Elected to Pfizer\u2019s Board of Directors", "labels": -0.1684888544}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 29 Conference Call with Analysts", "labels": 1.2415971917}, {"text": "Prevenar 13\u00ae Indication Extended in Japan", "labels": -0.9847410317}, {"text": "Two-Year Results From Pfizer\u2019s XELJANZ\u00ae (Tofacitinib Citrate) ORAL Start Study Published in The New England Journal of Medicine", "labels": 0.202803547}, {"text": "Pfizer And Cellectis Enter Into Global Strategic Cancer  Immunotherapy Collaboration", "labels": 0.202803547}, {"text": "Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration", "labels": 0.4375055434}, {"text": "Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine", "labels": 0.4375055434}, {"text": "X-Chem Enters into Multi-Target Collaboration with Pfizer Inc.", "labels": -0.033962451}, {"text": "Pfizer Announces Over 10 Abstracts for XELJANZ\u00ae (Tofacitinib Citrate) in Rheumatoid Arthritis to be Presented at the European League Against Rheumatism (EULAR) 2014 Annual Meeting", "labels": -0.033962451}, {"text": "KineMed Collaboration with Pfizer Inc. in Diabetes is  Extended", "labels": 0.5040115439}, {"text": "Pfizer Invites the Public to Listen to Webcast of Pfizer Discussion at Health Care Conference", "labels": 0.5040115439}, {"text": "Dr. Morris J. Birnbaum Joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research", "labels": -0.3375117556}, {"text": "Pfizer and the Avon Foundation for Women Announce $1 Million Grants Program to Address Gaps in Support for People Living with Metastatic Breast Cancer", "labels": -0.3375117556}, {"text": "Global Investigator Databank expands to five pharmaceutical  company members and announces new investigator website", "labels": -1.080711737}, {"text": "Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium\u00ae 24HR", "labels": -1.080711737}, {"text": "ANNOUNCEMENT REGARDING ASTRAZENECA PLC", "labels": -1.080711737}, {"text": "Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis", "labels": 0.1351056093}, {"text": "BioRestorative Therapies Signs Research Agreement with Pfizer Inc.", "labels": -0.2373892506}, {"text": "Roslin Cells Announces New Cell Therapy Manufacturing Contract  with Pfizer Inc.", "labels": 1.3823352564}, {"text": "New Survey Highlights The Impact Of Menopausal Symptoms On Women In The Workplace", "labels": 1.3823352564}, {"text": "Statement from Pfizer Inc.", "labels": -1.1281917023}, {"text": "PFIZER MAKES FINAL PROPOSAL TO ASTRAZENECA", "labels": -1.1281917023}, {"text": "Pfizer To Submit Palbociclib New Drug Application With FDA Based On Final Results Of PALOMA-1", "labels": 0.956296523}, {"text": "American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates", "labels": -0.2752907369}, {"text": "STATEMENT FROM PFIZER INC. (\u201cPFIZER\u201d)", "labels": -0.4794710169}, {"text": "Pfizer Prices $4.5 Billion Debt Offering", "labels": -0.4794710169}, {"text": "Pfizer Announces Positive Phase 2 Study Results for Investigational Meningococcal B Vaccine", "labels": 0.1029685338}, {"text": "Pfizer Reports First-Quarter 2014 Results", "labels": -2.8202685721}, {"text": "Second Genome Enters Into Agreement with Pfizer  Inc. on Microbiome Research Initiative in Obesity", "labels": -3.538063998}, {"text": "Pfizer Sends Letter to Rt Hon David Cameron MP Regarding Commitments If Proposed Combination with AstraZeneca is Completed", "labels": -1.0731690568}, {"text": "Pfizer Confirms Delivery of Increased Proposal to AstraZeneca", "labels": -1.0731690568}, {"text": "ALO-02 Demonstrates Significant Difference In Pain Scores In Chronic Low Back Pain Patients And Lower Abuse Potential Compared To Immediate-Release Oxycodone In Recreational Opioid Users", "labels": -1.0731690568}, {"text": "Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Possible Combination With AstraZeneca", "labels": 0.5352962103}, {"text": "Pfizer Hosts Annual Meeting of Shareholders Declares 26-Cent Second-Quarter 2014 Dividend", "labels": -0.4877569823}, {"text": "Pfizer Announces Positive Top-Line Results From Two Phase 3 Trials Of Tofacitinib In Adults With Moderate-to-Severe Chronic Plaque Psoriasis", "labels": 0.2264013116}, {"text": "Pfizer Invites Public To Listen To Webcast Of April 24 Annual Meeting Of Shareholders", "labels": 1.48387701}, {"text": "Advil\u00ae Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick Off a Nationwide \"Relief\" Tour", "labels": -0.5352955581}, {"text": "Pfizer\u2019s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer", "labels": -1.9760285595}, {"text": "Merck Serono Enters into Research Agreement with Pfizer and  Broad Institute", "labels": 1.1148979983}, {"text": "Lieber Institute Announces Consortium To Identify How Genes Build A Brain With The Goal Of Developing Treatments For Brain Disorders", "labels": -0.0313164512}, {"text": "Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium\u00ae 24HR", "labels": -0.2490653017}, {"text": "In A Subanalysis, The Benefits Of Eliquis\u00ae (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1", "labels": -1.2547140507}, {"text": "Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study", "labels": -1.2547140507}, {"text": "Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN\u00ae In Very Young Children Born Small For Gestational Age", "labels": 0.2803979699}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts", "labels": 1.274072948}, {"text": "Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI\u00ae (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)", "labels": 1.274072948}, {"text": "Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL\u00ae in Adults with Moderate-to-Severe Chronic Plaque Psoriasis", "labels": 0.1571342723}, {"text": "Pfizer\u2019s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease", "labels": 0.1864644015}, {"text": "Pfizer Launches 2013 Integrated Annual Review", "labels": 0.7568374271}, {"text": "U.S. FDA Approves Eliquis\u00ae (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery", "labels": 0.859308768}, {"text": "Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent", "labels": -3.3097574871}, {"text": "Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014", "labels": -3.3097574871}, {"text": "Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*", "labels": -3.3097574871}, {"text": "Pfizer Initiates Nationwide Voluntary Recall Of Two Lots Of Pfizer's Effexor XR\u00ae 150 mg Extended-Release Capsules And One Lot Of Greenstone's Venlafaxine HCI 150 mg Extended-Release Capsules Due To The Possible Presence Of Tikosyn\u00ae Capsule", "labels": -1.1409236984}, {"text": "Saniona Announces Collaboration With Pfizer To Research And Develop Small Molecule Treatments For Neurological Disorders.", "labels": 1.5203018952}, {"text": "Pfizer Announces FDA Approval To Include Radiographic Data On Reduction Of Progression Of Structural Joint Damage For Adults With Moderately To Severely Active Rheumatoid Arthritis In Labeling For XELJANZ\u00ae (tofacitinib citrate)", "labels": -0.3135887437}, {"text": "Pfizer Announces Positive Top-Line Results Of Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*", "labels": -0.3135887437}, {"text": "In a Subanalysis, Eliquis\u00ae (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation[i]", "labels": 0.9690510385}, {"text": "Pfizer And Merck To Collaborate On Innovative Anti-Cancer  Combination Studies", "labels": -1.0482653127}, {"text": "Pfizer Statement on Today\u2019s Joint Meeting of FDA Advisory Committees", "labels": -0.5694277253}, {"text": "New Funding For Fundamental Biomedical Research To Be Made Available", "labels": -0.5694277253}, {"text": "Ichor Enters Into An Agreement With Pfizer To Develop Electroporation Devices For Use In Therapeutic Cancer Vaccine Regimens", "labels": -0.4863963435}, {"text": "Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies", "labels": -0.4863963435}, {"text": "Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer", "labels": 1.3040516508}, {"text": "U.Va. Spinoff Neoantigenics Announces Collaboration with Pfizer,  Investment from CIT to Develop Antibody-based Therapeutics  For Cancer", "labels": -1.0960197807}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 Financial Guidance", "labels": -1.0960197807}, {"text": "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer", "labels": 1.2491801783}, {"text": "Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study", "labels": -3.0907176391}, {"text": "New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating", "labels": -0.9674306862}, {"text": "CHANTIX\u00ae/CHAMPIX\u00ae (varenicline) Demonstrates Smoking- Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly", "labels": -0.1599043433}, {"text": "Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer\u2019s Disease", "labels": -1.2707722476}, {"text": "MD Anderson teams up with Pfizer to advance cancer immunotherapy", "labels": -0.09760741}, {"text": "FDA Accepts For Review ELIQUIS\u00ae (apixaban) Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And For The Reduction In The Risk Of Recurrent DVT And PE", "labels": -1.7520691495}, {"text": "Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer", "labels": 1.3350676294}, {"text": "Pfizer Settles Viagra\u00ae Patent Litigation With Teva", "labels": 1.9174602511}, {"text": "Pfizer Names Albert Bourla Group President; Vaccines, Oncology And Consumer Healthcare Business", "labels": 1.9174602511}, {"text": "Pfizer Declares First-Quarter 2014 Dividend", "labels": -0.5308546438}, {"text": "Pfizer Expands Clinical Trial Data Access Policy And Launches Data Access Portal", "labels": 0.4479880016}, {"text": "Pfizer Acquires Polocard, Poland\u2019s Leading Over-The-Counter Heart Attack Prevention Brand", "labels": -1.2491985905}, {"text": "Just in Time for Peak Travel Season, Introducing New Robitussin\u00ae DM Max Liquid-Filled Capsules", "labels": -0.7211993054}, {"text": "Pfizer\u2019s XALKORI\u00ae Granted Regular FDA Approval", "labels": 0.8406203682}, {"text": "Pfizer And GSK To Initiate Study Of Novel Combination Therapy In Patients With Melanoma", "labels": 0.8406203682}, {"text": "Pfizer Announces FDA Approval Of Supplemental Application To Expand XELJANZ\u00ae (tofacitinib citrate) Labeling To Include Additional Patient-Reported Outcomes Data For Adults With Moderately To Severely Active Rheumatoid Arthritis", "labels": -1.3266057953}, {"text": "Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014", "labels": 0.8074502433}, {"text": "Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE\u00ae (sirolimus) In Renal Transplant Recipients", "labels": 1.1523400153}, {"text": "Former U.S. President Jimmy Carter And Pfizer Celebrate  15-Year Effort To Help End Blinding Trachoma As A  Public Health Concern", "labels": 0.0633628706}, {"text": "Pfizer Receives FDA Approval For A Prior Approval Supplement For EMBEDA\u00ae (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII", "labels": 0.2560789354}, {"text": "JDRF Teams Up with Pfizer\u2019s Centers for Therapeutic Innovation to  Support Novel Translational Research in Type 1 Diabetes", "labels": 0.2560789354}, {"text": "Pfizer Reports Third Quarter 2013 Results", "labels": 0.2909718757}, {"text": "Howie Mandel Challenges People To Learn The Fibs And Facts About Atrial Fibrillation And Its Associated Increased Stroke Risk", "labels": 2.5600285864}, {"text": "Pfizer Declares 24-Cent Fourth-Quarter 2013 Dividend", "labels": -0.2286776137}, {"text": "Pfizer Inc. Continues Development Program For Remoxy\u00ae (oxycodone) Extended-Release Capsules CII", "labels": 0.7189702146}, {"text": "Pfizer Reports Top-Line Results From Two Lyrica\u00ae Capsules CV Phase 3b Studies", "labels": 0.6907943117}, {"text": "Pfizer Receives European Approval For Label Update Regarding The Use Of Prevenar 13 In Certain High-Risk Populations", "labels": 2.261562719}, {"text": "Siemens enters into master agreement with  Pfizer for companion diagnostics", "labels": 3.3046953693}, {"text": "Grantmakers In Aging receives $1.3 million grant renewal from the Pfizer Foundation to help communities become more \u201cage-friendly\u201d", "labels": 3.3046953693}, {"text": "MaRS Innovation and Pfizer Fund Bio-Manufacturing Technology", "labels": 1.8074009011}, {"text": "ChapStick\u00ae Announces Olympic Gold Medalist Alex Morgan  As New Face Of The Brand", "labels": 1.8074009011}, {"text": "Pfizer Announces Top-Line Results Of The First Two Of Five Phase 3 Clinical Trials Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis", "labels": 1.8074009011}, {"text": "Pfizer Inc. Announces FDA Approval Of DUAVEETM (conjugated estrogens/ bazedoxifene) For The Treatment Of Moderate-To-Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause And The Prevention Of Postmenopausal Osteoporosis [1]", "labels": -0.0689541991}, {"text": "International Atherosclerosis Society And Pfizer Independent Grants For Learning & Change Collaborate On New Grant Opportunity", "labels": 0.2780542512}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of October 29 Conference Call With Analysts", "labels": 1.4822576819}, {"text": "Shantanu Narayen Elected To Pfizer\u2019s Board Of Directors", "labels": 0.6230504325}, {"text": "ADVIL\u00ae BECOMES OFFICIAL PAIN RELIEVER OF THE  NATIONAL HOCKEY LEAGUE AND THE 30 TEAM ATHLETIC TRAINERS", "labels": 0.6230504325}, {"text": "Pfizer Announces Data For XELJANZ\u00ae (tofacitinib citrate) In Rheumatoid Arthritis To Be Presented At The American College Of Rheumatology 2013 Annual Meeting", "labels": -0.8423647236}, {"text": "Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases", "labels": 1.114578036}, {"text": "Pfizer Invites Public To Listen to Webcast of Pfizer Discussion at Health Care Conference", "labels": -0.0352595749}, {"text": "Subanalysis of Phase III ARISTOTLE Trial of Eliquis\u00ae (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease", "labels": -0.0352595749}, {"text": "New Eliquis\u00ae (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon", "labels": -0.0352595749}, {"text": "Pfizer Completes Pneumococcal Pneumonia Case Accrual For CAPiTA,  Adult Vaccine Clinical Trial Of Prevenar 13*", "labels": 0.3190128553}, {"text": "Pfizer Reports Second-Quarter 2013 Results", "labels": 0.9100229612}, {"text": "Pfizer To Create Separate, Internal, Global Innovative And Value Businesses", "labels": 0.9100229612}, {"text": "Pfizer Signs New Agreement With UNICEF To Supply A Total Of Up To 740 Million Doses Of Prevenar 13* For The World\u2019s Poorest Countries Through 2025", "labels": 0.9100229612}, {"text": "CHMP Confirms Prior Opinion Regarding Marketing Authorization In Europe For Pfizer\u2019s XELJANZ\u00ae (tofacitinib citrate)", "labels": 1.1576175282}, {"text": "Pfizer Provides Historical Consolidated Statements of Income with the Animal Health Business (Zoetis) Reported as a Discontinued Operation", "labels": -0.8564529805}, {"text": "Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ\u00ae (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis", "labels": -0.3835870387}, {"text": "Is San Diego Ready for an Aging Population? New Local Survey Reveals San Diego-Area Residents Concerned About Rheir City and Themselves as They Get Old; New Website, \u201cBy the Decades\u201d Healthy Aging Checklist and Aging Communities Toolkit Offers Help", "labels": -0.1041666289}, {"text": "Is Kansas City Ready for an Aging Population? New Local Survey Reveals Kansas City-Area Residents Concerned About Their City and Themselves as They Get Old; New Website, \u201cBy the Decades\u201d Healthy Aging Checklist and Aging Communities Toolkit Offers Help", "labels": -0.1041666289}, {"text": "Is Boston Ready for an Aging Population? New Local Survey Reveals Bostonians\u2019 Concerned About Their City and Themselves as They Get Old; New Website, Healthy Aging \u201cBy the Decades\u201d Checklist and Aging Communities Toolkit Offers Help", "labels": -0.1041666289}, {"text": "Is Atlanta Ready for an Aging Population? New Local Survey Reveals Atlanta-Area Residents Concerned About Their City and Themselves as They Get Old; New Website, Healthy Aging \u201cBy the Decades\u201d Checklist and Aging Communities Toolkit Offer Help", "labels": -0.1041666289}, {"text": "FDA Accepts Eliquis\u00ae (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery", "labels": -0.1041666289}, {"text": "New survey on Atlanta Attitudes Toward Aging To Be Released Thursday, July 11", "labels": 1.0427748992}, {"text": "Pfizer Receives European Approval To Expand Use Of  Prevenar 13* To Adults Aged 18 To 49 Years For The Prevention Of Invasive Pneumococcal Disease", "labels": 1.0427748992}, {"text": "Eliquis\u00ae (apixaban) Demonstrated Comparable Efficacy And Significantly Lower Rates Of Major Bleeding In Patients Compared To Current Standard Of Care For The Treatment Of Acute Venous Thromboembolism", "labels": -0.9747863173}, {"text": "Pfizer Declares 24-Cent Third-Quarter 2013 Dividend", "labels": -1.3566774987}, {"text": "Pfizer Announces Final Results of Zoetis Exchange Offer", "labels": 0.3548839001}, {"text": "Advil\u00ae Is The Official Pain Reliever Of Tough Mudder\u00ae Bringing #ReliefinAction  To \u201cProbably The Toughest Event On The Planet\u201d", "labels": 0.0711719694}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts", "labels": -0.6073579127}, {"text": "Pfizer Announces Preliminary Results of Zoetis Exchange Offer and Adjusts 2013 Financial Guidance(1) Solely to Reflect Impact of Exchange Offer", "labels": -0.6073579127}, {"text": "Pfizer Announces FDA Acceptance For Review Of Application To Expand Labeling For XELJANZ\u00ae (tofacitinib citrate) For Adults With Moderately To Severely Active Rheumatoid Arthritis To Include Inhibition Of Progression Of Structural Damage", "labels": -1.9676770513}, {"text": "Pfizer Announces Final Exchange Ratio Of 0.9898 For Zoetis Exchange Offer And  Automatic Extension Of Offer To Midnight On Friday, June 21, 2013", "labels": -2.5488460035}, {"text": "Pfizer Obtains $2.15 Billion Settlement From Teva And Sun For Infringement Of Protonix\u00ae Patent", "labels": 1.3717971687}, {"text": "CytomX Announces Global Strategic Collaboration with Pfizer to Develop and  Commercialize Multiple Probody\u2122-Drug Conjugates in Oncology", "labels": 2.7601137702}, {"text": "Americans Believe Their Communities Are Ill-Prepared For Aging Population, New Survey Reveals; Survey Shows A Fear Of Getting Old Due To Health And Financial Concerns", "labels": -1.273651265}, {"text": "Pfizer Prices $4.0 Billion Debt Offering", "labels": -3.606812008}, {"text": "Pfizer Announces Plan for Split-Off of Zoetis", "labels": 2.013647457}, {"text": "Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility", "labels": -0.6602099083}, {"text": "Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting", "labels": 2.2108851059}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -1.0139755789}, {"text": "Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation", "labels": 0.3444884401}, {"text": "Facing Off Against Counterfeit Online Pharmacies: Pfizer Launches New Purchasing Website To Help Alleviate the Guesswork Around Buying Legitimate Viagra\u00ae (sildenafil citrate) Online", "labels": 0.3444884401}, {"text": "Pfizer Reports First-Quarter 2013 Results", "labels": -3.6119736641}, {"text": "Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes", "labels": -3.6119736641}, {"text": "Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes", "labels": -3.6119736641}, {"text": "Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevenar 13 In Adults Aged 18 To 49 Years", "labels": -3.6119736641}, {"text": "Pfizer Receives CHMP Negative Opinion Regarding Marketing Authorization In Europe For Rheumatoid Arthritis Treatment XELJANZ\u00ae (tofacitinib citrate)", "labels": -1.8610502937}, {"text": "Pfizer Hosts Annual Meeting Of Shareholders", "labels": -2.7098727815}, {"text": "Top-Line Data Show Celecoxib Met Primary Objective In Clinical Trial To Evaluate The Effects On Blood Pressure In Pediatric Patients With Juvenile Idiopathic Arthritis", "labels": -2.7098727815}, {"text": "Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders", "labels": -0.6865401296}, {"text": "Millions of US Teens May Be Missing Out on Annual Checkups, and the Opportunity to be Screened for Potential Health Risks", "labels": 1.0666322356}, {"text": "Pfizer\u2019s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer", "labels": 2.9745777281}, {"text": "Pfizer Launches Third Integrated Annual Review", "labels": 0.4466007542}, {"text": "Advil\u00ae Launches Advil\u00ae Relief in Action Campaign Celebrating Active Volunteers Who Don\u2019t Let Pain Hold Them Back", "labels": -0.2400799944}, {"text": "BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and  Commercialize Multiple Accurins", "labels": -0.2400799944}, {"text": "CHOP Collaborates With Pfizer\u2019s Centers For Therapeutic Innovation To Speed Pediatric Research & Development", "labels": -0.2400799944}, {"text": "Pfizer\u2019s BOSULIF\u00ae (bosutinib) Receives Conditional Marketing Authorization From The European Commission", "labels": 1.1781136865}, {"text": "Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts", "labels": 1.3268150666}, {"text": "Over 50? Of Course You\u2019ve Still Got It, and the Y and Pfizer are Launching 50 MOVING FORWARD to Help You Keep It", "labels": 0.5244931511}, {"text": "XELJANZ\u00ae (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)", "labels": 0.5244931511}, {"text": "New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure.", "labels": -0.7874148515}, {"text": "United States Patent & Trademark Office Grants Pfizer Reissue Patent For Celebrex\u00ae (celecoxib capsules)", "labels": 2.7075637353}, {"text": "Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevnar 13\u00ae In Adults With HIV", "labels": 2.7075637353}, {"text": "Top-Line Data Show Lyrica Met Primary Endpoint in Clinical Trial as Adjunctive Therapy versus Levetiracetam in Patients with Partial Onset Seizures", "labels": -0.875595941}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.6166301032}, {"text": "Pfizer Inc. Issues Statement on ZoetisTM IPO", "labels": 0.7600454385}, {"text": "Pfizer Wins RAPAMUNE\u00ae Patent Case in Delaware District Court", "labels": -0.9164498563}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2012 Results; Provides 2013 Financial Guidance", "labels": 2.1660365068}, {"text": "Pfizer Receives FDA Approval For The Use Of Prevnar 13 In Vaccine-Naive Children And Adolescents Aged 6 Years Through 17 Years For The Prevention Of Invasive Pneumococcal Disease", "labels": -0.5216059719}, {"text": "ChapStick\u00ae Sessions Applies a Spotlight on Musically Talented Lips", "labels": 0.4814817504}, {"text": "Study Shows Higher Dose Of Toviaz\u00ae (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder", "labels": 1.2290446316}, {"text": "Pfizer Announces Top-Line Efficacy Results From A Phase 4 Study Of PRISTIQ\u00ae (desvenlafaxine) For The Treatment Of Major Depressive Disorder (MDD) In Adults", "labels": 1.2290446316}, {"text": "CHANTIX\u00ae (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIX", "labels": 1.2290446316}, {"text": "Pfizer Partnership Organizations Significantly Benefit From Pfizer\u2019s Global Health Fellows Program", "labels": 0.300211002}, {"text": "Pfizer\u2019s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe", "labels": -0.7912347006}, {"text": "Pfizer Announces Availability Of Quillivant XR\u2122 (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States", "labels": 0.0375751003}, {"text": "Pfizer Receives European Approval To Expand Use Of Prevenar 13 To Older Children And Adolescents Aged 6 To 17 Years For The Prevention Of Pneumococcal Disease", "labels": 0.4227951332}, {"text": "Philogen S.p.A. Announces Worldwide Licensing Agreement with Pfizer Inc. for Dekavil, an Investigational Immunoregulatory Therapy for Autoimmune Diseases", "labels": -0.0770543037}, {"text": "Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program", "labels": -0.0770543037}, {"text": "EMD Serono and Pfizer Announce FDA Approval of Rebif\u00ae Rebidose\u00ae (interferon beta-1a)", "labels": -0.0770543037}, {"text": "UPDATE: With Multimedia: U.S. FDA Approves ELIQUIS\u00ae (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation", "labels": 1.237912109}, {"text": "ELIQUIS\u00ae (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation", "labels": 0.3579878784}, {"text": "Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop  And Commercialize Subcutaneous Biologics Using Recombinant Human  Hyaluronidase", "labels": -1.2360418062}, {"text": "Humedica and Pfizer Form Strategic Alliance", "labels": -0.956942698}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of January 29 Conference Call With Analysts", "labels": 1.8331033523}, {"text": "Pfizer Declares First-Quarter 2013 Dividend", "labels": 1.8331033523}, {"text": "U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis", "labels": -0.9928463432}, {"text": "New Robitussin\u00ae COUGHCAST\u2122 Tool Helps Consumers Prepare for Coughs, Colds and the Flu by Tracking Cough Incidence Rates in Their Area", "labels": -0.0784165361}, {"text": "ELIQUIS\u00ae (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment", "labels": 0.8580736241}, {"text": "Tanzania Expands Immunization Program To Include Pfizer\u2019s Prevenar 13 For Prevention Of Pneumococcal Disease", "labels": 2.340111178}, {"text": "Pfizer Presents Phase 2 Data Showing Investigational Therapy PD-0332991 Plus Letrozole Significantly Improved Progression Free Survival Compared With Letrozole Alone In Patients With ER Positive, HER2 Negative Advanced Breast Cancer", "labels": 2.340111178}, {"text": "Pfizer Completes Sale of Nutrition Business to Nestl\u00e9", "labels": 0.7174370885}, {"text": "Pfizer Completes Sale of Nutrition Business to Nestl\u00e9", "labels": 0.7174370885}, {"text": "Pfizer to Present Clinical Data from Its Hematology Portfolio at the 54th Annual Meeting of the American Society of Hematology", "labels": 2.4949621408}, {"text": "Pfizer Acquires NextWave Pharmaceuticals, Inc.", "labels": 2.4949621408}, {"text": "Pfizer Acquires NextWave Pharmaceuticals, Inc.", "labels": 1.6619398044}, {"text": "Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013", "labels": -0.3711757096}, {"text": "ELIQUIS\u00ae(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation", "labels": 1.0296791168}, {"text": "Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery  Agreement with Pfizer", "labels": 1.0296791168}, {"text": "Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer", "labels": 1.0296791168}, {"text": "Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release As Treatment For Patients With Fibromyalgia", "labels": 1.0296791168}, {"text": "Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures", "labels": 0.6286412023}, {"text": "Best-Selling Author and Award-Winning Life Coach, Gail Blanke, Leads the Charge for Disease Awareness During National Chronic Obstructive Pulmonary Disease (COPD) Awareness Month", "labels": -0.4157882355}, {"text": "Amgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting", "labels": -0.4157882355}, {"text": "MULTIMEDIA: U.S. Food And Drug Administration Approves Pfizer\u2019s XELJANZ\u00ae (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate", "labels": -1.2417411347}, {"text": "Auxilium and Pfizer Will Conclude Agreement on XIAPEX\u00ae EU Collaboration", "labels": -0.9138835939}, {"text": "U.S. Food and Drug Administration Approval of XELJANZ\u00ae (tofacitinib citrate) and Invitation to Media Briefing from Pfizer", "labels": -0.9138835939}, {"text": "U.S. Food And Drug Administration Approves Pfizer\u2019s XELJANZ\u00ae (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate", "labels": -0.9138835939}, {"text": "Bristol-Myers Squibb and Pfizer Announce New Data on Stroke Prevention in Atrial Fibrillation to be Presented at American Heart Association 2012 Scientific Sessions", "labels": -1.0998023147}, {"text": "Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS\u00ae and Portola\u2019s Universal Factor Xa Inhibitor Antidote PRT4445", "labels": -1.0998023147}, {"text": "Pfizer Reports Third-Quarter 2012 Results", "labels": -4.4806317713}, {"text": "Grantmakers In Aging Receives $1.3 million from the Pfizer Foundation to Boost \u2018Age-friendly\u2019 Communities", "labels": -4.4806317713}, {"text": "Pfizer Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to November 1, 2012 Due To Expected Severe Weather Conditions", "labels": -4.4806317713}, {"text": "Pfizer Declares A 22-Cent Fourth-Quarter 2012 Dividend", "labels": -0.1572750935}, {"text": "Pfizer\u2019s XALKORI\u00ae Receives Conditional Marketing Authorization from the European Commission for the Treatment of Adults with Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU", "labels": 1.3276071344}, {"text": "Pfizer To Acquire NextWave Pharmaceuticals, Inc.", "labels": -1.9452169278}, {"text": "Pfizer Consumer Healthcare Responds to PHS II Findings with Statement and Centrum\u00ae Silver\u00ae Multivitamin B-roll and Photo Assets", "labels": 0.6912154417}, {"text": "Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA\u00ae (axitinib) In Treatment-Na\u00efve Patients With Advanced Renal Cell Carcinoma", "labels": 0.5805131081}, {"text": "New Study With CHANTIX\u00ae/CHAMPIX\u00ae (varenicline) Tablets Suggests Favorable Benefit-Risk Profile In Adult Smokers With Major Depressive Disorder", "labels": 2.4418472765}, {"text": "Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02:", "labels": -0.8758155814}, {"text": "New Report Reveals Programs That Promote Healthy Ageing Can Help Reduce Rising Health Costs1", "labels": -0.5961792625}, {"text": "Pfizer Announces Top-Line Results Of Prevenar 13\u00ae Phase 3 Trial In Adults 18 To 49 Years Of Age", "labels": 0.9467587382}, {"text": "ELIQUIS\u00ae (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding", "labels": 1.2738561388}, {"text": "FDA Acknowledges Receipt of Resubmission of the ELIQUIS\u00ae (apixaban) New Drug Application to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation", "labels": 0.2003251361}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of October 30 Conference Call With Analysts", "labels": 1.1716988343}, {"text": "ELIQUIS\u00ae (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation", "labels": 1.5905186021}, {"text": "Pfizer Announces Data For Investigational Compound Tofacitinib In Rheumatoid Arthritis To Be Presented At The American College Of Rheumatology 2012 Annual Meeting", "labels": 1.3744063043}, {"text": "Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress", "labels": 1.3744063043}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -1.0083991566}, {"text": "Pfizer Recognized by Carbon Disclosure Project for Carbon Performance", "labels": -1.0083991566}, {"text": "Pfizer And Hisun Announce Launch Of Hisun-Pfizer Pharmaceuticals Co., Ltd.", "labels": 0.3710866572}, {"text": "Pfizer and Waste Management Launch Online Pharmaceutical Disposal Guide", "labels": 0.3710866572}, {"text": "Pfizer And Hisun Announce Launch Of Hisun-Pfizer Pharmaceuticals Co., Ltd.", "labels": 0.3710866572}, {"text": "World Health Organization Grants Expansion To The Prequalification For Prevenar 13 To Include Adults 50 Years Of Age And Older", "labels": -0.1240934223}, {"text": "Pfizer Settles Patent Litigation with Mylan Covering Detrol LA\u00ae", "labels": 0.5775217904}, {"text": "U.S. Food and Drug Administration Approves BOSULIF\u00ae (bosutinib) for Patients with Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML)", "labels": 0.5434307755}, {"text": "Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference", "labels": 0.5434307755}, {"text": "Pfizer Receives EU Marketing Authorization for INLYTA\u00ae (Axitinib)", "labels": 0.5434307755}, {"text": "VLST Corporation Announces In-licensing Agreement with  Pfizer for Anti-CD40 Monoclonal Antibody", "labels": -0.4204810716}, {"text": "Spiriva\u00ae HandiHaler\u00ae (tiotropium bromide inhalation powder) and COPD Data to be Presented at the 2012 European Respiratory Society (ERS) Congress", "labels": -0.0419278088}, {"text": "Pfizer Announces Conclusion of Consent Solicitation For $22.5 Million of Debt", "labels": -0.2935009934}, {"text": "Pfizer Announces Successful Consent Solicitation Results For Three Series Of Debt", "labels": 0.9995869553}, {"text": "U.S. Food And Drug Administration Extends Action Date For Tofacitinib New Drug Application By Three Months", "labels": -0.0844459816}, {"text": "ELIQUIS\u00ae (apixaban) Data Analyses To Be Presented At European Society of Cardiology Congress 2012", "labels": -0.0844459816}, {"text": "Pfizer Commences Consent Solicitation for Amendments to Pharmacia Indentures", "labels": 0.1665703126}, {"text": "Pfizer And Astrazeneca Enter Into Agreement For Over-The-Counter Nexium", "labels": 0.7089383535}, {"text": "Zoetis\u2122 Files IPO Registration Statement", "labels": 0.7089383535}, {"text": "Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC)", "labels": 0.459499274}, {"text": "Nodality Enters into a Multi-Year Strategic  Collaboration with Pfizer in Autoimmune Disease", "labels": 0.459499274}, {"text": "Pfizer Reduces Its Greenhouse Gas Emissions by 20 Percent", "labels": 0.6702778333}, {"text": "Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations", "labels": -0.7133749839}, {"text": "Pfizer Announces Co-Primary Clinical Endpoints Not Met In Second Phase 3 Bapineuzumab Study In Mild-To-Moderate Alzheimer\u2019s Disease Patients Who Do Not Carry The Apoe4 Genotype", "labels": -2.106148194}, {"text": "Summertime Shines a Light on the Need for Vitamin D", "labels": -2.106148194}, {"text": "Study Shows Toviaz Is Effective In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder After Suboptimal Response To Detrol LA", "labels": 1.9357650605}, {"text": "Pfizer Announces Positive Top-Line Results From The ORAL Start Phase 3 Study Of Tofacitinib In Rheumatoid Arthritis", "labels": 1.0393321673}, {"text": "Pfizer Reports Second-Quarter 2012 Results", "labels": 1.1230593362}, {"text": "Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab Phase 3 Program", "labels": -0.3849168429}, {"text": "Pfizer Reports Top-Line Results of EU Post-Authorization Safety and Efficacy Study of Lyrica\u2019s Discontinuation Effects In Patients with Generalized Anxiety Disorder", "labels": -0.3849168429}, {"text": "Pfizer Reports Top-Line Results of Study of Lyrica\u2019s Effect on Male Reproduction Conducted as a Post-Approval Commitment Required by the U.S. Food and Drug Administration", "labels": -0.3849168429}, {"text": "Pfizer\u2019s Crizotinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Adults With Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer In The EU", "labels": 0.421938484}, {"text": "Pfizer and Northwestern University Win LYRICA\u00ae Patent Case in Delaware District Court", "labels": 0.421938484}, {"text": "European Medicines Agency Accepts Regulatory Submission For Bazedoxifene/Conjugated Estrogens For The Treatment Of Symptoms Associated With Menopause And Osteoporosis", "labels": 1.1344447416}, {"text": "VERASTEM ACQUIRES CLINICAL-STAGE FAK INHIBITOR FROM PFIZER", "labels": 1.2351213236}, {"text": "Pfizer Declares A 22-Cent Third-Quarter 2012 Dividend", "labels": 1.6086923676}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 31 Conference Call with Analysts", "labels": 1.7380039507}, {"text": "Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS\u00ae (apixaban)", "labels": 1.7380039507}, {"text": "EMA Adopts Opinion On Taliglucerase Alfa Marketing Authorization Application", "labels": -0.1320062237}, {"text": "FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review", "labels": -0.7079508741}, {"text": "Pfizer Statement Regarding Prevnar 13\u00ae Receiving ACIP Recommendation for Prevention of Pneumococcal Disease in Adults With Immunocompromising Conditions", "labels": -0.7079508741}, {"text": "Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI\u00ae (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": 0.6164747647}, {"text": "FDA Issues Complete Response Letter For Pfizer\u2019s Tafamidis Meglumine New Drug Application", "labels": 0.6164747647}, {"text": "Have Americans Reached a New Era of Optimism about Aging?", "labels": 0.6164747647}, {"text": "Pfizer Provides Update On Animal Health Strategic Alternatives Review Process", "labels": 1.0027427169}, {"text": "Pfizer\u2019s Axitinib Receives Positive Opinion from the Committee for Human Medicinal Products for the Second-line Treatment of Advanced Kidney Cancer in the EU", "labels": -0.0903578204}, {"text": "FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine, Pfizer\u2019s Novel Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)", "labels": -1.0840332679}, {"text": "Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units", "labels": -1.7655252653}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 3 Pfizer Analyst and Investor Meeting at ASCO", "labels": -1.7655252653}, {"text": "Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients", "labels": -0.2215378243}, {"text": "Pfizer Provides Topline Results From Phase 3 Study Of Torisel\u00ae As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC)", "labels": 0.3533418778}, {"text": "Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting", "labels": -0.7174827285}, {"text": "Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference", "labels": -0.2207820509}, {"text": "FDA Arthritis Advisory Committee Recommends Approval of Tofacitinib for Adult Patients with Moderately to Severely Active Rheumatoid Arthritis", "labels": 3.3289563839}, {"text": "Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ\u00ae (desvenlafaxine) 50 mg/day For The Treatment Of Major Depressive Disorder In Adults", "labels": 0.8028932648}, {"text": "Pfizer Stops Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Neuropathic Pain Associated With HIV Neuropathy", "labels": -1.2958305589}, {"text": "Pfizer Reports Top-Line Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy", "labels": -1.2958305589}, {"text": "Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO\u2122 (taliglucerase alfa) For The Treatment Of Gaucher Disease", "labels": 0.132388854}, {"text": "Pfizer Inc. Issues Statement Regarding Pending Court Case", "labels": -1.0535563405}, {"text": "Pfizer Reports First-Quarter 2012 Results", "labels": -1.0535563405}, {"text": "Pfizer Hosts Annual Meeting Of Shareholders", "labels": 0.9099058864}, {"text": "The Advil\u00ae Congestion Relief Project Visits St. Louis To Expand Building Space For More Access To Local Family Social Service Program", "labels": 2.1415872732}, {"text": "Quark Pharmaceuticals Announces Phase 2a Study of  PF--04523655 (PF-655) in Patients with Moderate and Advanced OpenAngle Glaucoma (OAG", "labels": 1.148967436}, {"text": "The Advil\u00ae Congestion Relief Project Visits Dayton To Relieve Community Center Congestion Allowing More Students To Participate In Local Mentorship Program", "labels": 0.132995528}, {"text": "Pfizer Invites Public To Listen To Webcast Of April 26 Annual Meeting Of Shareholders", "labels": 0.132995528}, {"text": "The Advil\u00ae Congestion Relief Project Visits Dayton To Relieve Community Center Congestion Allowing More Students To Participate In Local Mentorship Program", "labels": 0.537189706}, {"text": "ADDING MULTIMEDIA The Advil\u00ae Congestion Relief Project Relieves Transportation Congestion in Albany to Help Get Students to Afterschool Programs", "labels": -0.9153162141}, {"text": "\u201cMasterChef\u201d Judge Joe Bastianich Cooks With \u201cHeart\u201d At New Chicago Walgreens Flagship Store", "labels": -0.3638344919}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of May 1 Conference Call With Analysts", "labels": 0.5355103042}, {"text": "Pfizer to Present New Data Highlighting Ongoing Research at 2012 Meeting of the American Association for Cancer Research", "labels": 2.4444006059}, {"text": "Data on ELIQUIS\u00ae (apixaban) for the Prevention of Stroke in Atrial Fibrillation To Be Presented At American College of Cardiology\u2019s 61st Annual Scientific Session", "labels": -0.4601517525}, {"text": "Biocon And Pfizer Conclude Commercialization Agreement", "labels": 2.4534408566}, {"text": "Biocon And Pfizer Conclude Commercialization Agreement", "labels": 2.4534408566}, {"text": "Pfizer\u2019s Prevnar 13\u00ae Shown to be Immunogenic in Older Children and Adolescents", "labels": 2.4534408566}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference", "labels": -0.1872015021}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.0473233084}, {"text": "Pfizer Acquires Alacer Corp., a Leading Vitamin Supplements Company", "labels": 2.1677562477}, {"text": "Pfizer Statement Regarding CDC\u2019s ACIP Discussion of Prevnar 13\u00ae for Use in Adults", "labels": -0.6181557388}, {"text": "Pfizer And Hisun Announce Progress On Potential Joint Venture  To Increase Access To High Quality Branded Generic Medicines", "labels": -1.2252566637}, {"text": "Pfizer And Hisun Announce Progress On Potential Joint Venture To Increase Access To High Quality Branded Generic Medicines", "labels": -1.2252566637}, {"text": "FDA Accepts Pfizer\u2019s New Drug Application for Tafamidis Meglumine, a Novel, Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)", "labels": -0.9000485787}, {"text": "Pfizer Issues Statement On Voluntary Recall", "labels": -0.6632104765}, {"text": "Pfizer Announces Voluntary Nationwide Recall Of Lo/Ovral\u00ae-28 And Norgestrel/Ethinyl Estradiol Tablets Due To Possibility Of Inexact Tablet Counts Or Out Of Sequence Tablets", "labels": -0.6632104765}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2011 Results; Updates 2012 Financial Guidance", "labels": 0.046699059}, {"text": "Private and Public Partners Unite to Combat 10 Neglected Tropical Diseases by 2020", "labels": 0.046699059}, {"text": "U.S. Food And Drug Administration Approves Pfizer\u2019s INLYTA\u00ae (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)", "labels": -0.0926974522}, {"text": "Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia", "labels": -1.3500771847}, {"text": "Alzheimer's Challenge 2012: Seeking New Tools To Help Improve Alzheimer\u2019s Care", "labels": 0.5547590574}, {"text": "KineMed announced a non-exclusive research collaboration with Pfizer for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.", "labels": 0.5547590574}, {"text": "MS LifeLines\u00ae Earns J.D. Power and Associates Call Center Certification for Customer Service Excellence in Providing Support Services to the MS Community", "labels": -1.2926999895}, {"text": "Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer\u2019s Disease", "labels": -0.0910715833}, {"text": "Ventana to collaborate with Pfizer and CST on companion  diagnostic to identify lung cancer patients with ALK gene rearrangements", "labels": -0.1826786168}, {"text": "Introducing nutritionpossible.com \u2013 A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health", "labels": 1.7320244256}, {"text": "SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma", "labels": 1.7320244256}, {"text": "PFIZER INITIATES PHASE 1 CLINICAL TRIAL FOR FVIIa HEMOPHILIA  DRUG CANDIDATE DEVELOPED BY CATALYST BIOSCIENCES", "labels": -0.6953890656}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -0.4134261686}, {"text": "Pfizer Receives FDA Approval to Extend Use of Prevnar 13\u00ae for Prevention of Pneumococcal Pneumonia and Invasive Disease in Adults 50 Years and Older", "labels": 2.1848053504}, {"text": "CollPlant to develop orthopedic product  with Pfizer", "labels": -1.0218140956}, {"text": "Karo Bio AB announced that it has entered into a research collaboration agreement with Pfizer to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.", "labels": -1.0218140956}, {"text": "Pfizer Reports Results From Three Phase 4 Studies Demonstrating EMBEDA\u00ae (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal Symptoms", "labels": 0.4160851451}, {"text": "Antares Pharma Enters Licensing Agreement With Pfizer Consumer Healthcare", "labels": 1.7066358341}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts", "labels": 1.5377382572}, {"text": "Pfizer Announces FDA Acceptance For Review Of New Drug Application For Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis", "labels": 1.5377382572}, {"text": "Sanofi joins Systems-based Pharmaceutics Alliance", "labels": 1.5377382572}, {"text": "Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabaline) Capsules CV In Restless Legs Syndrome", "labels": 0.3804097424}, {"text": "Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World\u2019s Poorest Countries", "labels": 0.3804097424}, {"text": "Progress of GlycoMimetics\u2019 Novel Compounds  Highlighted at 2011 Annual Meeting of the American Society of Hematology", "labels": 1.3902358141}, {"text": "New Survey Reveals Top Misperceptions Parents Have When Treating Their Child\u2019s Fever", "labels": 1.8304519091}, {"text": "Pfizer Elects CEO Ian Read As Chairman Of The Board", "labels": 1.8304519091}, {"text": "Pfizer Declares A 22-Cent First-Quarter 2012 Dividend", "labels": 1.8304519091}, {"text": "Jon Bon Jovi Reveals His True Advil\u00ae Story", "labels": 1.1673465204}, {"text": "The Advil\u00ae Congestion Relief Project Tackles Congestion in Chicago, the Country\u2019s #1 City for Traffic Congestion*", "labels": 0.3466965208}, {"text": "FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be Favorable", "labels": 0.3466965208}, {"text": "Pfizer\u2019s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients", "labels": 0.5437928038}, {"text": "Pfizer Completes Acquisition of Excaliard", "labels": -0.703912122}, {"text": "KineMed announces research collaboration with Pfizer for the  advancement of novel approaches in metabolic disease", "labels": -0.703912122}, {"text": "Karo Bio Enters Collaboration With Pfizer To Discover And Develop Innovative Drugs For Autoimmune Diseases", "labels": -0.703912122}, {"text": "Pfizer Completes Acquisition of Ferrosan Consumer Health\u2019s Business", "labels": 2.3464946589}, {"text": "New Research Initiative Examines Economic Impact of Smoke-free Policies on Restaurants and Bars", "labels": 2.3464946589}, {"text": "FDA Accepts ELIQUIS\u00ae (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation", "labels": 3.0412313145}, {"text": "Pfizer to Acquire Excaliard Pharmaceuticals", "labels": -1.5873013753}, {"text": "Pfizer And MIT Break Ground On New Research Units In Kendall Square", "labels": -1.5873013753}, {"text": "Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis", "labels": -1.5873013753}, {"text": "Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program", "labels": -0.2048247113}, {"text": "Pfizer\u2019s Vyndaqel\u00ae (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)", "labels": -0.924476514}, {"text": "The Advil\u00ae Congestion Relief Project Hits the Road to Relieve Congestion in Communities", "labels": -0.924476514}, {"text": "Kathryn Joosten Speaks Out About Lung Cancer Profiles; \u2018Desperate\u2019 to Share Her Personal Lung Cancer Story to Help Others", "labels": 1.2581781495}, {"text": "New Data Presented On Phase 3 Trial Of ELIQUIS\u00ae (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness", "labels": 1.2581781495}, {"text": "Children's Hospital Boston and Pfizer enter into novel collaborative research agreement for muscular dystrophy therapeutics", "labels": 1.0611549822}, {"text": "Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency", "labels": 3.4124275383}, {"text": "Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd Annual Meeting Of The American Society Of Hematology", "labels": 3.4124275383}, {"text": "Treatment with Enbrel\u00ae (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients with Moderately Active Disease", "labels": 3.4124275383}, {"text": "Pfizer Reports Third-Quarter 2011 Results", "labels": -1.2933114711}, {"text": "Pfizer Completes Acquisition Of Icagen", "labels": -3.1671896457}, {"text": "Pfizer Completes Acquisition Of Icagen", "labels": 0.9586256743}, {"text": "Pfizer Declares A 20-Cent Fourth-Quarter 2011 Dividend", "labels": 0.9586256743}, {"text": "Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease", "labels": 4.0322755566}, {"text": "Pfizer Establishes Precision Medicine Research Collaboration With Medco", "labels": 4.0322755566}, {"text": "Peggy Fleming and the Makers of Robitussin\u00ae Provide Relief this Cold and Flu Season with a Simple Question: \"Does Your Last Name Sound Contagious?\"", "labels": 0.2593198425}, {"text": "Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search", "labels": 0.2593198425}, {"text": "Pfizer Invites Public to View and Listen to Webcast of November 6 Pfizer Analyst and Investor Meeting at ACR", "labels": -0.4769521703}, {"text": "Additional Data From Pfizer\u2019s Prevnar 13\u00ae Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America", "labels": 1.4690809694}, {"text": "Pfizer Animal Health and the Resource Foundation Expand Initiative to Increase Productivity of Small Family Farms in Latin America and India", "labels": 0.15813978}, {"text": "Findings from DiaGenic, Pfizer R&D Collaboration  Show Promising Early Results for Blood-based Test for  Early Alzheimer Disease", "labels": -1.6585995231}, {"text": "Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for Seniors", "labels": 1.6806570268}, {"text": "deCODE Announces Agreement with Pfizer to Search  for Variants in the Human Genome that Confer Risk of  Systemic Lupus Erythematosis", "labels": -0.6929990349}, {"text": "Exonhit enters into Research Agreement with Pfizer to  identify Alzheimer\u2019s disease biomarkers", "labels": 0.636611241}, {"text": "Pfizer Announces Licensing Agreement  With Puma Biotechnology, Inc. For The  Development And Commercialization Of  Neratinib, An Investigational Pan-HER  Inhibitor", "labels": 3.7849730834}, {"text": "Lpath Granted Two Additional U.S. Patents Related to  iSONEP and ASONEP Drug Programs", "labels": 3.7849730834}, {"text": "Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor", "labels": 3.7849730834}, {"text": "Medimmune'in(Licenses'cancer'immunotherapy'tremelimumab'from'pfizer", "labels": -0.5685250434}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts", "labels": -0.5685250434}, {"text": "Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony", "labels": -2.4812341964}, {"text": "Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND\u00ae (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis", "labels": -0.6221864654}, {"text": "The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online", "labels": 1.2236190413}, {"text": "International Structural Genomics Consortium Announces $48.9 MILLION in Additional Funding to  Continue the Search for New Medicines", "labels": 1.2236190413}, {"text": "Even Famous Faces Have an Advil\u00ae Story to Share", "labels": -0.6876666239}, {"text": "New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia", "labels": -3.4305688292}, {"text": "Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.", "labels": 1.6447658607}, {"text": "Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.", "labels": 2.5095925567}, {"text": "Pfizer to Present Clinical Data from Oncology Portfolio at the 2011 European Multidisciplinary Cancer Congress", "labels": 2.5095925567}, {"text": "Lpath Initiates Dosing of iSONEP in First of Two Proof-ofConcept Trials", "labels": -1.8082461056}, {"text": "Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China", "labels": -3.2822732483}, {"text": "Introducing ProNutrients\u2122, A New Line Of Dietary Supplements From The Makers Of Centrum", "labels": -3.2822732483}, {"text": "Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting", "labels": -0.9032814906}, {"text": "Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference", "labels": -0.9032814906}, {"text": "Pfizer Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering Period", "labels": 4.103085093}, {"text": "Pfizer Extends Tender Offer To Acquire Icagen, Inc.", "labels": 0.160856196}, {"text": "Pfizer Signs Agreement With MIT For Future Cambridge Research Center", "labels": -2.4377012919}, {"text": "Jennewein Biotechnologie and Pfizer Nutrition Collaborate  on Human Milk Components", "labels": 0.6355907839}, {"text": "FDA Approval of XALKORI (crizotinib) and Invitation to Media Briefing from Pfizer", "labels": 0.6355907839}, {"text": "ELIQUIS\u00ae (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial", "labels": 0.6355907839}, {"text": "U.S. Food And Drug Administration Approves Pfizer\u2019s XALKORI\u00ae (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer", "labels": 5.5614771732}, {"text": "Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban At European Society of Cardiology Congress 2011", "labels": 1.4254722151}, {"text": "Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies", "labels": -4.0090441316}, {"text": "QIAGEN and Pfizer partner to develop  companion diagnostic for novel  compound in global clinical trials for lung Cancer", "labels": 1.2979990763}, {"text": "Pfizer Wins Viagra Patent Trial", "labels": 0.7100028043}, {"text": "Pfizer Expands California Centers For Therapeutic Innovation Five Year Partnership With UC San Diego Health Sciences To Accelerate Drug Discovery and Development", "labels": 2.7840526751}, {"text": "Biotica regains worldwide rights to its  rapamycin analogue program", "labels": -3.8018446968}, {"text": "Dana Delany Partners with Caltrate\u00ae to Celebrate Women and How They Move the World Every Day through Their Amazing Strength and Contributions", "labels": -3.8018446968}, {"text": "NCCN Receives $2M Educational Grant from Pfizer to Support Tailored Quality Improvement Plans at Leading Cancer Centers", "labels": -3.8018446968}, {"text": "Pfizer Reports Second-Quarter 2011 Results", "labels": -7.1664957195}, {"text": "Pfizer Completes Sale Of Capsugel Business To KKR", "labels": -7.1664957195}, {"text": "Pfizer Provides U.S. Regulatory Update on Prevnar 13\u00ae for Use in Adults 50 Years and Older", "labels": -1.0520464187}, {"text": "Pfizer To Acquire Icagen", "labels": 1.2562473916}, {"text": "Pfizer To Explore Strategic Alternatives  For Its Animal Health And Nutrition  Businesses", "labels": -2.3810313149}, {"text": "Pfizer To Explore Strategic Alternatives For Its Animal Health And Nutrition Businesses", "labels": -2.7186784171}, {"text": "Positive Top-Line Results For Pfizer\u2019s Lyrica In Phase 3 Study Of Patients With Fibromyalgia In Japan", "labels": 0.4812349055}, {"text": "A prototype Handheld Device that Analyses DNA to Predict How  Patients May Respond to their Prescription Medication has  Performed Well in a Preliminary Pilot Study, Researchers  Announce Today.", "labels": 0.4812349055}, {"text": "Cell Signaling Technology, Inc. Grants a Patent License  to Pfizer", "labels": 0.4812349055}, {"text": "Pfizer Affirms CHANTIX/CHAMPIX as Important Treatment Option for Smokers Wanting to Quit", "labels": 0.4812349055}, {"text": "Pfizer and ChemRar High Tech Center Announce Plans to Explore Innovative Medical Research and Development Partnership in Russia", "labels": 2.4673060129}, {"text": "Pfizer Nutrition Data Demonstrate that Appropriate Early Child Nutrition May Be Linked to Long-Term Health Outcomes in At-Risk Populations and Picky Eaters", "labels": 2.4673060129}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts", "labels": 2.4673060129}, {"text": "Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma", "labels": 2.1897989484}, {"text": "Pfizer Announces Data Presentations For Investigational Compounds In Its Lung Cancer Portfolio", "labels": 2.1897989484}, {"text": "FDA Complete Response Letter Received for REMOXY", "labels": -4.183250551}, {"text": "Pfizer Declares A 20-Cent Third-Quarter 2011 Dividend", "labels": -4.183250551}, {"text": "ELIQUIS\u00ae (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study", "labels": 1.4528013237}, {"text": "Pfizer\u2019s Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury", "labels": 1.6642023915}, {"text": "Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII", "labels": 1.6642023915}, {"text": "Pfizer Injectables Adds Doxorubicin Hydrochloride Injection, USP to Its Portfolio of Off-Patent Oncology Products", "labels": -0.790517331}, {"text": "pSivida Announces Phase I/II Clinical Study Evaluating  Bioerodible, Sustained Release Latanoprost Device in Ocular  Hypertension and Glaucoma", "labels": -1.7830841177}, {"text": "Lpath Granted 22nd Patent Related to Lipidomics-Based Drug  Development Program", "labels": -2.5857972179}, {"text": "Pfizer Recognized By CIO Magazine As One Of The CIO 100 Award Honorees", "labels": -0.5783033553}, {"text": "Boston\u2019s Top Academic Medical Centers Join Pfizer\u2019s Centers For Therapeutic Innovation", "labels": -0.5783033553}, {"text": "Pfizer Launches \u201cMigraines at Work\u201d Web Site to Educate Employers and Workers about the Condition", "labels": -1.2572689639}, {"text": "Pfizer Conducts First \u201cVirtual\u201d Clinical Trial Allowing Patients to Participate Regardless Of Geography", "labels": -1.2572689639}, {"text": "Pfizer to Announce New Boston-Area Research Partnerships Wednesday, June 8, 2011 2:00 p.m.", "labels": -0.3857265475}, {"text": "Pfizer and Hisun Sign MOU to Increase  Access to Quality and Low-Cost  Medicines for Patients in China", "labels": -0.9117065495}, {"text": "Clovis Oncology, Inc. Receives License for Worldwide  Development and Commercialization Rights to Pfizer\u2019s Oral  and IV PARP Inhibitor PF-01367338", "labels": -0.9117065495}, {"text": "Pfizer and Hisun Sign MOU to Increase Access to Quality and Low-Cost Medicines for Patients in China", "labels": -1.6190492475}, {"text": "Pfizer Files For European Regulatory Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma", "labels": 0.2375370114}, {"text": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference", "labels": 0.2375370114}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 6 Pfizer Analyst and Investor Meeting at ASCO", "labels": 0.2375370114}, {"text": "Pfizer Announces New Strategic Partnerships With ICON And PAREXEL International Corporation", "labels": 2.6315625422}, {"text": "Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel\u00ae (etanercept) for Patients with Chronic Inflammatory Conditions", "labels": 1.347442937}, {"text": "Pfizer Announces Detailed Results Of ORAL Sync Showing Investigational Compound Tofacitinib Reduces Signs And Symptoms And Improves Physical Function In Patients With Moderate-To-Severe Active Rheumatoid Arthritis, With Results Seen As Early As Two Weeks", "labels": 1.347442937}, {"text": "Adding Inspra\u00ae (eplerenone) To Standard Therapy Reduces The Incidence Of New Onset Atrial Fibrillation/Flutter (AF/F) In Patients With Systolic Heart Failure, Sub-Analysis Shows", "labels": 0.1461855944}, {"text": "SUTENT\u00ae Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors", "labels": -1.8455374852}, {"text": "ELIQUIS\u00ae (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement", "labels": -1.8455374852}, {"text": "Pfizer Presents New Phase 3 Data Showing Axitinib Significantly Extended Progression-Free Survival Compared With Sorafenib In Patients With Previously-Treated Advanced Renal Cell Carcinoma", "labels": -0.3804219982}, {"text": "Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare", "labels": 1.4191433679}, {"text": "Pfizer To Present New Research From Fifteen Compounds Highlighting Multiple Approaches To Targeting Cancer At 2011 ASCO Annual Meeting", "labels": 1.4191433679}, {"text": "Pfizer Animal Health And American Humane Association Partner To Conduct Research On The Power Of The Human-Animal Bond In Pediatric Cancer Patients", "labels": 0.574278071}, {"text": "Foundation for the NIH Launches Trial to  Develop Diabetes Diagnostic Tools", "labels": 0.574278071}, {"text": "Cellzome to Study Epigenetic Factors  with Neusentis", "labels": 0.574278071}, {"text": "Alzheimer\u2019s Association Salutes Advocate And Mountaineer Now Climbing Everest As Part Of The 7 Summits Climb For Alzheimer\u2019s", "labels": 1.5819866469}, {"text": "Staphylococcus aureus Investigational Vaccine Elicits a Positive  Immune Response in Phase 1 Study", "labels": 1.5819866469}, {"text": "Pfizer\u2019s Prevnar 13\u00ae Meets All Study Endpoints In Two Pivotal Phase 3 Trials In Adults Aged 50 And Older Presented Today", "labels": 1.5819866469}, {"text": "The European Commission Approves Pfizer\u2019s Revatio\u00ae (sildenafil) for the Treatment of Pulmonary Arterial Hypertension in Children", "labels": -0.1961474306}, {"text": "Oxford BioMedica Broadens 5T4  Antibody Collaboration With Pfizer", "labels": -0.1961474306}, {"text": "PRISTIQ\u00ae (desvenlafaxine) Extended Release Tablets Shown To Significantly Reduce Number And Severity Of Moderate-To-Severe Hot Flashes Associated With Menopause", "labels": -1.598878637}, {"text": "Pfizer Reports First-Quarter 2011 Results", "labels": -3.4246340483}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference", "labels": -3.4246340483}, {"text": "Centrum\u00ae multivitamins and Celebrity Personal Trainer Harley Pasternak Share Star-Tested Secrets to Shape up for Summer", "labels": -3.4246340483}, {"text": "Pfizer Hosts Annual Meeting of Shareholders", "labels": 1.5259842348}, {"text": "Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis", "labels": 2.7364692823}, {"text": "Pfizer Launches New Advanced GOLD Range Of Early Child Nutrition Products", "labels": 2.2782001948}, {"text": "Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005", "labels": -1.6385176793}, {"text": "Pfizer Invites Public To Listen To Webcast Of April 28 Annual Meeting Of Shareholders", "labels": -1.6385176793}, {"text": "Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership", "labels": -4.4972449465}, {"text": "Pfizer Announces Top-Line Results Of Third Phase 3 Clinical Trial Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis", "labels": 0.43832998}, {"text": "Tafamidis, An Oral, Investigational Compound For The Treatment Of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Sustained A Slowing Of Disease Progression Over 30 Months", "labels": -0.6353910225}, {"text": "FDA Advisory Committee Finds Data Support The Favorable Benefit-Risk Profile Of SUTENT\u00ae In Unresectable Pancreatic Neuroendocrine Tumors (NET)", "labels": -0.6353910225}, {"text": "Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease", "labels": -0.4398631278}, {"text": "Zacharon Pharmaceuticals Announces Research and Development  Collaboration with Pfizer to Develop Drugs for Multiple Rare Disorders", "labels": 0.8797711371}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of May 3 Conference Call With Analysts", "labels": -0.9857590431}, {"text": "Rigel Assumes Development Responsibility", "labels": -0.4889952991}, {"text": "Pfizer to Sell Capsugel to KKR", "labels": -0.4889952991}, {"text": "Pfizer and Shanghai Pharmaceutical Sign  Memorandum of Understanding for  Potential Strategic Partnership", "labels": -0.4889952991}, {"text": "Pfizer Receives Refusal To File Letter From U.S. FDA On Tafamidis New Drug Application", "labels": -0.4889952991}, {"text": "Pfizer to Sell Capsugel to KKR", "labels": -0.4889952991}, {"text": "Pfizer Oncology To Present Broad Array Of New Pre-Clinical And Clinical Data From Early And Late Stage Compounds", "labels": 0.5397291236}, {"text": "Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010", "labels": 0.5397291236}, {"text": "Greenstone Announces Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling", "labels": -0.1962821104}, {"text": "Pfizer Animal Health Continues to Invest in the Future of Veterinarians with Announcement of 2011 Veterinary Scholarship Recipients", "labels": 1.7199032783}, {"text": "SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation, New Study In NEJM Shows", "labels": 2.06892511}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference", "labels": -1.2913146905}, {"text": "Pfizer Announces Primary Endpoints Met In Second Phase 3 Clinical Trial Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis", "labels": 1.3733507809}, {"text": "Charles River Announces Agreement To Supply Pfizer\u2019s Genetically Modified Research Models", "labels": 1.3733507809}, {"text": "World-Class Professional Golfer Phil Mickelson Launches \u201cOn Course with Phil\u201d for People with Certain Inflammatory Joint and Skin Conditions", "labels": -0.8337767679}, {"text": "King Pharmaceuticals, Inc. Announces Final Results of Its Offer to Purchase Convertible Notes", "labels": -0.8337767679}, {"text": "Pfizer Completes Acquisition Of King Pharmaceuticals, Inc.", "labels": 0.9926720262}, {"text": "Pfizer Announces Updated, Interactive Development Pipeline", "labels": 0.9926720262}, {"text": "XIAPEX\u00ae (Collagenase Clostridium Histolyticum) Authorized in the European Union (EU) For Dupuytren\u2019s Contracture", "labels": 0.9926720262}, {"text": "NH Citizens Health Initiative to Premiere Mini-Documentaries on NH Multi-Stakeholder Patient Centered Medical Home Pilot", "labels": 0.6348918748}, {"text": "U.S. Supreme Court Decision In Bruesewitz V. Wyeth A Win For Public Health", "labels": -0.6396694004}, {"text": "New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin in Reducing Stroke and Systemic Embolism in Patients with Atrial Fibrillation Unsuitable for Warfarin Therapy", "labels": -0.9558936175}, {"text": "Pfizer To Acquire Ferrosan\u2019s Consumer Healthcare Business", "labels": -0.5741158803}, {"text": "Enbrel\u00ae (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis", "labels": 2.2798088769}, {"text": "New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan", "labels": 2.2798088769}, {"text": "National Family Caregivers Association Supports Advocate in His Mission to Raise Awareness of the Burden of Alzheimer\u2019s Disease", "labels": 0.4173492986}, {"text": "Pfizer Announces New $5 Billion Share Repurchase Program", "labels": 5.3590230251}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2010 Results; Provides 2011 Financial Guidance and Updates 2012 Financial Targets", "labels": 5.3590230251}, {"text": "Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.", "labels": 5.3590230251}, {"text": "Dr. Yvonne Greenstreet Joins Pfizer As Senior Vice President And Head Of Medicines Development, Specialty Care Business Unit", "labels": 5.3590230251}, {"text": "Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman Of The Year", "labels": -1.2121574241}, {"text": "Pfizer Announces HSR Clearance for the Acquisition of King Pharmaceuticals", "labels": -1.2121574241}, {"text": "Pfizer Inc and Progenics Alert Physicians and Patients to Information Related to Triad Group Alcohol Prep Products Included In U.S. RELISTOR Kit Packaging", "labels": -1.3616536812}, {"text": "Pfizer Announces Seven Of New York City\u2019s Top Research Hospitals Join Global Centers For Therapeutic Innovation", "labels": 0.757979915}, {"text": "Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc. to January 28, 2011", "labels": 0.2178454756}, {"text": "Pfizer Inc. UK Regulatory Announcement: Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc. to January 28, 2011", "labels": 0.2178454756}, {"text": "Pfizer Initiates Rolling Submission For A New Drug Application In The U.S. For Its Fast-Tracked Investigational Compound Crizotinib (PF-02341066) For Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": 1.0343105913}, {"text": "Pfizer Inc. UK Regulatory Announcement: Pfizer Initiates Rolling Submission For A New Drug Application In The U.S. For Its Fast-Tracked Investigational Compound Crizotinib (PF-02341066) For Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer", "labels": 1.0343105913}, {"text": "Pfizer Invites Public to View and Listen to Webcast of February 1 Conference Call with Analysts", "labels": 1.7669993748}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 1.7669993748}, {"text": "Pfizer Animal Health Completes Acquisition of Synbiotics Corporation", "labels": 1.6120006723}, {"text": "Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc.", "labels": 0.9871885881}, {"text": "Pfizer Declares A 20-Cent First-Quarter 2011 Dividend", "labels": -0.2922278016}, {"text": "Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman", "labels": -0.2922278016}, {"text": "Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine", "labels": -0.2922278016}, {"text": "Pfizer Stops Clinical Trials of Thelin\u00ae and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety", "labels": 1.4101244078}, {"text": "Angie Harmon and Children's Advil\u00ae Invite Families to Sing Away the Cold and Flu Season Blues", "labels": 0.4174294609}, {"text": "National Initiative Urges 10 Million At-Risk Boomers to 'Face Alzheimer's'", "labels": 0.4174294609}, {"text": "Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia", "labels": 0.4174294609}, {"text": "Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer", "labels": 0.4174294609}, {"text": "Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia", "labels": 0.5353876808}, {"text": "AVERROES Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy", "labels": 1.1983283701}, {"text": "Centrum\u00ae and Molly Shannon Search for 'America's Most Amazingly Energized Woman' This Holiday Season", "labels": 1.1983283701}, {"text": "SUTENT\u00ae Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)", "labels": 1.1983283701}, {"text": "Caltrate\u00ae Soft Chews Offer A New and Delicious Way to Help Americans Reach Their Recommended Daily Calcium and Vitamin D Intake", "labels": -0.6748435313}, {"text": "Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology", "labels": -0.6748435313}, {"text": "Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease", "labels": -0.6748435313}, {"text": "Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc.", "labels": -0.5431348279}, {"text": "Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)", "labels": 1.4880451914}, {"text": "APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued", "labels": 1.4880451914}, {"text": "Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco", "labels": -0.8495477229}, {"text": "Pfizer Launches New Advil\u00ae Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds", "labels": -2.2288708867}, {"text": "Adding INSPRA\u00ae (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows", "labels": -2.2288708867}, {"text": "Lower Protein in Infant Formula Supports Growth Rate Similar to Breast Milk, New Study Shows", "labels": -1.4259824108}, {"text": "Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent to Raise Awareness of Growing Prevalence and Burden of Alzheimer's Disease", "labels": -0.4120016869}, {"text": "In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function", "labels": -0.4120016869}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 0.282998473}, {"text": "Pfizer Reports Third-Quarter 2010 Results", "labels": -1.031531917}, {"text": "Pfizer's Lyrica\u00ae (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan", "labels": 0.057420326}, {"text": "Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend", "labels": 0.057420326}, {"text": "Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)", "labels": 0.9675609154}, {"text": "Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.", "labels": -0.74282151}, {"text": "New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia", "labels": 0.9642361452}, {"text": "Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil", "labels": 0.0566145362}, {"text": "Biocon and Pfizer Enter Into Global Commercialization Agreement", "labels": -1.9551553384}, {"text": "Alzheimer's Disease Caregivers Identify Memory Loss, Personal Safety and Confusion as Top Three Concerns Related to Progression of Their Loved One's Disease", "labels": 0.3963651432}, {"text": "Pfizer to Acquire King Pharmaceuticals, Inc.", "labels": 0.1144028653}, {"text": "Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets", "labels": 0.8055212407}, {"text": "Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis", "labels": 0.8055212407}, {"text": "Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A", "labels": 1.6897814934}, {"text": "Pfizer Reports Second-Quarter 2010 Results", "labels": 7.2215625193}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -1.1999900552}, {"text": "Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval for New Higher-Dose Aricept\u00ae (donepezil HCl) 23 mg Tablet for the Treatment of Moderate-to-Severe Alzheimer\u2019s Disease", "labels": -0.2057116911}, {"text": "Pfizer To Offer Free Public Access To Mental Health Assessment Tools To Improve Diagnosis And Patient Care", "labels": 1.7555459102}, {"text": "Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program; Some Studies Continue In Areas Of Unmet Medical Need", "labels": -0.4810765948}, {"text": "Pfizer And SMC Collaborate On Liver Cancer", "labels": -1.0782125282}, {"text": "New Research Presented At Alzheimer\u2019s Association International Conference On Alzheimer's Disease Indicates Alzheimer\u2019s Disease May Lead To Increased Comorbid Conditions And Economic Burden", "labels": 0.4056997664}, {"text": "Pfizer To Present More Than 40 Abstracts On Pre-Clinical, Clinical And Outcomes Research At Alzheimer's Association International Conference On Alzheimer\u2019s Disease", "labels": 3.4412620462}, {"text": "Pfizer Strengthens Manufacturing Capabilities In Asia With Expansion Of Singapore Nutrition Plant", "labels": 1.9835951313}, {"text": "Pfizer Announces European Union Approval Of A New Form Of Lipitor (atorvastatin) For Use In Children", "labels": 1.9835951313}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of August 3 Conference Call With Analysts", "labels": -2.8711668377}, {"text": "Pfizer Declares An 18-Cent Third-Quarter 2010 Dividend", "labels": -3.5961535127}, {"text": "Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program", "labels": -1.8145220951}, {"text": "Pfizer Enters Into Agreement With Ergonex Pharma To Acquire Investigational Treatment For Pulmonary Arterial Hypertension", "labels": -2.605246288}, {"text": "Caduet Reduces 10-Year Calculated Risk Of Coronary Heart Disease, Fatal Cardiovascular Disease", "labels": -2.605246288}, {"text": "New CELEBREX\u00ae (celecoxib) Study Using Novel Endpoint, Published By The Lancet, Contributes to Knowledge Of NSAID-Associated Gastrointestinal Adverse Events", "labels": 0.3231909397}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference", "labels": -1.9931256463}, {"text": "Phase 3 Study Showed MACUGEN\u00ae Improved Vision Over Standard Of Care In Patients With Diabetic Macular Edema", "labels": -3.3746584189}, {"text": "Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions", "labels": 0.2631731041}, {"text": "Pfizer Announces EMPHASIS-HF Trial To Halt Recruitment Due To Significant Benefit Observed In Patients Treated With Inspra\u00ae (Eplerenone)", "labels": 1.6915822494}, {"text": "Pfizer Appoints Mikael Dolsten President Of Worldwide Research And Development", "labels": 1.0588981716}, {"text": "Pfizer Animal Health Expands Global Commitment To A Safe Food Supply With A New Focus On Healthy Fish", "labels": -1.4608033942}, {"text": "Pfizer Oncology To Present New Clinical Data From Ten Molecules Across Multiple Tumor Types", "labels": -3.4143392585}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference", "labels": -2.0227436052}, {"text": "Pfizer Global Manufacturing Announces Plans To Reconfigure Its Global Plant Network", "labels": -2.0227436052}, {"text": "Pfizer, Washington University Announce Groundbreaking Collaboration", "labels": -2.4667525199}, {"text": "Pfizer Animal Health Announces First Recipients of New $2 Million Veterinary Scholarship Program", "labels": -1.3739750181}, {"text": "Pfizer Reports First-Quarter 2010 Results; Reaffirms 2010 Financial Guidance", "labels": 2.6651541015}, {"text": "World Bank And Pfizer Announce Initiative To Help Improve Healthcare Delivery In Developing Countries", "labels": 2.318676838}, {"text": "Pfizer And Medicines For Malaria Venture Seek To Expand Fight Against Malaria With Intermittent Preventive Treatment Option For Pregnant Women", "labels": 2.4246106029}, {"text": "Pfizer Discontinues Phase 3 Trial of Sutent\u00ae in Advanced Hepatocellular Carcinoma", "labels": 2.4246106029}, {"text": "Pfizer Hosts Annual Meeting Of Shareholders; Declares 18-Cent Second-Quarter 2010 Dividend", "labels": 2.4246106029}, {"text": "Pfizer Invites Public To Listen To Webcast Of April 22 Annual Meeting Of Shareholders", "labels": -1.4880887555}, {"text": "Stemgent and Pfizer Announce Collaboration", "labels": -1.4880887555}, {"text": "Pfizer Oncology To Present Over 30 Abstracts On Pre-Clinical And Clinical Research At The American Association For Cancer Research Annual Meeting", "labels": -0.820196533}, {"text": "Pfizer And Acacia Living Partner To Support Seniors In Living Independently", "labels": -1.8342821116}, {"text": "Pfizer Posts Details About Interactions With U.S. Physicians, Other Healthcare Professionals And Clinical Research Partners", "labels": -0.5854648863}, {"text": "Pfizer Invites Public to View and Listen to Webcast of May 4 Conference Call with Analysts", "labels": 0.3476263086}, {"text": "Pfizer Signs Long-Term Agreement To Supply Prevenar 13* To The World\u2019s Poorest Countries", "labels": 1.8739433995}, {"text": "Pfizer Animal Health Encourages Pet Owners to Consult Their Veterinarian for Safe, Effective Flea-and-Tick Control Recommendations", "labels": 3.0787046053}, {"text": "Study Shows Prevenar 13* Is Immunogenic In Young Children Previously Vaccinated With Prevenar*", "labels": -0.6391918858}, {"text": "Intensive Lipitor Therapy Was Associated With Reduced Risk Of Cardiovascular Events In Two High-Risk Patient Groups", "labels": 1.3325585467}, {"text": "Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer", "labels": -0.2341823374}, {"text": "Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint", "labels": -0.2341823374}, {"text": "ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior To Enoxaparin In The Prevention Of Venous Thromboembolism Following Knee Replacement Surgery", "labels": 0.7436799713}, {"text": "\u201cProject Runway\u2019s\u201d Tim Gunn Returns to Address Psoriasis\u2122 and Empower Patients to be Confident in Their Personal Style", "labels": -0.6924226536}, {"text": "Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer\u2019s Disease Clinical Development Program", "labels": -3.1755037863}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Investor Breakfast At Healthcare Conference", "labels": -0.0568695227}, {"text": "William Ringo, Pfizer\u2019s Senior Vice President, Worldwide Business Development, Strategy And Innovation, To Retire", "labels": -0.1139267204}, {"text": "CDC\u2019s Advisory Committee On Immunization Practices Recommends Pfizer\u2019s Prevnar 13\u2122 Vaccine For The Prevention Of Invasive Pneumococcal Disease In Infants And Young Children In The U.S.", "labels": -0.2826599569}, {"text": "Pfizer Receives FDA Approval for Prevnar 13\u2122 for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children", "labels": -0.2826599569}, {"text": "Lilly, Merck, And Pfizer Join Forces To Accelerate Research And Improve Treatment Of Lung And Gastric Cancers In Asia", "labels": -0.1684188843}, {"text": "Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness", "labels": -0.1678207071}, {"text": "QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients", "labels": -2.171486773}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2009 Results; Provides 2010 Financial Guidance and 2012 Financial Targets", "labels": -0.3945280958}, {"text": "New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas", "labels": -0.8051404153}, {"text": "Data Show Progression-Free Survival Advantage With Sutent\u00ae In Patients With Pancreatic Neuroendocrine Tumors", "labels": -5.6962053002}, {"text": "Pfizer and Auxilium Announce Commencement of European Regulatory Review of XIAFLEXTM for the Treatment of Dupuytren\u2019s Contracture", "labels": -4.2099575097}, {"text": "Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma", "labels": -0.7015686921}, {"text": "Pfizer and Strides Arcolab to Collaborate on Generic Products", "labels": -1.7204385078}, {"text": "Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference", "labels": 2.0900534068}, {"text": "Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference", "labels": 2.0900534068}, {"text": "European Commission Approves New Intravenous Formulation Of Pfizer\u2019s Revatio\u00ae (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension", "labels": 2.0900534068}, {"text": "Pfizer Provides U.S. Regulatory Update On Prevnar 13\u2122 Vaccine", "labels": -1.5942862246}, {"text": "Pfizer Discontinues A Phase 3 Trial Of Figitumumab In Non-Small Cell Lung Cancer (NSCLC) For Futility", "labels": -0.5945548982}, {"text": "Pfizer\u2019s Lyrica Receives Complete Response Letter From FDA For Generalized Anxiety Disorder Monotherapy Treatment", "labels": -0.8601991093}, {"text": "Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts", "labels": -1.1841030665}, {"text": "Despite Stresses of Today, Survey Finds Women and Men Set Health and Wellness Goals \u2013 But Sex Often Influences Success", "labels": 1.3971260489}, {"text": "FDA Approves SPIRIVA\u00ae HandiHaler\u00ae for the Reduction of COPD Exacerbations", "labels": -0.4371465726}, {"text": "Toviaz 8 Mg Was More Effective Than Detrol LA In Treating Urge Urinary Incontinence In Patients With Overactive Bladder", "labels": -0.8232887045}, {"text": "Takeda and Pfizer to Co-Promote Takeda\u2019s Actos\u00ae (Pioglitazone HCl) for the Treatment of Type 2 Diabetes in China", "labels": -0.9841447731}, {"text": "Pfizer Declares an 18-Cent First-Quarter 2010 Dividend", "labels": -0.9841447731}, {"text": "New pH1N1 Vaccine Available for Swine", "labels": -0.9841447731}, {"text": "Pfizer Inc. Affirms Confidence In Its Hormone Therapy Medicines As Important Treatment Options", "labels": -0.9841447731}, {"text": "Pfizer Announces Neratinib Data In HER2 Positive Breast Cancer", "labels": -0.9841447731}, {"text": "Prevenar 13 to provide the broadest coverage of any pneumococcal conjugate vaccine for infants and young children", "labels": -0.9289611189}, {"text": "Adele Gulfo joins Pfizer as U.S. President, Primary Care", "labels": -0.9289611189}, {"text": "Pfizer Extends Commitment to Help Unemployed Americans", "labels": -0.9289611189}, {"text": "Pfizer Announces Updated Trial Results for AROMASIN\u00ae (exemestane tablets) In Switch And Upfront Settings", "labels": 1.5830079092}, {"text": "Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System", "labels": 1.0416094635}, {"text": "CORRECTING and REPLACING Pfizer And Crown Bioscience Announce A Collaboration To Research And Develop New Treatments For Asian Cancers", "labels": 1.0416094635}, {"text": "Pfizer To Present Clinical Data From Expanded Breast Cancer Portfolio At The San Antonio Breast Cancer Symposium", "labels": -1.8388206413}, {"text": "Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher\u2019s Disease Treatment", "labels": 2.8647126755}, {"text": "Pfizer Receives FDA Approval For Geodon\u00ae (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults", "labels": 1.5795442352}, {"text": "FDA Approves Intravenous Formulation Of Pfizer\u2019s Revatio\u00ae (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension", "labels": 1.5795442352}, {"text": "FDA Advisory Committee Finds Data Support the Claim That SPIRIVA\u00ae HandiHaler\u00ae Reduces COPD Exacerbations", "labels": 1.5795442352}, {"text": "Pfizer Encourages Families To Bring Their Dogs To This Year\u2019s Holiday Celebration", "labels": 0.9939355059}, {"text": "FDA Advisory Committee Finds Data Support the Safety and Effectiveness of Prevnar 13\u2122 Vaccine for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children", "labels": 0.9939355059}, {"text": "Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases", "labels": 1.869188178}, {"text": "Pfizer Submits New Pediatric Data For Lipitor\u00ae (Atorvastatin) To The European Medicines Agency (EMEA)", "labels": 1.869188178}, {"text": "Pfizer Announces Global Research Network", "labels": 2.619562751}, {"text": "Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX\u00ae (Varenicline) Compared With Placebo", "labels": 0.5287794296}, {"text": "Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer\u2019s Disease", "labels": -0.9472911987}, {"text": "Pfizer Completes Consent Solicitation", "labels": -1.2331425085}, {"text": "Pfizer\u2019s Board Of Directors Approves Shareholder Advisory Vote On Executive Compensation", "labels": -1.2331425085}, {"text": "Pfizer Declares a 16-Cent Fourth-Quarter 2009 Dividend", "labels": -0.7536278929}, {"text": "Pfizer Reports Third-Quarter 2009 Results", "labels": 1.561627272}, {"text": "New Pfizer Animal Health is Unveiled with Acquisition of Wyeth", "labels": 1.561627272}, {"text": "CP-690,550, Pfizer\u2019s Oral JAK Inhibitor, Demonstrates Response Both Alone And In Combination With Methotrexate At 24 Weeks In Patients With Active Rheumatoid Arthritis", "labels": 1.561627272}, {"text": "Pfizer Commences Consent Solicitation for Amendments to Wyeth Indenture", "labels": 2.2509994897}, {"text": "Pfizer And Wyeth Become One: Working Together For A Healthier World\u2122", "labels": 2.2509994897}, {"text": "Pfizer Completes Acquisition Of Wyeth", "labels": 4.4733785153}, {"text": "Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau For Wyeth Acquisition", "labels": 2.7634033641}, {"text": "Pfizer Announces Settlement And License Agreement With Mylan Related To Vfend\u00ae", "labels": 2.7634033641}, {"text": "FDA Advisory Committee Recommends Approval of Pfizer\u2019s Selzentry for Use in Patients Starting HIV Therapy for the First Time", "labels": 7.0781e-06}, {"text": "Pfizer Receives Approval From Australian Competition And Consumer Commission (ACCC) For Pending Acquisition Of Wyeth", "labels": -0.1208723179}, {"text": "Pfizer Receives Approval from China\u2019s Ministry of Commerce for Pending Wyeth Acquisition", "labels": 1.9678295893}, {"text": "Frances D. Fergusson And John P. Mascotte Elected To Pfizer\u2019s Board Of Directors", "labels": 1.9678295893}, {"text": "Pfizer and Eisai Continue Aricept Collaboration", "labels": -0.2439066424}, {"text": "Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation", "labels": -2.554761473}, {"text": "New Survey of People with Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated", "labels": -2.554761473}, {"text": "Pfizer Again Named To Working Mother 100 Best Companies List", "labels": 1.5475979105}, {"text": "Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer\u2019s AROMASIN\u00ae (Exemestane Tablets)", "labels": 1.5475979105}, {"text": "Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim", "labels": 1.5475979105}, {"text": "Pfizer Commended For Leadership In Addressing Climate Change For Third Consecutive Year", "labels": 1.5475979105}, {"text": "Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents", "labels": 1.0216347552}, {"text": "Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department Of Justice Regarding Past Promotional Practices", "labels": -1.5970593019}, {"text": "Heading Back to School: Veterinarians Combine Stethoscopes with Microscopes", "labels": -1.5262087606}, {"text": "Novel Biomarkers, Including CRP, Did Not Predict Risk Of Cardiovascular Events In Patients With Heart Disease Who Were Treated With A Statin", "labels": -1.5262087606}, {"text": "Pfizer Inc Sponsors 7th Biennial U.S.\u2013Africa Business Summit", "labels": -0.119229928}, {"text": "For Sixth Consecutive Year, Pfizer Earns Highest Score In Human Rights Campaign Foundation LGBT Ranking", "labels": 0.4166665437}, {"text": "Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research", "labels": 2.9932509784}, {"text": "President Clinton, Pfizer, and Mylan Announce New Agreements to Lower Prices of Medicines for Patients with Drug-Resistant HIV in Developing Countries", "labels": -1.2032812502}, {"text": "Pfizer, Kano State Reach Settlement Of Trovan Cases", "labels": -0.3764599151}, {"text": "Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease", "labels": -0.3764599151}, {"text": "Pfizer and Fudan University Announce Joint Graduate Program in Clinical Research", "labels": -4.6983806407}, {"text": "Pfizer Announces Partnership With Shanghai Institutes For Biological Sciences For Drug Discovery Activities", "labels": -4.6983806407}, {"text": "Pfizer Reports Second-Quarter 2009 Results; Increases Full-Year 2009 Adjusted Diluted EPS(1) Guidance", "labels": 2.8355235797}, {"text": "96-Week MERIT ES Analysis Shows Efficacy Of Pfizer\u2019s HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Na\u00efve HIV Patients; Results Consistent With 48-Week Analysis", "labels": 4.2674826785}, {"text": "Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth", "labels": 1.1795653177}, {"text": "Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer\u2019s Disease At ICAD Annual Meeting", "labels": 2.396827607}, {"text": "Pfizer To Appeal Canadian Federal Court Decision On Company\u2019s Norvasc\u00ae Patent", "labels": -2.9577460592}, {"text": "Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer", "labels": -3.3839662483}, {"text": "Pfizer Invites Public to Listen to Teleconference on Important Update Related to Chantix \u00ae (varenicline)", "labels": -3.3839662483}, {"text": "Pfizer Discontinues Phase 3 Trial of Sutent\u00ae in Metastatic Colorectal Cancer", "labels": -2.4832579293}, {"text": "Pfizer Declares a 16-Cent Third-Quarter 2009 Dividend", "labels": 3.6208094303}, {"text": "Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors", "labels": 3.3920588376}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 22 Conference Call with Analysts", "labels": 4.6246127431}, {"text": "Pfizer Registration Statement Relating To Pending Wyeth Acquisition Declared Effective By SEC", "labels": 4.6246127431}, {"text": "Pfizer\u2019s Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show", "labels": 3.417617306}, {"text": "Pfizer Announces Completion Of European Debt Offering", "labels": -0.6044643491}, {"text": "FDA Approves First Canine Cancer Therapy", "labels": -0.6044643491}, {"text": "Pfizer Introduces New Treatment And Support Plan For Patients With Overactive Bladder", "labels": -2.5366968685}, {"text": "Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer", "labels": -2.5366968685}, {"text": "Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with Figitumumab", "labels": -2.5366968685}, {"text": "Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung Cancer", "labels": -0.2710138217}, {"text": "New Pfizer Data Helps to Identify Kidney Cancer Patients Who May Be Most Likely to Benefit from Treatment", "labels": -0.2710138217}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 12 Conference Call with Analysts at EULAR", "labels": -0.2710138217}, {"text": "Pfizer\u2019s Sutent is Recommended for Reimbursement for Gastrointestinal Stromal Tumor Patients by British Health Agency", "labels": -2.110261993}, {"text": "Pfizer Expands Its Generics Portfolio Through Innovative Licensing Deals, Increasing Access To Medicines For Billions Worldwide", "labels": -0.5294840033}, {"text": "Addition of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms in Patients Who Responded Only Partially to Previous GAD Treatments", "labels": -0.5294840033}, {"text": "EU Commission Approves Pfizer Animal Health\u2019s Vaccine Against Boar Taint", "labels": -0.5294840033}, {"text": "Pfizer Launches Free Medicines Program For Newly Unemployed Americans", "labels": 1.6297243278}, {"text": "Pfizer to Present New Clinical Data Highlighting Customized Treatment Approaches For Difficult-To-Treat Cancers", "labels": 1.6297243278}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 6.7452627424}, {"text": "Greg Simon, Noted Leader In Health And Science Policy, Joins Pfizer", "labels": 6.7452627424}, {"text": "Pfizer And Wisconsin Alumni Research Foundation (WARF) Sign License Agreement For Human Embryonic Stem Cells", "labels": 0.5517687114}, {"text": "Dr. Freda Lewis-Hall Joins Pfizer As Chief Medical Officer", "labels": 4.0616029472}, {"text": "Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show", "labels": 0.0748676764}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": 0.0748676764}, {"text": "Pfizer Reports First-Quarter 2009 Results; Reaffirms Full-Year 2009 Financial Guidance for Revenues and Adjusted Results(1)", "labels": 0.2240710058}, {"text": "Pfizer Supports The Global Fight Against Malaria And Commemorates World Malaria Day \u2013 \u201cCounting Malaria Out\u201d", "labels": 0.4555573277}, {"text": "Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Based Therapies", "labels": 0.4555573277}, {"text": "Pfizer Hosts Annual Meeting Of Shareholders; Declares A 16-Cent Second-Quarter 2009 Dividend", "labels": 0.4555573277}, {"text": "Pfizer and Medicines for Malaria Venture Advancing International Research Efforts in the Fight against Malaria", "labels": -1.1294786809}, {"text": "New Findings from Global Survey of Women Living with Metastatic Breast Cancer Highlight Strategies to Improve Patient Enrollment in Clinical Trials", "labels": -1.1294786809}, {"text": "Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders", "labels": -3.3284109794}, {"text": "Pfizer To Make A Tender Offer To Increase Stake In Pfizer Limited", "labels": -1.4242812264}, {"text": "Pfizer\u2019s Oncology Business Unit Appoints Vice President of Medical Affairs", "labels": -1.4242812264}, {"text": "Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition", "labels": -0.3700922899}, {"text": "Pfizer Receives Request for Additional Information from FTC Regarding Proposed Acquisition of Wyeth", "labels": 0.8752661187}, {"text": "Pfizer Becomes The First Pharmaceutical Company To Be Accredited For Protection Of Human Rights In Clinical Research", "labels": 0.8752661187}, {"text": "Pfizer Development Pipeline Shows Advances In High-Priority Disease Areas", "labels": -3.7638334727}, {"text": "Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue", "labels": 1.3072042324}, {"text": "Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix(\u00ae) (Varenicline) Compared With Placebo", "labels": -1.908955341}, {"text": "Intensive Lipitor Therapy Provided Sustained Risk Reduction Of Cardiovascular Events In Older Patients With Heart Disease", "labels": -1.908955341}, {"text": "Pfizer Announces Completion of $13.5 Billion Debt Offering", "labels": 2.4544559678}, {"text": "Pfizer\u2019s Oncology Business Unit Appoints Senior Executive to Head U.S. Region", "labels": -0.2155404968}, {"text": "Pfizer, PlaNet Finance Partner to Study Options for Expanding Access to Healthcare in China", "labels": -4.6221301205}, {"text": "Pfizer-Sponsored Prescription Savings Program - Together Rx Access\u00ae - Expands Eligibility Criteria in Response to Challenging Economic Times", "labels": -3.7226756347}, {"text": "U.S. Patent & Trademark Office Grants Reissue Patent Relating to Lipitor", "labels": -2.5946317517}, {"text": "Wide-Reaching Global Survey Reveals Majority of Women Living with Metastatic Breast Cancer Desire Increased Public Attention", "labels": 8.8720554201}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Investor Breakfast at Healthcare Conference", "labels": 5.4239387089}, {"text": "Pfizer and Bausch & Lomb to Co-Promote Products for the Treatment of Ophthalmic Conditions", "labels": -1.7691415185}, {"text": "Pfizer Expands Portfolio of Generic Medicines in the U.S. and Europe Through Licensing Agreements with Aurobindo", "labels": -1.7691415185}, {"text": "Pfizer Discontinues Development of Two Phase 3 Compounds", "labels": -0.8093973102}, {"text": "Pfizer to Publicly Disclose Payments to U.S. Physicians, Healthcare Professionals and Clinical Investigators", "labels": -7.4626500667}, {"text": "Pfizer and The Pfizer Foundation Recognize \"World Cancer Day\" Award $7 Million in Grants to Support Global Cancer Control Efforts", "labels": -3.724111666}, {"text": "Pfizer\u2019s Sutent is Recommended as First-Line Treatment for Kidney Cancer Patients by British Health Agency", "labels": 3.2474866996}, {"text": "Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease, According to New Study", "labels": 3.7499928432}, {"text": "Pfizer Discontinues Global Phase III Trial of Axitinib for Futility in Advanced Pancreatic Cancer", "labels": -1.3431949698}, {"text": "Geodon Proven Effective as Adjunctive Maintenance Treatment of Bipolar Disorder", "labels": -4.869662993}, {"text": "Pfizer Invites Public to Listen to Audio-Only Webcast of January 27 Investor Luncheon", "labels": -1.1010277643}, {"text": "MEDIA ADVISORY: Pfizer and Wyeth to Host Live Press Conference in New York", "labels": -4.1087371555}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2008 Results and 2009 Financial Guidance", "labels": -4.1087371555}, {"text": "Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company", "labels": -4.1087371555}, {"text": "Pfizer Receives FDA Complete Response Letter for Lasofoxifene", "labels": -3.3139387638}, {"text": "Stephen W. Sanger Elected to Pfizer\u2019s Board of Directors", "labels": -0.9280794677}, {"text": "U.S. Patent and Trademark Office Accepts Pfizer\u2019s Reissue Application on Lipitor Enantiomer Patent", "labels": -4.7455969734}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -2.0552086112}, {"text": "Bradley E. Lerman Joins Pfizer as Senior Vice President of Litigation", "labels": -2.0552086112}, {"text": "Pfizer Declares a 32-Cent First-Quarter 2009 Dividend", "labels": 2.5921502176}, {"text": "Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts", "labels": 2.5921502176}, {"text": "Pfizer Announces Results from Trial of AROMASIN in Postmenopausal Women with Hormone Sensitive Early Breast Cancer", "labels": 3.0142365775}, {"text": "Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria in Africa", "labels": -2.4286784586}, {"text": "Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows", "labels": 5.6558823565}, {"text": "Pfizer\u2019s Novel HIV/AIDS Treatment SELZENTRY\u2122 Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients", "labels": -1.6802044729}, {"text": "Pfizer Withdraws Application to Switch Viagra to Non-Prescription Status in Europe", "labels": -11.7647593867}, {"text": "Pfizer Launches Global Regenerative Medicine Research Unit", "labels": 2.456984299}, {"text": "New Analysis Suggests That Improvements in Kidney Function in Patients Treated with Lipitor Strongly Correlate with a Reduced Risk of Major Cardiovascular Events", "labels": -4.548282319}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference", "labels": -10.5070155403}, {"text": "Pfizer Discontinues Development Program for Its Phase 3 Obesity Compound (CP-945,598)", "labels": -10.5070155403}, {"text": "Pfizer's TOVIAZ(TM) (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder", "labels": 6.57588e-05}, {"text": "Pfizer's Novel HIV/AIDS Treatment Selzentry(TM) (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naive HIV Patients", "labels": 8.5297518765}, {"text": "Pfizer to Present Data on New Approaches to Pain and Inflammation Treatment at ACR Meeting", "labels": 8.5297518765}, {"text": "Pfizer Declares a 32-Cent Fourth-Quarter 2008 Dividend", "labels": -1.9311747579}, {"text": "Pfizer Completes Settlement Agreements with State Attorneys General Regarding its NSAID Pain Medications", "labels": 0.2923944428}, {"text": "Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit", "labels": -5.555543196}, {"text": "Pfizer Reports Third-Quarter 2008 Results", "labels": 0.5190262276}, {"text": "Pfizer and UCB Announce Formation of New Company 'Cyclofluidic' to Accelerate Drug Discovery Process", "labels": 0.5190262276}, {"text": "Pfizer Reaches Agreements in Principle to Resolve Litigation Involving Its NSAID Pain Medications", "labels": 2.1289134377}, {"text": "New Data across Pfizer's Pain and Inflammation Portfolio to Be Presented at Upcoming ACR Meeting", "labels": 3.8529027007}, {"text": "Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements over Four Years", "labels": -14.2668481294}, {"text": "Aetna and Pfizer Present ''State of Motion'' Health Fair in Hartford to Encourage Families to Adopt Healthy Lifestyles", "labels": -14.2668481294}, {"text": "EPA Honors Pfizer for Reducing Greenhouse Gas Emissions", "labels": -10.8487354559}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 28 Analyst and Investor Meeting at ACR", "labels": 0.0527896601}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 21 Conference Call with Analysts", "labels": 2.820653504}, {"text": "Pfizer Shows Accelerating Pipeline with Significant Growth in Late-Stage Clinical Development", "labels": 5.332631123}, {"text": "Established Safety Profile of Spiriva(R) Confirmed by 30 Rigorously Controlled Clinical Trials", "labels": 2.5751218819}, {"text": "Grameen Health and Pfizer Announce Novel Partnership to Explore Sustainable Healthcare Delivery Models for the Developing World", "labels": -1.167315952}, {"text": "Pfizer Recognized as Leader in Improving Climate Change for Second Consecutive Year", "labels": -1.6101754852}, {"text": "MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy", "labels": -1.6844438792}, {"text": "Pfizer Launches New Medicine Safety Website to Help Healthcare Professionals and Patients Make Better Informed Decisions about Treatment Options", "labels": -1.6844438792}, {"text": "Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008", "labels": -1.6844438792}, {"text": "Pfizer Animal Health Adds Former Schering-Plough Products to European Portfolio", "labels": 0.6525736813}, {"text": "Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial", "labels": -3.289465055}, {"text": "Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to Cancer Care and Research", "labels": -3.289465055}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": -3.289465055}, {"text": "Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases", "labels": -0.5208369226}, {"text": "Lipitor 80 mg Provided Sustained Risk Reduction of Cardiovascular Events in Patients with Heart Disease During the Five-Year TNT Trial", "labels": -0.5208369226}, {"text": "New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients", "labels": -0.5208369226}, {"text": "Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011", "labels": -0.3140236649}, {"text": "Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program", "labels": -2.5156958814}, {"text": "Pfizer Says Vacation with Your Dog before the Summer Ends", "labels": 1.4522498547}, {"text": "IAFF Launches Smoking Cessation Campaign with Pfizer", "labels": -0.4563778692}, {"text": "Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke in Patients with Heart Disease, Type 2 Diabetes and Chronic Kidney Disease", "labels": -1.093173716}, {"text": "Pfizer Reports Second-Quarter 2008 Results", "labels": 5.7157801134}, {"text": "Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting", "labels": -2.5028561035}, {"text": "Pfizer Fully Supports Updated PhRMA Code", "labels": -1.6638925461}, {"text": "Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows", "labels": 2.1440553663}, {"text": "Pfizer Changes Its Funding of Continuing Medical Education in the U.S.", "labels": 1.078319731}, {"text": "FDA Approves First and Only Single-Dose Antibiotic for Dogs and Cats", "labels": 2.4816868437}, {"text": "Pfizer Declares a 32-Cent Third Quarter 2008 Dividend", "labels": -3.3197362418}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 23 Conference Call with Analysts", "labels": -3.3197362418}, {"text": "Pfizer Invites Public to View and Listen to Webcast of July 28 Pfizer Analyst and Investor Meeting at ICAD", "labels": 1.5263227164}, {"text": "EyeCyte, Inc. Secures Series A Funding from Pfizer", "labels": 1.5263227164}, {"text": "Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide", "labels": -0.4501937452}, {"text": "Pfizer Celebrates 5 Years of High-Impact Corporate Volunteer MissionsPfizer Celebrates 5 Years of High-Impact Corporate Volunteer Missions", "labels": -1.0716491514}, {"text": "Pfizer Inc. and the University of Pennsylvania Announce $15 Million Partnership", "labels": -1.0716491514}, {"text": "Bristol-Myers Squibb and Pfizer Initiate New Study in the Apixaban Phase 3 Clinical Trial Program", "labels": -2.1082258513}, {"text": "Pfizer and UCSF Form Alliance to Advance a Broad Range of Research", "labels": -0.8919253742}, {"text": "Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.", "labels": -0.8919253742}, {"text": "Charles E. Triano Joins Pfizer as Head of Investor Relations", "labels": -4.3429602864}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": -1.6489655026}, {"text": "Pfizer Reviews Progress of Oncology Pipeline and New Commercial Business Unit Structure with Analysts", "labels": -2.2093651478}, {"text": "New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing's Sarcoma", "labels": -2.2093651478}, {"text": "Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting", "labels": -2.2093651478}, {"text": "Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers", "labels": 0.1032940966}, {"text": "Pfizer Names Amy W. Schulman as Senior Vice President and General Counsel", "labels": -1.4507473925}, {"text": "Australian Full Federal Court Upholds Basic Lipitor Patent, Preventing Launch of Generic Ranbaxy Product", "labels": -1.4507473925}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 2 Pfizer Analyst and Investor Meeting at ASCO", "labels": -1.6684101131}, {"text": "New Analysis Showed That High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients", "labels": -1.6684101131}, {"text": "FivePrime and Pfizer Enter Oncology and Diabetes Collaboration", "labels": 4.43553e-05}, {"text": "New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer and Other Difficult-to-Treat Tumor Types to Be Presented at ASCO", "labels": -0.1497428886}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": 0.2988248742}, {"text": "Pfizer Names Garry Nicholson to Head New Oncology Business Unit", "labels": 0.2988248742}, {"text": "As Part of New Transparency Initiative Pfizer Releases List of Grants and Charitable Contributions Made in the First Quarter of 2008", "labels": 0.2988248742}, {"text": "Pfizer Extends 10 Million Yuan to Earthquake Victims and Relief Efforts in China", "labels": 0.6008955909}, {"text": "Esperion Therapeutics Completes $22.75 M Series A Financing", "labels": 0.6849347186}, {"text": "U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent", "labels": -0.7458578818}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": -1.2351686657}, {"text": "Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology", "labels": 0.296579599}, {"text": "Pfizer Declares a 32-Cent Second Quarter, 2008, Dividend", "labels": 2.3494937336}, {"text": "Pfizer on Track to Deliver Greater Shareholder Value, CEO Kindler Tells Shareholders", "labels": 0.7983774312}, {"text": "Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products from Schering-Plough", "labels": 0.7983774312}, {"text": "Pfizer Japan to Launch Champix(R) the First Prescription Oral Smoking Cessation Aid in Japan", "labels": -2.8802618588}, {"text": "Pfizer Invites Public to Listen to Webcast of April 24 Annual Shareholders Meeting", "labels": -2.8802618588}, {"text": "High-Dose Lipitor Reduced the Risk of Heart Attack and Stroke in Patients with Chronic Kidney Disease", "labels": -2.8802618588}, {"text": "Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT", "labels": -2.8802618588}, {"text": "Pfizer Opens New Development Centre", "labels": -0.1465662873}, {"text": "Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010", "labels": -0.1465662873}, {"text": "Pfizer Reports First-Quarter 2008 Results; Reaffirms Full-Year 2008 Financial Guidance", "labels": -2.107877513}, {"text": "Results from Largest Statin Study of Patients with Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease", "labels": -2.107877513}, {"text": "Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer", "labels": -2.107877513}, {"text": "Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression", "labels": 2.3697136846}, {"text": "Pfizer Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc.", "labels": 0.8208739743}, {"text": "Pfizer Statement on Exubera Labeling Update in the United States", "labels": -2.2019719117}, {"text": "Pfizer Extends Subsequent Offering Period of Tender Offer for Shares of Encysive Pharmaceuticals", "labels": -2.047617134}, {"text": "Pfizer Reports Shares of Encysive Pharmaceuticals Inc. Tendered Pursuant to Guaranteed Delivery Procedures", "labels": -2.047617134}, {"text": "Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma", "labels": 2.1385834219}, {"text": "Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study", "labels": 2.1385834219}, {"text": "Pfizer Invites Public to View and Listen to Webcast of April 17 Conference Call with Analysts", "labels": 2.1385834219}, {"text": "Pfizer Successfully Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc. and Announces Subsequent Offer Period", "labels": 3.2272984664}, {"text": "Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent", "labels": 3.2272984664}, {"text": "Pfizer Obtains Clearance from Federal Cartel Office of Germany for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals Inc.; ``Regulatory Condition'' Now Satisfied", "labels": -1.2682813144}, {"text": "Pfizer Clears U.S. Antitrust Review for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals Inc.", "labels": -0.7782308277}, {"text": "Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent, Decision Prevents Launch of Generic Product by Ranbaxy until 2010", "labels": -0.4367079086}, {"text": "Pfizer Animal Health to Acquire Catapult Genetics and Bovigen", "labels": -1.0674336537}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": -0.2819267451}, {"text": "Pfizer's Waxman to Leave", "labels": -0.2819267451}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": 1.6114306917}, {"text": "Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex by Generic Manufacturer Teva", "labels": -2.9507907562}, {"text": "Pfizer Presents New Opportunities for Global Growth", "labels": -0.4535199454}, {"text": "Pfizer Announces Commencement of Tender Offer for All Outstanding Shares of Encysive Pharmaceuticals Inc.", "labels": -0.4535199454}, {"text": "Pfizer Names William Ringo Senior Vice President of Strategy and Business Development", "labels": -0.8093883686}, {"text": "Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform", "labels": -0.8093883686}, {"text": "Pfizer to Seek to Appeal Lipitor Enantiomer Patent Ruling in the Netherlands, Company Notes That Ruling Has No Commercial Impact", "labels": -1.0643104818}, {"text": "Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik", "labels": 1.4454316834}, {"text": "Appellate Court in the Netherlands Upholds Basic Lipitor Patent, Prevents Launch of Ranbaxy Product before November 2011", "labels": 0.3125257856}, {"text": "Pfizer to Acquire Encysive Pharmaceuticals", "labels": -0.1334899961}, {"text": "Pan-African Conference Focuses on Keeping the Medicine Supply in Africa Safe", "labels": 1.9348521265}, {"text": "Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on Retroviruses and Opportunistic Infections", "labels": -1.0145610481}, {"text": "Pfizer Japan Receives Manufacturing and Marketing Authorization for Champix(R)", "labels": 2.1139383438}, {"text": "Pfizer Reports Fourth-Quarter and Full-Year 2007 Results and 2008 Financial Guidance", "labels": 5.1618234072}, {"text": "Make a New Year's Resolution to Lose Weight - For Your Dog", "labels": 5.1618234072}, {"text": "Pfizer Invites Public to View and Listen to Webcast of March 5 Meeting with Analysts", "labels": -4.0000218939}, {"text": "Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States", "labels": -4.0000218939}, {"text": "Pfizer Reaffirms Leadership in International Corporate Volunteerism by Deploying the Largest Round of Global Health Fellows", "labels": -1.7521940875}, {"text": "Adding Lipitor Early to Effective Blood Pressure Treatment Provided a Significant Reduction in Heart Attacks or Deaths from Heart Attacks over Five Years", "labels": -1.7521940875}, {"text": "Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor", "labels": -1.7521940875}, {"text": "News & Media     Press Releases         Press Release Archive         Press Statements Archive     Featured Stories     Video Gallery     Frequently Requested Info     Press Kits     Download Multimedia     Social Media     Contact Pfizer Media Rela", "labels": -2.7553803985}, {"text": "Patients Treated with Lipitor Were Significantly Less Likely to Have a Cardiovascular Event Than Those Treated with Simvastatin, New Observational Study Shows", "labels": -2.7553803985}, {"text": "Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent", "labels": -2.7553803985}, {"text": "Pfizer Wins Key New York State Court Ruling on Celebrex", "labels": 2.4086532942}, {"text": "Pfizer Invites Public to View and Listen to Webcast of January 23 Conference Call with Analysts", "labels": 2.5919648896}, {"text": "ADDING MULTIMEDIA Pfizer Names Sally Susman Senior Vice President of Worldwide Communications and Chief Communications Officer", "labels": 2.3434188682}, {"text": "DoveBid(R) to Conduct Online Auction for Pfizer Japan", "labels": 2.3434188682}, {"text": "Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate", "labels": 2.3434188682}, {"text": "Pfizer to Appeal Canadian Federal Court Ruling on Lipitor Patent; Court's Decision Will Have No Immediate Commercial Impact", "labels": -0.6570856346}, {"text": "Talking to a Doctor about Smoking Makes Quitting Easier - New Survey Reveals", "labels": 1.811916695}, {"text": "Pfizer Inc Announces Completion of the Tender Offer Relating to Outstanding Shares of Coley Pharmaceutical Group, Inc.", "labels": 1.0785393456}, {"text": "Pfizer Receives Approvable Letter from FDA for Dalbavancin", "labels": -0.1714881886}, {"text": "Pfizer Statement on Results of Comparative Analysis of Tropism Assays", "labels": 0.6024138887}, {"text": "Pfizer to Acquire CovX to Extend Biotherapeutics Investment", "labels": 1.3692781508}, {"text": "Pfizer Inc Clears Antitrust Review for Acquisition of All Outstanding Shares of Coley Pharmaceutical Group, Inc.", "labels": 1.3692781508}, {"text": "Pfizer Declares a 32-Cent First Quarter, 2008, Dividend", "labels": 1.3692781508}, {"text": "Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds", "labels": 2.5854793702}, {"text": "Pfizer Inc Commences Tender Offer for All Outstanding Shares of Coley Pharmaceutical Group, Inc.", "labels": 1.59933035}, {"text": "Pfizer Invites Public to View and Listen to Webcast of November 30 Analyst Meeting in Hong Kong", "labels": -3.4346476697}, {"text": "Pfizer to Acquire Coley Pharmaceutical Group", "labels": -0.7267967835}, {"text": "Pfizer and Nektar Reach Agreement on Exubera(R)", "labels": 3.0573828362}, {"text": "Lipitor Provides Greater Benefit Compared to simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events", "labels": -0.3555194863}, {"text": "Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function", "labels": 1.3790349956}, {"text": "New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to Be Presented at Upcoming Annual Scientific Sessions of the American Heart Association", "labels": 1.3790349956}, {"text": "Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate", "labels": 0.6544195851}, {"text": "Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial Impact", "labels": 0.6544195851}, {"text": "Pfizer Announces Retirement of Vice Chairman David L. Shedlarz", "labels": 0.4936619806}, {"text": "Pfizer Declares a 29-Cent Fourth-Quarter, 2007, Dividend", "labels": 0.4936619806}, {"text": "Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent", "labels": -0.6255261716}, {"text": "Pfizer Reports Third-Quarter 2007 Results; Reconfirms 2007 and 2008 Revenue and Adjusted Diluted EPS(1) Guidance", "labels": -0.8557035703}, {"text": "Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care", "labels": -2.5172617812}, {"text": "Research Reveals New Trends and Best Practices among Multinational Corporations Engaging in International Corporate Volunteering Programs", "labels": -1.2272624626}, {"text": "Pfizer Invites Public to View and Listen to Webcast of October 18 Conference Call with Analysts", "labels": -0.1964702869}, {"text": "Dr. Martin Mackay Named President of Pfizer Global Research and Development", "labels": 1.7391251602}, {"text": "Pfizer Hires New Vice President and Chief Talent Officer", "labels": 0.7575994624}, {"text": "Canadian Federal Court Upholds Viagra Patent", "labels": 0.362110032}, {"text": "Pfizer Recognized as Leader in Addressing Climate Change", "labels": 0.362110032}, {"text": "Two New Directors Elected to Pfizer Board", "labels": -0.98239557}, {"text": "New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer", "labels": 0.9356451998}, {"text": "Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients", "labels": -1.7325984781}, {"text": "Court Rules for Pfizer in Patent Infringement Case on Neurontin", "labels": -1.5970523077}, {"text": "Pfizer and the European Foundation for the Study of Diabetes Announce a New Research Program Focused on Cardiovascular Risk in Patients with Diabetes", "labels": -1.3420507214}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": -0.5301866389}, {"text": "Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc)", "labels": 2.8537133647}, {"text": "New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years", "labels": 1.5484747376}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": -0.0823758369}, {"text": "Pfizer to Share New Data and Portfolio Update on Infectious Disease Portfolio at ICAAC Meeting; Invites Public to View and Listen to Webcast of September 18 Analyst Meeting", "labels": -0.0823758369}, {"text": "Canadian Court Finds Infringement of Lipitor Crystal Form Patent", "labels": 0.4953083966}, {"text": "Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer", "labels": -1.1372967585}, {"text": "Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education - Mobilize Against Malaria", "labels": -1.1372967585}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference", "labels": -1.1372967585}, {"text": "Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows", "labels": -0.2832680911}, {"text": "Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program", "labels": -1.062500721}, {"text": "Pfizer Names Frank A. D'Amelio Chief Financial Officer", "labels": 2.0689216269}, {"text": "Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA", "labels": 2.7104699566}, {"text": "Breast Cancer Guidelines Confirm Central Role of 'Switch Strategy'; Recommendations of St Gallen Panel Support Exemestane Indication", "labels": -0.8081457157}, {"text": "First Medication to Prevent and Treat Vomiting in Dogs Now Available by Prescription", "labels": -2.2968784519}, {"text": "Spanish Court Rules in Pfizer's Favor, Upholds Lipitor Patent", "labels": -0.7263939122}, {"text": "Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show", "labels": -0.7263939122}, {"text": "Pfizer Receives Positive Opinion from CHMP for Celsentri(R) (maraviroc) for Treatment-Experienced Patients Infected with CCR5-Tropic HIV-1", "labels": -1.2851356201}, {"text": "Pfizer Announces First Occupant in its Science Incubator", "labels": -0.7603290797}, {"text": "Pfizer Reports Second-Quarter 2007 Results, Reconfirms Full-Year 2007 and 2008 Financial Guidance and Updates Progress on Immediate Business Priorities", "labels": -3.6211919492}, {"text": "High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011", "labels": -1.290027337}, {"text": "Pfizer Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation", "labels": -1.290027337}, {"text": "Crystal Trial Confirms Central Role of Irinotecan in Metastatic Colorectal Cancer", "labels": -0.1555286854}, {"text": "Pfizer Declares a 29-cent Third-Quarter, 2007, Dividend", "labels": 0.4292007255}, {"text": "Pfizer Board of Directors to Initiate Face-to-Face Meetings with Company's Institutional Investors on Corporate Governance Policies and Practices", "labels": 0.4292007255}, {"text": "Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer", "labels": 0.4292007255}, {"text": "Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke", "labels": 0.3516745464}, {"text": "Exubera Demonstrated Pulmonary Safety with Blood Sugar Control in Three-Year Interim Analyses", "labels": -1.4566838808}, {"text": "Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review", "labels": -1.4184231422}, {"text": "Pfizer Receives Approvable Letter From FDA For Maraviroc", "labels": -1.7746947446}, {"text": "Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer", "labels": -1.7746947446}, {"text": "Slentrol, First Medication to Combat Canine Obesity, Now Available by Prescription", "labels": -1.4936814491}, {"text": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at June 14 Healthcare Conference", "labels": -0.8672447072}, {"text": "Pfizer to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts", "labels": -0.9897508214}, {"text": "New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy", "labels": -0.9897508214}, {"text": "Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show", "labels": -0.9897508214}, {"text": "New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer", "labels": -0.9897508214}, {"text": "Pfizer and Express Scripts Sign Agreement", "labels": -0.4013102648}, {"text": "UK Body Recommends Pfizer's Champix (varenicline) for Smokers", "labels": -0.4013102648}, {"text": "Pfizer Invites Public to View and Listen to Webcast of June 4 Pfizer Analyst Meeting at ASCO", "labels": -0.4013102648}, {"text": "Pfizer's Growing Strength in Oncology", "labels": -0.4013102648}, {"text": "New Pfizer Oncology Data Across Numerous Cancer Types to be Presented at ASCO", "labels": -0.4013102648}, {"text": "Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in Norway", "labels": -0.4013102648}, {"text": "Pfizer Animal Health Medicine Used to Treat Whales", "labels": -0.4013102648}, {"text": "Pfizer Supports Complete Smoking Ban in Public Areas and Improved Access to Smoking Cessation Treatments across Europe", "labels": -0.3299065174}, {"text": "Pfizer Says Research and Development Head John LaMattina Will Retire This Year", "labels": -0.182669106}, {"text": "Pharmacia and Upjohn Will Appeal Verdict in Simon Case, 'Ruling is Not Supported by the Evidence'", "labels": 0.4758327677}, {"text": "Counterfeit Drugs Put Lives at Risk", "labels": 0.3690178412}, {"text": "Pfizer Invites Public to Listen to Webcast of July 18 Conference Call with Analysts", "labels": 1.8094491501}, {"text": "Pfizer Launches Online Initiative Disclosing Its U.S. Post-Marketing Commitments", "labels": 0.9022764163}, {"text": "Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show", "labels": 0.9022764163}, {"text": "Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014", "labels": 0.1504484198}, {"text": "Pfizer Foundation's ConnectHIV Initiative Provides $7.5 Million in Grants to Community-Based AIDS Service Organizations Across 10 States", "labels": 0.1504484198}, {"text": "Pfizer Invites Public to View and/or Listen to Webcasts of Pfizer Participation at Healthcare Conferences", "labels": 0.7140272874}, {"text": "Pfizer Declares a 29-cent Second-Quarter, 2007, Dividend", "labels": 2.0209768255}, {"text": "Pfizer Focused on Delivering the Value Customers Expect and Shareholders Deserve, CEO Kindler Tells Shareholders", "labels": 2.0209768255}, {"text": "Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds", "labels": 2.0209768255}, {"text": "FDA Advisory Committee Recommends Accelerated Approval of Pfizer's Maraviroc for Treatment-Experienced Patients Infected with CCR5-tropic HIV-1", "labels": -0.5699454225}, {"text": "Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full-Year Expectations for 2007 and 2008", "labels": 1.2977625486}, {"text": "Pfizer Invites Public to Access Webcast of April 26 Annual Meeting of Shareholders", "labels": 1.2977625486}, {"text": "Pfizer Invites Public to Listen to Webcast of April 20 Conference Call with Analysts", "labels": 0.2692316406}, {"text": "Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer", "labels": 1.7140452078}, {"text": "Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show", "labels": -0.1569185776}, {"text": "Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients", "labels": -0.1569185776}, {"text": "Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis", "labels": -0.1569185776}, {"text": "Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone", "labels": 0.1947803125}, {"text": "Pfizer to Present New Lipitor Data, Including Results from Three Large Atherosclerosis Imaging Trials, at the American College of Cardiology Meeting", "labels": -0.0390009632}, {"text": "Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case", "labels": -0.0390009632}, {"text": "Pfizer Wins Celebrex Patent Challenge by Generic Manufacturer Teva", "labels": 2.3984011869}, {"text": "Vertex Announces U.S. FDA Approval for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations  -About 900 children with cystic fibrosis will now have a medicine to treat the underlying cause of their disease for the first time- BOSTON --(BUSINESS WIRE)--Apr. 26, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the", "labels": 3.7923196813}, {"text": "Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9  BOSTON --(BUSINESS WIRE)--Apr. 25, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT / 12:20 p.m. ET .", "labels": -3.4642785741}, {"text": "Vertex to Announce First Quarter 2023 Financial Results on May 1  BOSTON --(BUSINESS WIRE)--Apr. 10, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .", "labels": 1.3391545626}, {"text": "Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia  -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023 - BOSTON &amp; ZUG, Switzerland --(BUSINESS WIRE)--Apr. 3, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced", "labels": -0.1844623585}, {"text": "Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex\u2019s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes  - Vertex to receive non-exclusive rights to CRISPR Therapeutics\u2019 CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- - CRISPR Therapeutics to receive $100M upfront payment plus milestone and royalty payments on potential future gene-edited hypoimmune T1D products-", "labels": -0.4565020513}, {"text": "Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)  BOSTON --(BUSINESS WIRE)--Mar. 16, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine \u00a0 (NEJM) \u00a0 of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of", "labels": 1.4910247239}, {"text": "Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes  \u00a0 \u2013 Vertex to initiate a Phase 1/2 clinical trial in the coming months \u2013 \u2013 VX-264 is the second investigational program in Vertex\u2019s pipeline containing stem cell-derived, fully differentiated pancreatic islet cells for the treatment of type 1 diabetes \u2013 \u2013 VX-264 program does not require", "labels": -0.3690285457}, {"text": "Vertex to Present at Cowen\u2019s 43rd Annual Health Care Conference on March 7  BOSTON --(BUSINESS WIRE)--Feb. 21, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen\u2019s 43 rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:50 p.m. ET . A live webcast of management's remarks will be available through the", "labels": 1.2229840213}, {"text": "Vertex Reports Fourth Quarter and Full Year Financial 2022 Results  \u2014 Full year product revenue of $8.93 billion , an 18% increase compared to full year 2021 \u2014 \u2014 Full year GAAP and non-GAAP net income increased 42% and 53%, respectively, versus 2021\u2014 \u2014 Company provides full year 2023 product revenue guidance of $9.55 to $9.7 billion \u2014 \u2014 Exa-cel regulatory", "labels": -3.4977705094}, {"text": "Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7  BOSTON --(BUSINESS WIRE)--Jan. 17, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .", "labels": 2.055765642}, {"text": "Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9  BOSTON --(BUSINESS WIRE)--Jan. 4, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT .", "labels": -0.1424061703}, {"text": "Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA  - Novel, inhaled mRNA therapy intended for the ~5,000 people with CF who cannot benefit from CFTR modulators - - VX-522 clinical trial in people with CF to initiate in coming weeks - BOSTON --(BUSINESS WIRE)--Dec. 12, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that", "labels": -2.6474339704}, {"text": "Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition  - Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel - - Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia and burden of hematopoietic stem cell transplant - BOSTON and ZUG, Switzerland", "labels": -2.6474339704}, {"text": "Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)  - Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada\u2019s EEV-investigational candidate for the treatment of DM1 - BOSTON --(BUSINESS WIRE)--Dec.", "labels": -1.7071252807}, {"text": "Vertex to Participate in Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)--Nov. 9, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 , at 9:10 a.m. GMT ( 4:10 a.m.", "labels": 1.4564507594}, {"text": "Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)  BOSTON --(BUSINESS WIRE)--Nov. 4, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch \u201cPower Forward\u201d ( www.PowerForwardTogether.com ), an educational initiative aimed at raising awareness", "labels": -2.7701723418}, {"text": "Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference  - New clinical data show TRIKAFTA \u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) continues to deliver significant benefit across a variety of outcomes and over the long term in people with CF - BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today", "labels": 0.459819116}, {"text": "Vertex Reports Third Quarter 2022 Financial Results  \u2014 Product revenue of $2.33 billion , an 18% increase compared to Q3 2021 \u2014 \u2014 Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion \u2014 \u2014 Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities: Initiating global exa-cel", "labels": 1.0131011007}, {"text": "Vertex to Announce Third Quarter 2022 Financial Results on October 27  BOSTON --(BUSINESS WIRE)--Oct. 13, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .", "labels": 2.8375488725}, {"text": "Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency  \u00a0- Initiates first-in-human trial of next-wave AAT corrector, VX-634 - - Phase 2 study evaluating the impact of longer-term treatment with VX-864 to be initiated in the coming weeks - - Additional AAT correctors to enter the clinic starting in 2023 - BOSTON --(BUSINESS WIRE)--Oct.", "labels": -1.5200095088}, {"text": "Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022  - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 - - EMA and MHRA submissions are on track for Q4 2022 - - Exa-cel granted Fast Track, Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug", "labels": 4.267983595}, {"text": "Vertex Appoints Jonathan Biller as Chief Legal Officer  BOSTON --(BUSINESS WIRE)--Sep. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022 . Mr. Biller will report directly to Vertex\u2019s Chief Executive Officer and President, Reshma", "labels": 2.5127509178}, {"text": "Vertex Announces U.S. FDA Approval for ORKAMBI\u00ae (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months  -With this approval, approximately 300 children with two copies of the F508del mutation will have a medicine to treat the underlying cause of their disease for the first time- BOSTON --(BUSINESS WIRE)--Sep. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.", "labels": -3.958026578}, {"text": "Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9  BOSTON --(BUSINESS WIRE)--Aug. 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Wells Fargo Healthcare Conference on Friday, September 9, 2022 at 11:00 a.m. ET . A live webcast of management\u2019s remarks will be", "labels": 2.8738892159}, {"text": "Vertex Reports Second Quarter 2022 Financial Results  \u2014 Product revenues of $2.20 billion , a 22% increase compared to Q2 2021 \u2014 \u2014 Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion \u2014 \u2014 Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta", "labels": 3.6871142458}, {"text": "Vertex Advances VX-548 in Acute and Neuropathic Pain  - VX-548 advances into pivotal development for people with acute pain ; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - BOSTON --(BUSINESS WIRE)--Jul.", "labels": -0.3066818738}, {"text": "Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease  Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated&nbsp;(Nasdaq: VRTX) and Verve Therapeutics, Inc.  General Business", "labels": -1.9745071332}, {"text": "Vertex to Announce Second Quarter 2022 Financial Results on August 4  BOSTON --(BUSINESS WIRE)--Jul. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .", "labels": -1.129139829}, {"text": "Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes  - ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex\u2019s fully differentiated, insulin-producing, stem cell derived islets - - ViaCyte to be acquired for $320 million in cash- BOSTON --(BUSINESS WIRE)--Jul.  General Business", "labels": -1.3758112134}, {"text": "Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes  BOSTON --(BUSINESS WIRE)--Jul. 5, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated  General Business", "labels": 1.799694384}, {"text": "Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress  \u2013 \u00a0 Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure \u2013 \u2013 Safety profile generally consistent with myeloablative conditioning and  General Business", "labels": -0.6945542456}, {"text": "Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference  - TRIKAFTA \u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show \u00a0 improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fibrosis (CF) - - Study in people with CF  General Business", "labels": -4.531566243}, {"text": "Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15  BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT .  Webcasts", "labels": -4.8132458269}, {"text": "Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA  - Vertex granted nine Breakthrough Therapy Designations and three PRIME designations across its pipeline programs to date \u2013 BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin  General Business", "labels": -4.8132458269}, {"text": "Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions  \u2013 \u00a0 Patient 1 showed blood glucose time-in-range change from 40.1% on 34.0 units per day of exogenous insulin at baseline to 99.9% and insulin independence at Day 270 \u2013 \u2013 \u00a0 Patient 2 showed blood glucose time-in-range change from 35.9% on 25.9 units per day of exogenous insulin at baseline to 51.9%  General Business", "labels": 0.1544850043}, {"text": "Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001\u2122 at the 2022 Annual European Hematology Association (EHA) Congress  \u00a0- Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation \u2013 BOSTON &amp; ZUG, Switzerland &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics  General Business", "labels": 0.3191864093}, {"text": "Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference  BOSTON --(BUSINESS WIRE)--May 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell\u2011derived, fully differentiated  General Business", "labels": -1.7148565585}, {"text": "Suketu Upadhyay Elected to Vertex Board of Directors  BOSTON --(BUSINESS WIRE)--May 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (\u201cSuky\u201d) Upadhyay \u00a0 has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the  General Business", "labels": -2.0121352324}, {"text": "Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies  -New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built- -Facility to support continued R&amp;D growth- BOSTON --(BUSINESS WIRE)--May 17, 2022-- At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston\u2019s Seaport, Vertex  General Business", "labels": -1.375074752}, {"text": "Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants  \u00a0\u2013 Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes \u2013 \u2013 The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center \u2013 \u2013 Additional Vertex Foundation grant to Year Up to support health care workforce training \u2013  General Business", "labels": -1.375074752}, {"text": "Vertex Reports First Quarter 2022 Financial Results  \u2014 Product revenues of $2.10 billion , a 22% increase compared to Q1 2021 \u2014 \u2014 Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion \u2014 \u2014 Mid- and late-stage clinical pipeline now spans 6 disease areas \u2014 BOSTON --(BUSINESS WIRE)--May 5, 2022-- Vertex Pharmaceuticals  Financial", "labels": -6.9940575268}, {"text": "Vertex to Announce First Quarter 2022 Financial Results on May 5  BOSTON --(BUSINESS WIRE)--Apr. 21, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -5.7614029283}, {"text": "Health Canada Grants Marketing Authorization for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation  -Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA \u00ae - - Vertex has submitted this indication to CADTH &amp; INESSS for Health Technology Assessments- BOSTON --(BUSINESS WIRE)--Apr. 20, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has  General Business", "labels": -0.9335859439}, {"text": "Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain  -\u00a0 Treatment with the NaV1.8 inhibitor VX-548 met the primary endpoint in both Phase 2 proof-of-concept acute pain studies following abdominoplasty or bunionectomy surgery - - VX-548 was generally well tolerated - - Results further highlight NaV1.8 as a new mechanism that could create an  General Business", "labels": 2.3107247934}, {"text": "Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene  - With this reimbursement agreement in place, more than 2,200 people with CF will have PBS -funded access to TRIKAFTA \u00ae , including more than 700 who will now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Mar. 26, 2022-- Vertex Pharmaceuticals Incorporated  General Business", "labels": 1.6086553138}, {"text": "Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease  \u2013 Single pivotal trial to initiate later this month targets the broad patient population with two APOL1 mutations and proteinuric kidney disease \u2013 \u2013 Pathway for accelerated approval using an interim analysis at Week 48 of eGFR slope, supported by reduction in proteinuria \u2013 \u2013 Final analysis  General Business", "labels": -0.4030145409}, {"text": "Vertex to Present at Cowen\u2019s 42nd Annual Health Care Conference on March 8  BOSTON --(BUSINESS WIRE)--Mar. 1, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen\u2019s 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:50 p.m. ET . A live webcast of management's remarks will be available through Vertex  Webcasts", "labels": 2.1015753945}, {"text": "Vertex Reports Fourth Quarter 2021 and Full Year Financial Results  -Full year product revenues of $7.57 billion , a 22% increase compared to full year 2020- -Company provides full year 2022 product revenue guidance of $8.4 to $8.6 billion - - Advancing broad clinical pipeline across six disease areas; multiple programs in mid- and late-stage development with  Financial", "labels": 0.7010805779}, {"text": "Vertex to Announce Fourth Quarter 2021 Financial Results on January 26  BOSTON ----(BUSINESS WIRE)--Jan. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -0.2555867039}, {"text": "European Commission Approves KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years  - More than 1,500 children now eligible to receive a treatment targeting the underlying cause of cystic fibrosis for the first time - LONDON --(BUSINESS WIRE)--Jan. 11, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for  General Business", "labels": 0.8578767342}, {"text": "Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10  BOSTON --(BUSINESS WIRE)--Jan. 4, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 a.m. ET . A live webcast of management's remarks will be available  Webcasts", "labels": 0.3116260713}, {"text": "Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis  \u2013 Treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6% at 13 weeks compared to baseline and was well tolerated \u2013 \u2013 Results provide clinical proof of concept for the first genetically targeted approach to treating  General Business", "labels": 4.3335782551}, {"text": "Vertex Announces Reimbursement Agreement in Spain for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene  \u2013 With this reimbursement agreement approximately 700 people with cystic fibrosis now have access to a CFTR modulator therapy for the first time \u2013 LONDON --(BUSINESS WIRE)--Nov. 19, 2021-- Vertex Pharmaceuticals Incorporated \u00a0 (Nasdaq: VRTX) today announced that the Spanish government has approved  General Business", "labels": -1.8292051373}, {"text": "Vertex Receives CHMP Positive Opinion for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11  - If approved, more than 1,500 children would be eligible for a medicine \u00a0 that can treat the underlying cause of their disease for the first time - LONDON --(BUSINESS WIRE)--Nov. 12, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency\u2019s  General Business", "labels": -0.0802707353}, {"text": "Vertex Reports Third-Quarter 2021 Financial Results  -Product revenues of $1.98 billion , a 29% increase compared to Q3 2020- -Company raises full-year 2021 guidance for product revenues to $7.4 to $7.5 billion - -Broad pipeline advancing with recent progress marked by unprecedented VX-880 clinical results in T1D; Phase 2 clinical results for VX-147  Financial", "labels": 1.8035666843}, {"text": "Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases  Vertex to use Mammoth\u2019s proprietary ultra-small CRISPR systems to discover and develop novel in vivo gene-editing therapies BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences , a biotech company building the next generation  General Business", "labels": -2.2548921057}, {"text": "Vertex to Announce Third-Quarter 2021 Financial Results on November 2  BOSTON --(BUSINESS WIRE)--Oct. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -0.9622134853}, {"text": "Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)  - 96-week interim results of TRIKAFTA \u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) study show no loss of pulmonary function in people with at least one F508del allele, a first for any CFTR modulator \u2013 - Real-world data from people treated with KALYDECO \u00ae (ivacaftor) over approximately 6 years  General Business", "labels": 1.8491605116}, {"text": "Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes  - First patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 Visit - - 91% decrease in daily insulin requirement and simultaneous robust improvements in glucose control as measured by  General Business", "labels": 1.5694965777}, {"text": "Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th  BOSTON --(BUSINESS WIRE)--Sep. 13, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Virtual 19 th Annual Global Healthcare Conference on Wednesday, September 15 th , 2021 at 11:00 a.m. ET .  Webcasts", "labels": -0.8810591953}, {"text": "Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis  BOSTON --(BUSINESS WIRE)--Aug. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in The \u00a0 New England Journal of Medicine \u00a0 (NEJM) of results from a Phase 3 study of TRIKAFTA \u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis  General Business", "labels": -0.5102062234}, {"text": "Vertex and Arbor Biotechnologies Establish New Partnership  to Develop Novel ex vivo Engineered Cell Therapies   Vertex to use Arbor\u2019s CRISPR gene-editing technology to enhance efforts in developing novel cell therapies for the treatment of serious diseases CAMBRIDGE, MA \u2013 August 24, 2021 \u2013 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Arbor Biotechnologies (Arbor) today announced a new collaboration  General Business", "labels": 1.2467066428}, {"text": "Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer  BOSTON --(BUSINESS WIRE)--Aug. 4, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the company\u2019s Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex\u2019s Executive Vice  General Business", "labels": 1.4729816307}, {"text": "Vertex Reports Second-Quarter 2021 Financial Results  - Product revenues of $1.79 billion , an 18% increase compared to Q2 2020 - - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B - \u00a0 - Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones  Financial", "labels": -0.5704900715}, {"text": "Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis  - Phase 2 study met primary endpoint and all secondary endpoints - - Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA \u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) - - Initiation of  General Business", "labels": -1.2326585291}, {"text": "Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain  - Proof-of-concept study of VX-548 in acute pain following bunionectomy surgery open for enrollment - - Second Phase 2 study of VX-548 in acute pain following abdominoplasty surgery to begin in the coming weeks - BOSTON --(BUSINESS WIRE)--Jul. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq:  General Business", "labels": -2.8542358297}, {"text": "Vertex to Announce Second-Quarter 2021 Financial Results on July 29  BOSTON --(BUSINESS WIRE)--Jul. 16, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  Webcasts", "labels": -0.6825941442}, {"text": "Vertex Announces National Reimbursement Agreement in France for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI\u00ae (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients  - With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Jun. 28, 2021-- Vertex Pharmaceuticals Incorporated \u00a0 (Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health", "labels": -0.1118006007}, {"text": "Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO\u00ae, SYMKEVI\u00ae and Additional Indications of ORKAMBI\u00ae and KALYDECO\u00ae for Eligible Patients With Cystic Fibrosis  - Reimbursement agreement also includes certain future indication extensions across all Vertex CF medicines - - Approximately 1,400 patients will now have access to a CFTR modulator for the first time - LONDON --(BUSINESS WIRE)--Jun. 25, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  General Business", "labels": 2.9420721407}, {"text": "Health Canada Grants Marketing Authorization for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation  -Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease- BOSTON --(BUSINESS WIRE)--Jun. 18, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA \u00ae  General Business", "labels": -0.4368712507}, {"text": "Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001\u2122 at European Hematology Association Annual Meeting  - Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion - BOSTON &amp; ZUG, Switzerland &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.  General Business", "labels": 0.3901487442}, {"text": "Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency  - Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated - - Results provide proof-of-mechanism, although magnitude of treatment effect observed unlikely to translate into substantial  General Business", "labels": -10.7760867223}, {"text": "Vertex Announces U.S. FDA Approval for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations  - With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  General Business", "labels": 2.2004909251}, {"text": "Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001\u2122 For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress  CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) --&nbsp; Vertex Pharmaceuticals Incorporated &nbsp;(Nasdaq: VRTX) and&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for  General Business", "labels": 1.0683501188}, {"text": "Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13  BOSTON --(BUSINESS WIRE)--May 10, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET .  Webcasts", "labels": -1.2347440764}, {"text": "Vertex Reports First-Quarter 2021 Financial Results  -Product revenues of $1.72 billion , a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 2021 - BOSTON --(BUSINESS WIRE)--Apr.  Financial", "labels": 2.1081534872}, {"text": "Vertex Announces European Commission Approval for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene  - New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type - - People with gating (F/G) or residual function (F/RF) mutations now eligible for the triple combination therapy - LONDON --(BUSINESS WIRE)--Apr.  General Business", "labels": -1.8030737536}, {"text": "Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001\u2122 for Transfusion-Dependent Beta Thalassemia   BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- Vertex &nbsp;Pharmaceuticals Incorporated (Nasdaq: VRTX) and&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an  General Business", "labels": -1.0253824184}, {"text": "Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development  - Proof-of-concept studies of VX-548 in acute pain to initiate in the second half of the year - BOSTON --(BUSINESS WIRE)--Apr. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective \u00a0 NaV1.8 inhibitor, VX-548, into Phase 2 clinical  General Business", "labels": -1.0253824184}, {"text": "Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing  - Multi-year strategic research collaboration leverages Obsidian\u2019s proprietary cytoDRiVE\u00ae platform to discover controllable genetic therapies to treat serious diseases - Vertex will pay Obsidian up to $75 million in equity, upfront payments and potential research milestones BOSTON &amp; CAMBRIDGE,  General Business", "labels": 0.3625485582}, {"text": "Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001\u2122 in Sickle Cell Disease and Beta Thalassemia  - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CRISPR to receive $900 million upfront payment with potential for additional $200 million  General Business", "labels": 0.418637692}, {"text": "Vertex to Announce First-Quarter 2021 Financial Results on April 29  BOSTON --(BUSINESS WIRE)--Apr. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  Webcasts", "labels": -0.31794919}, {"text": "Vertex Receives CHMP Positive Opinion for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation  - If approved, people ages 12 years and older who have one copy of the F508del mutation and a gating (F/G) or residual function (F/RF) mutation will now be eligible for triple combination therapy - LONDON --(BUSINESS WIRE)--Mar. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  General Business", "labels": 1.9426914233}, {"text": "Vertex Receives Australian TGA Approval for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation  - With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - LONDON --(BUSINESS WIRE)--Mar. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods  General Business", "labels": -0.5886230912}, {"text": "Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes  \u2013 VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated, insulin-producing pancreatic islet cells for the treatment of type 1 diabetes \u2013 \u2013 VX-880 is the first and only pancreatic islet replacement therapy known to receive Fast Track Designation \u2013 BOSTON  General Business", "labels": -0.9993070956}, {"text": "Vertex to Present at the Cowen Health Care Conference on March 2  BOSTON --(BUSINESS WIRE)--Feb. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET . The audio portion of management's remarks will be available live through Vertex  Webcasts", "labels": -1.3334640124}, {"text": "Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results  -Full-year 2020 GAAP product revenues of $6.20 billion - -Full-year 2020 non-GAAP product revenues of $6.20 billion , a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion - BOSTON --(BUSINESS WIRE)--Feb.  Financial", "labels": -6.2899728771}, {"text": "Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)  - Vertex will initiate a Phase 1/2 clinical trial in first half of 2021 - - VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D - BOSTON --(BUSINESS WIRE)--Jan. 28, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  General Business", "labels": 0.995284949}, {"text": "Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations  -FDA grants Priority Review of the application and sets a PDUFA target action date of June 8, 2021 - BOSTON --(BUSINESS WIRE)--Jan. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug  General Business", "labels": -6.7391754387}, {"text": "Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1  BOSTON --(BUSINESS WIRE)--Jan. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 1.6824821183}, {"text": "Vertex to Present at the J.P. Morgan Healthcare Conference on January 11  BOSTON --(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET ( 6:10 a.m. PT ). The audio portion of management\u2019s remarks can be accessed  Webcasts", "labels": 3.8396650226}, {"text": "Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada  BOSTON , Dec. 28, 2020 /CNW/ -\u00a0 Vertex Pharmaceuticals Incorporated \u00a0 (Nasdaq: VRTX) today announced its New Drug Submission for TRIKAFTA\u00ae, Vertex 's investigational triple combination medicine, has been accepted for Priority Review by Health Canada for the treatment of cystic fibrosis (CF) in  General Business", "labels": -0.8180171992}, {"text": "Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases  Vertex receives exclusive options to license a number of Skyhawk\u2019s product candidates directed at serious diseases Skyhawk receives $40 million upfront as well as potential milestones and royalty payments on future sales WALTHAM, Mass. &amp; BOSTON --(BUSINESS WIRE)--Dec.  General Business", "labels": 0.3519342961}, {"text": "Vertex Announces FDA Approvals of TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for Use in People With CF With Certain Rare Mutations  - More than 600 people with certain rare CF mutations are now eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Dec. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA \u00ae  General Business", "labels": 0.8003361741}, {"text": "CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001\u2122 at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine  - Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion - - Sickle cell disease: All three patients were free of vaso-occlusive crises with 3 to 15 months of follow-up after CTX001 infusion - - Nineteen patients have been dosed with  General Business", "labels": -0.509071122}, {"text": "CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001\u2122 in Sickle Cell Disease and Beta Thalassemia  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON , Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m.  General Business", "labels": -0.3396578222}, {"text": "Vertex Announces European Commission Approval for SYMKEVI\u00ae (tezacaftor/ivacaftor) With KALYDECO\u00ae (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years  - The combination therapy is a new treatment option for CF patients who are homozygous for F508del - - The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations - LONDON --(BUSINESS WIRE)--Nov.  General Business", "labels": 3.5740941338}, {"text": "Vertex Recommends Rejection of \u2018Mini-Tender\u2019 Offer From TRC Capital Investment Corporation  BOSTON --(BUSINESS WIRE)--Nov. 13, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been notified of an unsolicited \u201cmini-tender\u201d offer dated November 9, 2020 , made by TRC Capital Investment Corporation , an Ontario, Canada , corporation to purchase up to  General Business", "labels": 0.8873257481}, {"text": "Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19  BOSTON --(BUSINESS WIRE)--Nov. 12, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Jefferies Virtual London Health Care Conference on Thursday, November 19, 2020 at 9:05 a.m. ET ( 2:05 p.m. GMT ).  Webcasts", "labels": 3.7557649256}, {"text": "Vertex Announces European Commission Approval for KALYDECO\u00ae (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age  - Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe - LONDON --(BUSINESS WIRE)--Nov. 5, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension  General Business", "labels": 0.0907921506}, {"text": "CRISPR/Cas9 Gene-Editing Therapy CTX001\u2122 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9  General Business", "labels": 0.5512991975}, {"text": "Vertex Reports Third-Quarter 2020 Financial Results  -Product revenues of $1.54 billion , a 62% increase compared to Q3 2019- -Company raises revenue guidance; now expects 2020 product revenues of $6.0 to $6.2 billion - BOSTON --(BUSINESS WIRE)--Oct. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial", "labels": -0.3119571389}, {"text": "Vertex to Announce Third-Quarter 2020 Financial Results on October 29  BOSTON --(BUSINESS WIRE)--Oct. 19, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October 29, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -2.1161595446}, {"text": "Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency  - Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data - - Phase 2 study of VX-864 continues to enroll and dose patients; data expected in H1 2021 - - AATD research program continues to progress - BOSTON --(BUSINESS  General Business", "labels": -27.8288758834}, {"text": "FDA Approves KALYDECO\u00ae (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age  -Approval provides opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from a cohort of the Phase 3 ARRIVAL study support treatment with KALYDECO in children ages four to   General Business", "labels": 1.3558453419}, {"text": "Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators  - Oral presentation of interim results from TRIKAFTA \u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) open-label safety extension study to be presented at the ECFS Digital Conference - - Six presentations highlighting data from KALYDECO \u00ae (ivacaftor), ORKAMBI \u00ae (lumacaftor/ivacaftor) and TRIKAFTA  General Business", "labels": 2.2522105274}, {"text": "CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001\u2122 for the Treatment of Sickle Cell Disease  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Inco r porated &nbsp;(Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an  Cystic Fibrosis", "labels": 0.0606487975}, {"text": "Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing  Second collaboration between Moderna and Vertex based on Moderna\u2019s proprietary mRNA and LNP technology Collaboration will leverage Vertex\u2019s investments and capabilities in genetic technologies for CF Moderna to receive $75 million upfront, with potential for additional development, regulatory and  General Business", "labels": 0.1694509208}, {"text": "Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation  LONDON --(BUSINESS WIRE)--Sep. 14, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO \u00ae* (ivacaftor/tezacaftor/elexacaftor)  General Business", "labels": 2.1023105643}, {"text": "Vertex Announces Positive Phase 3 Study for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals  BOSTON --(BUSINESS WIRE)--Sep. 10, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company has completed a global Phase 3 study of TRIKAFTA \u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) \u00a0 in children ages 6 through 11 years old with cystic fibrosis (CF) who have  General Business", "labels": -1.9344165441}, {"text": "The Vertex Foundation Announces \u20ac1 Million Donation to Ronald McDonald House Charities at the New Children\u2019s Hospital in Ireland  LONDON --(BUSINESS WIRE)--Sep. 10, 2020-- The Vertex Foundation , a nonprofit charitable foundation, today announced a \u20ac1 million donation to Ronald McDonald House Charities (RMHC) to support the construction of a Ronald McDonald House at the new children\u2019s hospital in Dublin, Ireland .", "labels": -1.9344165441}, {"text": "FDA Accepts Vertex\u2019s Supplemental New Drug Applications for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for Additional CFTR Mutations  - More than 600 people with certain rare CF mutations could become newly eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Sep. 1, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental  General Business", "labels": 1.426095045}, {"text": "European Commission Approves KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older  \u2013 For the first time, up to 10,000 people in Europe ages 12 years and older with one F508del mutation and one minimal function mutation will be eligible for a medicine that treats the underlying cause of cystic fibrosis \u2013 \u2013 People 12 years of age and older who have two F508del mutations will also  General Business", "labels": -1.6079042846}, {"text": "Vertex Reports Second-Quarter 2020 Financial Results  -Product revenues of $1.52 billion , a 62% increase compared to Q2 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.7 to $5.9 billion - BOSTON --(BUSINESS WIRE)--Jul. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial", "labels": -1.1323480045}, {"text": "Positive Phase 3 Study Results for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation  -Phase 3 study met primary endpoint and all secondary endpoints- -Study is a U.S. post-marketing commitment and will be submitted to FDA- -Data also will be submitted to the European Medicines Agency to support indication expansion of the EU label following triple combination approval- BOSTON  General Business", "labels": -0.4426934015}, {"text": "Vertex to Announce Second-Quarter 2020 Financial Results on July 30  BOSTON --(BUSINESS WIRE)--Jul. 16, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  Webcasts", "labels": 0.8555967216}, {"text": "Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO\u00ae (ivacaftor)  -CF patients in England will be among the first in Europe to benefit from access to KAFTRIO \u00ae , if the medicine is approved by the European Commission - LONDON --(BUSINESS WIRE)--Jun. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its  General Business", "labels": -0.4890295873}, {"text": "CHMP Grants Positive Opinion for KAFTRIO\u00ae (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO\u00ae (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes  \u2013 If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease \u2013 \u2013 People 12 years of age and older who have two  General Business", "labels": -2.6299180141}, {"text": "Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice  - Vertex Foundation Announces $1.5 Million Gift to Boston University\u2019s New Center for Antiracist Research - -Biotechnology-focused curriculum established in partnership with Year Up- -Additional commitments made to STEAM education- BOSTON --(BUSINESS WIRE)--Jun.  General Business", "labels": -2.180747157}, {"text": "CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001\u2122 in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress  -Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for CTX001 in transfusion-dependent beta thalassemia- -Sickle cell disease: Patient is free of vaso-occlusive crises at 9 months after CTX001 infusion-  General Business", "labels": -0.1307114755}, {"text": "Vertex Announces European Commission Approval for KALYDECO\u00ae (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene  - KALYDECO \u00ae (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, in children as young as 6 months of age - LONDON --(BUSINESS WIRE)--Jun.  General Business", "labels": -4.4980842238}, {"text": "Vertex Appoints Diana McKenzie to its Board of Directors  BOSTON --(BUSINESS WIRE)--Jun. 3, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Diana McKenzie has been appointed to its board of directors as an independent director. Ms. McKenzie is a senior technology leader and innovator with deep experience across pharma,  General Business", "labels": -3.9953059174}, {"text": "New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001\u2122 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress  ZUG, Switzerland&nbsp;and&nbsp;CAMBRIDGE, Mass.&nbsp;and&nbsp;BOSTON,&nbsp;May 14, 2020&nbsp;(GLOBE NEWSWIRE) --&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) and&nbsp; Vertex Pharmaceuticals Incorporated &nbsp;(Nasdaq: VRTX) today announced that new data from two ongoing Phase 1/2 clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001 in  General Business", "labels": 3.8553482243}, {"text": "CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001\u2122 for the Treatment of Severe Hemoglobinopathies  CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia ZUG, Switzerland&nbsp;and&nbsp;CAMBRIDGE, Mass.&nbsp;and&nbsp;BOSTON,&nbsp;May 11,  General Business", "labels": 1.8157445623}, {"text": "Vertex Receives European CHMP Positive Opinion for KALYDECO\u00ae (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene  - If approved, KALYDECO \u00ae (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age - LONDON --(BUSINESS WIRE)--May 1, 2020-- Vertex  General Business", "labels": 5.8294638227}, {"text": "Vertex Reports First-Quarter 2020 Financial Results  -Product revenues of $1.52 billion , a 77% increase compared to Q1 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.3 to $5.6 billion - BOSTON --(BUSINESS WIRE)--Apr. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial", "labels": -3.8893329583}, {"text": "Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials  BOSTON --(BUSINESS WIRE)--Apr. 28, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, due to public health and travel safety concerns related to the ongoing COVID-19 pandemic, its 2020 Annual Meeting of Shareholders will be held as a virtual meeting.  General Business", "labels": -6.7516418013}, {"text": "Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies  Affinia Therapeutics\u2019 proprietary AAV vector technology to be used in Vertex\u2019s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis BOSTON &amp; WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 27, 2020-- Vertex Pharmaceuticals Incorporated  General Business", "labels": -7.0205515041}, {"text": "The Vertex Foundation Announces Donation to Food Banks Canada to Help With COVID-19 Response  TORONTO , April\u00a024,\u00a02020 /CNW/ - Vertex Pharmaceuticals Incorporated announced that the Vertex Foundation , a nonprofit charitable foundation, will donate $50,000 CAD to Food Banks Canada to support their COVID-19 Response Fund . Food banks across Canada have been severely impacted by COVID-19.", "labels": -0.5995997516}, {"text": "Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI\u00ae (lumacaftor/ivacaftor) and SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients  Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland LONDON --(BUSINESS WIRE)--Apr. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has  General Business", "labels": -1.3475906555}, {"text": "Vertex to Announce First-Quarter 2020 Financial Results on April 29  BOSTON --(BUSINESS WIRE)--Apr. 20, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2020 financial results on Wednesday, April 29, 2020 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": -3.4893507815}, {"text": "The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response  BOSTON --(BUSINESS WIRE)--Apr. 7, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match  General Business", "labels": -5.4033445632}, {"text": "Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs  BOSTON --(BUSINESS WIRE)--Mar. 27, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today confirmed its 2020 business outlook and the continuity of the company\u2019s supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its development programs given the ongoing  General Business", "labels": 5.385480162}, {"text": "The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare , a Boston -based nonprofit hospital and physician network, to support the needs of patients  General Business", "labels": -9.2406222457}, {"text": "Vertex Confirms Supply Chain Continuity and 2020 Business Outlook  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that the global coronavirus outbreak has not had any impact on the company\u2019s supply chain or its 2020 business outlook. \u201cThe challenges facing the world with the spread of COVID-19 are significant, but it  Webcasts", "labels": 5.3967235604}, {"text": "Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference . Following implementation of a companywide travel and meetings policy that is designed to reduce  Webcasts", "labels": 1.6779119965}, {"text": "Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO\u00ae (ivacaftor) in New Zealand  LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO \u00ae (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1 . Clinicians are able to apply for patient access using the  General Business", "labels": -2.6460953143}, {"text": "Vertex to Present at the Cowen Health Care Conference on March 3  BOSTON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 a.m. ET . The audio portion of management's remarks will be available live through Vertex  Webcasts", "labels": -2.6460953143}, {"text": "Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results  - Full-year 2019 total GAAP product revenues of $4.16 billion - - Full-year 2019 total non-GAAP product revenues of $4.00 billion , a 32% increase compared to the full-year 2018 - - Company provides full-year 2020 total product revenue guidance of $5.1 billion to $5.3 billion - BOSTON --(BUSINESS  Financial", "labels": -1.6692328717}, {"text": "Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30  BOSTON --(BUSINESS WIRE)--Jan. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -0.5242725052}, {"text": "Vertex to Present at the J.P. Morgan Healthcare Conference on January 13  BOSTON --(BUSINESS WIRE)--Jan. 8, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management\u2019s remarks can be accessed  Webcasts", "labels": 1.8978525239}, {"text": "Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed  LONDON --(BUSINESS WIRE)--Dec. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic  General Business", "labels": -0.3143519095}, {"text": "Vertex Announces European Commission Approval for KALYDECO\u00ae (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene  - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in children this young - LONDON --(BUSINESS WIRE)--Dec. 10, 2019-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label  General Business", "labels": 0.2636371959}, {"text": "French Authorities Approve National Reimbursement of ORKAMBI\u00ae (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis  LONDON --(BUSINESS WIRE)--Nov. 20, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the French Authorities (Comit\u00e9 \u00e9conomique des produits de sant\u00e9, or CEPS ) have approved national reimbursement of ORKAMBI \u00ae (lumacaftor/ivacaftor) for people ages two and older with  General Business", "labels": 0.334107295}, {"text": "CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001\u00ae for Severe Hemoglobinopathies  -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta thalassemia: Patient is transfusion independent with total hemoglobin level of 11.9 g/dL  General Business", "labels": 0.9764290845}, {"text": "Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants  -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019&nbsp;-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.  General Business", "labels": 2.3860487827}, {"text": "Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines  -Eligible patients in Wales will soon have access to ORKAMBI \u00ae (lumacaftor/ivacaftor) and SYMKEVI \u00ae (tezacaftor/ivacaftor), expanded access to KALYDECO \u00ae (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:  General Business", "labels": 0.0}, {"text": "Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines  -Eligible patients in Northern Ireland will soon have access to ORKAMBI \u00ae (lumacaftor/ivacaftor) and SYMKEVI \u00ae (tezacaftor/ivacaftor), expanded access to KALYDECO \u00ae (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 12, 2019-- Vertex Pharmaceuticals Incorporated  General Business", "labels": 2.3949814426}, {"text": "Vertex to Present at the Credit Suisse Healthcare Conference on November 12  BOSTON --(BUSINESS WIRE)--Nov. 7, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET . Management\u2019s remarks will be available live through Vertex\u2019s website at  Webcasts", "labels": 2.439026239}, {"text": "Phase 3 Results from Two Studies of TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet  - Both studies met primary and all key secondary endpoints demonstrating significant improvements in lung function and other measures of the disease - - Results of both studies to be presented today at the 33rd Annual North American Cystic Fibrosis Conference as part of six presentations from  General Business", "labels": 1.9309270607}, {"text": "Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis  - Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations - LONDON --(BUSINESS WIRE)--Oct.  General Business", "labels": 1.9309270607}, {"text": "Vertex Reports Third-Quarter 2019 Financial Results  - Product revenues of $950 million , a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - BOSTON --(BUSINESS WIRE)--Oct. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial", "labels": -1.3454087069}, {"text": "Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines  -Eligible patients in England will have access to ORKAMBI \u00ae (lumacaftor/ivacaftor) and SYMKEVI \u00ae (tezacaftor/ivacaftor), expanded access to KALYDECO \u00ae (ivacaftor)- LONDON --(BUSINESS WIRE)--Oct. 24, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an access agreement with  General Business", "labels": 1.4345254081}, {"text": "Vertex to Announce Third-Quarter 2019 Financial Results on October 30  BOSTON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": 7.2385648528}, {"text": "ADDING\u00a0MULTIMEDIA FDA Approves TRIKAFTA\u2122 (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease\u2013 -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex\u2019s three other FDA -approved  General Business", "labels": 7.2385648528}, {"text": "FDA Approves TRIKAFTA\u2122 (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease\u2013 -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex\u2019s three other FDA -approved  General Business", "labels": 7.2385648528}, {"text": "Spanish Government Approves National Reimbursement of ORKAMBI\u00ae (lumacaftor/ivacaftor) and SYMKEVI\u00ae (tezacaftor/ivacaftor) in Combination With KALYDECO\u00ae (ivacaftor)  LONDON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI \u00ae (lumacaftor/ivacaftor) and SYMKEVI \u00ae (tezacaftor/ivacaftor) in combination with KALYDECO \u00ae  General Business", "labels": 7.2385648528}, {"text": "Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI\u00ae (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia  LONDON --(BUSINESS WIRE)--Oct. 19, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO \u00ae (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who  General Business", "labels": 7.2385648528}, {"text": "Vertex Receives European CHMP Positive Opinion for KALYDECO\u00ae (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age  - If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - LONDON --(BUSINESS WIRE)--Oct. 18, 2019-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency\u2019s (EMA) Committee for  General Business", "labels": 1.7871731058}, {"text": "Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer  \u00a0 BOSTON --(BUSINESS WIRE)--Oct. 1, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic , M.D., has been appointed as the company\u2019s Executive Vice President, Global Medicines Development and Medical Affairs. Dr.  General Business", "labels": -1.5176046292}, {"text": "Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics  &nbsp; -Partnership will leverage Ribometrix\u2019s discovery platform for up to three therapeutic programs- &nbsp; &nbsp; -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones and royalty payments- &nbsp; &nbsp; BOSTON &amp; DURHAM, N.C. --(BUSINESS WIRE)--Sep.  General Business", "labels": -1.1755586581}, {"text": "Vertex Announces New Access Agreement with Scottish Government for ORKAMBI\u00ae (lumacaftor/ivacaftor) and SYMKEVI\u00ae (tezacaftor/ivacaftor)  Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor LONDON --(BUSINESS WIRE)--Sep. 12, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that eligible cystic fibrosis", "labels": 0.3143952464}, {"text": "Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11  BOSTON --(BUSINESS WIRE)--Sep. 10, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET . The audio portion of management\u2019s remarks can be accessed  Webcasts", "labels": -0.5314529292}, {"text": "Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes  -Semma\u2019s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired for $950 million in cash- BOSTON &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.", "labels": -2.1037161014}, {"text": "FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment  -FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020 - -Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in  General Business", "labels": -0.3433473233}, {"text": "Vertex Reports Second-Quarter 2019 Financial Results  - Product revenues of $940 million , a 25% increase compared to 2018 - - Company increases full-year 2019 total product revenue guidance to $3.6 to $3.7 billion - - Company advancing programs in 5 additional diseases beyond cystic fibrosis - BOSTON --(BUSINESS WIRE)--Jul.  Financial", "labels": 5.8564339301}, {"text": "Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer  BOSTON --(BUSINESS WIRE)--Jul. 25, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden , M.D., Ph.D, into the role of Executive Chairman of the  General Business", "labels": -3.2308333816}, {"text": "Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis  -Application supported by positive results from two global Phase 3 studies in people with CF ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations- BOSTON --(BUSINESS WIRE)--Jul. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:  General Business", "labels": 1.0842325358}, {"text": "Vertex to Announce Second-Quarter 2019 Financial Results on July 31  BOSTON --(BUSINESS WIRE)--Jul. 17, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 0.6513581256}, {"text": "FDA Approves SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene  -SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation- -Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range- BOSTON --(BUSINESS WIRE)--Jun.  General Business", "labels": -1.2816219261}, {"text": "Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics  -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1- -CRISPR to receive an upfront payment of $175 million , with potential for additional milestone and royalty payments- -Exonics to be acquired for an  General Business", "labels": 0.1671334766}, {"text": "Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF  BOSTON --(BUSINESS WIRE)--Jun. 4, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from six scientific abstracts from the company\u2019s portfolio of cystic fibrosis (CF) medicines will be presented at the 42 nd European Cystic Fibrosis Conference , taking place June  General Business", "labels": 2.9491547783}, {"text": "Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis  -Mean absolute improvement in ppFEV 1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo (p  General Business", "labels": -0.6498988318}, {"text": "Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases  -Multi-year collaboration leveraging Kymera\u2019s proprietary targeted protein degradation platform to develop novel medicines- -Kymera to receive $70 million upfront, including equity investment, and potential additional milestone and royalty payments for up to six programs in the collaboration-  General Business", "labels": 2.8314587243}, {"text": "Vertex Reports First-Quarter 2019 Financial Results  - First-quarter 2019 product revenues of $857 million , a 34% increase compared to $638 million in 2018- - First-quarter 2019 GAAP operating income increased 115% to $277 million ; non-GAAP operating income increased 81% to $377 million - - On track to choose best triple combination regimen in Q2  Financial", "labels": -0.7705599799}, {"text": "FDA Approves KALYDECO\u00ae (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age  -Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages six to   General Business", "labels": -0.7705599799}, {"text": "CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia  ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass. \u2013 April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the  General Business", "labels": -9.9778424509}, {"text": "Vertex to Announce First-Quarter 2019 Financial Results on April 30  BOSTON --(BUSINESS WIRE)--Apr. 12, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -1.6055633665}, {"text": "Vertex Appoints Charles Wagner as Chief Financial Officer  BOSTON --(BUSINESS WIRE)--Apr. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019 . Mr. Wagner will report directly to Vertex Chairman,  General Business", "labels": 1.0271928693}, {"text": "Vertex Receives Approval for SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations  -A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis- -First medicine in Australia to treat the underlying cause of cystic fibrosis in patients who have certain mutations that result in residual CFTR function- BOSTON --(BUSINESS  General Business", "labels": 2.429176816}, {"text": "Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis  -Mean absolute improvement in ppFEV 1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation (F/MF) compared to placebo (p  General Business", "labels": -5.3580382021}, {"text": "CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001  -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass., Feb.  General Business", "labels": 1.1539237227}, {"text": "Vertex Appoints Lloyd Carney to its Board of Directors  BOSTON --(BUSINESS WIRE)--Feb. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Lloyd Carney has been appointed to its board of directors as an independent director. Mr. Carney is a prominent technology executive with experience leading innovative, high-growth  General Business", "labels": -1.044359657}, {"text": "Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission  -Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) through 8 weeks of tezacaftor/ivacaftor treatment- -Tezacaftor in combination with ivacaftor was generally well tolerated and safety data were consistent with previous  General Business", "labels": 1.8875965936}, {"text": "Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results  - Full-year 2018 CF product revenues of $3.04 billion , a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million - - Full-year 2018 GAAP operating income increased 415% to $635 million ; non-GAAP operating income increased 97% to $1.11 billion - -  Financial", "labels": -1.875101804}, {"text": "Health Canada Grants Market Authorization for KALYDECO\u00ae (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene  -KALYDECO is the first and only approved medicine in Canada to treat the underlying cause of cystic fibrosis in these young patients- BOSTON --(BUSINESS WIRE)--Jan. 28, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for  General Business", "labels": -1.3735365874}, {"text": "Vertex Announces Departure of Ian Smith, Names Interim CFO  BOSTON --(BUSINESS WIRE)--Jan. 23, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately. Mr. Smith\u2019s termination is the result of personal behavior that  General Business", "labels": -4.3359396819}, {"text": "Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5  BOSTON --(BUSINESS WIRE)--Jan. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -1.8905663012}, {"text": "Vertex Announces European Commission Approval for ORKAMBI\u00ae (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease  Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del mutation LONDON --(BUSINESS WIRE)--Jan. 21, 2019-- Vertex Pharmaceuticals (Europe) Limited today  General Business", "labels": -1.8905663012}, {"text": "CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics&nbsp;(NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the  General Business", "labels": 5.6582381926}, {"text": "Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies  -Multi-year research collaboration funded by Vertex using Arbor\u2019s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases- -Arbor to receive up-front cash payment and convertible note investment, research funding, and potential for additional  General Business", "labels": 3.9779937687}, {"text": "Vertex to Present at the J.P. Morgan Healthcare Conference on January 7  BOSTON --(BUSINESS WIRE)--Jan. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management\u2019s remarks can be accessed  Webcasts", "labels": 1.5391126119}, {"text": "Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI\u00ae (lumacaftor/ivacaftor) as well as SYMKEVI\u00ae (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal  - If accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland , eligible patients could have access to these precision cystic fibrosis medicines in 2019 - - While the SMC reviews the submissions, clinicians can apply for access to these CF medicines via the PACS Tier 2  General Business", "labels": -1.0787292011}, {"text": "Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150  -Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study for VX-150 further validates the potential role of NaV1.8 inhibition for the treatment of multiple  General Business", "labels": -5.9246146978}, {"text": "Health Canada Grants Market Authorization for ORKAMBI\u00ae (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease  - ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)--Dec. 13, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization  General Business", "labels": -2.9401388168}, {"text": "Vertex Announces European Commission Approval for KALYDECO\u00ae (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene  Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in these young patients LONDON --(BUSINESS WIRE)--Nov. 29, 2018-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label  General Business", "labels": 2.1571956642}, {"text": "Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis  -Mean absolute improvement in ppFEV 1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p  General Business", "labels": 5.5779862847}, {"text": "Vertex Receives European CHMP Positive Opinion for ORKAMBI\u00ae (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease  - If approved, lumacaftor/ivacaftor will be the first medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 young children with two copies of the F508del mutation - LONDON --(BUSINESS WIRE)--Nov. 16, 2018-- Vertex Pharmaceuticals (Europe) Limited today  General Business", "labels": -3.2221934231}, {"text": "Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI\u00ae (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO\u00ae), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene  - A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis - - First medicine in the EU to treat the CFTR protein defect in patients who have one copy of the F508del mutation and one copy of one of 14 mutations that result in residual  General Business", "labels": 2.1813139395}, {"text": "Vertex Reports Third-Quarter 2018 Financial Results  -Third-quarter 2018 total CF product revenues of $783 million , a 42% increase compared to $550 million in the third quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;D and SG&amp;A expense  Financial", "labels": -5.6820262227}, {"text": "Vertex Receives European CHMP Positive Opinion for KALYDECO\u00ae (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene   If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for these young children LONDON --(BUSINESS WIRE)--Oct. 19, 2018-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency\u2019s (EMA) Committee for Medicinal  General Business", "labels": -1.0992177419}, {"text": "Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis  - Phase 2 results of VX-659 and VX-445 triple combination regimens concurrently published in The New England Journal of Medicine - - Phase 3 ARRIVAL data support treating the underlying cause of cystic fibrosis with KALYDECO \u00ae (ivacaftor) as early as six months of age - - Patient-reported outcomes  General Business", "labels": -4.8949802067}, {"text": "Vertex to Announce Third Quarter 2018 Financial Results on October 24  BOSTON --(BUSINESS WIRE)--Oct. 16, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 3.5637269585}, {"text": "CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease  ZUG, Switzerland &nbsp; and &nbsp; BOSTON &nbsp; and &nbsp; CAMBRIDGE, Mass. , &nbsp; Oct. 10, 2018 &nbsp; (GLOBE NEWSWIRE) -- &nbsp; CRISPR Therapeutics&nbsp; (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and &nbsp; Vertex Pharmaceuticals Incorporated &nbsp; (NASDAQ:VRTX)  Other", "labels": -5.2715440702}, {"text": "Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines  - First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI \u00ae (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON  General Business", "labels": -0.6825472138}, {"text": "Vertex to Present at the Morgan Stanley Healthcare Conference on September 14  BOSTON --(BUSINESS WIRE)--Sep. 11, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET . The audio portion of management\u2019s remarks will be available live  Webcasts", "labels": -0.3308267074}, {"text": "Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility  -- Ms. Jensen to oversee global CSR efforts and lead The Vertex Foundation -- BOSTON --(BUSINESS WIRE)--Sep. 10, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). In this role, Ms.  General Business", "labels": -0.7782315575}, {"text": "Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis  -Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F508del mutations- -Enrollment of two Phase 3 studies of VX-445 in triple combination with tezacaftor and ivacaftor  General Business", "labels": -1.6938726614}, {"text": "Vertex Announces Reimbursement Agreement in Australia for ORKAMBI\u00ae (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation  - Approximately 1,300 patients in Australia join the thousands of patients worldwide who already have access to lumacaftor/ivacaftor - - A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has also been established - LONDON --(BUSINESS WIRE)--Sep.  General Business", "labels": -0.0109104377}, {"text": "Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines  Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines BOSTON &amp; OXFORD, United Kingdom --(BUSINESS WIRE)--Aug. 30, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a  General Business", "labels": -0.3253829302}, {"text": "Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations  \u2013 Ludovic Fenaux to lead Vertex\u2019s expanding International organization \u2013 \u2013 Simon Bedson announces retirement \u2013 LONDON --(BUSINESS WIRE)--Aug. 23, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International  General Business", "labels": -0.4976277432}, {"text": "Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI\u00ae (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation  - PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible - LONDON --(BUSINESS WIRE)--Aug.  General Business", "labels": 0.1357036596}, {"text": "Vertex Awards Two College Students Full Scholarships to the University of Massachusetts  -- Boston Public High School Students Nora Nguyen and Sonny Mei Receive Vertex Science Leaders Scholarship to Pursue STEAM Degrees at UMass -- BOSTON --(BUSINESS WIRE)--Aug. 16, 2018-- Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride  General Business", "labels": 1.0790601633}, {"text": "FDA Approves KALYDECO\u00ae (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene   -Data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages 12 to  General Business", "labels": 0.3315053777}, {"text": "FDA Approves ORKAMBI\u00ae (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease  - Approximately 1,300 people in the U.S. ages 2 through 5 years have two copies of the F508del mutation, the most common genetic form of the disease - BOSTON --(BUSINESS WIRE)--Aug. 7, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.  General Business", "labels": -0.3650880653}, {"text": "Vertex Receives European CHMP Positive Opinion for SYMKEVI\u00ae (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene  If approved, SYMKEVI \u00ae (tezacaftor/ivacaftor) will be Vertex\u2019s third medicine to treat the CFTR protein defect in patients with cystic fibrosis \u2013 a rare life-shortening disease LONDON --(BUSINESS WIRE)--Jul. 27, 2018-- Vertex Pharmaceuticals (Europe) Limited , today announced that the European  General Business", "labels": -0.4357267027}, {"text": "Vertex Reports Second-Quarter 2018 Financial Results  -Second-quarter 2018 total CF product revenues of $750 million , a 46% increase compared to $514 million in the second quarter of 2017- -Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;D and SG&amp;A expense  Financial", "labels": 0.6197739058}, {"text": "Vertex to Announce Second Quarter 2018 Financial Results on July 25  BOSTON --(BUSINESS WIRE)--Jul. 12, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 3.0360087133}, {"text": "Health Canada Approves PrSYMDEKO\u2122 (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene  -SYMDEKO is Vertex\u2019s third medicine to treat the underlying cause of CF- -Approximately 2,000 people in Canada are ages 12 and older and have two copies of the F508del mutation or at least one mutation in the CF gene that is responsive to treatment with SYMDEKO- BOSTON --(BUSINESS WIRE)--Jun.  General Business", "labels": 13.0442530901}, {"text": "Vertex\u2019s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis  BOSTON --(BUSINESS WIRE)--Jun. 21, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year\u2019s Warren Alpert Foundation Prize for \u201ctransformative discoveries in the fields of genetics,  General Business", "labels": 0.822914466}, {"text": "Vertex Opens Expanded Research Site in San Diego  BOSTON --(BUSINESS WIRE)--Jun. 18, 2018-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines , San Diego . The new site represents a significant expansion of the Company\u2019s research presence in the area, and  General Business", "labels": 0.3883534651}, {"text": "Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI\u00ae (lumacaftor/ivacaftor)  - The agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1 - - A framework for assessment and access to our future cystic fibrosis medicines is included as part of the agreement - LONDON --(BUSINESS WIRE)--Jun.  General Business", "labels": 0.3883534651}, {"text": "The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program  BOSTON --(BUSINESS WIRE)--Jun. 14, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company\u2019s new dollar-for-dollar matching gift program.  General Business", "labels": 1.6643025158}, {"text": "Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF  - Data from KALYDECO \u00ae (ivacaftor) studies show the potential to modify the long-term progression of the disease - - Interim analysis of the ongoing extension study of tezacaftor/ivacaftor combination (approved in the U.S. as SYMDEKO TM ) continues to demonstrate consistent safety and sustained  General Business", "labels": 2.2915954024}, {"text": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 13  BOSTON --(BUSINESS WIRE)--Jun. 6, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET ( 2:40 p.m. PT ). The audio portion of management\u2019s remarks will be  Webcasts", "labels": 0.0205823529}, {"text": "CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease  BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug  General Business", "labels": -1.3896099933}, {"text": "Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members  All in for CF Scholarship Program Doubles to Help 80 Recipients Pursue Higher Education BOSTON --(BUSINESS WIRE)--May 1, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program.  General Business", "labels": -2.4553409641}, {"text": "Vertex Reports First-Quarter 2018 Financial Results  -First-quarter 2018 total CF product revenues of $638 million , a 33% increase compared to $481 million in the first quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.65 to $2.80 billion and combined non-GAAP R&amp;D and SG&amp;A expense guidance of $1.50 to $1.55  Financial", "labels": -0.3524530862}, {"text": "Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis  -VX-445 triple combination regimen is the second of two different triple combination regimens to enter Phase 3 development in 2018- -Phase 3 study in approximately 360 patients with one F508del mutation and one minimal function mutation designed to support New Drug Application based on 4-week  General Business", "labels": -0.3524530862}, {"text": "Vertex to Announce First Quarter 2018 Financial Results on April 26  BOSTON --(BUSINESS WIRE)--Apr. 17, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 1.7262532527}, {"text": "Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer  BOSTON --(BUSINESS WIRE)--Mar. 29, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.", "labels": -2.2519380254}, {"text": "Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.  General Business", "labels": -2.2519380254}, {"text": "Vertex to Present at the Cowen Healthcare Conference on March 13  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET . The audio portion of management's remarks will be available live through Vertex's website,  Webcasts", "labels": -0.8801973177}, {"text": "Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -Global Phase 3 study to enroll approximately 100 patients with the most common genetic form of the disease- -Phase 2 data showed mean absolute improvement in ppFEV 1 &nbsp;of 9.7 percentage points when VX-659 was added in people with CF who have two F508del mutations who were already receiving  General Business", "labels": 2.5755644747}, {"text": "Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer  - Jeffrey Chodakewitz , M.D., to retire and serve as senior advisor through early 2019- - Dr. Kewalramani to become CMO and Executive Vice President, Global Medicines Development and Medical Affairs, on April 1, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  Other", "labels": -0.6269551818}, {"text": "Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis  -Global Phase 3 study to enroll 360 patients with one F508del mutation and one minimal function mutation- -Study designed to support submission of New Drug Application in the U.S. based on 4-week primary efficacy endpoint and 12-week safety data- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  General Business", "labels": -1.9290618793}, {"text": "Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study  -VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine hydrocodone+acetaminophen to support evaluation of VX-150 treatment effect- -Phase 2 study in acute pain is the  General Business", "labels": 5.1634133419}, {"text": "FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene  - SYMDEKO is Vertex's third medicine to treat the underlying cause of CF - - SYMDEKO to begin shipping to pharmacies this week - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved SYMDEKO \u2122  General Business", "labels": 0.4735926628}, {"text": "Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis  - Phase 2 data showed mean absolute improvements in ppFEV 1 of up to 13.3 and 13.8 percentage points for VX-659 and VX-445, respectively, in triple combination with tezacaftor and ivacaftor in people with CF who have one F508del mutation and one minimal function mutation (F508del/Min); triple  General Business", "labels": -4.7341162519}, {"text": "Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results  -Total 2017 CF product revenues of $2.17 billion , a 29% increase compared to $1.68 billion in 2016; 2017 KALYDECO revenues of $845 million and 2017 ORKAMBI revenues of $1.32 billion - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated  Financial", "labels": 3.6244893192}, {"text": "Vertex Receives EU Approval for ORKAMBI\u00ae (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - - Existing reimbursement agreements in countries like Ireland will enable rapid access to ORKAMBI; country-by-country reimbursement processes will now begin in other countries- LONDON  General Business", "labels": 1.5151477203}, {"text": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET ( 9:30 a.m. PT ). The audio portion of management's remarks can be accessed live through  Webcasts", "labels": -0.2809124291}, {"text": "Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and \u03b2-Thalassemia  -Vertex selects CTX001 as first gene edited treatment to be developed as part of collaboration with CRISPR Therapeutics - -Clinical Trial Application for CTX001 submitted in Europe to support initiation of Phase 1/2 clinical study in \u03b2-thalassemia in 2018- -Preclinical data for CTX001 presented  General Business", "labels": 3.2872994926}, {"text": "Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO\u00ae (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years  -Study met primary safety endpoint and showed improvements across multiple endpoints, including measures of pancreatic function- -Potential to modify the course of CF in children as young as one year of age- -Results support FDA and EMA filings in the first quarter of 2018- BOSTON --(BUSINESS  General Business", "labels": 3.9621213127}, {"text": "Vertex Receives CHMP Positive Opinion for ORKAMBI\u00ae (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive  General Business", "labels": -0.1553710258}, {"text": "Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF  - Data from ongoing extension study of ORKAMBI \u00ae (lumacaftor/ivacaftor) in children ages 6-11 and real-world KALYDECO \u00ae (ivacaftor) data demonstrate long-term safety and other benefits of these medicines - - New data from ongoing extension study of tezacaftor/ivacaftor combination demonstrate  General Business", "labels": 3.9803952516}, {"text": "Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine  - Data showed significant improvements in lung function (ppFEV 1 ) with a favorable safety profile across multiple patient groups - - Tezacaftor/ivacaftor currently under review by the FDA and EMA; FDA Priority Review action date of February 28, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex  General Business", "labels": 3.9803952516}, {"text": "Vertex to Present at the Credit Suisse Healthcare Conference on November 7  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com  Webcasts", "labels": 5.3077326459}, {"text": "Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers  The Vertex Research Innovation Award (RIA) Program Will Now Provide up to $10M in Grants Over the Next Five Years to New Postdoctoral and Faculty Researchers from Around the World BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated\u00a0 (Nasdaq: VRTX) announced today a new $750,000 program  General Business", "labels": -1.6908297517}, {"text": "Vertex Reports Third-Quarter 2017 Financial Results  -Third-quarter 2017 cystic fibrosis product revenues of $550 million , up 34% versus Q3 2016; $336 million for ORKAMBI and $213 million for KALYDECO- -Company increases total 2017 CF product revenue guidance to $2.10 to $2.15 billion ; increases ORKAMBI revenue guidance to $1.29 to $1.32 billion  Financial", "labels": -4.3962211782}, {"text": "Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families  Now Accepting Applications for the \"All in for CF\" Scholarship Program Through Jan. 3, 2018 BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family members.  General Business", "labels": -2.7860543292}, {"text": "Vertex Announces 10-Year, $500 Million Corporate Giving Commitment  Dedicates $50M to science, technology, engineering, arts and math (STEAM) education for underserved students and establishes The Vertex Foundation Expands global efforts for providing patient and caregiver support including access to our medicines; developing young scientists and physicians; and  General Business", "labels": 0.1356884612}, {"text": "Vertex to Announce Third Quarter 2017 Financial Results on October 25  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 1.2512108373}, {"text": "Vertex to Present at the Leerink Partners Roundtable Series on September 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease &amp; Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.m. ET Management's remarks will be available live through  Webcasts", "labels": -1.2957865827}, {"text": "Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference  -Eleven abstracts from Vertex's CF program accepted for presentation- -Late-breaking abstract submitted with data from three different triple combination regimens in CF patients- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its  General Business", "labels": -0.3601381924}, {"text": "Vertex to Present at the Morgan Stanley Healthcare Conference on September 11  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Monday, September 11, 2017 at 1:40 p.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com  Webcasts", "labels": 1.1018069507}, {"text": "Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO). Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice  General Business", "labels": -0.056455891}, {"text": "Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA  - FDA grants Priority Review of the application and sets action date of February 28, 2018 - -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function  General Business", "labels": -0.2153075108}, {"text": "FDA Approves KALYDECO\u00ae (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO \u00ae (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who have one of five residual function  General Business", "labels": 2.8689331545}, {"text": "Vertex Reports Second-Quarter 2017 Financial Results  -Second-quarter 2017 cystic fibrosis product revenues of $514 million ; $324 million for ORKAMBI and $190 million for KALYDECO- -Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidance for combined GAAP and non-GAAP R&amp;D and SG&amp;A expenses- -Pipeline of  Financial", "labels": -3.8158597618}, {"text": "Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656  BOSTON &amp; LEXINGTON, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the completion of their previously announced asset purchase agreement. Under the completed agreement, Vertex now has worldwide  General Business", "labels": -2.1539617623}, {"text": "Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)  -Phase 2 data showed mean absolute improvements in ppFEV 1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min patients; Initial data from Phase 1 study showed mean absolute improvement in ppFEV 1 of 9.6  General Business", "labels": 19.0869780585}, {"text": "Vertex Awards Two First-Generation College Students Full Scholarships to the University of Massachusetts  Boston Public High School Students Hannah Mei and Sayed Shah Receive Vertex Science Leaders Scholarship to Pursue STEM Degrees at UMass BOSTON --(BUSINESS WIRE)-- Vertex , Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the annual Vertex Science  General Business", "labels": 1.3014536721}, {"text": "Vertex to Announce Second Quarter 2017 Financial Results on July 26  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2017 financial results on Wednesday, July 26, 2017 after the financial markets close. The company will host a conference call and webcast at 5:15 p.m. ET .  Webcasts", "labels": -0.572562767}, {"text": "Vertex Announces Reimbursement Agreement in Italy for ORKAMBI\u00ae (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  - Effective immediately, agreement enables hundreds of people in Italy to access this important medicine - - Recent pricing and reimbursement agreements have enabled broad access to ORKAMBI for thousands of eligible patients in multiple European countries; negotiations continue in a number of other  General Business", "labels": -0.572562767}, {"text": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 13  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Tuesday, June 13, 2017 at 12:20 p.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in  Webcasts", "labels": -3.3755659455}, {"text": "Vertex Announces Nine Presentations of Data on ORKAMBI\u00ae (lumacaftor/ivacaftor) and KALYDECO\u00ae (ivacaftor) at the European Cystic Fibrosis Society (ECFS) Conference  - Presentation of data from a Phase 3 study of ORKAMBI in children ages 6-11 with two copies of the F508del mutation demonstrated improvements in lung function and sweat chloride; study also published online in The Lancet Respiratory Medicine today - - ECFS data presentations demonstrate that  General Business", "labels": -3.3755659455}, {"text": "Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors  BOSTON --(BUSINESS WIRE)-- Shareholders of Vertex Pharmaceuticals Incorporated \u00a0(Nasdaq: VRTX) today elected Alan M. Garber , M.D., Ph.D. as an independent member of its board of directors.\u00a0Dr. Garber is Provost of Harvard University , the Mallinckrodt Professor of Health Care Policy at Harvard  General Business", "labels": -1.9077093331}, {"text": "Vertex Announces Long-Term Reimbursement Agreement with the Republic of Ireland for ORKAMBI\u00ae (lumacaftor/ivacaftor), KALYDECO\u00ae (ivacaftor) and Future Cystic Fibrosis Medicines  -Agreement provides access to ORKAMBI for people who have two copies of the F508del mutation and expands access to KALYDECO for all eligible patients- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached an agreement with the Health Service  General Business", "labels": 4.5419508651}, {"text": "Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members  - New Program Helps CF Families Pursue Higher Education - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated \u00a0(Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program. Each of the 40 scholarship recipients will be awarded $5,000 for the  General Business", "labels": 0.9836941099}, {"text": "Vertex to Present at the UBS Healthcare Conference on May 23  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in the  Webcasts", "labels": 2.0928602454}, {"text": "FDA Approves KALYDECO\u00ae (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations  - Precision medicine decision based on in vitro data and supported by more than five years of real-world clinical data that demonstrate KALYDECO's strong safety and efficacy profile for eligible patients - - Vertex working with FDA to obtain rapid approval for more than 600 additional people who  General Business", "labels": 0.4154989083}, {"text": "Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis  Third Annual CF \"Circle of Care\" Grants Connect CF Community Members Around the World to Share Their Ideas and Inspiration BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program, an  General Business", "labels": -4.1361896129}, {"text": "Vertex Reports First-Quarter 2017 Financial Results  -First-quarter 2017 cystic fibrosis product revenues of $481 million ; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million -  Financial", "labels": 1.944212166}, {"text": "Vertex to Announce First Quarter 2017 Financial Results on April 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": -0.3778561456}, {"text": "Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis  \u00a0 - Study in people who have two copies of the F508del mutation demonstrated a mean absolute improvement in ppFEV 1 of 4.0 percentage points compared to placebo (p   Cystic Fibrosis", "labels": 16.3873754537}, {"text": "Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis  -Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF- -Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  Cystic Fibrosis", "labels": 1.7192287561}, {"text": "Vertex to Present at the Cowen Healthcare Conference on March 6  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com in the \"Investors\"  Webcasts", "labels": 0.2771925859}, {"text": "Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results  -2016 total CF product revenues of $1.68 billion compared to $982 million in 2015; $980 million for ORKAMBI and $703 million for KALYDECO- -Fourth-quarter 2016 total CF product revenues of $454 million ; $277 million for ORKAMBI and $177 million for KALYDECO- -Company reiterates 2017 financial  Financial", "labels": 3.2579382628}, {"text": "Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex  -Merck KGaA, Darmstadt, Germany licenses two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs- -Vertex receives upfront payment of $230 million plus royalties on future sales- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  Other", "labels": -0.94671536}, {"text": "Vertex Provides Update on Business and Financial Performance and Research and Development Programs  -Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI  General Business", "labels": 3.7742641287}, {"text": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2016 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 12:30 p.m. ET ( 9:30 a.m. PT ).  Webcasts", "labels": 4.8570660972}, {"text": "Vertex Announces German Reimbursement Agreement for ORKAMBI\u00ae (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI \u00ae (lumacaftor/ivacaftor) with the German Federal Association of the Statutory Health Insurances (GKV-SV).  Cystic Fibrosis", "labels": -0.0261599195}, {"text": "Positive Phase 3 Study of ORKAMBI\u00ae in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutation Supports a Submission to the European Medicines Agency in the First Half of 2017  - Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) compared to placebo through 24 weeks of treatment - - ORKAMBI was well tolerated with safety data that were similar to data from previous Phase 3 open-label safety study -  Cystic Fibrosis", "labels": 3.1449580402}, {"text": "Vertex to Present at the Credit Suisse Healthcare Conference on November 8  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8 th at 3:30 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com in the  Webcasts", "labels": 0.115850128}, {"text": "Vertex Presents Long-Term Data Demonstrating that ORKAMBI\u00ae (lumacaftor/ivacaftor) and KALYDECO\u00ae (ivacaftor) Show the Potential to Modify the Progression of CF  - 12 abstracts presented at 30 th Annual North American Cystic Fibrosis Conference highlight data from Vertex's CF program - ORLANDO, Fla. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI \u00ae  Cystic Fibrosis", "labels": -2.3330723329}, {"text": "Vertex Reports Third Quarter 2016 Financial Results  -Third quarter 2016 cystic fibrosis product revenues of $410 million ; $234 million for ORKAMBI \u00ae (lumacaftor/ivacaftor) and $176 million for KALYDECO \u00ae (ivacaftor)- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the  Financial", "labels": -0.2159803976}, {"text": "Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis  -VX-440 to be evaluated as part of 4-week triple combination dosing with tezacaftor (VX-661) and ivacaftor; VX-152 to be evaluated as part of 2-week triple combination dosing- -Studies to enroll people with cystic fibrosis who have one copy of the F508del mutation and a minimal function mutation  Cystic Fibrosis", "labels": -0.2159803976}, {"text": "Vertex to Announce Third Quarter 2016 Financial Results on October 25  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2016 financial results on Tuesday, October 25, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 0.721101096}, {"text": "U.S. Food and Drug Administration Approves ORKAMBI\u00ae (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation  -Approximately 2,400 children ages 6 through 11 have two copies of the F508del mutation in the U.S. - - Vertex revises ORKAMBI revenue guidance for 2016 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  Cystic Fibrosis", "labels": -6.4823554544}, {"text": "Vertex to Present at Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated \u00a0(Nasdaq: VRTX) today announced that management will present at The Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 14 th at 11:40 a.m. ET . Vertex will also present at The Leerink Partners Roundtable  Webcasts", "labels": 1.5838984693}, {"text": "Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis  -Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the study- -Enrollment complete in Phase 3 study in people with two copies of the F508del mutation-  Cystic Fibrosis", "labels": -1.9599990845}, {"text": "Vertex Reports Second Quarter 2016 Financial Results  -Second quarter 2016 cystic fibrosis product revenues of $426 million ; $245 million for ORKAMBI \u00ae (lumacaftor/ivacaftor) and $180 million for KALYDECO \u00ae (ivacaftor)- -Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705  Financial", "labels": 1.6214505493}, {"text": "Vertex to Announce Second Quarter 2016 Financial Results on July 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts", "labels": 1.3634804789}, {"text": "Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics\u2122 for Cystic Fibrosis  -Collaboration to explore use of mRNA Therapeutics to treat the underlying cause of CF by enabling cells to produce functional CFTR proteins in the lungs- - Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential  Cystic Fibrosis", "labels": 4.3198214967}, {"text": "Vertex Announces Presentations of Data for KALYDECO\u00ae (ivacaftor) and ORKAMBI\u00ae (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference  -Real-world data presented at ECFS show long-term impact of KALYDECO across multiple measures of disease- -Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS- BASEL, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  Cystic Fibrosis", "labels": -2.1427020342}, {"text": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 7  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde , CA on Tuesday, June 7 th at 1:40 p.m. ET ( 10:40 a.m. PT ). Management's remarks will be accessible live  Webcasts", "labels": 3.4930763855}, {"text": "U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI\u00ae (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation  -Approximately 2,400 children ages 6 to 11 have two copies of the F508del mutation in the U.S. - -Target review date of September 30, 2016 set for the FDA's decision on the application- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the U.S.  Cystic Fibrosis", "labels": 3.4930763855}, {"text": "Vertex Reports First Quarter 2016 Financial Results  -First quarter 2016 cystic fibrosis product revenues of $394 million ; $223 million for ORKAMBI \u00ae (lumacaftor/ivacaftor) and $171 million for KALYDECO \u00ae (ivacaftor)- -Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion ; increases 2016 guidance for KALYDECO product revenues  Financial", "labels": 3.412102691}, {"text": "Vertex to Announce First Quarter 2016 Financial Results on April 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2016 financial results on Wednesday, April 27, 2016 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": -5.0468599936}, {"text": "Vertex to Present at the Barclays Healthcare Conference on March 15  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Barclays Healthcare Conference in Miami, FL on Tuesday, March 15 th at 10:15 a.m. ET . Management's remarks will be accessible live through Vertex's website at  Webcasts", "labels": 1.2752126674}, {"text": "Vertex Receives Australian Approval for ORKAMBI\u00ae (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  -In Australia, approximately 1,000 people with CF ages 12 and older have two copies of the F508del mutation- -ORKAMBI reimbursement process already underway in Australia - LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods  Cystic Fibrosis", "labels": -7.0896847391}, {"text": "Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated\u00a0 (Nasdaq: VRTX) today announced it has awarded the company's 2016 Cystic Fibrosis (CF) Circle of Care grants , totaling approximately\u00a0$1 million,\u00a0to 18 non-profit medical, academic, patient and community organizations.  Cystic Fibrosis", "labels": 1.6485397555}, {"text": "Vertex to Present at Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it will present at the Leerink Healthcare Conference in New York, NY on Thursday, February 11 th at 11:10 a.m. ET . Vertex will also present at the Cowen Healthcare Conference in Boston, MA on Tuesday,  Webcasts", "labels": 1.8108446056}, {"text": "Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO\u00ae (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for the use of KALYDECO \u00ae (ivacaftor) in people with cystic  Cystic Fibrosis", "labels": -9.4878033894}, {"text": "Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results  -Full-year 2015 total non-GAAP revenues of $1.01 billion , including net product revenues of $351 million for ORKAMBI \u00ae (lumacaftor/ivacaftor) and $632 million for KALYDECO \u00ae (ivacaftor) in cystic fibrosis- -Vertex reiterates 2016 financial guidance for KALYDECO net product revenues of $670 to $690  Financial", "labels": 0.4420048002}, {"text": "Health Canada Approves PrORKAMBI\u00ae (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation  -Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved Pr ORKAMBI \u00ae  Cystic Fibrosis", "labels": -0.216212917}, {"text": "Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases  -Approximately 25,000 people with cystic fibrosis worldwide currently eligible for treatment with ORKAMBI \u00ae (lumacaftor/ivacaftor) or KALYDECO \u00ae (ivacaftor); Vertex advancing the development of multiple medicines with the goal of treating all people with cystic fibrosis- -Fourth quarter 2015 net  General Business", "labels": -6.0208393482}, {"text": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 34 th Annual J.P. Morgan Healthcare Conference on Monday, January 11 at 12:30 p.m. ET ( 9:30 a.m. PT ).  Webcasts", "labels": -1.3580921109}, {"text": "Vertex to Present at the Piper Jaffray Healthcare Conference on December 1  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 1 at 11:00 a.m. ET . Management's remarks will be available live through  Webcasts", "labels": 1.7651964376}, {"text": "Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)\u00a0today announced the appointment of Michael J. Parini\u00a0to the role of Executive Vice President and Chief Legal Officer. Mr. Parini will serve as a member of Vertex's Executive Committee, reporting directly to Jeffrey Leiden  General Business", "labels": 1.7651964376}, {"text": "Vertex Receives EU Approval for ORKAMBI\u00ae (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  -In Europe, approximately 12,000 people with CF ages 12 and older have two copies of the F508del mutation- -Positive CHMP Opinion was received in September 2015 - -Country-by-country reimbursement process will now begin- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  Cystic Fibrosis", "labels": -0.1889787684}, {"text": "Vertex Receives Two EU Approvals for KALYDECO\u00ae (ivacaftor) for People with Cystic Fibrosis  - European Commission approves expanded use of ivacaftor in children with cystic fibrosis ages 2 to 5 who have one of 9 gating mutations; approximately 125 children ages 2 to 5 have one of the approved gating mutations in Europe - - European Commission approves expanded use of ivacaftor in people  Cystic Fibrosis", "labels": 1.5913340214}, {"text": "Vertex to Present at the Credit Suisse Healthcare Conference on November 10  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 10 th at 11:30 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in  Webcasts", "labels": -5.7173332879}, {"text": "Vertex Reports Third Quarter 2015 Financial Results  -Third quarter 2015 revenues of $310 million , including net product revenues of $131 million for ORKAMBI \u00ae (lumacaftor/ivacaftor) and $166 million for KALYDECO \u00ae (ivacaftor) in cystic fibrosis- -Vertex increases guidance for 2015 KALYDECO net revenues; now expects KALYDECO revenues of $605 to $620  Financial", "labels": 4.5731923015}, {"text": "Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases  -Gene editing technology to be used to discover treatments to address the mutations and genes known to cause and contribute to cystic fibrosis- -Vertex and CRISPR to utilize gene editing approach to discover treatments for genetic diseases, including sickle cell disease- -Companies establish  Cystic Fibrosis", "labels": 5.5532609719}, {"text": "Vertex to Announce Third Quarter 2015 Financial Results on October 28  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2015 financial results on Wednesday, October 28, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": 3.3819000716}, {"text": "Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease  -Two next-generation correctors to enter clinical development in November; studies of a triple combination of a next-generation corrector with VX-661/ivacaftor planned for 2016 in people with CF- -Treating the underlying cause of CF with ORKAMBI \u00ae (lumacaftor/ivacaftor) or KALYDECO \u00ae (ivacaftor)  Cystic Fibrosis", "labels": 0.6818181818}, {"text": "Supplemental New Drug Application for Use of KALYDECO\u00ae (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S. FDA  -More than 1,500 people with CF are ages two and older and have one of these 23 residual function mutations in the U.S.- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a  Cystic Fibrosis", "labels": -1.3849418996}, {"text": "Vertex Receives CHMP Positive Opinions for ORKAMBI\u2122 (lumacaftor/ivacaftor) and KALYDECO\u00ae (ivacaftor) in the European Union  -CHMP recommends Marketing Authorization for lumacaftor in combination with ivacaftor for people with cystic fibrosis ages 12 and older with two copies of the F508del mutation- -CHMP recommends Marketing Authorization for ivacaftor for children with cystic fibrosis ages 2 to 5 with 9 gating  Cystic Fibrosis", "labels": -14.0203020899}, {"text": "Vertex to Present at the Morgan Stanley Healthcare Conference on September 16  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16 th at 11:40 a.m. ET .  Webcasts", "labels": 0.015393823}, {"text": "Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts  Hosts August 19 th back to school event with Bottom Line for 200+ first-generation college students BOSTON --(BUSINESS WIRE)-- Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship , a four-year scholarship to pursue their  General Business", "labels": -5.6730066048}, {"text": "Vertex Reports Second Quarter 2015 Financial Results  -Second quarter 2015 total revenues of $166 million , including net product revenues of approximately $155 million for KALYDECO \u00ae (ivacaftor) in cystic fibrosis- -Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million - -ORKAMBI\u2122  Financial", "labels": 5.3004632945}, {"text": "Vertex to Announce Second Quarter 2015 Financial Results on July 29  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2015 financial results on Wednesday, July 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": 6.3955672835}, {"text": "ADDING MULTIMEDIA FDA Approves ORKAMBI\u2122 (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  Cystic Fibrosis", "labels": 1.4049562697}, {"text": "FDA Approves ORKAMBI\u2122 (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  Cystic Fibrosis", "labels": 1.4049562697}, {"text": "Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia , M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. \" Dr.  General Business", "labels": 2.6710330513}, {"text": "Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference  -Analysis from TRAFFIC and TRANSPORT extension study of lumacaftor in combination with ivacaftor showed that improvements in lung function and other measures of disease were maintained through 48 weeks in people with cystic fibrosis who have two copies of the F508del mutation- BRUSSELS --(BUSINESS  Cystic Fibrosis", "labels": -1.2061756133}, {"text": "Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases  -ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development and regulatory milestones and royalty payments- BOSTON &amp; DURHAM, N.C.  Cystic Fibrosis", "labels": 1.1857103685}, {"text": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 11  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 11 th at 12:20 p.m. ET ( 9:20 a.m. PT ).  Webcasts", "labels": 2.0167048517}, {"text": "New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor)\u00a0in People with Cystic Fibrosis who have Two Copies of the F508del Mutation  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the\u00a0 New England Journal of Medicine (NEJM) \u00a0published data from the two Phase 3 studies of ORKAMBI TM (lumacaftor/ivacaftor), an investigational medicine designed to treat the underlying cause of  Cystic Fibrosis", "labels": 1.6366600531}, {"text": "Vertex to Present at the UBS Healthcare Conference on May 19  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jeffrey Leiden , M.D., Ph.D., Chairman, President &amp; CEO of Vertex will present at the UBS Healthcare Conference in New York, NY on Tuesday, May 19 th at 11:00 a.m. ET .  Webcasts", "labels": -6.7073170732}, {"text": "Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI\u2122 (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation  - FDA decision expected by July 5, 2015 PDUFA date- -Approximately 8,500 people with cystic fibrosis in the U.S. have two copies of the F508del mutation and are ages 12 and older- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the\u00a0U.S.  Cystic Fibrosis", "labels": 1.1472234309}, {"text": "Vertex Reports First Quarter 2015 Financial Results  -First quarter 2015 total revenues of $139 million , including net product revenues of $130 million for KALYDECO \u00ae (ivacaftor) in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.2 billion on March\u00a031, 2015 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  Financial", "labels": -1.0545125443}, {"text": "Vertex to Announce First Quarter 2015 Financial Results on April 29  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2015 financial results on Wednesday, April 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": 3.7362831837}, {"text": "Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -The combination was generally well tolerated and all patients completed 12 weeks of treatment- -Mean within-group absolute improvement from baseline in lung function of 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively, in patients who  Cystic Fibrosis", "labels": 0.5790522861}, {"text": "Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO\u00ae (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated\u00a0(Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration\u00a0(FDA) approved KALYDECO \u00ae for use in children ages 2 to 5 with cystic fibrosis (CF) who have one of 10 mutations in the cystic fibrosis transmembrane conductance  Cystic Fibrosis", "labels": 3.441337145}, {"text": "Vertex to Present at Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24 th at 11:30 a.m. ET . Vertex will also present at the Cowen and Company Healthcare Conference in  Webcasts", "labels": 0.8665483645}, {"text": "Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015  -Full-year 2014 total revenues of $580 million , including net product revenues of $464 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.4 billion on December\u00a031, 2014 - -Company expects total 2015 KALYDECO net revenues of $560 to $580  Financial", "labels": -9.304365519}, {"text": "Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis  -Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015 - -More than 3,700 people with CF expected to be eligible to receive KALYDECO by end of 2015 supporting  General Business", "labels": -1.9983446871}, {"text": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 33 rd Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 12:30 p.m. ET ( 9:30 a.m. PT ).  Webcasts", "labels": -0.538698721}, {"text": "U.S. Food and Drug Administration Approves KALYDECO\u00ae (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation  --Approximately 500 people with cystic fibrosis ages 6 and older have the R117H mutation in the United States -- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated \u00a0(Nasdaq: VRTX) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) approved a supplemental new drug  Cystic Fibrosis", "labels": 1.0407031875}, {"text": "David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated today announced that David Altshuler , M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard  General Business", "labels": -8.397977185}, {"text": "Vertex to Present at Deutsche Bank BioFEST on December 2  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com  Webcasts", "labels": -1.3285419275}, {"text": "Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -U.S. submission includes request for Priority Review; Accelerated Assessment has been granted in the EU- -Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:  Cystic Fibrosis", "labels": 2.2337818451}, {"text": "Vertex to Present at the Credit Suisse Healthcare Conference on November 11  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the  Webcasts", "labels": 3.0450997192}, {"text": "Vertex Reports Third Quarter 2014 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September\u00a030, 2014 . Vertex reported total third quarter 2014 GAAP revenues of $179 million , including revenues of $127 million from KALYDECO \u00ae  Financial", "labels": -2.2381939792}, {"text": "FDA Advisory Committee Recommends Approval of KALYDECO\u00ae (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO \u00ae (ivacaftor) in people with cystic fibrosis (CF) ages 6 and  Cystic Fibrosis", "labels": 0.2919822586}, {"text": "Vertex to Announce Third Quarter 2014 Financial Results on October 28  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2014 financial results on Tuesday, October 28, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": -5.8555868035}, {"text": "Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis  -Data from across Vertex's cystic fibrosis research and development programs to be presented at the 28 th Annual North American Cystic Fibrosis Conference (NACFC) beginning today- -Interim analysis of rollover study following the Phase 3 TRAFFIC and TRANSPORT studies showed sustained improvements  Cystic Fibrosis", "labels": -1.0121240567}, {"text": "Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014  -Data from Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor and from Phase 3 rollover study of patients who completed TRAFFIC and TRANSPORT to be presented- -Other presentations include studies of ivacaftor in people with cystic fibrosis who have the R117H mutation,  Webcasts", "labels": -2.094068826}, {"text": "Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10 at 8:35 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in  Webcasts", "labels": -1.5837117276}, {"text": "Vertex Receives European Approval for KALYDECO\u2122 (ivacaftor) in Eight Non-G551D Gating Mutations  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  Cystic Fibrosis", "labels": -3.5530682666}, {"text": "Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June\u00a030, 2014. Vertex reported total second quarter 2014 revenues of $138 million , including revenues of $113 million from KALYDECO \u00ae (ivacaftor).  Financial", "labels": -3.6843813835}, {"text": "Vertex to Announce Second Quarter 2014 Financial Results on July 29  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2014 financial results on Tuesday, July 29, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": -2.7245466861}, {"text": "Vertex Announces Retirement of Peter Mueller, Ph.D.  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller , Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr.  General Business", "labels": 2.9474090824}, {"text": "Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO\u00ae (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation  -Marketing Authorization Application (MAA) variation in Europe planned for third quarter of 2014- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S.  Cystic Fibrosis", "labels": 2.1700593262}, {"text": "Vertex Receives European CHMP Positive Opinion for KALYDECO\u2122 (ivacaftor) in Eight Non-G551D Gating Mutations  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  Cystic Fibrosis", "labels": 1.6793451227}, {"text": "Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation  -Combination of lumacaftor and ivacaftor is the first regimen designed to treat the underlying cause of CF in people with two copies of the F508del mutation, the most common form of the disease- -All four 24-week treatment arms achieved primary endpoint of mean absolute improvement in FEV 1  Cystic Fibrosis", "labels": -9.080787867}, {"text": "Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza  -VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Janssen  Other", "labels": -2.4756400611}, {"text": "Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO\u00ae (ivacaftor) in Canada for Eligible People with Cystic Fibrosis  -Before patients can get access through public reimbursement, each participating province or territory must decide to reimburse KALYDECO through its individual drug program- -Approximately 100 people ages 6 and older in Canada have the G551D mutation - BOSTON --(BUSINESS WIRE)-- Vertex  Cystic Fibrosis", "labels": -4.9628233461}, {"text": "Vertex Announces Presentation of New KALYDECO\u2122 (ivacaftor) Data at European Cystic Fibrosis Society Conference  -New data showed that KALYDECO reduced the loss of lung function by half over 3 years in people with CF who have the G551D mutation compared to similar untreated patients- -New data from rollover study of ivacaftor in people with the R117H mutation support earlier results from Phase 3 study that  Cystic Fibrosis", "labels": -0.394612769}, {"text": "Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation  -Data are consistent with in vitro observations in residual function mutations showing that ivacaftor improved CFTR activity- -8-week open-label period showed improvements in lung function- -Data support plans to initiate a Phase 3 study of ivacaftor in people with CF who have a residual function  Cystic Fibrosis", "labels": 0.6296182588}, {"text": "Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 11:00 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the  Webcasts", "labels": 1.2940562353}, {"text": "Vertex to Present at the UBS Global Healthcare Conference on May 20  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the UBS Global Healthcare Conference on Tuesday, May 20 at 11:00 a.m. ET . The audio portion of the remarks will be accessible live through Vertex's website at www.vrtx.com in the  Webcasts", "labels": 0.1034121618}, {"text": "William Young Joins Vertex Board of Directors  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members. \"Mr.  General Business", "labels": -4.2162988384}, {"text": "Addition of VX-661 to KALYDECO\u00ae (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study  -Data provide proof-of-concept for use of VX-661 to further enhance CFTR function in people taking KALYDECO who have the F508del mutation and another mutation known to respond to KALYDECO alone- -Statistically significant improvements in lung function, as well as decreases in sweat chloride,  Cystic Fibrosis", "labels": -1.7628418269}, {"text": "Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities  -Net product revenues of $100 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of $1.32 billion on March 31, 2014 - -Six-month dosing period complete for Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor for people with CF  Cystic Fibrosis", "labels": -1.7628418269}, {"text": "U.S. Food and Drug Administration Approves KALYDECO\u2122 (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis  -KALYDECO is the first medicine to treat the underlying cause of CF for people with specific mutations in the CFTR gene- -KALYDECO facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein- -The eight additional mutations are present in  Cystic Fibrosis", "labels": -0.583687327}, {"text": "Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014  -Full-year 2013 total revenues of $1.21 billion , including net product revenues of $371.3 million for KALYDECO in cystic fibrosis and $466.3 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.47 billion on December\u00a031, 2013- -Company expects  Financial", "labels": 4.370059526}, {"text": "Vertex Reviews Corporate Strategy and Outlines Key 2014 Business Priorities at the 32nd Annual J.P. Morgan Healthcare Conference  -KALYDECO: 2014 revenue growth anticipated from geographic expansion and approval for use in patients with additional CFTR mutations- -Lumacaftor in combination with ivacaftor: results from two Phase 3 studies, TRAFFIC and TRANSPORT, expected mid-year in people with two copies of the F508del  General Business", "labels": 1.9400364938}, {"text": "Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first data from the initial cohorts of an open-label Phase 2a study of VX-135, Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor, in combination with daclatasvir, Bristol-Myers  HCV", "labels": 3.541742329}, {"text": "Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Jeffrey A. Chodakewitz , M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in the  General Business", "labels": 2.3191780007}, {"text": "Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation  -Mean absolute treatment difference in lung function across all patients was 2.1 percentage points (p=0.20) and mean relative treatment difference was 5.0% (p=0.06)(n=69); study did not meet its primary endpoint- -Pre-specified analysis of patients 18 years of age and older (n=50) showed  Cystic Fibrosis", "labels": 6.7242123179}, {"text": "Vertex Sells INCIVO \u00ae Product Royalty Rights for $152 Million  -Vertex to receive $152 million cash payment from Janssen in 2013; will no longer receive royalties on INCIVO sales beginning in 2014- -Company increases 2013 year-end guidance for cash, cash equivalents and marketable securities to in excess of $1.4 billion - CAMBRIDGE, Mass.  HCV", "labels": 5.5865988073}, {"text": "Vertex Focuses Investment on Future Opportunities in Cystic Fibrosis and Other Key Research and Development Programs and Reduces Workforce Related to INCIVEK  -Changes result from the continued and rapid decline in the number of people being treated with INCIVEK as new hepatitis C medicines near approval- -370 positions, including 175 in Massachusetts , to be eliminated, primarily related to support of INCIVEK- CAMBRIDGE, Mass.  Cystic Fibrosis", "labels": -6.0348457576}, {"text": "Vertex Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014  -Third quarter 2013 total revenues of $222 million , including net product revenues of $101 million for KALYDECO in cystic fibrosis and $86 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.42 billion on September\u00a030, 2013- -Company reduces  Financial", "labels": -6.0348457576}, {"text": "Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study  -All doses of VX-509 showed statistically significant ACR20 and ACR50 responses compared to placebo and statistically significant improvement from baseline in DAS28 compared to placebo- -Three highest doses of VX-509: ACR20 of 58% to 68% versus 18% for placebo; statistically significant ACR70  Other", "labels": -3.2690279493}, {"text": "Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis  -Enrollment complete for TRAFFIC and TRANSPORT Phase 3 studies of lumacaftor (VX-809) in combination with ivacaftor for people with two copies of the F508del mutation (homozygous); data expected in mid-2014- -12-week Phase 2 study of VX-661 in combination with ivacaftor planned for people with two  Cystic Fibrosis", "labels": 2.5045423908}, {"text": "Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for KALYDECO\u2122 (ivacaftor) Monotherapy for People with Non-G551D Gating Mutations  -sNDA also includes long-term safety and efficacy data for KALYDECO from PERSIST open-label rollover study- -Marketing Authorization Application (MAA) variation in\u00a0Europe planned for October 2013 - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today  Cystic Fibrosis", "labels": 2.2072150381}, {"text": "Vertex to Announce Third Quarter 2013 Financial Results on October 29  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2013 financial results on Tuesday, October 29, 2013 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts", "labels": 2.5872151563}, {"text": "Results from Phase 3 Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People with non-G551D Gating Mutations  -Mean absolute treatment difference in lung function (percent predicted FEV 1 ) between treatment with ivacaftor and placebo was 10.7% (p &lt; 0.0001); mean relative treatment difference between treatment with ivacaftor and placebo was 14.2% (p &lt; 0.0001)- -Statistically significant improvements  Cystic Fibrosis", "labels": 2.3440431113}, {"text": "Vertex Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs  -Second quarter 2013 total revenues of $311 million , including net product revenues of $99 million for KALYDECO in cystic fibrosis and $156 million for INCIVEK in hepatitis C; cash position of approximately $1.43 billion on June 30, 2013 - -Data from Phase 3 study of ivacaftor monotherapy support  Financial", "labels": 2.3440431113}, {"text": "Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C  -U.S. Study: FDA places partial clinical hold on ongoing Phase 2 U.S. study of VX-135, preventing evaluation of 200 mg dose following observation of elevated liver enzymes in patients receiving 400 mg of VX-135 in combination with ribavirin in Phase 2 study in Europe ; evaluation of 100 mg dose  HCV", "labels": -5.0303526263}, {"text": "Vertex Receives Australian Approval for KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)  -- Approximately 250 people in Australia have the G551D mutation in the CFTR gene -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods Administration (TGA) of Australia has approved KALYDECO\u2122 (ivacaftor) for people  Cystic Fibrosis", "labels": 1.1391478591}, {"text": "Vertex Completes Redemption of Convertible Senior Subordinated Notes  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has completed its previously announced call for redemption of $400 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015.  General Business", "labels": -1.5538706072}, {"text": "Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015  -2015 Notes convertible at a conversion price of approximately $48.83 per share- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that it has called for redemption of its outstanding $400.0 million in aggregate principal amount of 3.35% Convertible  General Business", "labels": -1.7317188096}, {"text": "Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C  -First quarter 2013 total revenues of $328 million , including net product revenues of $206 million for INCIVEK in hepatitis C and $62 million for KALYDECO in cystic fibrosis- -Cystic fibrosis: Enrollment ongoing in Phase 3 program for VX-809 in combination with ivacaftor for people with two copies  Financial", "labels": -1.3666476602}, {"text": "Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype  - Interim analysis of the Phase 3b CONCISE study showed SVR12 rates of 87 percent with 12 total weeks of treatment and 97 percent with 24 total weeks of treatment among people who achieved RVR and completed 12 weeks of treatment - AMSTERDAM --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  HCV", "labels": -1.1827651293}, {"text": "ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection  - After seven days of once-daily dosing with 200 mg of ALS-2200, genotype 1 patients with cirrhosis had a median 4.08 log 10 reduction in HCV RNA; among people with genotypes 3 or 4, there was a median 4.65 log 10 reduction in HCV RNA - - Data are consistent with previously reported ALS-2200  HCV", "labels": -2.7020292777}, {"text": "Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -Treatment with combination of VX-661 and ivacaftor for 28 days in two highest dose groups resulted in mean relative increases in lung function (percent predicted FEV 1 ) of 9.0% (p=0.01) and 7.5% (p=0.02) versus placebo - -VX-661 was generally well-tolerated alone and in combination with  Cystic Fibrosis", "labels": 36.7523360342}, {"text": "Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C  -Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS' investigational NS5A replication complex inhibitor daclatasvir- -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013- -Study in people with  General Business", "labels": 0.9290892356}, {"text": "VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study  - Treatment with highest dosing regimen of VX-787 reduced viral shedding by 94 percent versus placebo; Duration of flu symptoms were reduced by nearly half - - VX-787 is an investigational new class of medicine designed to directly inhibit replication of the influenza virus - CAMBRIDGE, Mass.  Other", "labels": 4.7796426356}, {"text": "Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -Global studies to evaluate two different doses of VX-809 in combination with ivacaftor- - 24-week safety and efficacy data and submission of New Drug Application expected in 2014- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation  Cystic Fibrosis", "labels": 4.2367503231}, {"text": "Republic of Ireland Approves Funding for KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the Health Service Executive (HSE) in the Republic of Ireland will fund KALYDECO\u2122 (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and  Cystic Fibrosis", "labels": -0.9410669032}, {"text": "Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs  -2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -Full-year 2012 revenues of $1.53 billion , including net product revenues of $1.16 billion for INCIVEK in hepatitis C and $171.6 million for KALYDECO in cystic fibrosis- -Company ends 2012  Financial", "labels": -3.2698746575}, {"text": "Vertex Outlines Corporate Strategy and Defines Key 2013 Business Priorities  -2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -First two Breakthrough Therapy Designations from U.S. FDA granted to ivacaftor monotherapy and to the combination regimen of VX-809 and ivacaftor for the treatment of cystic fibrosis- SAN  General Business", "labels": 5.4020596534}, {"text": "NHS in England Funds KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a decision has been made by the National Health Service (NHS) in England to fund KALYDECO\u2122 (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people  Cystic Fibrosis", "labels": 1.2459642677}, {"text": "Vertex Announces Update to U.S. Prescribing Information for INCIVEK\u00ae (telaprevir)  - Revised label includes Boxed Warning detailing risk of serious skin reactions observed in the post-marketing setting that require treatment discontinuation - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the INCIVEK \u00ae (telaprevir)  HCV", "labels": 1.2459642677}, {"text": "Health Canada Approves KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)  -- Approximately 100 people in Canada have the G551D mutation in the CFTR gene -- -- First medicine resulting from 1989 co-discovery of CF gene by researchers in Canada and the U.S. -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that  Cystic Fibrosis", "labels": -0.8356495374}, {"text": "INCIVEK\u2122 (telaprevir) Now Funded in Alberta and New Brunswick for People with Hepatitis C  - Majority of provinces now fund INCIVEK -   HCV", "labels": -1.1887381108}, {"text": "Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily  - New Phase 2 data showed approximately 3 of 4 people co-infected with hepatitis C virus (HCV) and HIV achieved HCV viral cure (SVR24) with telaprevir combination treatment - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data from a Phase 3  General Business", "labels": 3.1745980944}, {"text": "Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C  - 4.54 log 10 median reduction in HCV RNA after 7 days of dosing; ALS-2200 was well-tolerated with no serious adverse events and no discontinuations due to adverse events - - Vertex moving forward with multiple Phase 2 trials in early 2013 exploring all-oral combinations, including VX-135 with  HCV", "labels": 3.1745980944}, {"text": "Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs  -Third quarter 2012 total revenues of $336 million , including third quarter 2012 net product revenues of approximately $254 million for INCIVEK in hepatitis C and $49 million for KALYDECO in cystic fibrosis- -Cystic Fibrosis: Three ongoing Phase 3 label expansion studies for ivacaftor monotherapy;  Financial", "labels": -8.8869143505}, {"text": "Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of VX-135 and Simeprevir (TMC435) for the Treatment of Hepatitis C  -Companies to evaluate two-drug combination of Vertex's investigational nucleotide analogue VX-135 and Janssen's investigational protease inhibitor simeprevir (TMC435)- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment  HCV", "labels": -8.8869143505}, {"text": "Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C  -Companies to evaluate two-drug combination of Vertex's investigational nucleotide analogue VX-135 and GSK's investigational NS5A inhibitor GSK2336805- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen-  HCV", "labels": -8.8869143505}, {"text": "Vertex Announces the Date of its Third Quarter 2012 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2012 financial results on Monday, October 29, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT .  Webcasts", "labels": 1.575537121}, {"text": "Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference  -- Additional KALYDECO\u2122 (ivacaftor) and CF pipeline presentations highlight Vertex's commitment to advancing CF treatment by targeting the underlying cause of the disease -- ORLANDO, Fla. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from a Phase 2  Cystic Fibrosis", "labels": -7.1361849093}, {"text": "Vertex Announces Presentation of New Data from Hepatitis C Development Program at AASLD Annual Meeting  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its hepatitis C research and development program will be presented at The Liver Meeting \u00ae , the 63rd Annual Meeting of the American Association for the Study of Liver  HCV", "labels": 2.3743027921}, {"text": "Vertex Announces Presentation of Data at North American Cystic Fibrosis Conference  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 10 abstracts from its cystic fibrosis (CF) research and development program will be presented at the 26th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Fla.  Cystic Fibrosis", "labels": -7.7049501286}, {"text": "Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158  - ALS-2158: Well-tolerated in a seven-day viral kinetic study; development discontinued due to lack of efficacy - - ALS-2200: Data from additional cohort of seven-day viral kinetic study with ALS-2200 (200 mg, QD) in combination with ribavirin show median 4.18 log 10 reduction in HCV RNA with 5 of  HCV", "labels": -7.7049501286}, {"text": "Yuchun Lee Appointed to the Vertex Board of Directors  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Yuchun Lee joined its board of directors as an independent director. Mr. Lee was appointed to the class of directors whose term expires in 2013.  General Business", "labels": 0.9844554055}, {"text": "Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at  General Business", "labels": 3.0732903979}, {"text": "Vertex Reports Second Quarter 2012 Financial Results and Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis  -Second quarter 2012 total revenues of $418 million , including second quarter 2012 net product revenues of approximately $328 million for INCIVEK in hepatitis C and $46 million for KALYDECO in cystic fibrosis; company revises financial guidance for full-year 2012 INCIVEK net revenues- -Cystic  Financial", "labels": -2.0408198572}, {"text": "Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C  - 4.54 log 10 median reduction in HCV RNA observed in people with genotype 1 hepatitis C treated with a once-daily 200 mg dose of ALS-2200 for seven days; treatment was well-tolerated- - Phase 2 studies of 12-week all-oral regimens planned for this year - CAMBRIDGE, Mass.  HCV", "labels": -2.0408198572}, {"text": "Vertex Receives European Approval for KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People With a Specific Genetic Mutation (G551D)  - European Commission approval comes two months after positive CHMP opinion - GENEVA --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has approved KALYDECO TM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who  Cystic Fibrosis", "labels": -0.540433272}, {"text": "Final Data from Phase 2 Combination Study of VX-809 and KALYDECO\u2122 (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  - Mean absolute improvement in lung function of 6.1 percentage points within group (p &lt; 0.001) and 8.6 percentage points compared to placebo (p &lt; 0.001) in homozygous patients receiving combination treatment (Day 28 to 56) with highest study dose of VX-809 (600mg) - - Adverse events were  Cystic Fibrosis", "labels": 3.5586515181}, {"text": "Vertex Announces Collaboration with the Boston Public Schools to Enhance Science Education  - Vertex commits more than $1 million to support education for BPS students and to prepare teachers for new science education standards- -Company dedicates 3,000 square foot learning laboratory at new Fan Pier headquarters to local community- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  General Business", "labels": 1.6774403148}, {"text": "Vertex Appoints Ken Horton as Executive Vice President and Chief Legal Officer and Announces Retirement of Nancy Wysenski as Chief Commercial Officer  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced two changes to its executive leadership team. Following a comprehensive search, Vertex has appointed Kenneth Horton to the role of Chief Legal Officer, where he will take on the additional title  General Business", "labels": -4.0072803044}, {"text": "Data From Follow-Up Study of KALYDECO\u2122 (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People with Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D)  - Data from nine presentations at the European Cystic Fibrosis Society Conference underscore Vertex's ongoing commitment to change CF treatment by targeting the underlying cause of the disease - DUBLIN --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today new data  Cystic Fibrosis", "labels": -2.5272001374}, {"text": "Vertex Corrects and Provides Additional Data from Recent Interim Analysis of Phase 2 Combination Study of VX-809 and KALYDECO\u2122 (ivacaftor) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  - Corrected Data: Responder analysis showed 35% of patients experienced an absolute improvement in lung function (FEV 1 ) of at least 5 percentage points and 19% had at least a 10 percentage-point improvement when treated with VX-809 and KALYDECO - - Additional Data: Patients treated with VX-809  Cystic Fibrosis", "labels": 16.6832849196}, {"text": "Vertex Receives European CHMP Positive Opinion for KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis  - Global studies showed significant and sustained improvements in lung function and other measures of disease among people with a specific genetic mutation - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Committee for  Cystic Fibrosis", "labels": -11.6435979776}, {"text": "Vertex Appoints David Altshuler, M.D., Ph.D., to its Board of Directors  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that David Altshuler , M.D., Ph.D., joined its board of directors as an independent director. Dr. Altshuler was appointed to the class of directors whose term expires in 2015.  General Business", "labels": 1.6499610177}, {"text": "The Crohn's and Colitis Foundation of Canada and Vertex Announce Collaboration to Fund Research in Inflammatory Bowel Disease  -Unique collaboration between a biotech company, nonprofit organization and academic centres to focus on underlying biology of IBD-<br>\r-Collaboration complements Vertex's ongoing IBD research efforts \rat its Canadian research and development site-\r  Other", "labels": -2.689927489}, {"text": "Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO\u2122 (ivacaftor) Showed Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  \u00a0 - Interim analysis showed 46% of patients experienced at least 5% absolute improvement in lung function (FEV 1 ) from baseline; 30% of patients experienced at least 10% absolute improvement - - Vertex plans to start a pivotal study of VX-809 and KALYDECO to treat the underlying cause of CF in  Cystic Fibrosis", "labels": 18.7655923364}, {"text": "Vertex Reports First Quarter 2012 Financial Results and Provides Update on Launch of KALYDECO\u2122  -Approximately 600 people with cystic fibrosis have started treatment with KALYDECO since approval on January 31 - -Multiple ongoing clinical trials to generate data beginning in second quarter, including study of KALYDECO combined with VX-809 in cystic fibrosis and first data for Alios nucleotides  Financial", "labels": 2.4857563724}, {"text": "INCIVEK\u2122 (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan  - Vertex working with other provincial funding agencies to make INCIVEK available to more people in Canada - LAVAL, Quebec --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the province of Quebec is now funding INCIVEK \u2122 (telaprevir) tablets for residents  HCV", "labels": 2.8139039292}, {"text": "Vertex Advances INCIVEK\u2122 (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C  - Subanalysis of Phase 2 data shows 12 weeks of INCIVEK combination treatment resulted in a viral cure (SVR) for 100% of people with hepatitis C who had the IL28B CC genotype; Phase 3 study enrolling - - Vertex's four direct-acting antivirals allow for the clinical exploration of multiple  HCV", "labels": 1.6639405698}, {"text": "Data from Phase 2 Study of an INCIVEK\u00ae Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12)  - INCIVEK was well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens, and no patients experienced HIV breakthrough - - Enrollment is ongoing in Phase 3 study evaluating 24- and 48-week treatment durations in people who are co-infected - SEATTLE --(BUSINESS WIRE)--  HCV", "labels": 1.5467740614}, {"text": "Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK\u00ae, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C  - Company plans to start Phase 2b study in Q3 2012 to evaluate this interferon-free combination regimen in a total treatment duration as short as 12 weeks - - Vertex also announces the advancement of its broad portfolio of direct acting antivirals, including its two structurally-distinct nucleotide  HCV", "labels": 1.7712954311}, {"text": "Vertex Reports Fourth Quarter and Full-Year 2011 Financial Results  -Successful launch of INCIVEK (telaprevir) for hepatitis C and recent approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for continued growth, earnings and cashflow- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated  Financial", "labels": -3.1810821709}, {"text": "FDA Approves KALYDECO\u2122 (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis  - FDA approval received 3 months after submission of New Drug Application - - KALYDECO approved to treat people with CF who have a specific genetic mutation - - Vertex launches a comprehensive financial assistance and patient support program - CAMBRIDGE, Mass.  Cystic Fibrosis", "labels": 7.7451762182}, {"text": "Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis  -More than 25,000 people have started treatment for hepatitis C with INCIVEK \u00ae , positioning Vertex for continued growth, earnings and cashflow in 2012- -Preparations for approval and launch of KALYDECO TM ongoing; additional studies of KALYDECO planned for mid-2012- -Nine new medicines in  General Business", "labels": 3.6343604238}, {"text": "FDA Grants Priority Review for KALYDECO\u2122 (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis  -- Six-month review date of April 18, 2012 set by FDA -- -- European Medicines Agency accepts KALYDECO regulatory submission for accelerated assessment -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S.  Cystic Fibrosis", "labels": 9.0533757259}, {"text": "Vertex Announces CEO Succession Plan for 2012  - Jeffrey Leiden , M.D., Ph.D., to become CEO in February 2012 - - Matthew Emmens elects to retire in May; will remain director for Vertex Board- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has appointed Jeffrey  General Business", "labels": 9.0533757259}, {"text": "Vertex and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C  -Studies to evaluate safety and effects on viral kinetics in people with chronic genotype-1 hepatitis C- -Data expected in second quarter of 2012 could enable initiation of interferon-free, nucleotide-based combination studies in the second half of 2012- CAMBRIDGE, Mass.  HCV", "labels": -1.5332158424}, {"text": "Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis  -Data to be presented at American College of Rheumatology Annual Meeting next week- -Phase 2b study evaluating longer treatment duration for VX-509 planned for early 2012- CHICAGO --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from a Phase  Other", "labels": -14.7783247529}, {"text": "Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK\u2122 (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR)  - Vertex announces it intends to start a Phase 3 study to evaluate a 12-week regimen in treatment naive and relapser patients with genotype 1 hepatitis C - SAN FRANCISCO --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today interim results from ZENITH, an ongoing  HCV", "labels": -14.7783247529}, {"text": "Positive Interim Data From a Phase 2 Study of INCIVEK\u2122 (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting\u00ae  - Data showed 74% of people had undetectable hepatitis C virus 24 weeks after starting INCIVEK combination treatment - - Vertex to initiate Phase 3 study to evaluate 24- and 48-week treatment durations in people who are co-infected - SAN FRANCISCO --(BUSINESS WIRE)-- Vertex Pharmaceuticals  HCV", "labels": -14.7783247529}, {"text": "Vertex Announces Recipients of Special Grants Initiative to Support People with Hepatitis C  - Hep-C Circle of Care grants will fund new and existing programs with the potential to enhance patient care - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of  HCV", "labels": -9.2414195726}, {"text": "Phase 3 Study of KALYDECO\u2122 (ivacaftor) in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks  - Additional presentations at the North American CF Conference include data from PERSIST that showed sustained safety and efficacy of KALYDECO through 60 weeks of treatment among adolescents and adults treated in the Phase 3 STRIVE study - ANAHEIM, Calif.  Cystic Fibrosis", "labels": -2.1566941791}, {"text": "Data from the First Part of a Phase 2 Study Support the Approach of Treating the Most Common Form of Cystic Fibrosis (F508del) by Targeting the Underlying Cause of the Disease With a Combination of KALYDECO\u2122 (ivacaftor) and VX-809  - New data at North American CF Conference showed a reduction in sweat chloride when KALYDECO was added to VX-809 in people with the F508del mutation \u2014 - Part 2 of study now enrolling patients - ANAHEIM, Calif. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced  Cystic Fibrosis", "labels": -2.1566941791}, {"text": "New England Journal of Medicine Publishes Data from Phase 3 STRIVE Study of KALYDECOTM (ivacaftor) in People Ages 12 and Older with a Specific Type of Cystic Fibrosis  \u00a0 - Study shows that treating CF by targeting the underlying cause of the disease leads to significant clinical benefits among people with the G551D mutation - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the New England Journal of  Cystic Fibrosis", "labels": -4.0404026729}, {"text": "Vertex Reports Profitable Third Quarter and Provides Updates on INCIVEKTM (telaprevir) Launch and Medicines in Development  - $420 million in net product revenues for INCIVEK for the first full quarter since launch- -Continued strength in launch of INCIVEK for hepatitis C; submissions of KALYDECO TM (VX-770, ivacaftor) approval applications complete- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals  Financial", "labels": -5.8201011601}, {"text": "Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology  -Final data to be presented from Phase 2 study in rheumatoid arthritis- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that two abstracts related to its investigational oral JAK3 inhibitor, VX-509, will be presented at the 2011 Annual Meeting  Other", "labels": 3.9464639439}, {"text": "Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK\u2122 Combination Therapy  \u2014 CONCISE study will evaluate twice-daily INCIVEK in combination with pegylated-interferon and ribavirin among patients new to treatment and prior relapsers who have the \u2018CC' variation near the IL28B gene \u2014 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  HCV", "labels": 3.9464639439}, {"text": "Vertex Submits Application for Priority Review and Approval of KALYDECO\u2122 (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis  -- Accelerated assessment of KALYDECO granted by the European Medicines Agency ; MAA submission planned in EU by the end of October -- -- Phase 3 registration studies of KALYDECO showed significant improvements in lung function and other measures of disease among a subset of people with CF --  Cystic Fibrosis", "labels": 2.790918494}, {"text": "INCIVEK&#153; (telaprevir) Now Available in Canada for People with Hepatitis C  Nearly 4 out of 5 people treated for the first time cleared the virus with INCIVEK combination treatment  HCV", "labels": -0.4224606408}, {"text": "Vertex Announces Presentation of New Data on VX-770 and VX-809 at North American Cystic Fibrosis Conference  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that nine abstracts from its cystic fibrosis (CF) research program, which is aimed at discovering and developing medicines that target the underlying cause of CF, will be presented at the 25th  Cystic Fibrosis", "labels": -2.2868973038}, {"text": "Vertex Named Top Biopharma Employer by Science  -Vertex hiring for 150 jobs across the company to support global growth; Company plans to add more than 500 jobs through 2015- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Science has ranked the company #1 in the magazine's annual list  General Business", "labels": -1.068885413}, {"text": "New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK\u2122 (telaprevir) in Hepatitis C  - High viral cure rate achieved with a 24-week INCIVEK combination regimen - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK\u2122 (telaprevir) tablets  HCV", "labels": -0.2194744866}, {"text": "Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis  -12-week data support initiation of Phase 2b study to evaluate longer treatment duration for VX-509- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a  Other", "labels": 6.9663411875}, {"text": "Health Canada Approves INCIVEK\u2122 (telaprevir) for People With Hepatitis C  - Nearly 4 out of 5 people treated for the first time cleared the virus with INCIVEK combination treatment - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved INCIVEK\u2122 (telaprevir) tablets for a broad group of  HCV", "labels": -1.1707093283}, {"text": "Vertex Reports Second Quarter 2011 Financial Results and Provides Updates on Launch of INCIVEKTM (telaprevir) and Development Programs  -Quarter highlighted by approval and launch of INCIVEK TM for hepatitis C and completion of VX-770 Phase 3 program in cystic fibrosis- -Continued progress in advancing new combinations of medicines for the future treatment of hepatitis C and cystic fibrosis- CAMBRIDGE, Mass.  Financial", "labels": 7.5973821732}, {"text": "Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK\u2122 Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks  -First data to show potential for viral cure in many patients with a 12-week combination regimen of multiple direct-acting antivirals- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from ZENITH, an ongoing Phase 2 study  HCV", "labels": -3.234564088}, {"text": "New England Journal of Medicine Publishes Data From Two Phase 3 Studies of INCIVEK\u2122 (telaprevir) in Hepatitis C  -INCIVEK was recently approved by the FDA and is now available for people with the most common form of chronic hepatitis C who are new to treatment and those who were treated before but not cured- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced  HCV", "labels": 5.1020423565}, {"text": "Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex's Efforts to Develop New Combinations of Medicines for Hepatitis C  -Vertex gains worldwide rights to two distinct nucleotide analogues, ALS-2200 and ALS-2158, that act on hepatitis C polymerase- -Collaboration provides multiple opportunities to develop new \"all-oral\" combination regimens- CAMBRIDGE, Mass. , &amp; SOUTH SAN FRANCISCO, Calif.  Other", "labels": -3.1209981558}, {"text": "Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis  - Complete data presented at ECFS showed improvements in lung function and reductions in sweat chloride observed at week two of treatment were sustained through 48 weeks -\r<br><br>\r-  Vertex also announces that 48-week data from the ENVISION study of VX-770 among children ages 6 to 11 years are consistent with previously announced 24-week results -\r  Cystic Fibrosis", "labels": -1.6299674338}, {"text": "Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease  -13.17 mmol/L reduction in sweat chloride in one arm supports further evaluation of a combination approach to treating the root cause of cystic fibrosis- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from the first part of a  Cystic Fibrosis", "labels": -4.253110383}, {"text": "FDA Approves INCIVEK\u2122 (telaprevir) for People with Hepatitis C  -79% of people treated for the first time achieved a SVR (viral cure) with INCIVEK combination treatment- -Vertex launches a comprehensive financial assistance and patient support program- -Conference call today at 11:00 a.m. ET to provide more information on the commercialization of INCIVEK-  HCV", "labels": 2.1507271962}, {"text": "Vertex Appoints Terrence C. Kearney to its Board of Directors  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Terrence C. Kearney has joined its board of directors. The addition of Mr. Kearney brings the number of Vertex board members to nine. Mr. Kearney was appointed to the class of directors  General Business", "labels": -3.1216229053}, {"text": "Vertex Shareholders Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2011 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Matthew W. Emmens and Wayne J. Riley , M.D.  General Business", "labels": 2.3138448625}, {"text": "Vertex Reports First Quarter 2011 Financial Results and Reviews Milestones for Key Development Programs  -Hepatitis C: FDA decision on NDA for INCIVEK TM (telaprevir) expected this month- -Cystic Fibrosis: Phase 3 program for VX-770 supports applications for approval in U.S. and E.U., with NDA and MAA planned for second half of 2011- -Financial: Vertex enters second quarter with more than $820 million  Financial", "labels": 0.5604797787}, {"text": "FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis  HCV", "labels": -0.8901029705}, {"text": "Trading of Vertex Common Stock Halted Today  - Advisory Committee for the Food and Drug Administration reviewing the telaprevir New Drug Application for the treatment of hepatitis C- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced that NASDAQ today halted trading of the company's common stock.  General Business", "labels": -0.8901029705}, {"text": "Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis  -Expanded collaboration supports development of a second corrector, VX-661, and accelerated discovery and development of next-generation correctors- -Phase 2 study of VX-661 planned for 2011 in people with CF who have the F508del mutation- CAMBRIDGE, Mass.  Cystic Fibrosis", "labels": 3.4468435479}, {"text": "Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status  - 90% of people with the \u2018CC' variation of IL28B who were new to treatment and received a telaprevir-based regimen achieved a viral cure, 78% of them were eligible to stop all treatment at 24 weeks - - Nearly three-fold improvement in viral cure rates was observed among people with the \u2018CT' and  HCV", "labels": -1.7860863026}, {"text": "Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful  - All major subgroups achieved significantly higher viral cure rates with telaprevir-based therapy compared to pegylated-interferon and ribavirin: 86% vs. 24% in prior relapsers, 57% vs. 15% in prior partial responders and 31% vs. 5% in prior null responders - - No clinical benefit was observed in  HCV", "labels": -1.7860863026}, {"text": "Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C  BERLIN--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from an ongoing Phase 2 study (ZENITH) designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease  HCV", "labels": -1.7860863026}, {"text": "Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks  -Mean relative improvement in lung function of 17.4% and mean absolute improvement of 12.5% from baseline compared to placebo in children treated with VX-770- - No discontinuations due to adverse events through 24 weeks - -Vertex on track to submit regulatory applications for the approval of VX-770  Cystic Fibrosis", "labels": 0.1650124115}, {"text": "Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment  -Results support continued development of VX-765 in people with treatment-resistant epilepsy- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a recently completed Phase 2 study of VX-765 in 60 people with treatment-resistant  Other", "labels": -0.5812711589}, {"text": "New Data on Telaprevir and VX-222 for the Treatment of Hepatitis C Accepted For Presentation at EASL Annual Meeting  \u00a0 - Complete results from pivotal Phase 3 REALIZE study of telaprevir in people who had not achieved a viral cure (SVR) with currently available medicines - - First presentation of data from ongoing Phase 2 study evaluating response-guided, 12- and 24-week regimens of telaprevir and VX-222 combined  HCV", "labels": -8.9957246861}, {"text": "Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference  Early results from ongoing study showed that the hepatitis C virus was undetectable by week 4 in 70% of people treated with telaprevir-based combination therapy  HCV", "labels": 7.7677697875}, {"text": "Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis  \u00a0 - Relative mean improvement in lung function of approximately 17% from baseline compared to placebo achieved by people treated with VX-770; mean absolute improvement from baseline of approximately 10.5% compared to placebo; both measures through 24 and 48 weeks - - Significant improvements in all  Cystic Fibrosis", "labels": -0.0458849064}, {"text": "Vertex Reports 2010 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs  \u00a0 -Hepatitis C: Regulatory agencies in U.S., Europe and Canada to provide accelerated reviews of telaprevir applications- -Cystic Fibrosis: First Phase 3 registration data for VX-770 expected in first quarter 2011; potential regulatory submissions in the U.S. and E.U.  Financial", "labels": 2.4075032564}, {"text": "U.S. FDA and Health Canada Grant Priority Reviews for Telaprevir for the Treatment of Hepatitis C  -Six-month review date of May 23, 2011 set by FDA- CAMBRIDGE, Mass., Jan 20, 2011 (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration ( FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the  HCV", "labels": 1.7973070295}, {"text": "Vertex Announces Key Business Objectives To Support Planned Launch of Telaprevir in Hepatitis C and Continued Progress in Other Serious Diseases  -Hepatitis C: Submission of New Drug Application complete for telaprevir- -Cystic Fibrosis: First Phase 3 data for VX-770 expected in first quarter 2011- -Additional ongoing trials in HCV, CF, epilepsy and rheumatoid arthritis- -Vertex enters 2011 with cash and cash equivalents position of more  General Business", "labels": 2.2832294963}, {"text": "Vertex Provides Update to Ongoing Phase 2 Study Evaluating Combinations of Telaprevir and VX-222 for the Treatment of Hepatitis C  -Two-drug treatment arm of telaprevir and VX-222 alone discontinued- -Study continues with three arms, including all-oral combination of Vertex's lead protease and polymerase inhibitors with ribavirin- -Both of the four-drug treatment arms are fully enrolled; the majority of patients in these arms  HCV", "labels": -1.3386534108}, {"text": "Vertex Completes New Drug Application for Telaprevir for Hepatitis C  - Submission based on results from Phase 3 studies that showed high SVR (viral cure) rates with telaprevir-based combination therapy compared to approved medicines - - Six-Month Priority Review Requested - CAMBRIDGE, Mass., Nov 23, 2010 (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:  HCV", "labels": -0.4728127857}, {"text": "New England Journal of Medicine Publishes Phase 2 Study of VX-770 as a New Approach to Treat the Underlying Cause of Cystic Fibrosis  -Treatment with VX-770 resulted in improvements in lung function and markers of disease- -There were no discontinuations of treatment due to adverse events- -Late-stage Phase 3 clinical trials for VX-770 ongoing- CAMBRIDGE, Mass., Nov 17, 2010 (BUSINESS WIRE)-- In a study published in this week's  Cystic Fibrosis", "labels": 2.7204954125}, {"text": "Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C  -New treatment arm to evaluate all oral, triple combination regimen of telaprevir, VX-222, and ribavirin- CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2  HCV", "labels": 1.9719988806}, {"text": "New Data From Phase 3 Studies Showed Superior SVR (Viral Cure) Rates Achieved with Telaprevir-Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease  <i>-75% of people treated in the Phase 3 ADVANCE study achieved a viral \r      cure with telaprevir; majority of people treated for a total of 24 weeks-</i>\r    <br />\r    \r      <i>-62% of African Americans/Blacks in the ADVANCE study achieved a \r      viral cure with telaprevir-</i>\r    <br />\r    \r      <i>-Low discontinuation rates of all drugs due to adverse events-</i>\r    <br />  HCV", "labels": -3.4871327637}, {"text": "Vertex Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights Progress in Hepatitis C and Cystic Fibrosis Development Programs  <i>-Hepatitis C:</i> <i>New Drug Application submission for telaprevir \r      on track for fourth quarter 2010-</i>\r    <br />\r    \r      <i>-Cystic Fibrosis:</i> <i>Phase 3 registration program ongoing for \r      VX-770-</i>\r    <br />\r    \r      <i>-Pipeline:</i> <i>Ongoing proof-of-concept clinical trials in \r      hepatitis C, cystic fibrosis, epilepsy and rheumatoid arthritis-</i>\r    <br />\r    \r      <i>-Financial:</i> <i>Company ends third quarter with a cash position of \r      $1.2 billion-</i>\r    <br />  Financial", "labels": 2.2618473853}, {"text": "Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C  <i>- First Phase 3 study to evaluate twice-daily (BID) dosing of a \r      protease inhibitor for hepatitis C -</i>\r    <br />\r    \r      <i>- All patients will receive telaprevir-based combination therapy -</i>\r    <br />  HCV", "labels": 2.2618473853}, {"text": "Vertex Pharmaceuticals Initiates Clinical Trial to Evaluate Combination Regimens of VX-770 and VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis  <i><b>-Primary endpoints of safety, tolerability and effect on CFTR \r      function as measured by sweat chloride-</b></i>\r    <br />\r    \r      <i><b>-Phase 2a proof of mechanism clinical trial to enroll people with \r      the most common mutation of cystic fibrosis, known as F508del-</b></i>\r    <br />  Cystic Fibrosis", "labels": 2.914198033}, {"text": "Vertex Pharmaceuticals Announces Exercise of Underwriter's Option to Purchase Additional Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Sep 24, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate  General Business", "labels": -2.4096403571}, {"text": "Vertex Pharmaceuticals Announces Pricing of its Public Offering of Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Sep 23, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.  General Business", "labels": 5.9652947376}, {"text": "Vertex Pharmaceuticals Announces Proposed Public Offering of Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Sep 22, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that intends to offer, subject to market and other conditions, $375.0 million aggregate principal amount of convertible senior subordinated notes due 2015 in an underwritten public  General Business", "labels": -0.1937976104}, {"text": "65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study  <i>-17% of people achieved SVR with pegylated-interferon and ribavirin \r      alone in the control arm-</i>\r    <br />\r    \r      <i>-Safety and tolerability results were consistent with prior Phase 3 \r      studies-</i>\r    <br />\r    \r      <i>-Completion of rolling New Drug Application submission on track for \r      the fourth quarter 2010-</i>\r    <br />  HCV", "labels": -0.4993073758}, {"text": "Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment  <i>-Viral cure rates of 92% and 88% with 24 and 48-week regimens, \r      respectively, in people who met certain response criteria-</i>\r    <br />\r    \r      <i>-Safety and tolerability results were similar to those seen in the \r      Phase 3 ADVANCE study</i>-\r    <br />  HCV", "labels": -3.4965034965}, {"text": "Vertex Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress  <i>-Hepatitis C: Rolling submission of New Drug Application underway; \r      data from second pivotal Phase 3 trial - REALIZE - expected in the third \r      quarter of 2010-</i>\r    <br />\r    \r      <i>-Cystic Fibrosis: Phase 3 registration program for VX-770 fully \r      enrolled; data expected in first half of 2011-</i>\r    <br />\r    \r      <i>-Financial: Vertex ends second quarter with cash position of \r      approximately $980 million-</i>\r    <br />  Financial", "labels": -3.8945122171}, {"text": "Vertex Pharmaceuticals Appoints Wayne J. Riley, M.D., to its Board of Directors  CAMBRIDGE, Mass., Jul 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Wayne J. Riley, M.D., M.B.A., joined its board of directors as an independent director. The addition of Dr. Riley brings the number of Vertex board members to 10. Dr.  General Business", "labels": 1.2023456474}, {"text": "75% of Treatment-Na\u00efve Patients with Chronic Hepatitis C Achieve SVR (Viral Cure) with Telaprevir-Based Treatment in Phase 3 Trial  <i><b>-Majority of patients treated with telaprevir received a 24-week \r      regimen-</b></i>\r    <br />\r    \r      <i><b>-6.9% and 7.7% treatment discontinuation rates due to adverse \r      events in 12- and 8-week telaprevir-based treatment arms -- lower than \r      previous telaprevir trials-</b></i>\r    <br />\r    \r      <i><b>-First Phase 3 trial results for a direct acting antiviral therapy \r      in hepatitis C-</b></i>\r    <br />  HCV", "labels": 3.2527375173}, {"text": "Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2010 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Dr. Joshua Boger, Dr. Charles A. Sanders and Elaine S.  General Business", "labels": -2.0822280114}, {"text": "Vertex Pharmaceuticals Reports First Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress  <i>-HCV: Rolling submission of New Drug Application for telaprevir \r      expected to begin in summer of 2010; first Phase 3 SVR data expected in \r      second quarter 2010 from ADVANCE trial-</i>\r    <br />\r    \r      <i>-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of \r      Phase 3 registration program for VX-770; data expected in first half of \r      2011-</i>\r    <br />\r    \r      <i>-Pipeline: Multiple ongoing or planned proof-of-concept clinical \r      trials with compounds for rheumatoid arthritis and epilepsy and with \r      novel combination regimens for HCV and CF-</i>\r    <br />\r    \r      <i>-Financial: Vertex ends first quarter with cash position of \r      approximately $1.1 billion-</i>\r    <br />  Financial", "labels": -5.9858198219}, {"text": "Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial  <i>-VX-222 was well-tolerated across all four dose groups through three \r      days of dosing, with all adverse events being mild to moderate in \r      severity-</i>\r    <br />\r    \r      <i>-Greater than 3 log</i><sub><i>10 </i></sub><i>reduction in HCV RNA \r      observed across all four VX-222 dose groups-</i>\r    <br />\r    \r      <i>-Results support previously announced Phase 2 proof-of-concept \r      clinical trial evaluating VX-222 in combination with Vertex's lead HCV \r      protease inhibitor telaprevir-</i>\r    <br />  HCV", "labels": 0.5751521562}, {"text": "59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection  <i>-56% of prior treatment null responder patients achieved SVR with a \r      48-week telaprevir-based regimen-</i>\r    <br />\r    \r      <i>-97% of prior treatment relapsers and 55% of prior treatment partial \r      responders achieved SVR with 24-week or 48-week telaprevir-based \r      regimens-</i>\r    <br />  HCV", "labels": 0.5751521562}, {"text": "New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy  <i><b>-51% and 53% SVR rates when telaprevir was dosed in combination \r      with pegylated-interferon and ribavirin in treatment-failure patients, \r      compared to 14% SVR rate with pegylated-interferon and ribavirin alone-</b></i>\r    <br />\r    \r      <i><b>-Telaprevir Phase 3 SVR data expected in second quarter 2010 for \r      treatment-na\u00efve patients and third quarter 2010 for treatment-failure \r      patients-</b></i>\r    <br />\r    \r      <i><b>-New Drug Application submission planned for second half of 2010 \r      in treatment-na\u00efve and treatment-failure HCV patients-</b></i>\r    <br />  HCV", "labels": -1.2559657944}, {"text": "Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting  CAMBRIDGE, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45 th  HCV", "labels": -2.1698069241}, {"text": "Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies  <i>-Trial will evaluate safety and SVR rates with multiple 12-week \r      response-guided regimens of telaprevir/VX-222-based combination therapy, \r      including two-drug regimens of telaprevir and VX-222-</i>\r    <br />\r    \r      <i>-Interim clinical data expected in the second half of 2010-</i>\r    <br />\r    \r      <i>-Multiple clinical trial sites in the U.S. to enroll patients-</i>\r    <br />  HCV", "labels": 2.8202684055}, {"text": "Vertex Pharmaceuticals Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013  CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the  General Business", "labels": 3.3182497117}, {"text": "Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs  <i>-HCV: New Drug Application planned for telaprevir in second half of \r      2010; increasing investment in commercialization and launch preparedness \r      activities-</i>\r    <br />\r    \r      <i>-CF: Development progress with two compounds in orphan disease of \r      cystic fibrosis; combination trial planned with VX-770 and VX-809 based \r      on Phase 2 data for VX-809-</i>\r    <br />\r    \r      <i>-Pipeline: Proof-of-concept clinical trials planned for 2010 with \r      novel combination regimens for hepatitis C and cystic fibrosis and with \r      compounds for rheumatoid arthritis and epilepsy-</i>\r    <br />\r    \r      <i>-Financial: Vertex enters 2010 with approximately $1.3 billion in \r      cash, cash equivalents and marketable securities and approximately $32 \r      million in outstanding 2013 convertible debt; 2010 investment to support \r      long-term business objectives-</i>\r    <br />  Financial", "labels": -5.7697371277}, {"text": "Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis  <i>-VX-809 was well-tolerated at all dose levels when dosed once daily \r      for 28 days-</i>\r    <br />\r    \r      <i>-Statistically significant changes observed in measurement of sweat \r      chloride suggest increased CFTR activity-</i>\r    <br />\r    \r      <i>-Data support planned combination trial of VX-809 and VX-770 in \r      second half of 2010 for CF patients with the F508del mutation-</i>\r    <br />  Cystic Fibrosis", "labels": -5.0494600049}, {"text": "Vertex Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company  <i>-HCV:</i><i>New Drug Application planned for telaprevir in second \r      half of 2010, robust commercialization and launch preparedness \r      activities ongoing-</i><br /><i>-CF:</i><i>Advancing development efforts in orphan disease of cystic \r      fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment, \r      VX-809 Phase 2 data expected in first quarter 2010-</i><br /><i>-Pipeline:</i><i>Proof-of-concept clinical trials planned for 2010 \r      with novel combination regimens for hepatitis C and cystic fibrosis and \r      with compounds for rheumatoid arthritis and epilepsy-</i><br /><i>-Financial:</i><i>Vertex enters 2010 with approximately $1.3 billion \r      in cash, cash equivalents &amp; marketable securities and approximately $32 \r      million in outstanding convertible debt-</i><br />  General Business", "labels": 2.3450574797}, {"text": "Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer  CAMBRIDGE, Mass., Dec 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer. Ms. Wysenski has more than 30 years of experience in building commercial operations and  Webcasts", "labels": -0.6516248411}, {"text": "Vertex Pharmaceuticals Announces Exercise of Option by Underwriters of its Public Offering of Common Stock  CAMBRIDGE, Mass., Dec 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per  Webcasts", "labels": -2.6537406276}, {"text": "Vertex Pharmaceuticals Announces Pricing of Public Offering of Common Stock  <i>- 11.5 million shares of common stock at $38.50 per share for gross \r      proceeds of $442.8 million -</i><br />  Webcasts", "labels": 1.2928902088}, {"text": "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  CAMBRIDGE, Mass., Dec 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering under an effective shelf registration  Webcasts", "labels": 1.2928902088}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Nov 20, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m.  Webcasts", "labels": 1.6768288546}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Lazard Capital Markets Annual Healthcare Conference  CAMBRIDGE, Mass., Nov 12, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST.  Webcasts", "labels": -1.4785570405}, {"text": "Vertex Pharmaceuticals Announces Agreements to Exchange $109.0 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock  CAMBRIDGE, Mass., Nov 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued  Webcasts", "labels": 3.7469517226}, {"text": "More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens  <ul><li class=\"bwlistitemmarginbottom\"><i><b>83% SVR achieved with twice-daily regimen of telaprevir dosed \r        with PEGASYS and ribavirin</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>Results highlight the use of response-guided therapy in managing \r        treatment outcomes</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>Similar safety and tolerability observed between \r        telaprevir-based regimens dosed either twice daily or three times daily</b></i></li></ul>  Webcasts", "labels": -0.5960477421}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Oct 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Oppenheimer 20 th Annual Healthcare Conference on Wednesday, November 4, 2009 at 2:10 p.m.  Webcasts", "labels": 6.6943343886}, {"text": "Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment  <ul><li class=\"bwlistitemmarginbottom\"><i><b>57% of prior treatment null responder patients achieved an SVR \r        with a 48-week telaprevir-based regimen</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>90% of prior treatment relapsers and 55% of prior treatment \r        partial responders achieved an SVR with 24-week or 48-week \r        telaprevir-based regimens</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>Results provide further support for the ongoing Phase 3 \r        registration study, REALIZE, in treatment-failure patients</b></i></li></ul>  Webcasts", "labels": 0.7385524705}, {"text": "Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and Highlights Recent Business and Clinical Progress  <i>-Phase 3 registration programs in hepatitis C and cystic fibrosis on \r      track-</i><br /><i>-Vertex to present telaprevir SVR data from Study C208 at AASLD \r      meeting this week-</i><br />  Webcasts", "labels": 2.756961937}, {"text": "Vertex Pharmaceuticals Announces the Date of its Third Quarter 2009 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Oct 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": 4.0272213175}, {"text": "Vertex Pharmaceuticals Provides Corporate Update  <i>-Vertex announces plans to initiate a Phase 2 proof-of-concept trial \r      for VX-509 in rheumatoid arthritis-</i><br /><i>-Vertex to add $260 million to cash position; company increases \r      guidance for year-end cash position to approximately $800 million and \r      adjusts net loss guidance-</i><br /><i>-Vertex announces executive leadership change-</i><br />  Webcasts", "labels": -10.2309269034}, {"text": "Vertex Pharmaceuticals to Receive $155 Million in Cash Related to Future Telaprevir Milestone Payments  CAMBRIDGE, Mass., Sep 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes  Webcasts", "labels": -10.2309269034}, {"text": "Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting  <i><b>Presentations to include SVR results from Study C208 exploring \r      twice-daily telaprevir-based dosing regimen, final PROVE 3 results and \r      additional sub-analysis of PROVE 1 and PROVE 2 in \"difficult-to-cure\" \r      patients</b></i><br />  Webcasts", "labels": -0.467166767}, {"text": "Vertex Pharmaceuticals Employees Participate in First Companywide Day of Service  <i>-More than 800 Vertex employees take part in service activities at \r      more than 20 nonprofit and community organizations around the globe-</i><br /><i>-Several events focused on promoting students' interest in science-</i><br /><i>-Day of Service held to honor Vertex founder and long-time CEO Joshua \r      Boger, Ph.D.-</i><br />  Webcasts", "labels": -1.2709605909}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Sep 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 2:30 p.m. EDT and at the JMP Securities Healthcare Conference on  Webcasts", "labels": 0.5772794993}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Sep 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Thomas Weisel Partners 2009 Healthcare Conference on Wednesday, September 9, 2009 at 2:40 p.m.  Webcasts", "labels": 0.688325997}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams Global Growth Conference  CAMBRIDGE, Mass., Aug 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009 at 10:30 a.m. EDT.  Webcasts", "labels": -4.9942642676}, {"text": "Vertex Pharmaceuticals Reports Second Quarter 2009 Financial Results and Highlights Recent Clinical Progress and Business Development Activity  <i>- Telaprevir Phase 3 registration program in hepatitis C on track; \r      NDA submission anticipated in second half of 2010 -</i><br /><i>- Vertex advancing two drug candidates aimed at the underlying \r      disease mechanism of the orphan disorder cystic fibrosis -</i><br /><i>- Vertex ends second quarter with $754 million of cash, cash \r      equivalents and marketable securities; Vertex will add to this position \r      with $105 million of cash through an amended agreement with Mitsubishi \r      Tanabe Pharma Corporation -</i><br />  Webcasts", "labels": -8.278428537}, {"text": "Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia  <i>-- Vertex to receive $105 million from Mitsubishi following signing, \r      plus the potential for additional milestones upon commercialization --</i><i>-- Phase 3 registration program for telaprevir in Japan expected to \r      complete enrollment in the third quarter of 2009 --</i>  Webcasts", "labels": -1.6106688645}, {"text": "Vertex Pharmaceuticals Announces the Date of its Second Quarter 2009 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jul 27, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2009 financial results on Wednesday, August 5, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": 1.4408436009}, {"text": "Vertex Pharmaceuticals Announces Intention to Sell Its Rights to European Milestone Payments for Telaprevir  <i>- Vertex holds rights to earn up to $250 million in milestones \r      associated with filing, approval and launch of telaprevir in Europe -</i>  Webcasts", "labels": -0.4546762763}, {"text": "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors  CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. \"Jeff and Dennis add tremendous medical and biomedical business perspective to our board.  Webcasts", "labels": -0.6831106904}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2009 Piper Jaffray Europe Conference  CAMBRIDGE, Mass., Jun 23, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2009 Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 4:30 p.m. BST (11:30 a.m. EDT).  Webcasts", "labels": 2.7050814888}, {"text": "Vertex Pharmaceuticals Announces Agreements to Exchange $103.3 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock  CAMBRIDGE, Mass., Jun 08, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for  Webcasts", "labels": 0.3273272557}, {"text": "Vertex Pharmaceuticals Announces Agreements to Exchange an Additional $40.2 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock  <i>-- Together with agreements announced earlier today, a total of \r      $143.5 million in convertible notes to be exchanged--</i>  Webcasts", "labels": 0.3273272557}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Jun 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Goldman Sachs 30 th Annual Global Healthcare Conference. Matt Emmens, Chairman, President and Chief Executive Officer of Vertex, will  Webcasts", "labels": -2.9239753036}, {"text": "Vertex Pharmaceuticals Initiates Phase 3 Registration Program for VX-770, an Oral CFTR Potentiator Targeting the Defective Protein Responsible for Cystic Fibrosis  <i><b>-Registration program to evaluate improvements in lung function \r      (FEV</b></i><sub><i><b>1</b></i></sub><i><b>), restoration of CFTR \r      activity and safety-</b></i><i><b>-Program designed to support registration in cystic fibrosis \r      patients with the G551D mutation and to provide first evaluation of \r      activity in patients with F508del mutations-</b></i><i><b>-Primary endpoint for patients with G551D mutation is improvement \r      in FEV</b></i><sub><i><b>1 </b></i></sub><i><b>through 24 weeks-</b></i>  Webcasts", "labels": -2.8144525595}, {"text": "New Report Forecasts Hepatitis C Virus Epidemic Among Baby Boomers; Untreated HCV Progressing to Severe Liver Disease Seen Driving U.S. Costs to $85 Billion  <i>-Over 3 million Americans have chronic hepatitis C -</i>\r    \r    \r      -<i>Baby boomers account for 2 of every 3 cases of hepatitis C virus and \r      vast majority unaware they have this chronic disease </i>-\r    \r    \r      -<i>Cost burden of hepatitis C to Medicare projected to increase 500% as \r      baby boomers with HCV age into severe complications of liver disease-</i>  Webcasts", "labels": 2.5221532627}, {"text": "Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass., May 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2009 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Amended and Restated 2006 Stock and Option Plan  Webcasts", "labels": -1.9271170968}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences  CAMBRIDGE, Mass., May 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, 2009 at 8:40 a.m. EDT; at R. W.  Webcasts", "labels": -3.8844934852}, {"text": "Vertex Promotes Dr. Peter Mueller to Global R&D Chief and Chief Science Officer  CAMBRIDGE, Mass., May 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex's Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of  Webcasts", "labels": -0.9933749321}, {"text": "New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir  <i><b>-Addition of telaprevir to standard HCV therapies significantly \r      improved rates of sustained viral response in half the time of current \r      treatments-</b></i><i><b>-SVR rates in Phase 2b studies of up to 69% with 24 weeks of \r      telaprevir-based treatment-</b></i><i><b>-Phase 3 program ongoing in more than 2,200 patients-</b></i>  Webcasts", "labels": -4.6722863107}, {"text": "Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study  <i>- Superior SVR rates with telaprevir across all HCV genotype 1 \r      non-responders and relapser patients and patients with cirrhosis - up to \r      76% in prior relapsers -</i><i>- PROVE 3 showed 51% and 52% SVR rates in telaprevir-based regimens \r      compared to 14% in the 48-week control arm</i><i>-</i><i>- Treatment-failure patient population represents the greatest unmet \r      medical need in HCV -</i>  Webcasts", "labels": 14.366374041}, {"text": "Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio  <i>-PROVE 3 results to be presented at late breaker session on Saturday, \r      April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate \r      activity across multiple genotypes in treatment-na\u00efve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid, \r      powerful antiviral activity with favorable safety and tolerability \r      profile-</i>  Webcasts", "labels": -3.0562791545}, {"text": "Vertex Pharmaceuticals Reviews First Quarter Business Progress and Reports First Quarter 2009 Financial Results  <i>- Telaprevir registration program on track; VCH-222 enters \r      multi-dose, 3-day viral kinetic study -</i><i>- VX-770 will start registration program in CF patients with G551D \r      mutation -</i><i>-Vertex ends first quarter with $869 million of cash, cash \r      equivalents and marketable securities-</i>  Webcasts", "labels": 2.3546194479}, {"text": "Vertex Pharmaceuticals Announces the Date of its First Quarter 2009 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Apr 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2009 financial results on Thursday, April 16, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": -6.2846610384}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Mar 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at Citi's 4 th Annual Biotech Day on Wednesday, April 1, 2009 at 2:40 p.m. EDT and at the Canaccord Adams Hepatitis C Conference on  Webcasts", "labels": -1.0094010447}, {"text": "Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis  <i><b>- Primary endpoints of safety and tolerability to be evaluated in \r      Phase 2a clinical trial -</b></i><i><b>- Measurements of CFTR function to be assessed as secondary \r      endpoints -</b></i><i><b>- Trial to enroll approximately 90 patients with the F508del CFTR \r      mutation -</b></i>  Webcasts", "labels": 2.1206076315}, {"text": "Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VCH-222 Abstracts for Presentation at EASL Annual Meeting  <i><b>- PROVE 3 SVR results accepted as late-breaker oral presentation -</b></i><i><b>- First clinical results for VCH-222 in HCV patients accepted as \r      poster presentation -</b></i>  General Business", "labels": 1.4660767347}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Cowen & Company 29th Annual Health Care Conference  CAMBRIDGE, Mass., Mar 13, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen &amp; Company 29 th Annual Health Care Conference on Tuesday, March 17, 2009 at 2:25 p.m. EDT.  Webcasts", "labels": -6.5549934611}, {"text": "Vertex Pharmaceuticals Closes on Acquisition of ViroChem Pharma  <b>-Purchase Price $100 Million and 10.7 Million Shares-</b><b>-Vertex Acquires Two HCV Polymerase Inhibitors in Deal-</b>  Webcasts", "labels": 6.9759472853}, {"text": "Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir  <i>- Vertex to acquire privately-held ViroChem Pharma in cash and stock \r      transaction -</i><i>- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have \r      demonstrated significant antiviral activity in early clinical trials -</i><i>- First STAT-C combination trial with telaprevir planned for 2H 2009 \r      start -</i>  Webcasts", "labels": 2.8540889219}, {"text": "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  CAMBRIDGE, Mass., Feb 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf  Webcasts", "labels": 1.2759652684}, {"text": "Vertex Pharmaceuticals Announces Pricing of Common Stock Offering  <b> 10 million shares of common stock at $32 per share for gross \r      proceeds of $320 million</b>  Webcasts", "labels": 1.2759652684}, {"text": "Vertex Pharmaceuticals Provides HCV and Cystic Fibrosis Update and Reports 2008 Financial Results  CAMBRIDGE, Mass., Feb 09, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated : Telaprevir dosing in Phase 3 ADVANCE clinical trial complete and Phase 3 REALIZE clinical trial completes enrollment VX-770 expected to commence registration program for cystic fibrosis in first half of 2009  Webcasts", "labels": -10.098438936}, {"text": "Vertex Pharmaceuticals Announces Transition in Company Leadership  CAMBRIDGE, Mass., Feb 05, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated President, CEO, and Founder Joshua Boger, Ph.D. Will Retire in May 2009 Vertex Board Member Matthew Emmens Appointed President and Will Transition to President, CEO and Chairman in May 2009 The board of directors  Webcasts", "labels": 5.4285757882}, {"text": "Vertex Pharmaceuticals Announces the Date of its 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Feb 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its 2008 financial results on Monday, February 9, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.  Webcasts", "labels": 1.0542237373}, {"text": "Vertex Outlines 2009 Business Priorities: Registration Programs in Hepatitis C and Cystic Fibrosis; Balanced Investment to Maintain Financial Strength  - Broad telaprevir registration program for treatment-naive and <br>      treatment-failure HCV patients nears enrollment completion -- Vertex expects to initiate VX-770 registration program in cystic <br>      fibrosis -- Vertex ends 2008 with approximately $830 million in cash, cash <br>      equivalents & marketable securities -  Webcasts", "labels": 3.8104343393}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 27th Annual J.P. Morgan Healthcare Conference  CAMBRIDGE, Mass., Jan 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 27 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 p.m. PST (4:30 p.m. EST).  Webcasts", "labels": -1.2690343043}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Nov 26, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Piper Jaffray 20 th Annual Health Care Conference on Tuesday, December 2, 2008 at 10:30 a.m.  Webcasts", "labels": -7.2135820494}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Nov 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 19, 2008 at 2:30 p.m.  Webcasts", "labels": -6.1117328688}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Nov 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at Deutsche Bank's 2008 Biotech Boston Confab on Tuesday, November 11, 2008 and at the Credit Suisse 2008 Healthcare Conference on Thursday,  Webcasts", "labels": 3.5688528453}, {"text": "New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection   New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration PROVE 2 final results confirm 69% SVR in HCV treatment-na\u00efve patients with 24-week  General Business", "labels": 5.9915940328}, {"text": "Vertex Pharmaceuticals Highlights Progress with Hepatitis C and Cystic Fibrosis Programs and Reports Third Quarter 2008 Results  <B><P>-- Phase 3 ADVANCE study of telaprevir in HCV completes enrollment --<br>\r-- Registration program for VX-770 in cystic fibrosis being discussed with global authorities --<br>\r-- As of September 30, 2008, Vertex had $920 million of cash, cash equivalents and marketable securities--</P></B>\r  Webcasts", "labels": -1.6409274317}, {"text": "Vertex Announces Positive 28-Day Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis  <ul><li>VX-770 was well-tolerated when dosed as 150 mg and 250 mg twice daily for 28 days</li><li>VX-770 resulted in a significant increase in FEV1, and significant changes in sweat chloride and nasal potential difference, important markers of CFTR function</li>\r<li>Researchers to present 28-day results at the North American Cystic Fibrosis Conference on October 23</li></ul>  Cystic Fibrosis", "labels": -6.5412937096}, {"text": "Vertex Pharmaceuticals Announces the Date of its Third Quarter 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Oct 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2008 financial results on Monday, October 27, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": 2.6869179356}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the JMP Securities Healthcare Focus Conference  CAMBRIDGE, Mass., Oct 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 9:30 a.m. EDT.  Webcasts", "labels": -7.1937821672}, {"text": "Telaprevir Presentations at the 59th AASLD Meeting to Feature SVR Data in Treatment-Na\u00efve and Treatment-Failure Genotype 1 HCV Patients, and Clinical Data Exploring Twice-Daily Dosing Regimens  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - News) today announced that key data on sustained viral response (SVR) rates in both treatment-na\u00efve and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens  HCV", "labels": 15.8499741706}, {"text": "Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatology  CAMBRIDGE, Mass., Sep 24, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology. The title of the abstract is \"Phase 2 Study of Telaprevir Administered q8h or  HCV", "labels": 15.8499741706}, {"text": "Vertex Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares  CAMBRIDGE, Mass., Sep 22, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter has exercised in full its option to purchase 1,125,000 shares of common stock at a public offering price of $25.50 per share.  General Business", "labels": -5.7142909044}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the UBS 2008 Global Life Sciences Conference  CAMBRIDGE, Mass., Sep 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the UBS 2008 Global Life Sciences Conference on Wednesday, September 24, 2008 at 10:00 a.m. EDT.  Webcasts", "labels": -3.5055992435}, {"text": "Vertex Pharmaceuticals Announces Pricing of its Public Offering of Common Stock  CAMBRIDGE, Mass., Sep 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an underwritten offering at a price to the public of $25.50 per share, which would result in  General Business", "labels": 11.7606855865}, {"text": "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  CAMBRIDGE, Mass., Sep 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf  General Business", "labels": 0.9315665722}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Sep 04, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. EDT and at the Morgan Stanley Global Healthcare Unplugged  Webcasts", "labels": 0.8384120247}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Thomas Weisel Partners Healthcare Conference 2008  CAMBRIDGE, Mass., Aug 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Thomas Weisel Partners Healthcare Conference 2008 on Wednesday, September 3, 2008 at 8:00 a.m. EDT.  Webcasts", "labels": -1.6086805557}, {"text": "Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients  First HCV protease inhibitor in pivotal trial for this difficult<br>                      to treat patient population<br><br>      Trial to enroll all major treatment-failure patient groups,<br>      including null responders, partial responders and relapsers<br><br>   Two telaprevir registration programs to address significant unmet<br>        need in treatment-naive and treatment-failure patients  HCV", "labels": -5.5851110857}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams 28th Annual Global Growth Conference  CAMBRIDGE, Mass., Aug 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams 28th Annual Global Growth Conference on Wednesday, August 13, 2008 at 8:30 a.m. EDT.  Webcasts", "labels": -2.1182060888}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference  CAMBRIDGE, Mass., Aug 05, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference on Wednesday, August 6, 2008 at 9:00 a.m. EDT.  Webcasts", "labels": 3.2974029339}, {"text": "Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results  --  Treatment-failure data and treatment-naive data strengthen<br>        telaprevir's potential profile and highlight broad opportunity<br>        in treatment of chronic hepatitis C virus (HCV) infection<br><br>   --  VX-770, for cystic fibrosis (CF), completes enrollment for<br>        28-day Phase 2a study; 2009 targeted for initiation of<br>        registration studies, pending 28-day study results  Webcasts", "labels": -1.2538221341}, {"text": "Vertex Pharmaceuticals Announces the Date of its Second Quarter 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jul 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": -4.6052609957}, {"text": "Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development  CAMBRIDGE, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has  General Business", "labels": 2.3008925041}, {"text": "Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc.  Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. -Vertex to receive up to $4 million in funding for Huntington's disease research- -Novel venture philanthropy model used in Vertex's Cystic Fibrosis R&amp;D efforts to support new Huntington's disease  General Business", "labels": -0.9036121391}, {"text": "Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment  --  73% of prior relapsers achieved SVR12 with 24-week<br>        telaprevir-based treatment<br><br>   --  41% of prior non-responders achieved SVR12 with 24-week<br>        telaprevir-based regimen  HCV", "labels": -3.9529311932}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference  CAMBRIDGE, Mass., Jun 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Goldman Sachs 29th Annual Global Healthcare Conference on Wednesday, June 11, 2008 at 4:00 p.m. PDT (7:00 p.m. EDT).  Webcasts", "labels": 1.4519041812}, {"text": "Vertex Pharmaceuticals Sells HIV Product Royalty Stream for $160 Million  CAMBRIDGE, Mass., Jun 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva(R) and Agenerase(R) under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors  General Business", "labels": 0.2426332544}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Citi Investment Research Global Healthcare Conference  CAMBRIDGE, Mass., May 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008 at 1:00 p.m. EDT.  Webcasts", "labels": -1.8558960603}, {"text": "Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass., May 15, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2008 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Articles of Organization increasing the number of  General Business", "labels": 1.9884281999}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences CAMBRIDGE, Mass., May 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Bank of America 2008 Health Care  Webcasts", "labels": -2.7451010311}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Deutsche Bank 33rd Annual Health Care Conference  CAMBRIDGE, Mass., May 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Deutsche Bank 33rd Annual Health Care Conference on Monday, May 5, 2008 at 1:20 p.m. EDT.  Webcasts", "labels": 2.2061689268}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference  CAMBRIDGE, Mass., Apr 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008 at 4:20 p.m. EDT.  Webcasts", "labels": 1.4778302337}, {"text": "Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment  -Interim results to be presented in late-breaker poster<br>                   presentation at EASL on April 24-<br><br>   -Significant early on-treatment viral response from patients who<br>                      previously failed therapy-  HCV", "labels": 3.1881793029}, {"text": "Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments  - High sustained virologic response (SVR) rates of 61% in PROVE 1<br> and 68% in PROVE 2 with 24-week telaprevir-based treatment regimen -<br><br>  - Telaprevir first and only investigational HCV protease inhibitor<br>                 in Phase 3, ADVANCE trial underway -  HCV", "labels": -9.6385528325}, {"text": "Vertex Pharmaceuticals Reviews Clinical Advancements and Reports First Quarter 2008 Financial Results  --Telaprevir data in HCV patients who failed current therapies to<br>                        be presented at EASL--<br><br>     --Pharmacokinetic analyses in HCV patients show potential for<br>                  twice-daily dosing of telaprevir--<br><br>   --VX-770 for cystic fibrosis to advance based on positive results<br>                       reported in March 2008--  HCV", "labels": 4.8148119891}, {"text": "Vertex Pharmaceuticals Announces the Date of its First Quarter 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2008 financial results on Monday, April 21, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": -0.574931459}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord|Adams Hepatitis C Conference  CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord|Adams Hepatitis C Conference on Wednesday, April 9, 2008 at 4:00 p.m. EDT.  Webcasts", "labels": -0.574931459}, {"text": "Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on Telaprevir, Investigational HCV Protease Inhibitor, for Presentation at EASL Annual Meeting  CAMBRIDGE, Mass., Mar 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data related to its investigational hepatitis C protease inhibitor telaprevir will be featured in a late-breaker poster presentation during the 43rd Annual Meeting of the  HCV", "labels": 19.952773417}, {"text": "Vertex Announces Positive Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis  --Interim analysis of 14-day study of VX-770 shows a significant<br>                    improvement in lung function --<br><br>    --Lung function data supported by corresponding improvements in<br>                     disease-related biomarkers--<br><br>      --Results to be shared with health authorities in order to<br>                identify the most rapid path forward --  Cystic Fibrosis", "labels": 2.2508042858}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Cowen and Company 28th Annual Health Care Conference  CAMBRIDGE, Mass., Mar 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 8:00 a.m. EDT.  Webcasts", "labels": -4.8233697369}, {"text": "Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients  - First hepatitis C protease inhibitor to begin Phase 3 clinical\r                             development -\r\r    - Trial designed to confirm potential of telaprevir to increase\rsustained viral response (SVR) rates with 24-week treatment duration -  HCV", "labels": -0.323835441}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference  CAMBRIDGE, Mass., Feb 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the Company will participate in an HCV panel, entitled: \"HCV: Protease Inhibitors and Beyond\" at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in  Webcasts", "labels": -3.8111494835}, {"text": "Vertex Pharmaceuticals Announces Completion of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Feb 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5  General Business", "labels": -2.9900383804}, {"text": "Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes CAMBRIDGE, Mass., Feb 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that  General Business", "labels": 0.7034586796}, {"text": "Vertex Pharmaceuticals Announces Pricing of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.  General Business", "labels": 14.4200643516}, {"text": "Vertex Pharmaceuticals Reviews 2008 Business Priorities and Reports 2007 Financial Results  -- Focused on first-to-market opportunity with HCV protease<br>                        inhibitor telaprevir --<br><br>  -- Additional drug candidates directed at HCV, cystic fibrosis and<br>                      immune-mediated diseases--  General Business", "labels": -6.4760831381}, {"text": "Vertex Pharmaceuticals Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf  General Business", "labels": -6.4760831381}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the BIO CEO & Investor Conference 2008  CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the BIO CEO &amp; Investor Conference 2008 on Tuesday, February 12, 2008 at 10:15 a.m. EST.  Webcasts", "labels": -4.118616352}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference  CAMBRIDGE, Mass., Jan 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology &amp; Medical Device Conference on Tuesday, February 5, 2008 at 11:40 a.m.  Webcasts", "labels": 2.0904244606}, {"text": "Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jan 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2007 financial results on Monday, February 11, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.  Webcasts", "labels": 6.9249410731}, {"text": "Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor  --  Primary Phase 3 trial will focus on studying 24-week         telaprevir-based regimens     --  Vertex plans concurrent second study to support registration     --  Final data from both trials anticipated in mid- 2010   HCV", "labels": -4.880584231}, {"text": "Vertex Pharmaceuticals Reports Progress in Development of Investigational HCV Drug Telaprevir and Provides Business Update  - Formal European scientific advice obtained for telaprevir                          development program -      - Meeting scheduled with FDA for January 2008 on Phase 3 trial                        design and recent data -     - Next-generation HCV protease inhibitor and two investigational         compounds for cystic fibrosis in clinical development -   HCV", "labels": 2.7447409182}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual JPMorgan Healthcare Conference  CAMBRIDGE, Mass., Jan 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008 at 2:00 p.m. PST (5:00 p.m. EST).  Webcasts", "labels": -1.6744214435}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference  CAMBRIDGE, Mass., Nov 21, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the CIBC World Markets 3rd Annual Mid &amp; Small Cap 'Best Ideas' Conference on Wednesday, November 28, 2007 at 8:45 a.m. EST.  Webcasts", "labels": 2.7777771088}, {"text": "Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data  -- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers --          -- Merck to initiate clinical development of VX-689 --   Other", "labels": -7.6890373643}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations\r at Two Investor Conferences\r  Cambridge, MA, November 5, 2007 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 2:45 p.m.  Webcasts", "labels": -3.672655107}, {"text": "First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients  Two Large Phase 2 Trials of Telaprevir, an Investigational   Hepatitis C Protease Inhibitor, Dosed in Combination with Pegylated         Interferon and Ribavirin Show SVR Rates of 61% and 65%       Initial Rapid Viral Decline Appears Important to Achieve SVR           Safety Profile Consistent with Prior Interim Analyses   HCV", "labels": -19.6013261142}, {"text": "Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update  Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD \u0096 Additional compounds for HCV and Cystic Fibrosis scheduled to enter development \u0096 Cambridge, MA, October 29, 2007 \u0097 Vertex  General Business", "labels": -0.4696293551}, {"text": "Vertex Pharmaceuticals Announces the Date of its Third Quarter 2007 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Oct 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2007 financial results on Monday, October 29, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": -0.3851532606}, {"text": "Vertex Announces Publication of Abstracts for Presentation at 58th AASLD Meeting  -- Conference Presentations to Include Data from Two Randomized,   Controlled Phase 2 Clinical Studies of Investigational HCV Protease                         Inhibitor Telaprevir --   General Business", "labels": 4.9255982337}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Sep 14, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotech &amp; Medtech Conference on Tuesday, September 18th at 1:00 p.m. GMT (8:00 a.m.  Webcasts", "labels": -3.5425908621}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 20th Annual Healthcare Conference  CAMBRIDGE, Mass., Sep 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bear Stearns 20th Annual Healthcare Conference on Monday, September 10th at 3:00 p.m. EDT.  Webcasts", "labels": 2.3703681098}, {"text": "Vertex Pharmaceuticals Reports Second Quarter 2007 Financial Results and Provides Development Pipeline Update  CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. \"Vertex achieved its major development pipeline milestones in the first  General Business", "labels": 11.7950256023}, {"text": "Vertex Pharmaceuticals Announces the Date of its Second Quarter 2007 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jul 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2007 financial results on Tuesday, July 24, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts", "labels": -0.8418090817}, {"text": "Vertex Pharmaceuticals Announces Two Executive Appointments  CAMBRIDGE, Mass., Jun 29, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Kurt C. Graves as Executive Vice President, Chief Commercial Officer and Head, Strategic Development. Vertex also announced today that Amit K.  General Business", "labels": -1.4441699761}, {"text": "Vertex Pharmaceuticals Reports 2007 Pipeline Progress  --  More than 1000 patients have now been enrolled in Phase 2b         PROVE trials     --  More than 350 patients have completed 12 weeks of telaprevir         dosing in PROVE trials     --  Interim results from PROVE 2 consistent with findings from         PROVE 1   HCV", "labels": 0.6215724824}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Jun 01, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Bear Stearns Biotech Confab on Thursday, June 7th at 7:50 a.m. EDT and at the Goldman Sachs 28th Annual Global Healthcare Conference on Wednesday, June 13th at  Webcasts", "labels": -1.5609128013}, {"text": "Stockholders of Vertex Pharmaceuticals Re-elect Directors at Annual Meeting  CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S.  General Business", "labels": -1.2474741778}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at Citigroup's 2007 Global Healthcare Conference  CAMBRIDGE, Mass., May 17, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentation at Citigroup's 2007 Global Healthcare Conference on May 23, 2007 at 4:00 p.m. EDT. The presentation will be webcast live and may be accessed from the 'Events Calendar'  Webcasts", "labels": -2.3204054783}, {"text": "Vertex Pharmaceuticals Reports First Quarter 2007 Financial Results  CAMBRIDGE, Mass., Apr 30, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2007. \"In 2007, a major goal for Vertex is to build the product profile of the investigational hepatitis C protease  HCV", "labels": -4.1073194739}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Apr 26, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2007 at 2:15 p.m. EDT and at Deutsche Bank's 32nd Annual Health Care Conference on May 3, 2007  Webcasts", "labels": 0.9247477994}, {"text": "Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C  -- PROVE 1 data support potential to shorten treatment duration in               treatment-naive, genotype 1 HCV patients --   HCV", "labels": 9.5643960147}, {"text": "Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)  In vitro results support expansion of telaprevir clinical            development into genotype 2, 3 and 4 HCV patients   HCV", "labels": -2.6941436113}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Mar 07, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Cowen and Company 27th Annual Health Care Conference on March 13, 2007 at 8:45 a.m. EDT and at the Citigroup Small &amp; Mid-Cap Conference on March 14, 2007 at  Webcasts", "labels": -0.409832408}, {"text": "Vertex Pharmaceuticals Announces Completion of Conversion of Outstanding 5.75% Convertible Senior Subordinated Notes due 2011  CAMBRIDGE, Mass., Mar 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in connection with the previously announced redemption of its 5.75% Convertible Senior Subordinated Notes due 2011, holders of all of the outstanding notes converted their notes  General Business", "labels": 1.016608411}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns Ninth Annual London Healthcare Conference  CAMBRIDGE, Mass., Feb 22, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns Ninth Annual London Healthcare Conference on Tuesday, February 27, 2007 at 11:20 a.m. GMT (6:20 a.m. EST).  Webcasts", "labels": 2.0541603885}, {"text": "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences Cambridge, MA, February 5, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotechnology  Webcasts", "labels": -1.5412460537}, {"text": "Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011  Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011 Cambridge, MA, February 2, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 5, 2007 it will redeem the outstanding $59.6 million aggregate principal amount of  General Business", "labels": -7.9950751461}, {"text": "Vertex Pharmaceuticals Reports 2006 Financial Results  Vertex Pharmaceuticals Reports 2006 Financial Results Cambridge, MA, February 1, 2007 \u2013 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ended December 31, 2006. \u201c2006 was characterized by significant progress across our  General Business", "labels": -4.4470798113}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference Cambridge, MA, January 24, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Wachovia  Webcasts", "labels": -3.2248779221}, {"text": "Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference  --PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950)--<br><br>\r-- Expanding clinical development into important HCV sub-populations --<br><br>\r-- Vertex building foundation for commercialization of telaprevir --  Other", "labels": -6.2887544591}, {"text": "Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference  Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950) Expanding clinical development into important HCV sub-populations Vertex building foundation for commercialization of  HCV", "labels": -6.2887544591}, {"text": "Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias  - Vertex Earns $25 Million Milestone Payment Upon Start of Patient Dosing -  Other", "labels": -0.9864109921}, {"text": "Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950)  Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950) Cambridge, MA, December 13, 2006 \u2013\u2013 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a planned  HCV", "labels": 6.1224463651}, {"text": "Vertex Pharmaceuticals Added to NASDAQ-100 Index  Vertex Pharmaceuticals Added to NASDAQ-100 Index Cambridge, MA, December 11, 2006 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Company will be added to the NASDAQ-100 Index(R), effective with the market open on Monday, December 18, 2006.  General Business", "labels": -10.6345138691}, {"text": "Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders  - Additional Preclinical Combination Studies Suggest Synergistic Activity of MK-0457 and Other Kinase Inhibitors -  Other", "labels": -10.6345138691}, {"text": "New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting  &#8212; Combination therapy with telaprevir and pegylated interferon suppressed both wild-type and resistant HCV &#8212;  HCV", "labels": -0.2004053976}, {"text": "Vertex Pharmaceuticals Reports Third Quarter 2006 Financial Results  - Company Reiterates Anticipated Timeline of Clinical Milestones -  General Business", "labels": 16.8962099303}, {"text": "Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study  Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study San Francisco, CA, September 28, 2006 -- Data presented today show low rates of virologic failure and antiviral drug resistance with the HIV protease inhibitor LEXIVA boosted with  General Business", "labels": -1.4858840337}, {"text": "Vertex Pharmaceuticals Announces Completion of Common Stock Offering  Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, September 20, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common stock. The gross proceeds, before commissions and  General Business", "labels": -0.9747172616}, {"text": "Vertex Pharmaceuticals Announces Pricing of Common Stock Offering  Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, September 14, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common stock at a price of $33.00 per share.  General Business", "labels": -3.3959943827}, {"text": "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, September 11, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 8,000,000 shares of its newly issued common stock in an underwritten public offering.  General Business", "labels": -1.7346009583}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference Cambridge, MA, September 8, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns 19th Annual Healthcare Conference.  Webcasts", "labels": 0.057439569}, {"text": "Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet  LEXIVA(R)/r Twice-Daily Provided Comparable Efficacy to Kaletra Twice-Daily in Treatment-Naive HIV Patients   General Business", "labels": 1.1922941014}, {"text": "Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens  Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens Toronto, Canada, August 13, 2006 -- Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor  General Business", "labels": 2.3756731303}, {"text": "Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011  Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior  General Business", "labels": 0.6507563728}, {"text": "Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results  - VX-950 Global Phase 2b Clinical Development Plan On Track -<br>\r        - Collaboration with Janssen Pharmaceutica, a Johnson &amp; Johnson Company,\r      Adds Important Strengths<br>\r      and Development Capabilities for VX-950 -  HCV", "labels": -5.8435745441}, {"text": "Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV  Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson &amp; Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals  General Business", "labels": 1.5313135848}, {"text": "Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C  Vertex Retains all North American Rights Janssen Obtains Exclusive Rights in Europe and Other Regions Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization New Brunswick, NJ and Cambridge, MA, June 30, 2006 -- Vertex  HCV", "labels": 1.5313135848}, {"text": "Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Na\u00efve HCV Patients  - PROVE 1 & PROVE 2 Studies Expected to Enroll 580 Patients -  HCV", "labels": 6.2382438712}, {"text": "Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients  - 12 of 12 (100%) patients HCV RNA undetectable with no evidence of viral breakthrough at end of 28 days VX-950 dosing -<br />\r- 92% (11 of 12) continued to have undetectable HCV RNA through 12 weeks of follow-on therapy -  HCV", "labels": 2.2764252453}, {"text": "Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis  - FDA Grants Fast Track Designation to VX-770 -  Cystic Fibrosis", "labels": -9.2959647713}, {"text": "GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV  GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and  General Business", "labels": -6.9932324469}, {"text": "Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  - Company Updates Corporate Governance Practices -  General Business", "labels": -3.6799014596}, {"text": "Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients  -New data show that plasma HCV RNA levels were below limit of detection (10 IU/mL) in 8 of 8 patients continued on peg-IFN+RBV for 12 weeks-  HCV", "labels": -7.9397328651}, {"text": "New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950  Results to be Presented at 41st Annual Meeting of the European Association for the Study of the Liver  HCV", "labels": 0.5005570349}, {"text": "Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results  &#150;&#150; Company on Track to Achieve Clinical, Research and Corporate Objectives &#150;&#150;  General Business", "labels": -10.5686396824}, {"text": "Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)  - Vertex earns $10 million milestone payment -   Other", "labels": -7.4600371487}, {"text": "Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF  Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF Cambridge, MA, March 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.  Cystic Fibrosis", "labels": -3.3744842702}, {"text": "Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis  --Vertex to Advance Clinical Program; Company Expects to Initiate Combination Study of VX-702 and Methotrexate by Mid-2006--  Other", "labels": -2.2906765202}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference Cambridge, MA, February 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Citigroup 2006 Healthcare Conference in Washington, DC.  Webcasts", "labels": 10.8796312036}, {"text": "Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program  -Plasma HCV RNA levels are less than 10 IU/mL in 12 of 12 patients after 28 days of dosing with VX-950/peg-IFN/RBV in Phase II study-\r  HCV", "labels": 2.2204161604}, {"text": "Vertex Pharmaceuticals Reports 2005 Financial Results  - Clinical, Research and Financial Objectives Achieved -  General Business", "labels": 4.4032127547}, {"text": "Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research  Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.  General Business", "labels": 0.2658793402}, {"text": "Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference  &#8212;Product Candidates with Transformational Potential Highlighted&#8212;   General Business", "labels": 6.1985915206}, {"text": "VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon  --Median 5.5 log10 reduction in HCV RNA achieved in patients receiving VX-950 and peg-IFN in 14-day clinical study--   General Business", "labels": 6.1985915206}, {"text": "Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference  -Product Candidates with Transformational Potential Highlighted-  General Business", "labels": 6.1985915206}, {"text": "GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir  - Positive Data Presented at 45th Annual ICAAC -\r  General Business", "labels": -3.2484280392}, {"text": "GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain  - VX-409 is first in a new class of subtype selective ion channel modulators -  General Business", "labels": 2.3765982065}, {"text": "GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain  - VX-409 is first in a new class of subtype selective ion channel modulators -  General Business", "labels": 2.3765982065}, {"text": "FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to  HCV", "labels": 3.0211452073}, {"text": "FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  FDA Grants Fast Track Designation to Vertex\u2019s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to  General Business", "labels": 3.0211452073}, {"text": "Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study  - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -  Other", "labels": 2.552203526}, {"text": "Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study  - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -  General Business", "labels": 2.552203526}, {"text": "Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  - Investigational New Drug Application Activated in the U.S. -  HCV", "labels": -1.212615793}, {"text": "Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  - Investigational New Drug Application Activated in the U.S. -  General Business", "labels": -1.212615793}, {"text": "FDA Approves Updated Labeling for LEXIVA  - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -  General Business", "labels": -3.7022873477}, {"text": "FDA Approves Updated Labeling for LEXIVA  - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -  General Business", "labels": -3.7022873477}, {"text": "AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor  Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S.  HCV", "labels": 0.7254697601}, {"text": "Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting  Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST.  Webcasts", "labels": 3.3593773341}, {"text": "Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations   Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company  General Business", "labels": 7.0663794072}, {"text": "Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results   - VX-950 Phase Ib Combination Study Initiated -<BR>\r- Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved -   General Business", "labels": -5.4806796982}, {"text": "Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis   Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on  HCV", "labels": -10.4250554091}, {"text": "New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track   New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track Montreal, Canada, October 3, 2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV  HCV", "labels": 8.1214093946}, {"text": "Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock  Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated  General Business", "labels": 3.7947574517}, {"text": "Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock  Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated  General Business", "labels": -0.1275478552}, {"text": "Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results  Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 \u2013 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. \u201cVertex\u2019s progress in the second quarter of 2005 was  General Business", "labels": -4.679804431}, {"text": "Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis   - Combination of Lexiva/r and Truvada Evaluated -  General Business", "labels": 4.0683883488}, {"text": "Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy  - Combination of Lexiva/r and Truvada Evaluated -  General Business", "labels": 4.0683883488}, {"text": "FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385)   - GlaxoSmithKline To Initiate Phase IIb Clinical Trial in HIV-infected Patients -  General Business", "labels": 3.8483322141}, {"text": "Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680  Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I  Other", "labels": 12.2576614522}, {"text": "Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters  Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Cambridge, MA, June 15, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock  General Business", "labels": 2.7240151945}, {"text": "Vertex Pharmaceuticals Announces Completion of Common Stock Offering  Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, June 13, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offering of 11,750,000 shares of common stock. The gross proceeds, before commissions and expenses, of  General Business", "labels": 2.8782312755}, {"text": "Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702  Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in  Other", "labels": 2.6315817778}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs' Twenty-Sixth Annual Global Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs\u2019 Twenty-Sixth Annual Global Healthcare Conference Cambridge, MA, June 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Goldman Sachs' 26th Annual Global Healthcare  Webcasts", "labels": -0.0762793985}, {"text": "Vertex Pharmaceuticals Announces Pricing of Common Stock Offering  Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, June 7, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the pricing of its public offering of 11,750,000 shares of its common stock at a price of $13.00 per share.  General Business", "labels": 2.406019879}, {"text": "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, May 31, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 9,500,000 shares of its newly issued common stock in an underwritten public offering.  General Business", "labels": -5.405407534}, {"text": "Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study  -- Five Patients on 14-day Clinical Study Achieve Plasma Levels Below Limit of Quantitation --  HCV", "labels": 5.8394175319}, {"text": "Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  -- Eugene Cordes, Ph.D., Appointed to Vertex's Board of Directors --  General Business", "labels": -0.9708746162}, {"text": "Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study  - Presentation of Study Results Planned at DDW -  HCV", "labels": 5.7462651195}, {"text": "Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders  Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders Cambridge, MA, May 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will webcast its 2005 Annual Meeting of Shareholders on Wednesday, May 11, 2005. Joshua Boger, Ph.D., Vertex's Chairman and Chief Executive  Webcasts", "labels": 9.1079750995}, {"text": "New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium  New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium Quebec City, April 29, 2005 --Today GlaxoSmithKline (GSK) presented new pharmacokinetic (PK) data on taking the HIV protease inhibitor LEXIVA(R) (fosamprenavir calcium, FPV) Tablets with the proton pump inhibitor (PPI), Nexium(R)  General Business", "labels": 2.4416188328}, {"text": "New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir  New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir Quebec City, April 29, 2005 --Today new study results announced by GlaxoSmithKline showed the pharmacokinetics (PK) of the HIV protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed in combination with  General Business", "labels": 2.4416188328}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, April 27, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at Deutsche Bank's 30th Annual Health Care Conference on May 2, 2005 and at Morgan Stanley's  Webcasts", "labels": -3.9173082349}, {"text": "Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update  Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update Cambridge, MA, April 26, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended March 31, 2005.  General Business", "labels": -5.608462896}, {"text": "Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast  Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast Cambridge, MA, April 4, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its first quarter 2005 financial results on Tuesday, April 26, 2005 after the financial  Webcasts", "labels": -2.1087633247}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference Cambridge, MA, March 11, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at SG Cowen's 25th Annual Health Care Conference in Boston.  Webcasts", "labels": 2.5280941016}, {"text": "Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals  Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals Cambridge, MA, February 23, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the United States District Court for the District of Massachusetts has granted its motion to dismiss a  General Business", "labels": 6.0735676957}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, February 18, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the BIO CEO and Investor Conference on February 23, 2005 and at the SunTrust Robinson  Webcasts", "labels": -6.2670260312}, {"text": "Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer  Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer Cambridge, MA, and Germantown, MD, February 15, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Avalon Pharmaceuticals Incorporated today announced that  Other", "labels": -1.2259224377}, {"text": "Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance  Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance Cambridge, MA, February 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ending December 31, 2004.  General Business", "labels": 2.6501700101}, {"text": "Vertex Pharmaceuticals Announces Two Senior Management Changes  Vertex Pharmaceuticals Announces Two Senior Management Changes Cambridge, MA, February 8, 2005 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that Dr. Vicki Sato will retire as President of the Company effective during the second quarter of 2005. Dr.  General Business", "labels": -6.1611337135}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology &amp; Medical Device Conference Cambridge, MA, February 3, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Merrill Lynch's  Webcasts", "labels": 6.0177017141}, {"text": "Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast  Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast Cambridge, MA, February 2, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its fourth quarter and full year 2004 financial results on Wednesday,  Webcasts", "labels": -1.7029357651}, {"text": "Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference  Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005  General Business", "labels": -0.2747228275}, {"text": "Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers  Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I  Other", "labels": 3.5271677181}, {"text": "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at JPMorgan's 23rd Annual Healthcare Conference in San  Webcasts", "labels": 3.8022866426}, {"text": "Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART  Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART Montego Bay, Jamaica, December 15, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD)  General Business", "labels": -0.9666050577}, {"text": "Novartis Selects Drug Candidate for Clinical Development from Protein Kinase Research Collaboration with Vertex  --Novel compound, VX-322, targets key mechanisms implicated in leukemia and other cancers--  General Business", "labels": 2.1830414124}, {"text": "Vertex Pharmaceuticals Receives Distinguished Recognition by Scientific American Magazine  - Company named Business Leader in Medical Treatment in the 2004 &quot;Scientific American 50&quot; -  General Business", "labels": 2.7923184447}, {"text": "Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C  -- First study in HCV patients will evaluate dosing up to 14 days --  HCV", "labels": 2.7923184447}, {"text": "Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C  -Encouraging Results Support Initiation of Phase Ib Clinical Study-  HCV", "labels": 0.0}, {"text": "Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update  Company continues to achieve its financial and pipeline goals  General Business", "labels": 2.3785903616}, {"text": "Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients   -First demonstration of CRP reduction in cardiovascular patients using an oral cytokine inhibitor-  Other", "labels": -2.3437478172}, {"text": "Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C  Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, September 7, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has successfully completed the  HCV", "labels": 0.0975632086}, {"text": "Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update  --Company on Track to Achieve 2004 Milestones--  General Business", "labels": 3.7233983191}, {"text": "GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV  GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV London, UK, July 16, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received marketing approval from the  General Business", "labels": -4.9850449981}, {"text": "Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC  Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC Bangkok, July 13, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium, formerly GW433908, or 908) in combination with abacavir and lamivudine demonstrated sustained efficacy and safety  General Business", "labels": -1.3916439742}, {"text": "Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC   Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC Bangkok, July 12, 2004 -- HIV treatment regimens containing the protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir  General Business", "labels": 0.0}, {"text": "48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS  48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS Research Triangle Park, NC, July 8, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once-daily (QD) as part of a  General Business", "labels": -6.2874164869}, {"text": "Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer  Merck &amp; Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Whitehouse Station, NJ and Cambridge, MA, June 22, 2004 -- Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today  Other", "labels": 0.3813151833}, {"text": "Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries  Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries Cambridge, MA, June 14, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that Vertex and Mitsubishi  HCV", "labels": 2.5906736775}, {"text": "Vertex Pharmaceuticals Announces Discovery of Two New Classes of Compounds Targeting Cystic Fibrosis  Research Results Presented at CF Foundation's Williamsburg Conference   General Business", "labels": 1.2972960601}, {"text": "Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C  Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, June 8, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the initiation of a Phase I clinical  HCV", "labels": -2.4498917399}, {"text": "Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceuticals Under Expanded Agreement   - New Collaboration Builds on Drug Discovery Progress at Vertex -   General Business", "labels": -0.4624273251}, {"text": "Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting  Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting Cambridge, MA, May 6, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today results of the voting at its 2004 Annual Meeting of Shareholders.  General Business", "labels": -8.6752725435}, {"text": "Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV  Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV Tucson, AZ, May 4, 2004 -- New preclinical data for two proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex Pharmaceuticals  HCV", "labels": 0.6451657891}, {"text": "Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress   Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress Cambridge, MA, April 26, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2004.  General Business", "labels": 2.8662468745}, {"text": "Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches  Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches Berlin, Germany, April 16, 2004 -- New data for proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex  HCV", "labels": 1.9845574152}, {"text": "GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R)  GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R) Cambridge, MA, March 25, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received a positive opinion from the European Committee for Proprietary  General Business", "labels": 3.1521735638}, {"text": "Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors   - Study Published in Nature Medicine -  Other", "labels": -10.9090891751}, {"text": "Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange  Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange Cambridge, MA, February 13, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has completed the exchange of approximately $153 million in aggregate principal amount of its 5% Convertible  General Business", "labels": 6.0634380225}, {"text": "Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004  Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Cambridge, MA, February 11, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the year ended December 31, 2003.  General Business", "labels": -0.0986121782}, {"text": "Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007  Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007 Cambridge, MA, February 10, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that five holders of its existing 5% Convertible  General Business", "labels": 3.7328104425}, {"text": "Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference  -Company to Provide Financial Guidance for 2004-  General Business", "labels": 1.1677245837}, {"text": "Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference  -Company to Provide Financial Guidance for 2004-  General Business", "labels": 1.1677245837}, {"text": "Vertex Researchers Publish Structure of FLT-3 Kinase in Molecular Cell  -Potential Mechanism Underlying Various Types of Leukemia Described-  General Business", "labels": -1.8163502316}, {"text": "Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS)  Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) Cambridge, MA and Research Triangle Park, NC, January 20, 2004 -- The final 48-week results from the NEAT trial, an open-label, multi-center study  General Business", "labels": -0.77896709}, {"text": "Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference  Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference Cambridge, MA, January 12, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented its 2003 accomplishments and 2004 outlook at the 22nd Annual JPMorgan  General Business", "labels": -5.4736890291}, {"text": "Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results  Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Cambridge, MA, October 24, 2001 \u2014 Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reported consolidated financial results today for the three and nine months ended September 30, 2001.  General Business", "labels": 2.1548244999}]